Reports Required by Government Auditing Standards and OMB Circular A-133 for the Year Ended August 31, 2015 EIN 36-2167817

CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED AUGUST 31, 2015	
Independent Auditor's Report	Page 3
Northwestern University Financial Statements	Page 5
FEDERAL FINANCIAL ASSISTANCE PROGRAMS FOR THE YEAR ENDED AUGUST 31, 2015	
Schedule of Expenditures of Federal Awards	Page 31
Notes to the Schedule of Expenditures of Federal Awards	Page 112
SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED AUGUST 31, 2015	
Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	Page 127
Independent Auditor's Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance With OMB Circular A-133	et Page 129
Schedule of Findings and Questioned Costs	Page 131
Summary Schedule of Prior Audit Findings	Page 135
Management's Corrective Action Plan	Page 137



Independent Auditor's Report

To the Board of Trustees of Northwestern University

We have audited the accompanying consolidated financial statements of Northwestern University (the "University"), which comprise the consolidated statement of financial position as of August 31, 2015, and 2014, the related consolidated statements of activities and changes in net assets for the year ended August 31, 2015, and the related consolidated statements of cash flows for the years ended August 31, 2015 and 2014.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Northwestern University as of August 31, 2015 and 2014, and the changes in its net assets for the year ended August 31, 2015, and its cash flows for the years then ended August 31, 2015 and 2014, in accordance with accounting principles generally accepted in the United States of America.



Other Matters

We have previously audited the University's August 31, 2014 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated January 12, 2015. In our opinion, the summarized comparative information presented herein as of and for the year ended August 31, 2014 is consistent, in all material respects, with the audited financial statements from which it has been derived.

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by Office of Management and Budget Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations* and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated January 22, 2016 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended August 31, 2015. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

sicewaterhouse Coopers LLP

Chicago, Illinois January 22, 2016

Northwestern University Consolidated Statements of Financial Position As of August 31, 2015, and August 31, 2014

(in thousands of dollars)	2015	2014
Assets		
Cash and cash equivalents	\$277,129	\$366,158
Accounts receivable, <i>net</i>	282,926	266,900
Notes receivable, <i>net</i>	146,760	149,618
Contributions receivable, net	169,018	99,963
Investments	10,497,764	10,012,161
Land, buildings, and equipment, <i>net</i>	2,043,447	1,859,851
Other assets	18,731	21,656
Total assets	\$13,435,775	\$12,776,307
Liabilities		
Accounts payable and accrued expenses	\$223,461	\$235,734
Deferred revenue	270,962	266,290
Deposits payable and actuarial liability of annuities payable	123,770	119,975
Government advances for student loans	38,830	38,775
Asset retirement obligations	121,035	115,459
Bonds, notes, and other debt payable	1,864,739	1,336,328
Total liabilities	\$2,642,797	\$2,112,561
Net assets		
Unrestricted	\$6,822,964	\$6,824,273
Temporarily restricted	2,555,415	2,585,463
Permanently restricted	1,414,599	1,254,010
Total net assets	\$10,792,978	\$10,663,746
Total liabilities and net assets	\$13,435,775	\$12,776,307

See Notes to the Consolidated Financial Statements, beginning on page 8.

Consolidated Statements of Activities For the fiscal year ended August 31, 2015, and summarized financial information for the fiscal year ended August 31, 2014

(in thousands of dollars)		20	015		2014
Operating revenues	Unrestricted	Temporarily restricted	Permanently restricted	Total	Total
Tuition and fees	\$911,130			\$911,130	\$876,211
(less scholarships and fellowships)	(343,380)			(343,380)	(329,863
Net tuition and fees	567,750			567,750	546,348
Auxiliary services	77,226			77,226	77,63′
Grants and contracts	565,589			565,589	546,165
Private gifts	202,428			202,428	465,563
Investment return designated for operations	334,562	\$139,313		473,875	408,614
Sales and services	154,686			154,686	154,036
Professional fees	24,150			24,150	26,305
Royalties and trademarks	77,486			77,486	52,742
Other income	1,227			1,227	1,640
Total operating revenues	2,005,104	139,313	_	2,144,417	2,279,044
Net assets released from restrictions	228,267	(228,267)		-	_
Total operating revenues and					
other additions (reductions)	2,233,371	(88,954)	_	2,144,417	2,279,044
Operating expenses Salaries, wages, and benefits	1,147,813			1,147,813	1,096,970
Services, supplies, travel, and other	538,037			538,037	512,93
Depreciation and ARO accretion	117,831			117,831	117,270
Operations of plant, rent, and equipment	90,700			90,700	98,51
Utilities and communications	53,969			53,969	55,289
Royalty and trademark fees	47,889			47,889	51,530
Interest on indebtedness	37,094			37,094	40,504
Total operating expenses	2,033,333	_		2,033,333	1,973,02
Excess (deficit) of operating revenues over expenses	200,038	(88,954)	_	111,084	306,01
Nonoperating revenues and expenses Private gifts and grants for buildings and equipment	10,845			10,845	23,15
Restricted private gifts	10,045	121,162	\$166,810	287,972	116,12
Net (loss) gain on annuity obligations		(3,081)		(9,302)	
	(214,941)				9,86
Investment returns, reduced by operating distribution		(59,175)		(274,116)	1,036,91
Change in value of derivative instruments	(1,552)			(1,552)	5,31

Other nonoperating net revenues	4,301			4,301	13,868
Excess (deficit) of nonoperating					
revenues over expenses	(201,347)	58,906	160,589	18,148	1,205,242
Change in net assets	(1,309)	(30,048)	160,589	129,232	1,511,258
Beginning net assets	6,824,273	2,585,463	1,254,010	10,663,746	9,152,488
Ending net assets	\$6,822,964	\$2,555,415	\$1,414,599	\$10,792,978	\$10,663,746

See Notes to the Consolidated Financial Statements, beginning on page 8.

Consolidated Statements of Cash Flows For the fiscal years ended August 31, 2015, and August 31, 2014

(in thousands of dollars)	2015	2014
Cash flows from operating activities		
Change in net assets	\$129,232	\$1,511,258
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities		
Depreciation	112,083	111,769
Accretion for asset retirement obligations	5,748	5,507
Asset retirement obligations reduction	(172)	(22,105
Net losses on retirements and sales of buildings and equipment	1,527	6,426
Net amortization of discounts (and accretion) of premiums on bonds payable	(1,063)	(78
Allowance for student loans receivable	527	784
Net realized and unrealized gains on investments	(148,346)	(1,388,390
Gift of contributed securities	(139,961)	(48,487
Proceeds from sale of contributed securities	39,057	48,487
Change in value of derivative instruments	1,552	(5,317
Private gifts and grants for buildings and equipment	(10,845)	(23,153
Changes in assets and liabilities		
Accounts receivable	(11,309)	(5,544
Contributions receivable	(69,055)	16,432
Other assets	(648)	(3,030
Accounts payable and accrued expenses	(4,454)	2,407
Deferred revenue	4,672	5,606
Government advances for student loans	55	27
Net cash provided by (used in) operating activities	(91,400)	212,599
Cash flows from (used in) investing activities		
Purchases of investments	(2,372,293)	(1,804,158
Proceeds from sales of investments	2,138,701	1,604,252
Acquisitions of land, buildings, and equipment	(307,625)	(274,417
Proceeds from sale of buildings or equipment	1,047	210
Student loans disbursed	(26,391)	(24,472
Student loans purchased	_	(61,011
Principal collected on student loans	28,722	24,870
Dther	(7,478)	(11,254
Net cash provided by (used in) investing activities	(545,317)	(545,980
Cash flows from (used in) financing activities		
Proceeds from issuance of bonds payable and notes payable	686,017	586,000
Refunding of bonds payable	(149,164)	(185,010
Principal payments on notes, bonds, and other debt payable	(3,805)	(13,550
Proceeds from private gifts and grants for buildings and equipment	10,845	23,153
ncrease (decrease) in deposits payable and annuities payable	3,795	(45,805
Net cash provided by (used in) financing activities	547,688	364,788
	(00.020)	04 (07
Decrease) increase in cash and cash equivalents	(89,029)	31,407
Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year	366,158 \$277,129	334,751 \$366,158
Supplemental disclosure of cash flow information	ψ277,129	φ300,130
Accrued liabilities for construction in progress	\$22,582	\$27,979
Capitalized interest	φ22,382 15,041	¢27,973 11,677
Cash paid for interest	46,867	52,420
	-0,007	52,420

See Notes to the Consolidated Financial Statements, beginning on page 8.

1. Summary of Significant Accounting Policies

University Activities

Northwestern University (Northwestern or the University) is a major private research university with more than 21,000 students enrolled in 12 academic divisions on two lakefront campuses in Evanston and Chicago and an international campus in Doha, Qatar.

Northwestern's mission is to provide the highest-quality education for its students, to develop innovative programs in research, and to sustain an academic community that embraces these enterprises. Activi-ties supporting its mission may be classified as either operating or nonoperating. Operating revenues include student tuition, research funding, investment return designated for operations, educational sales and services, private gifts, royalties, and auxiliary services. Operating expenses reflect support for all functions of the University. Nonoperating activities include unrealized gains and losses on investments, temporarily restricted gifts for building, and all permanently restricted endowment gifts.

Basis of Accounting

General

The University maintains its accounts and prepares its consolidated financial statements on the accrual basis of accounting in conformity with generally accepted accounting principles in the United States of America (GAAP). The Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the source of authoritative GAAP. The University prepares its consolidated financial statements in accordance with the Not-for-Profit Entities Topic of the FASB ASC. These statements include all wholly owned subsidiaries. All significant intercompany transactions and accounts have been eliminated.

Net Asset Classifications

Net assets and the flow of those net assets are classified in three categories according to the existence or absence of donor-imposed restrictions. For further discussion of the classification of donor-restricted endowment funds and disclosures about both donor-restricted and board-designated endowment funds, see note 9.

The category *Permanently Restricted Net Assets* applies to gifts, trusts, and pledges whose donors required that the principal be held in perpetuity and that only the income be available for stipulated program operations.

The category *Temporarily Restricted Net Assets* includes gifts for which donor-imposed restrictions have not been met (these are primarily future capital projects), as well as trust activity and pledges receivable whose ultimate use is not permanently restricted. In addition, the excess of the fair value over the historical cost of permanently restricted endowments is classified as temporarily restricted net assets until appropriated for expenditure.

The category *Unrestricted Net Assets* describes funds that are legally available for any purpose and have no donor-imposed restrictions. All revenues, expenses, gains, and losses are classified as unrestricted net assets unless they are changes in temporarily or permanently restricted net assets. Net unrealized losses on permanently restricted endowment funds for which the historical cost exceeds fair value are recorded as a reduction to unrestricted net assets.

Revenue from temporarily restricted sources is reclassified as unrestricted revenue when the circumstances of the restriction have been fulfilled. Donorrestricted revenues whose restrictions are met within the same fiscal year are reported as unrestricted revenue. The expiration of a donor-imposed restriction on a contribution is recognized in the period in which the restriction expires. All expenditures are reported in the unrestricted class of net assets, since the use of restricted contributions in accordance with the donor's stipulations causes the release of the restriction. Donor-restricted purposes include instruction, research, library collections, scholarship and awards, and building construction.

Fair Value Measurements

The University makes fair value measurements and enhanced disclosures about fair value measurements as required by the Fair Value Measurements and Disclosures Topic of the FASB ASC. For further discussion, see notes 4 and 8.

Cash and Cash Equivalents

Cash reflects currency and deposits or other accounts with financial institutions that may be deposited or withdrawn without restriction or penalty. *Cash equivalents* represent short-term and highly liquid investments that convert readily to cash and carry little risk of change in value at maturity due to interest-rate changes; maturities of the investments are three months or less at the date of purchase.

Contributions

Contributions received, including unconditional promises to give (pledges), are recognized by the University as revenues at their fair values. Private gifts, including unconditional promises to give, are recognized as revenues in the period received. Conditional promises to give are not included in revenue until the conditions are substantially met.

Investments

Investments in securities and financial instruments are recorded at fair value. The University values its investments using a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity; unobservable inputs reflect the entity's own assumptions about how market participants would value an asset or a liability based on the best information available. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The following describes this hierarchy and the primary valuation methodologies used by the University for financial instruments measured at fair value on a recurring basis:

Level 1: Quoted prices in active markets for identical assets or liabilities. Market-price data are generally obtained from relevant exchanges or dealer markets.

Level 2: Inputs other than Level 1 that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially all of the same term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of

input significant to the fair value measurement. In the event that changes in the inputs used in the fair value measurement of an asset or liability result in a transfer of the fair value measurement to a different categorization, such transfers between fair value categories are recognized at the end of the reporting period. The categorization of an investment is based upon its pricing transparency and liquidity and does not necessarily correspond to the University's perceived risk of that investment. As a practical expedient as permitted under GAAP, the reported net asset value (NAV) of investments with external managers is used to estimate their fair value. Investments that use NAV as a practical expedient for valuation purposes are shown separately from the valuation hierarchy. For further discussion, see note 4.

Equity securities with readily determinable fair values and debt securities are valued at the last sale price (if quotations are readily available) or at the closing bid price in the principal market in which such securities are normally traded (if no sale price is available). The fair values for these securities are classified as Level 1 because the securities have observable market inputs. Certain fixed income securities are valued based on dealer-supplied valuations; since these securities have significant other observable inputs, they are classified as Level 2.

The estimated fair values of equity securities that do not have readily determined fair values, and of other investments that are generally less liquid, are based on valuation information received on the relevant entity and may include last sale information or independent appraisals of value. In addition, standard valuation techniques, including discounted cash flow models or valuation multiples based on comparable investments, may be used. The fair values for these securities are classified as Level 3, reflecting significant unobservable inputs that are supported by little or no market inputs.

Investments in certain real assets and other investments are recorded at acquisition or construction cost, or at fair value as of donation date if received as a contribution. The University performs a periodic assessment of these assets for impairment by comparing the future cash flows expected from the asset to the carrying value of the asset. An impairment loss is recognized for the difference between estimated fair value and carrying value. In management's opinion, no impairment of investments held at cost existed as of August 31, 2015. For further discussion of such investments, see note 4.

The methods described above may produce a fair value that may not be indicative of net realizable value or of future fair values. Furthermore, while the University believes its valuation methods are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Investment income is recorded on the accrual basis, and purchases and sales of investment securities are reflected on a trade-date basis.

Derivative Financial Instruments

The University uses various financial instruments to obtain equity market exposure (e.g., equity price risk) of an underlying investment strategy; if applicable, these have a reference index (e.g., S&P 500) that is the same as, or highly correlated with, the reference index of the investment strategy. Such instruments are not designated as hedges for accounting purposes and are recorded at fair value.

The University enters into swap agreements to hedge future interest-rate movements. It may also add various interest-rate options to hedge the overall portfolio and use an interest-rate swap agreement to hedge variable interest-rate exposure. Interest-rate swaps are valued using observable inputs, such as quotations received from the counterparty, dealers, or brokers, whenever they are available and considered reliable. If and when models are used, the value of the interest-rate swap depends on the contractual terms of and specific risks inherent in the instrument, as well as the availability and reliability of observable inputs. Such inputs include market prices for reference securities, yield curves, credit curves, measures of volatility, and prepayment rates as well as correlations of such inputs. For further discussion, see notes 4 and 8.

Fair Values of Financial Instruments Other Than Investments

The fair values of financial instruments other than investments are based on a variety of factors. In some cases, fair values represent quoted market prices for identical or comparable instruments. In other cases, fair values have been estimated based on assumptions about the amount and timing of estimated future cash flows and assumed discount rates reflecting varying degrees of risk. Accordingly, the fair values may not represent actual values that could have been realized at year-end or that will be realized in the future.

Accounts and Notes Receivable

Accounts receivable are recorded at net realizable value. Those generally expected to be collected within one year are carried without an allowance. The allowance for student accounts receivable is based on an analysis of outstanding account balances and is calculated using percentages based on historical collection data applied to the outstanding accounts receivable balances. Accounts receivable deemed to be uncollectible are expensed at that time.

Notes receivable are recorded at net realizable value and are predominantly student loans with varying maturities. Notes receivable deemed to be uncollectible are expensed at that time.

Management assesses the adequacy of the allowance for credit losses on a regular basis by performing ongoing analysis of the student loan portfolio. Factors considered are differing economic risks associated with each loan category, the financial condition of specific borrowers, the economic environment in which the borrowers operate, the level of delinquent loans, and other significant influences. Loans disbursed under federally guaranteed student loan programs have special provisions. Based on this evaluation and management judgment, an uncollectible percentage is calculated and applied to each category of student loan balances outstanding. Management considers the allowance for student loan portfolio credit losses to be prudent and reasonable.

Contributions Receivable

Contributions receivable arising from unconditional promises to give are carried net of an allowance for uncollectible pledges. Additionally, unconditional promises are presented at estimated fair value considering duration and collection risk. There were no significant conditional promises to give as of August 31, 2015, and August 31, 2014.

Land, Buildings, and Equipment

The value of land, buildings, and equipment is recorded at cost or, if received as gifts, at fair value at the date of the gift. Significant renewals and replacements are capitalized. The cost of repairs and maintenance is expensed as incurred. Purchases of library books and works of art are also expensed.

Depreciation is calculated using the straight-line method over the useful lives of the equipment, which are estimated to be 3 to 20 years; of the buildings and land improvements, which are estimated to be up to 40 years; and of the leasehold improvements, which are estimated to be the shorter of the useful life or the lease term. The useful life of land is deemed indefinite and not depreciable.

The University reviews long-lived assets for impairment by comparing the future cash flows expected from the asset to the carrying value of the asset. If the carrying value of an asset exceeds the sum of estimated undiscounted future cash flows, an impairment loss is recognized for the difference between estimated fair value and carrying value. In management's opinion, no impairment existed as of August 31, 2015.

Charitable Remainder Trusts

Charitable remainder trusts are classified as permanently restricted net assets if, upon termination of the trust, the donor permanently restricts the remaining trust assets. If the remainder is not permanently restricted by the donor, the charitable remainder trust assets are recorded as temporarily restricted net assets.

Annuities Payable

Annuities payable consist of annuity payments currently due and the actuarial amount of annuities payable. The actuarial amount of annuities payable is the present value of the aggregate liability for annuity payments over the expected lives of the beneficiaries.

Self-Insurance Reserves

The University maintains a self-insurance program for general liability, professional liability, and certain employee and student insurance coverages. This program is supplemented with commercial excess insurance above the University's self-insurance retention. The reserves for self-insurance and postretirement medical and life insurance benefits are based on actuarial studies and management estimates. See notes 10 and 12 for additional discussion.

Asset Retirement Obligations

The University records all known asset retirement obligations (ARO) for which the fair value of the liability can be reasonably estimated, including certain obligations relating to regulatory remediation. Asset retirement obligations covered include those for which an entity has a legal obligation to perform an asset retirement activity; however, the timing and/ or method of settling the obligation are conditional on a future event that may or may not be within the control of the entity. The reserves for asset retirement obligations are based on analyses of University assets, review of applicable regulatory and other guidance, and management estimates.

Revenue Recognition

Revenues from tuition and fees are reported in the fiscal year in which they are earned, including prorata adjustments for educational programs crossing over fiscal years. Fiscal year 2016 fall-quarter tuition and fees, billed but not collected in fiscal year 2015, are reported as deferred revenue in fiscal year 2015. Similarly, fiscal year 2015 fall-quarter tuition and fees, billed but not collected in fiscal year 2014, are reported as deferred revenue in fiscal year 2014.

Revenues from auxiliary services, such as residence and food services, represent fees for goods and services furnished to University students, faculty, and staff; these revenues are recognized in the fiscal year in which the goods and services are provided. Grants and contracts revenue is recognized as expenses are incurred. Professional fees arise from faculty and department services provided to external institutions such as hospitals. Sales and services revenues represent fees for services and goods provided to external parties in the course of educational activities and also include revenues from the provision of physical plant services and goods to external institutions contiguous to the University campuses. Trademark and royalty revenues arise from licensing of innovative technologies, copyrights, and other intellectual property; these revenues are recognized in the fiscal year in which they are earned. Other income includes revenues not otherwise categorized that are also recognized in the fiscal year in which they are earned.

Federal Grants and Contracts Revenue The University receives funding or reimbursement from federal agencies. In addition, indirect cost recovery on federal grants and contracts is based on an institutional rate negotiated with its cognizant federal agency, the United States Department of Health and Human Services.

Income Taxes

The Internal Revenue Service has determined that the University is exempt from income taxes under Section 501(c)(3) of the US Internal Revenue Code, except with regard to unrelated business income, which is taxed at corporate income tax rates. The University files federal and various state and local tax returns. The statute of limitations on the University's federal tax returns remains open for fiscal years 2011 through 2015.

The University makes an assessment of individual tax positions and follows a process for recognition and measurement of uncertain tax positions. Tax positions are evaluated on whether they meet the "more likely than not" standard for sustainability on examination by tax authorities.

Uses of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenues and expenses during the relevant period. Actual results could differ from those estimates.

The University believes that the methods and assumptions used are appropriate.

Recent Accounting Pronouncements In May 2015, the FASB issued Accounting Standards Update (ASU) 2015-07, "Fair Value Measurement: Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent)." Under this guidance, investments measured at NAV, as a practical expedient for fair value, are excluded from the fair value hierarchy. This is intended to reduce the diversity in practice that currently exists with respect to the categorization of these investments. Although effective for fiscal year 2017, early adoption is permitted. The University implemented in the current fiscal year and accordingly applied the new guidance retrospectively to fiscal year 2014. As a result, investments totaling \$1.4 billion and \$6.2 billion, categorized in fiscal year 2014 as Level 2 and Level 3, respectively, were recategorized as investments measured at NAV as Practical Expedient totaling \$7.6 billion for fiscal year 2014. For further discussion, see note 4.

In May 2014, the FASB issued ASU 2014-09 "Revenue from Contracts with Customers," a new revenue recognition topic in the Codification. In August 2015, ASU 2015-14 was issued to defer the effective date of ASU 2014-09 for all entities for one year. Now effective in fiscal year 2019 for the University, it provides a principle-based framework to replace earlier industry-specific and rule-based revenue recognition standards. Under the new ASU, revenue is recognized at an amount that reflects consideration to which the entity expects to be entitled from another entity in exchange for contracted services or goods that are an output of its ordinary activities. This approach requires use of more judgments and estimates by management, as well as more disclosures to describe estimation methods, inputs, and assumptions used. The University is evaluating the impact of its implementation on policies, procedures, and the consolidated financial statements.

Summarized Comparative Information The financial statements include certain prior-year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with the University's financial statements for the year ended August 31, 2014, from which the summarized information was derived.

Revisions and Reclassifications

In 2015, the University identified that cash flows from contributed securities were not correctly classified on the fiscal 2014 consolidated statements of cash flows. As a result, the University revised the 2014 consolidated statements of cash flows to reflect gifts of contributed securities (\$48.5 million) in net cash provided by operations, and purchases of investments of (\$1.8 billion) in net cash used in investing activities. The impact of this revision decreased net cash provided by operating activities by \$48.5 million while decreasing net cash used in investing activities by the same amount. There was no effect on the consolidated statements of financial position or consolidated statement of activities. The University believes the impact of the misclassification is not material to the prior year consolidated financial statements.

Certain fiscal year 2014 accounts receivable totaling \$37.3 million were reclassified from the category of other receivables to student receivables in note 2 to the consolidated financial statements.

2. Accounts Receivable and Notes Receivable

Accounts receivable are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Research and other sponsored programs support	\$76,966	\$77,050
Student receivables	121,654	124,197
Royalty receivables	23,000	21,373
Other receivables	61,909	44,867
Accounts receivable subtotal	283,529	267,487
Less allowances for student uncollectible amounts	(603)	(587)
Total accounts receivable	\$282,926	\$266,900

Notes receivable are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Notes receivable	\$149,582	\$151,913
Less allowances for student uncollectible amounts	(2,822)	(2,295)
Total notes receivable	\$146,760	\$149,618

Activity within the allowances was insignificant for fiscal years 2015 and 2014.

3. Contributions Receivable

Contributions receivable consisted of the following:

Total contributions receivable	\$169.018	\$99,963
Other reserves	(8,077)	(7,266)
Discount to present value	(33,878)	(5,753)
Less discount to present value and other reserves		
More than five years	91,715	13,098
One year to five years	78,200	59,509
Less than one year	\$41,058	\$40,375
Unconditional promises expected to be collected in		
(in thousands of dollars)	August 31, 2015	August 31, 2014

Contributions receivable are discounted based on the weighted average borrowing rates for short-term and long-term bonds, notes, and other debt payable to correspond to the terms of the pledges receivable. The discount rate for pledges made in fiscal years 2015 and 2014 was 3.5 percent and 2.7 percent, respectively; the discount rate for pledges made in prior fiscal years ranged from 2.7 to 6.5 percent. The University deems these yields to be a Level 3 input. The next table summarizes the change in contributions receivable for the fiscal years ended August 31, 2015, and 2014.

Balance at end of year	\$169,018	\$99,963
(Increase) decrease in other reserves	(811)	473
Increase in discount to present value	(28,125)	(48)
Adjustments to pledges	(5,363)	(10,427)
Collections on pledges	(55,318)	(64,878)
New pledges	158,672	58,448
Balance—beginning of year	\$99,963	\$116,395
(in thousands of dollars)	2015	2014

4. Investments

The University's investments are overseen by the Investments Committee of the Board of Trustees. Guided by the policies established by the Investments Committee, the University's Investment Office or external equity investment managers, external and internal fixed income and cash managers, and various limited partnership managers direct the investment of endowment and trust assets, certain working capital, temporarily invested expendable funds, and commercial real estate.

Substantially all of these assets are merged into internally managed investment pools on a market value basis. Each holder of units in the investment pools subscribes to or disposes of units on the basis of the market value per unit at the beginning of each month.

Investment Fair Value

The following charts show the estimated fair value of investments and derivatives, grouped by the valuation hierarchy as defined in note 1, as of August 31, 2015, and 2014:

(in thousands of dollars)					August 31, 2015
	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	NAV as Practical Expedient (NAV)	Total fair value
Cash and cash equivalents	\$476,756	_	—	_	\$476,756
US equity securities	537,839	\$67,061	—	\$696,404	1,301,304
International equity	309,097	26,469	\$63	1,160,180	1,495,809
Fixed income	337,513	750,837	_	205,316	1,293,666
High-yield credit	_	_	_	337,109	337,109
Absolute return	(5,917)	298,749	_	1,773,810	2,066,642
Private investments	_	321	16,903	2,026,851	2,044,075
Real assets	67,427	2,595	101,502	1,248,323	1,419,847
Other investments	_	9,970	24,325	455	34,750
Interest-rate derivatives	_	(6,261)	_	_	(6,261)
Subtotal investment assets at fair value	1,722,715	1,149,741	142,793	7,448,448	10,463,697 ^(a)
Interest-rate swaps	—	(27,004)	—	—	(27,004)
Total	\$1,722,715	\$1,122,737	\$142,793	\$ 7,448,448	\$10,436,693

^(a) Investments held at cost totaling \$34,067 thousands should be added to the subtotal investment assets at fair value to reflect total investment assets as of August 31, 2015.

- 14 -

Notes to the Consolidated Financial Statements For the fiscal years ended August 31, 2015, and August 31, 2014

	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	NAV as Practical Expedient (NAV)	Total fair value
Cash and cash equivalents	\$432,470				\$432,470
US equity securities	482,070	\$73,331	\$71	\$798,526	1,353,998
International equity	309,170	29,627	249	1,118,117	1,457,163
Fixed income	32,153	758,013	_	313,343	1,103,509
High-yield credit	_	_	_	367,962	367,962
Absolute return	(52)	75,881	_	1,651,559	1,727,388
Private investments	111	_	13,216	1,945,775	1,959,102
Real assets	50,010	2,041	94,343	1,410,939	1,557,333
Other investments	_	3,483	20,733	_	24,216
Interest-rate derivatives	_	(6,163)	_	_	(6,163)
Subtotal investment assets at fair value	1,305,932	936,213	128,612	7,606,221	9,976,978
Interest-rate swaps	—	(25,452)	—	—	(25,452)
Total	\$1,305,932	\$910,761	\$128,612	\$7,606,221	\$9,951,526

^(a) Investments held at cost totaling \$35,183 thousands should be added to the subtotal investment assets at fair value to reflect total investment assets as of August 31, 2014.

Investments included as NAV as Practical Expedient consist primarily of the University's ownership in external investments (principally limited partnership interests in long-only equity and credit, hedge, private equity, real estate, and other similar funds). As a practical expedient, when quoted market prices are not available, the estimated fair values of these investments are generally based on reported partners' capital or NAV provided by the associated external investment managers. In cases where the practical expedient threshold is not met, such as an investment not being in compliance with GAAP, or where a statement of partners' capital is not provided, the investment is recorded as Level 3. Since a range of possible values exists for these partnership investments, the estimated values may be materially different from the values that would have been used had a ready market for these partnerships existed. The University exercises diligence in assessing the policies, procedures, and controls of external investment managers; management's assessment includes a valuation review process of the most recent available audited and

unaudited financial statements and discussions with the majority of external investment managers about the aggregate carrying value of the respective investments at August 31, 2015. The assessment may result in adjustment to the external managers' valuations of the securities' fair value if those valuations are not in accordance with GAAP. Management reviewed the valuation policies for all partnerships in which the University is invested and deemed that its policies are appropriate and that the carrying amount of these assets represents a reasonable estimate of fair value. A small number of investments within certain partnerships may have holdings at a carrying value of cost. In the absence of another basis, management has determined this method to be appropriate for these specific investments and representative of an approximation of the fair value.

The following tables summarize changes in the investments and derivatives classified by the University in Level 3 of the fair value hierarchy for the fiscal years ended August 31, 2015, and 2014:

Notes to the Consolidated Financial Statements For the fiscal years ended August 31, 2015, and August 31, 2014

(in thousands of dollars)	August 31, 2014						August 31, 2015
	Fair value	Purchases	Sales and settlements	Unrealized gains (losses)	Realized gains (losses)	Transfers into and out of Level 3	Fair value
US equity securities	\$71					(\$71)	_
International equity	249		(\$131)	(\$17)	(\$38)		\$63
Private investments	13,216	\$2,958	(802)	1,884	(32)	(321)	16,903
Real assets	94,343	40,332	(5,986)	(28,430)	1,243		101,502
Other investments	20,733		(711)	4,303			24,325
Total investments	\$128,612	43,290	(7,630)	(22,260)	1,173	(392)	\$142,793

(in thousands of dollars) August 31, 2013

· · · · · · · · · · · · · · · · · · ·							
	Fair value	Purchases	Sales and settlements	Unrealized gains (losses)	Realized gains (losses)	Transfers into and out of Level 3	Fair value
US equity securities	\$71						\$71
International equity	1,593	\$308	(\$1,348)	(\$304)			249
Private investments	47,411	4,479	(5,312)	(33,317)	(\$45)		13,216
Real assets	76,394	7,609	(11,279)	21,283	336		94,343
Other investments	19,363	34	(323)	1,659			20,733
Interest-rate derivatives	2,301			(8,464)		\$6,163	—
Total investments	147,133	12,430	(18,262)	(19,143)	291	6,163	128,612
Interest-rate swaps	(30,769)			5,317		25,452	_
Total	\$116,364	12,430	(18,262)	(13,826)	291	31,615	\$128,612

There were no significant transfers or reclassifications between Levels 1 and 2 during fiscal years 2015 and 2014. In fiscal year 2015, the transfers out of Level 3 consist primarily of investments reclassified from Level 3 to Level 2 based on observable discounted cash flow inputs. In fiscal year 2014, interest-rate derivatives and swaps were transferred from Level 3 to Level 2 based on observable inputs such as interest rates and contractual payment obligations.

As of August 31, 2015, and 2014, investments held at cost included real estate totaling \$19.4 million. Investments held at cost also included property co-ownerships, mortgages, and other investments totaling \$14.7 million and \$15.8 million as of August 31, 2015, and 2014, respectively.

The next table presents funding obligations and redemption terms of investments by asset class. The University is required under certain partnership agreements to advance additional funding up to specified levels over a period of several years. These uncalled commitments have fixed expiration dates and other termination clauses. At August 31, 2015, the University was committed to making future capital contributions in the amount of \$1,764 million, primarily in the next five years, as detailed below. Certain agreements also contain notice periods, lock-ups, and gates that limit the University's ability to initiate redemptions.

August 31, 2014

	Fair value	Remaining life	Uncalled commitments	Redemption terms	Redemption restrictions
US equity securities	\$1,301,304	No limit	_	Daily to annually, with 1–90-day notice periods	Lock-up provisions ranging from none to 1 year
International equity	1,495,809	No limit	\$26,422	Daily to annually, with 1–90-day notice periods	Lock-up provisions ranging from none to 2 years
Fixed income	1,293,666	No limit	_	Daily to quarterly, with 1–90-day notice periods	No lock-up provisions
High-yield credit	337,109	No limit to 12 years	187,154	Certain partnerships ineligible for redemption; other funds quarterly to annually, with 90-day notice periods	Certain partnerships not redeemable; lock-up provisions on all other funds, ranging from none to 1 year with side pockets
Absolute return	2,066,642	No limit		Weekly to annually, with 5–120-day notice periods	Lock-up provisions ranging from none to 3 years; side pockets on many funds
Private investments	2,044,075	1–12 years	781,317	Partnerships ineligible for redemption	Not redeemable
Real assets	1,419,847	No limit to 14 years	769,064	Partnerships ineligible for redemption; commodity and equity funds are weekly to quarterly, with 1–45-day notice periods	Drawdown partnerships not redeemable; no restriction on commodity and equity funds

(in thousands of dollars)

Cash and cash equivalents for investment purposes include bank accounts holding cash and money market funds consisting of short-term US Treasury securities. Cash and cash equivalents are highly liquid and are carried at amortized cost, which approximates fair value.

Northwestern's marketable securities categories include investments in US equities, international equity, and fixed income strategies via separately managed accounts, partnerships, and commingled funds. US equity strategies include large-, mid-, and small-cap public equities. One investment in this category currently may not be redeemed over the next year, while two others may only be partially redeemed. International equities include developed market (ex-US public equities) and emerging market strategies. Two investments in this category may not be redeemed over the next year, while three others may only be partially redeemed.

Fixed income strategies include US government securities, agency securities, inflation-linked bonds (TIPS), corporate bonds, global bonds, and short-term cash investments. As of August 31, 2015, one investment in this category may be only partially redeemed each year over the next four years. The high-yield credit portfolio includes investments in distressed debt and other credit instruments with fixed income characteristics but more specific risk tied to the securities and their underlying cash flows.

The absolute return portfolio is weighted toward long-short equity managers, uncorrelated strategies, and diversifying event-driven or hedged tactical credit strategies. Four investments in this portfolio currently may not be redeemed in the next year due to lock-up provisions. As of August 31, 2015, the remaining investments have either full or partial liquidity over the next year, with the exception of those having side pockets.

The private investments portfolio includes investments in global buyout and venture capital funds. The real assets portfolio includes the University's investments in energy, timber, real estate, and public investments in some commodity and equity funds.

Management's estimate of the lives of the funds could vary significantly depending on the investment decisions of the external fund managers, changes in the University's portfolio, and other circumstances. Furthermore, the University's obligation to fund these commitments may be waived by the fund managers for a variety of reasons, including the market environment and/or changes in investment strategy.

Investment Return

The components of total investment return were as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Investment income	\$46,696	\$56,499
Net realized gains	518,214	441,347
Change in net unrealized (losses) gains	(365,151)	947,686
Total investment return	\$199,759	\$1,445,532

Investment return designated for operations is defined as the investment payout, according to the spending guideline for the Long-Term Balanced Pool and the actual investment income for all other investments. Gross investment income from specific investments held at cost totaled \$18.6 million and \$19 million at August 31, 2015, and 2014, respectively. Investment expenses related to specific investments held at cost totaled \$2.4 million and \$2.6 million at August 31, 2015, and 2014, respectively. All other investment returns are categorized as nonoperating. As reflected in the consolidated statement of activities, investment return was as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Changes in unrestricted net assets		
Operating: investment return	\$334,562	\$278,599
Nonoperating: investment returns, reduced by operating distribution	(214,941)	664,595
Changes in temporarily restricted net assets		
Operating: investment return	139,313	130,015
Nonoperating: investment returns, reduced by operating distribution	(59,175)	372,323
Total investment return	\$199,759	\$1,445,532

Certain expenses paid directly by the University for investment management and custody services totaled \$59.6 million and \$52 million for the fiscal years ended August 31, 2015, and 2014, respectively, and have been netted against investment earnings.

Derivative Financial Instruments

The University has entered into hedging transactions via various interest-rate swaps and options and has maintained those positions since fiscal year 2010. These instruments are held in the fixed income asset class in the summary of changes in investments within Level 2.

Credit exposure represents the University's potential loss if all the counterparties fail to perform under the terms of the contracts, and if all collateral, if any, becomes worthless. This exposure is measured by the fair value of the cash collateral held at the counterparties at the reporting date. The University manages its exposure to credit risk by using highly rated counterparties, establishing risk-control limits, and obtaining collateral where appropriate. As a result, the University has limited credit risk. The University has entered into margin collateral agreements with major investment banks that impose a \$1 million threshold on both parties. As of August 31, 2015, the University posted collateral of \$7 million to one counterparty. To date, the University has not incurred any losses on derivative financial instruments due to counterparty nonperformance.

The University has hired an external manager to use derivative financial instruments to obtain market exposure in equity and fixed income indices on excess cash balances. The University regularly reviews the use of derivative financial instruments by each of the managers of alternative investment funds in which it participates. While these outside managers generally use such instruments for hedging purposes, derivative financial instruments are employed for trading purposes by numerous independent asset managers of the University.

For further discussion of credit-related derivatives, see note 8.

The following tables summarize the derivative financial instruments held by the University as of August 31, 2015, and 2014:

(in thousands of dollars)				August 31, 2015
	Notational amount	Assets	Liabilities	Fiscal year net gain (loss)
Investment-related derivatives				
Interest-rate swaptions	\$400,000	\$7,000	(\$6,261)	(\$98)
Equity futures	78,337	9,878	_	(9,552)
Total investment-related	478,337	16,878	(6,261)	(9,650)
Credit-related derivatives				
Interest-rate swaps	125,000	_	(27,004)	(1,552)
Total credit-related	125,000	—	(27,004)	(1,552)
Total derivative financial instruments	\$603,337	\$16,878	(\$33,265)	(\$11,202)
(in thousands of dollars)				August 31, 2014
	Notational amount	Assets	Liabilities	Fiscal year net gain (loss)
Investment-related derivatives				
Interest-rate swaptions	\$400,000	\$6,040	(\$6,163)	(\$8,464)
Faults futures	224,000	12,579	_	31,200
Equity futures				
Total investment-related	624,000	18,619	(6,163)	22,736
Total investment-related	624,000	18,619	(6,163)	22,736
Total investment-related	624,000 125,000	18,619	(6,163)	22,736 5,317
		18,619 — —		

5. Land, Buildings, and Equipment

Land, buildings, and equipment consisted of the following:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Land	\$28,389	\$28,389
Construction in progress	542,730	359,714
Buildings and leasehold improvements	2,393,140	2,321,606
Equipment	517,152	496,607
Accumulated depreciation	(1,437,964)	(1,346,465)
Total land, buildings, and equipment	\$2,043,447	\$1,859,851

The estimated cost to complete construction in progress at August 31, 2015, is \$497.1 million. Costs included in construction in progress are building and leasehold improvement capitalizations. Building costs are funded by bonds, gifts (received or pledged), grants, and unrestricted funds.

Under the University's interest capitalization policy, actual interest expense incurred during the period of

construction of an asset for University use is capitalized until that asset is substantially completed and ready for use. The capitalized cost is reflected in the total cost of the asset and depreciated over the useful life of the asset. Assets may include buildings and major equipment.

Northwestern University Notes to the Consolidated Financial Statements For the fiscal years ended August 31, 2015, and August 31, 2014

Asset Retirement Obligations

Asset retirement obligations were adjusted during fiscal years 2015 and 2014 as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Balance at beginning of year	\$115,459	\$132,057
Reduction in asset retirement obligations	(172)	(22,105)
Accretion expense	5,748	5,507
Balance at end of year	\$121,035	\$115,459

Lease Obligations

The University is obligated under numerous operating leases to pay base rent through the lease expiration dates. Operating leases consist primarily of leases for the use of real property and have terms expiring in various years through fiscal year 2030. Real estate lease expenses totaled \$12.3 million at August 31, 2015. In fiscal year 2014, real estate lease expenses totaled \$13.4 million at August 31. Sublease rentals totaled \$3.1 million at August 31, 2015, and there were none in fiscal year 2014. There were no subleases that are noncancelable for one year or more at August 31, 2015. The future minimum lease payments under noncancelable operating leases through August 31 of each period are shown at right.

Rentals Under Leases

The University is entitled under numerous operating leases to receive rental payments. Operating leases consist primarily of leases for the use of real property and have terms expiring in various years through fiscal year 2021. The future minimum rental payments under noncancelable operating leases through August 31 of each period are shown at right.

(in thousands of dollars)	
2016	\$11,785
2017	11,137
2018	11,175
2019	10,827
2020	10,394
2021 and thereafter	31,399
Total	\$86,717

(in thousands of dollars)	
2016	\$1,877
2017	1,881
2018	1,924
2019	1,968
2020	536
2021	36
Total	\$8,222

6. Other Assets

Other assets are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Prepaid bond expenses	\$9,155	\$9,860
Inventories	2,864	2,783
Other assets	6,712	9,013
Total other assets	\$18,731	\$21,656

7. Deposits Payable and Actuarial Liability of Annuities Payable

Deposits payable and actuarial liability of annuities payable are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Agency deposits payable	\$83,666	\$83,867
Actuarial liability of annuities payable	22,669	16,855
Student loan deposits payable	13,041	16,276
Other deposits payable	4,394	2,977
Total deposits payable and actuarial liability of annuities payable	\$123,770	\$119,975

8. Bonds, Notes, and Other Debt Payable

Bonds and notes payable are as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
IFA-Series 2004	\$135,800	\$135,800
IFA-Series 2006	—	145,130
Plus unaccreted premium on IFA–Series 2006	—	4,398
IFA-Series 2008	125,000	125,000
Taxable–Series 2012	200,000	200,000
Taxable–Series 2013	582,195	586,000
Less unamortized loss on Taxable–Series 2013	(2,451)	—
Taxable Series 2015	500,000	—
Less unamortized loss on Taxable–Series 2015	(657)	—
IFA-Series 2015	128,545	_
Plus unaccreted premium on Tax–Exempt Series 2015	16,307	_
Bonds payable subtotal	1,684,739	1,196,328
Notes payable-commercial paper, taxable	180,000	140,000
Total bonds and notes payable	\$1,864,739	\$1,336,328

Debt issuance	Interest-rate mode	Interest rate	Maturity
IFA-Series 2004	Variable	.01% ^(a)	December 1, 2034
IFA–Series 2008	Variable	.01% ^(a)	December 1, 2046
Taxable–Series 2012	Fixed	4.2%	December 1, 2039, to December 1, 2047
Taxable–Series 2013	Fixed	4.48% ^(b)	December 1, 2015, to December 1, 2044
Taxable–Series 2015	Fixed	3.78% ^(b)	December 1, 2038, to December 1, 2048
IFA-Series 2015	Fixed	4.24% ^(b)	December 1, 2022, to December 1, 2028
Notes payable–commercial paper, taxable	Fixed	.18% ^(b)	September 3, 2015, to September 29, 2015

^(a) Interest rate reset weekly

^(b) Weighted average interest rate at August 31, 2015

Total obligations including bonds and notes payable at August 31, 2015, are scheduled to mature through August 31 of each period as noted below. The schedule has been prepared based on the contractual maturities of the debt outstanding at August 31, 2015. Accordingly, if remarketing of bonds fails in future periods, debt repayments may become more accelerated than presented here. The potential failed remarketings coincide with the interest rate reset dates and amounts noted above.

(in thousands of dollars)

Total	\$1,851,540
Thereafter	1,647,500
2020	5,085
2019	4,935
2018	4,770
2017	4,715
2016	\$184,535

Bonds Payable

The IFA-Series 2015 Revenue Bonds were issued to acquire, construct, renovate, improve, and equip certain educational facilities of the University as defined in the Illinois Finance Authority Act and to pay certain expenses incurred in connection with the issuance of the bonds as permitted under the Illinois Finance Authority Act, subject to conditions set forth in a trust indenture between the Illinois Finance Authority and Wells Fargo Bank, National Association; and a loan agreement between Northwestern University and the Illinois Finance Authority.

The Taxable–Series 2015 Fixed Rate Bonds were issued to acquire, construct, renovate, and equip certain educational facilities of the University, to refund \$145.1 million of the University's outstanding IFA–Series 2006 Revenue Bonds, and to pay certain expenses incurred in connection with the redemption and the issuance of the bonds, subject to conditions set forth in a trust indenture between the University and Wells Fargo Bank, National Association.

The Taxable–Series 2013 Fixed Rate Bonds were issued to acquire, construct, renovate, and equip certain educational facilities of the University, to refund \$185 million of the University's outstanding IEFA–Series 2003 Fixed Rate Revenue Bonds, and to pay certain expenses incurred in connection with the redemption and issuance of the bonds, subject to conditions set forth in a trust indenture between the University and Wells Fargo Bank, National Association.

The Taxable–Series 2012 Fixed Rate Bonds were issued to acquire, construct, and equip certain educational facilities of the University and to pay certain costs relating to the issuance of the bonds, subject to conditions set forth in a trust indenture between the University and Wells Fargo Bank, National Association.

The IFA-Series 2008 Adjustable Rate Revenue Bonds were issued to acquire, construct, renovate, remodel, improve, and equip certain educational facilities of the University as defined in the Illinois Finance Authority Act and to pay certain expenses incurred in connection with the issuance of the bonds as permitted under the Illinois Finance Authority Act, subject to conditions set forth in a trust indenture between the Illinois Finance Authority and Wells Fargo Bank, National Association; and a loan agreement between Northwestern University and the Illinois Finance Authority. The bonds may operate in a daily, weekly, adjustable, or auction-rate mode.

The IFA-Series 2006 Revenue Bonds were issued to refund \$145.1 million of the University's outstanding IEFA-Series 1997 Adjustable Medium-Term Revenue Bonds and to pay certain expenses incurred in connection with the issuance and advance refunding of the bonds, all as permitted under the Illinois Finance Authority Act and subject to conditions set forth in a trust indenture between the Illinois Finance Authority and Wells Fargo Bank, National Association; and a loan agreement between Northwestern University and the Illinois Finance Authority.

The IFA-Series 2004 Adjustable Rate Revenue Bonds were issued to acquire, construct, renovate, improve, and equip certain educational facilities of the University as defined in the Illinois Finance Authority Act and to pay certain expenses incurred in connection with the issuance of the bonds as permitted under the Illinois Finance Authority Act, subject to conditions set forth in a trust indenture between the Illinois Finance Authority and Wells Fargo Bank, National Association; and a loan agreement between Northwestern University and the Illinois Finance Authority. The bonds may operate in a daily, weekly, adjustable, or auction-rate mode.

- 22 -

Based on Level 2 observable inputs, at August 31, 2015, the fair value of the University's fixed-rate debt of \$1,487.1 million exceeded the carrying value of \$1,410.7 million by \$76.4 million. At August 31, 2014, the fair value of the University's fixed-rate debt of \$998.5 million exceeded the carrying value of \$931.1 million by \$67.4 million.

Derivative Financial Instruments

The University has entered into interest-rate swap agreements to hedge variable interest-rate exposure related to its variable-rate debt. The agreements effectively fix the interest rate from 4.12 percent to 4.38 percent. The notional value is \$125 million through expiration on August 31, 2023.

The University recognized a net unrealized loss on the swap investment totaling \$1.6 million for the fiscal year ended August 31, 2015, and a net unrealized gain of \$5.3 million for the fiscal year ended August 31, 2014. Based on Level 2 observable inputs, the fair values of the swap position were in a liability position of \$27 million and \$25.5 million as of August 31, 2015, and 2014, respectively, and are included in accounts payable and accrued expenses on the consolidated statements of financial position. Also see note 4.

Notes Payable

The University places commercial paper under a \$300 million Taxable Commercial Paper Note.

Other Debt Payable

At August 31, 2015, the University held or had the ability to draw \$350 million in standby lines of credit to supplement working capital requirements as follows:

(in thousands of dollars)

Expiration date	Available credit
December 14, 2015 ^(a)	\$25,000
March 31, 2016	75,000
June 13, 2016	50,000
June 30, 2016	25,000
July 24, 2016	125,000
August 8, 2016	50,000
Total	\$350,000

^(a) Renewed on December 11, 2015, through December 9, 2016

9. Endowments

The FASB ASC Not-for-Profit Entities Presentation of Financial Statements Subtopic provides guidance on the net asset classification of donor-restricted endowment funds for not-for-profit organizations subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act (UPMIFA) and improves disclosure about an organization's endowment funds, both donor-restricted and board-designated, regardless of whether the organization is subject to UPMIFA.

The University interprets UPMIFA as requiring that the fair value of the original donor-restricted endowment gift be preserved as of the gift date unless there are explicit donor stipulations to the contrary. Therefore, the University classifies as permanently restricted net assets the original value of gifts donated to the permanent endowment, the original value of subsequent gifts, and accumulations to the permanent endowment made in accordance with the applicable donor gift instrument at the time the accumulation was added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until it is appropriated for University expenditure in a manner consistent with UPMIFA's standard of prudence. In accordance with UPMIFA, the University considers the following factors in determining to appropriate or accumulate donor-restricted endowment funds:

- The duration and preservation of the endowment fund
- The purposes of the institution and of the endowment fund
- General economic conditions
- · The possible effects of inflation or deflation
- The expected total return from income and appreciation of investments
- Other resources of the institution
- · The institutional investment policy

The University's endowment consists of about 2,400 individual donor-restricted endowment funds and about 1,000 funds it designates to function as endowments. The net assets associated with endowment funds, including funds designated by the University to function as endowments, are classified and reported based on whether there are donor-imposed restrictions. Institution-designated endowment funds include quasi-endowments established by specific Board of Trustees approval as well as endowments created by management under general guidelines and policies approved by the Board of Trustees.

The following tables present the endowment net asset composition by type of fund at fair value as of August 31, 2015, and 2014:

(in thousands of dollars)				August 31, 2015
Endowment net asset composition by type of fund	Unrestricted	Temporarily restricted	Permanently restricted	Total
Donor-restricted endowment funds	(\$487)	\$2,333,376	\$1,342,956	\$3,675,845
Institution-designated endowment funds	3,912,184			3,912,184
Total endowment funds	\$3,911,697	\$2,333,376	\$1,342,956	\$7,588,029
(in thousands of dollars)				August 31, 2014
Endowment net asset composition by type of fund	Unrestricted	Temporarily restricted	Permanently restricted	Total
•	Unrestricted (\$55)			<u> </u>
by type of fund		restricted	restricted	Total

Investment and Spending Policies

The University's endowment is primarily invested in the Long-Term Balanced Pool, which is managed with the objective of long-term total return. The Investments Committee of the Board of Trustees annually reviews asset allocation policy for the pool.

The principal objective for the Long-Term Balanced Pool is to preserve purchasing power and to provide a growing stream of income to fund University programs. On average, the pool seeks to achieve an annual total rate of return (i.e., actual income plus appreciation) equal to inflation plus actual spending. This objective of preserving purchasing power emphasizes the need for a long-term perspective in formulating both spending and investment policies.

The Board of Trustees has adopted a guideline for the annual spending rate from the University's Long-Term Balanced Pool. The calculation blends market and spending elements for the total annual spending rate. The market element is an amount equal to 4.35 percent of the market value of a unit in the pool, averaged for the 12 months ended October 31 of the prior fiscal year. It is weighted at 30 percent in determining the total. The spending element is an amount equal to the current fiscal year's spending amount increased by 1.5 percent plus the actual rate of inflation. It is weighted at 70 percent in determining the total.

If investment income received is not sufficient to support the total-return objective, the balance is provided from realized and unrealized gains. If the income received is in excess of the objective, the balance is reinvested in the Long-Term Balanced Pool on behalf of the unit holders.

The University's policy is to allocate the current income of all other investment pools.

Changes in Endowment Net Assets

The following tables represent the changes in endowment net assets for the years ended August 31, 2015, and 2014:

(in thousands of dollars)				August 31, 2015
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Endowment net assets, beginning of year	\$3,925,634	\$2,397,857	\$1,177,625	\$7,501,116
Net investment loss	(6,706)	(6,687)		(13,393)
Net appreciation, realized and unrealized	85,039	85,664		170,703
Total investment return	78,333	78,977	_	157,310
Contributions		831	153,777	154,608
Appropriation of endowment assets for expenditure	(147,932)	(139,562)	_	(287,494)
Other changes				
Transfers to create institutional funds	106,937	_	_	106,937
Transfers of institutional funds per donor requirement		(66)	7,720	7,654
Spending of institution-designated endowment fund	(52,102)	_	_	(52,102)
Other reclassifications	827	(4,661)	3,834	—
Endowment net assets, end of year	\$3,911,697	\$2,333,376	\$1,342,956	\$7,588,029

(in thousands of dollars)				August 31, 2014
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Endowment net assets, beginning of year	\$3,148,299	\$2,026,346	\$1,108,485	\$6,283,130
Net investment loss	(23,592)	(20,762)		(44,354)
Net appreciation, realized and unrealized	597,411	522,060		1,119,471
Total investment return	573,819	501,298	_	1,075,117
Contributions		374	56,494	56,868
Appropriation of endowment assets for expenditure	(138,509)	(130,141)	_	(268,650)
Other changes				
Transfers to create institutional funds	447,285	_	_	447,285
Transfers of institutional funds per donor requirement		340	12,343	12,683
Spending of institution-designated endowment fund	(105,317)	_	—	(105,317)
Other reclassifications	57	(360)	303	_
Endowment net assets, end of year	\$3,925,634	\$2,397,857	\$1,177,625	\$7,501,116

Underwater Endowment Funds

The University monitors endowment funds to identify those for which historical cost was more than fair value. As of August 31, 2015, and 2014, the historical cost of such accounts was approximately \$39.6 million and \$1 million, and the market value totaled \$39.1 million and \$960,000, respectively. Associated unrealized losses are recorded in the unrestricted net assets classification; subsequent gains increase unrestricted net assets.

10. Retirement Plans

The University maintains two contributory retirement plans for its eligible faculty and staff. The plans offer employees two investment company options, Teachers Insurance and Annuity Association (TIAA) and College Retirement Equities Fund (CREF), and the mutual funds offered by Fidelity Investments. Participating employee and University contributions are immediately vested. The University contributed \$66.9 million and \$64.2 million to the two plans in 2015 and 2014, respectively. It expects to contribute \$70.2 million to the two plans in 2016.

The University currently sponsors a healthcare plan permitting retirees to continue participation on a "pay-all" basis; it has no liability for participants past age 65. The retiree contribution is based on the average per-capita cost of coverage for the plan's entire group of active employees and retirees rather than the per-capita cost for retirees only. Retirees are also eligible to participate in certain tuition reimbursement plans and may receive a payment for sick days accumulated at retirement. The accrued cost for postemployment benefits was \$13 million and \$13.4 million at August 31, 2015, and 2014, respectively, and is included in accounts payable and accrued expenses on the consolidated statements of financial position.

The University recognizes an asset or a liability in the consolidated statements of financial position for the plans' overfunded or underfunded status. The asset or liability is the difference between the fair value of plan assets and the related benefit obligation, defined as the projected benefit obligation for post-employment benefit programs and the accumulated postretirement benefit obligation (APBO) for postretirement benefit programs, such as a retiree healthcare plan. In the consolidated statement of activities, the University recognizes actuarial gains or losses and prior service costs or credits that arise during the period but are not components of net periodic benefit cost. The University measures plan assets and obligations as of the date of its fiscal year-end and makes specified disclosures for the upcoming fiscal year.

The University funds the benefit costs as they are incurred. The following table sets forth the plan's obligations, benefits paid, contributions, net periodic postretirement benefit cost, and assets:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Benefit obligations	\$12,567	\$16,702
Benefits paid	1,219	823
Employer contributions	654	228
Contributions from participants	565	595
Net periodic postretirement benefit cost	1,702	1,462
Fair value of plan assets	_	_

The accumulated other comprehensive income included in unrestricted net assets on the consolidated statements of financial position totaled net gains of \$2.8 million and net losses of \$2.4 million as of August 31, 2015, and 2014, respectively; an increase of \$5.2 million due to net gains during the fiscal year.

The APBO was \$12.6 million and \$16.7 million at August 31, 2015, and 2014, respectively, and is included in accounts payable and accrued expenses on the consolidated statements of financial position.

The following tables present key actuarial assumptions used in determining APBO as of August 31, 2015, and 2014. For both fiscal years 2015 and 2014, the ultimate healthcare cost trend rate was 5 percent, and the year when the trend rate will reach the ultimate trend rate was 2023.

Additional assumptions used to determine benefit obligations were as follows:

	August 31, 2015	August 31, 2014
Settlement (discount) rate	3.9%	3.6%
Weighted average rate of increase in future compensation levels	3%	3%
Healthcare cost trend rate	7%	7.25%

Next, the assumptions used to determine net periodic benefit cost:

	August 31, 2015	August 31, 2014
Discount rate	3.6%	4.3%
Weighted average rate of increase in future compensation levels	3%	3%
Healthcare cost trend rate	7.25%	7.5%

A one-percentage-point change in assumed healthcare cost trend rates would have had these effects in fiscal year 2015:

(in thousands of dollars)	1% point decrease	1% point increase
(Decrease) increase in total of service and interest cost	(\$102)	\$118
(Decrease) increase in postretirement benefit obligation	(519)	583

Estimated future benefit payments reflecting anticipated service, as appropriate, are expected to be paid as shown below:

(in thousands of dollars)

Total	\$7,625
2021–25	4,724
2020	737
2019	617
2018	543
2017	492
2016	\$512

The University offers a deferred compensation plan under Internal Revenue Code 457(b) to a select group of management and highly compensated employees. There is no University contribution related to this deferred compensation plan. The University has recorded both an asset and a liability related to the deferred compensation plan that totaled \$56.4 million and \$53.6 million in fiscal years 2015 and 2014, respectively; these are included in investments and deposits payable and actuarial liability of annuities payable on the consolidated statements of financial position.

11. Related Parties

Members of the University's Board of Trustees, senior management, and faculty may on occasion be associated either directly or indirectly with entities doing business with the University. The University bylaws and conflict of interest policies establish guidelines for disclosure and regulation of such activities as circumstances warrant. When such associations exist, measures are taken, in the best interests of the University, to mitigate any actual or perceived conflict. Transactions with related parties may include investment management, common membership in investment partnerships or other investment vehicles, and the purchase of goods or services.

Northwestern Medical Group (NMG) is a not-forprofit, multispecialty physician organization committed to providing clinical care to patients and to supporting the research and academic endeavors of Northwestern's Feinberg School of Medicine (Feinberg). NMG is governed by a board of directors, and its physicians are full-time faculty members or researchers at Feinberg. It is a wholly owned subsidiary of Northwestern Memorial Healthcare Corporation (NMHC), the not-for-profit parent corporation of Northwestern Memorial Hospital (NMH), which is the primary teaching hospital of Feinberg. As such, NMHC and NMG are related parties of the University. Under terms of agreements effective in fiscal 2014 between the University, NMG, and NMHC, the University received one-time payments in 2014 and continues to receive recurring contributions from NMHC to support the Feinberg research and education programs, basic and applied biomedical research facilities and programs, and research and educational support services.

As of August 31, 2015, accounts receivable arising from operational activities with NMHC totaled \$7.6 million and are included in accounts receivable on the consolidated statements of financial position. For the year ended August 31, 2015, contributions totaling \$137.5 million have been made from NMHC to the University and are included in private gifts on the consolidated statement of activities. As of August 31, 2014, accounts receivable and accounts payable arising from operational activities with NMHC totaled \$11.3 million and \$6.4 million, respectively, and are included in accounts receivable and in accounts payable and accrued expenses, respectively, on the consolidated statements of financial position. Through August 31, 2014, one-time contributions totaled \$289.1 million, and other contributions totaled \$125.6 million from NMHC to the University; these are included in private gifts on the consolidated statement of activities.

12. Self-Insurance Reserves and Other Contingencies

Reserves for losses under the University's self-insurance program, aggregating \$5.8 million and \$5.6 million at August 31, 2015, and 2014, respectively, include reserves for probable known losses and for losses incurred but not yet reported. A portion of the reserves pertaining to professional, general, and automobile liability has been determined on a discounted present-value basis. The discount rate was 7.5 percent in fiscal years 2015 and 2014. Self-insurance reserves are based on estimates of historical loss experience, and while management believes that the reserves are adequate, the ultimate liabilities may be more or less than the amounts provided. These reserves are included in accounts payable and accrued expenses on the consolidated statements of financial position.

Under an agreement in effect through fiscal year 2013 between the University and NMG, a proportionate share of primary medical professional liability costs that arise out of events prior to November 1, 2004, was borne by NMG. As a part of the clinical integration agreement between NMG, NMHC, and the University, signed September 1, 2013, any remaining liabilities related to the period prior to November 1, 2004, are the obligations of the University and included in the reserves, beginning in fiscal 2014, for losses noted above.

In August 2009, the University, as originating lender, began participation in a student loan securitization program. It sold student loans to a school trust totaling \$65 million in 2009, \$19.8 million in 2010, and \$22.5 million in 2012; the University issued Universityguaranteed notes, which were purchased by a funding trust that procures financing to support the lending program. The programs are managed to break even and generate no servicing assets or liabilities. Guaranteed notes under these programs totaled \$39.3 million and \$50.7 million as of August 31, 2015, and 2014, respectively. These loans are included in notes receivable and deposits payable on the consolidated statements of financial position. Reserves in anticipation of securitized student loan future defaults totaled \$122,000 and \$157,000 at August 31, 2015, and 2014, respectively. Notes receivable on the consolidated statements of financial position are shown net of these reserves in fiscal years 2015 and 2014.

In October 2013, the University purchased a \$61 million portfolio of private education loans from a lending agency; these loans were previously purchased by the lending agency from the University prior to 2009 and were serviced by the University. As of August 31, 2015, and 2014, respectively, these loans totaled \$41.6 million and \$54.7 million, and are included in notes receivable on the consolidated statements of financial position. The University continues to service the repurchased loans. Service revenues were the excess of the actual interest collected above the agreed-upon warehouse fees on the serviced loans. The University managed the program to break even and generated no servicing assets or liabilities through these activities in fiscal year 2014. At August 31, 2015, and 2014, \$129,000 and \$170,000, respectively, were reserved in anticipation of future defaults. Notes receivable on the consolidated statements of financial position are shown net of these reserves in fiscal years 2015 and 2014.

From time to time, various claims and suits generally incidental to the conduct of normal business are pending or may arise against the University. It is the opinion of management of the University, after taking into account insurance coverage, that any losses from the resolution of pending litigation should not have a material effect on the University's financial position or results of operations.

All funds expended in connection with government grants and contracts are subject to audit by government agencies. While any ultimate liability from audits of government grants and contracts by government agencies cannot be determined at present, management believes that it should not have a material effect on the University's financial position or results of operations.

13. Grants and Contracts

Grants and contracts are summarized on the consolidated statement of activities as follows:

(in thousands of dollars)	August 31, 2015	August 31, 2014
Federal grants	\$408,533	\$401,885
Private grants and contracts	154,017	134,600
State grants	3,039	9,680
Total grants and contracts	\$565,589	\$546,165

14. Functional Classification of Expenses

Expenses by functional categories reflect salaries, wages, benefits, goods, and services used for those specific purposes. The University has allocated functional expenses for maintenance of facilities, as well as for depreciation, accretion for asset retirement

obligations, and interest on indebtedness, to other functional categories based on the functional use of space on the University's campuses.

Operating expenses incurred in the fiscal years ended August 31, 2015, and 2014, were as follows:

(in thousands of dollars)					August 31, 2015
	Maintenance of facilities	Depreciation and accretion	Interest on indebtedness	All other operating expenses	Total
Instruction	\$24,956	\$17,530	\$5,518	\$714,441	\$762,445
Research	42,981	30,193	9,505	347,691	430,370
Academic support	33,348	23,426	7,375	214,213	278,362
Student services	21,587	15,164	4,774	150,399	191,924
Institutional support	6,804	4,780	1,505	255,326	268,415
Auxiliary services	38,063	26,738	8,417	28,599	101,817
Total	\$167,739	\$117,831	\$37,094	\$1,710,669	\$2,033,333

(in thousands of dollars)

	Maintenance of facilities	Depreciation and accretion	Interest on indebtedness	All other operating expenses	Total
Instruction	\$26,765	\$16,855	\$5,821	\$668,990	\$718,431
Research	47,806	30,108	10,398	341,589	429,901
Academic support	35,170	22,149	7,650	198,581	263,550
Student services	24,041	15,140	5,229	139,072	183,482
Institutional support	8,493	5,348	1,847	248,721	264,409
Auxiliary services	43,946	27,676	9,559	32,074	113,255
Total	\$186,221	\$117,276	\$40,504	\$1,629,027	\$1,973,028

15. Subsequent Event

The University has evaluated subsequent events in accordance with the FASB ASC Subsequent Event Topic through January 22, 2016, the date when financial statements were available to be issued. The following event was identified:

On December 18, 2015, the University executed a development and purchase agreement with the Ann & Robert Lurie Children's Hospital of Chicago (LCH).

Upon substantial completion of construction of the new biomedical research building under development by Northwestern, LCH will purchase and own title to four laboratory floors in exchange for \$160 million. Terms of the agreement include other provisions regarding building construction, management, usage, leasing, and repurchase rights. The building is expected to be completed no later than 2019.

August 31, 2014

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Research and Development Cluster				
Agency for International Development				
Intravaginal Devices for the Sustained Delivery of Tenof	52	98.001	AGMT-APSA-13-008//AID-0AA-A-10-0006	<u>\$153,705</u>
Agency for International Development Total				\$153,705
Department of Agriculture				
New Evidence on Why Children's Food Security Varies Acro Department of Agriculture Total	251	10.3048108673-12-657/AG-3198-B-10-0028	3048108673-12-657/AG-3198-B-10-0028	\$8,035 \$8,035
Department of Commerce				
National Institute of Standards and Technology				
Advanced Materials Center for Excellence: Center for Hie		11.609	70NANB14H012 Amd 3	\$3,603,706
Rapid Qualification & Certification (RQC) Using Calorime	163	11.609	G2A62519 P0143327//70NANB13H194-02	\$688,351
				\$4,292,057
SURF-Gaithersburg application-Northwestern University		11.620	70NANB15H142	\$20,528
U.S. Census Bureau				
The Use of Commercial Data to Adjust Housing Estimates f		11.YA1323-15-SE-0097	YA1323-15-SE-0097	\$5,115
United States Patent and Trademark Office				
Research Roundtable on Patents and Technology Standards		11.NIN147A1500172	NIN147A1500172	\$44,675
Department of Commerce Total				\$4,362,375
Department of Defense				
Air Force Office of Scientific Research				
ABC Stochastic Multiresolution Theory for Microstructure		12.800	FA9550-14-1-0032	\$333,026
Active and Passive User Trust in Sociotechnical Systems	280	12.800	409K754 Amend No.3//FA9550-12-1-0311	\$60,752
Biomimetic Lipid Nanoparticles: Bio-Sensing and Bio-Func		12.800	FA9550-13-1-0192	\$223,007
BioProgrammable One-,Two-, and Three-Dimensional Materi	а	12.800	FA9550-11-1-0275 Mod. P00006	\$1,493,309
Carbon Nanotube Thermoelectric Coolers		12.800	FA9550-11-1-0311/P00002	\$10,918
Combinatorial Screening of Emergent Nanophotonic Behavio		12.800	FA9550-12-1-0280/P00005	\$616,401
Convergent Evolution to Engineering: Multiscale Structur	235	12.800	S-000700 // FA9550-15-1-0009-01	\$82,722
Electrochemical Imaging and Mechanistic Studies		12.800	FA9550-14-1-0003/P00002	\$1,956,671
Electronic Structure Theory for Photo-Induced Spin-Forbi		12.800	FA9550-15-1-0031	\$76,048
Fundamental studies of reactive processes at plasma-surf	173	12.800	00002165//FA9550-14-1-0053	\$199,372

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

(Continued)

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Fundamentals of Filament Interaction	239	12.800	217178/05 // FA9550-11-1-0001	\$64,599
Hybrid Plasmonic-MOF Nanoparticle Superlattices		12.800	FA9550-14-1-0274	\$416,700
Logic-Enabled Spectroscopy of Single Trapped Molecular I		12.800	FA9550-13-1-0116/ P00002	\$255,519
Molecular models to investigate diamagnetic anisotropy:		12.800	FA9550-14-1-0358	\$83,064
MURI Center for Dynamic Magneto-optics	258	12.800	3003023213 // FA9950-14-1-0040	\$272,192
Nanostructured Interfaces and Patterning Tools for Probi		12.800	FA9550-12-1-0141/P00003	\$174,156
New Directions in Theory-Guided Realization of Ultra-Hig	208	12.800	R732735//FA9550-11-1-0121	\$40,882
Novel Characterization Methods for Anisotropic and Mixed		12.800	FA9550-15-1-0247	\$46,918
Optical Buffering Switching and On-Line Data Sampling vi		12.800	FA9550-10-1-0228	\$148,585
Optically Controlled Distributed Quantum Computing Using		12.800	FA9550-09-1-0652/P00006	\$81,452
Paradigms for Emergence of Shape and Function in Biomole		12.800	FA-9550-10-1-0167 P00003	\$647,562
Plasmonic Encoding		12.800	FA9550-09-1-0294/P00008	-\$6,974
Plasmonic Optoelectronic Interactions		12.800	FA2386-13-1-4124 Mod. P00002	\$118,126
Polymeric and Molecular Materials for Advanced Organic E		12.800	FA9550-11-1-0142 P00002	\$23,855
Polymeric and Molecular Materials for Advanced Organic E		12.800	FA9550-15-1-0044	\$19,774
Spatial and Spectral Control of Excitons within Quantum		12.800	FA9550-14-1-0005	\$472,271
Spinning Disk Confocal Microscope for the Analysis of Na		12.800	FA2386-14-1-3004	\$392,000
Understanding how to build long-lived learning		12.800	FA2386-10-1-4128/P00008	\$237,851
				\$8,540,758
Modified Nanoparticles for Lipophilic Toxin Sequestratio	18	12.Agmt 6/10/13//FA9550-13-C-0007	Agmt 6/10/13//FA9550-13-C-0007	-\$11,753
Air Force Research Laboratory				
Developing Topological Insulator Fiber based Photon Pair		12.300	FA8750-15-1-0117	\$48,696
Center of Excellence for Advanced Bioprogrammable Nanoma	1	12.800	FA8650-15-2-5518	\$147,808
Managing the Mosaic of Microstructure	34	12.800	1150119-294722 Amd 4//FA9550-12-1-0458	\$305,150
				\$501,654
MSEE on Unified Foundation for Representation, Inference	234	12.910	1015 G PA097/5 // FA8650-11-1-7149	\$51,331
Quantum-Entanglement Based QKD Security Guarantee Over	Q 192	12.1016-NW1408//FA9453-14-M-0316	1016-NW1408//FA9453-14-M-0316	\$49,999
Research and Development of InAs/InAsSb Superlattices fo	222	12.15-T5690-15-C1//FA8650-11-D-5401/0004	15-T5690-15-C1//FA8650-11-D-5401/0004	\$49,302
Compact and Integrated IMU for GPS Denied Navigation Usi	63	12.Agmt 3/26/2013 // FA8651-13-C-0018	Agmt 3/26/2013 / 01 // FA8651-13-C-0018	\$60,172
STTR Phase-II Extension: Novel Protocol for Quantum Key	165	12.Agmt 6/4/14 // FA8750-12-C-0241	Agmt 6/4/14 // FA8750-12-C-0241	\$59,245
STTR Phase-II: Novel Protocol for Quantum Key Distributi	165	12.Agmt 9/4/12 // FA8750-12-C-0241	Agmt 9/4/12 // FA8750-12-C-0241	\$1,573
Ultrasensitive and Compact Superluminal Ring Laser Accel	63	12.Agreement 3/26/13//FA8651-13-C-0011	Agreement 3/26/13 / 01//FA8651-13-C-0011	\$51,935

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Simultaneous Inversion for Three Dimensional Velocity St		12.FA9453-11-C-0231	FA9453-11-C-0231	\$28,964
Next Generation Nano-electronic Circuit Elements Using G	63	12.FA9453-13-C-0045	Agmt 11/3/13 // FA9453-13-C-0045	\$87,819
Army				
A New and Comprehensive Approach for the Development of	61	12.360	14-001 HEH//W911NF-13-10152-02	\$29,955
13321010: Astrocytic Disruption in Traumatic Brain Injur		12.420	W81XWH-13-1-0243	\$335,039
A Novel Approach to Assay DNA Methylation in Prostate Ca		12.420	W81XWH-13-1-0319	\$165,807
Aberrant Recapitulation of Developmental Program: Novel		12.420	W81XWH-12-1-0471	\$342,302
Adaptations in Locus Ceruleus Induced by Post-Traumatic		12.420	W81XWH-13-1-0018	\$376,255
Alternative RNA Splicing of CSF3R in Promoting Myelodysp		12.420	W81XWH-15-1-0153	\$27,506
An Innovative Residual Limb Lengthening Device	181	12.420	CL3938//W81XWH-14-1-0136	\$6,778
BC123474: Fas protects breast cancer stem cells from dea		12.420	W81XWH-13-1-0301	\$106,850
BIOMASK: The Use of an In-Vivo Bioreactor as a Biologic		12.420	W81XWH-11-1-0839	-\$40,777
Delivery of Nano-Tethered Therapies to Brain Metastases		12.420	W81XWH-13-1-0341	\$115,127
Development of Sub-Ischial Prosthetic Sockets with Assis		12.420	W81XWH-10-1-0744	\$277,550
Disruption of Trophic Inhibitory Signaling in Autism Spe		12.420	W81XWH-14-1-0433	\$184,218
Effect of Teriparatide, Vibration & the Combination on B		12.420	W81XWH-10-1-0951	\$357,972
Glutamate Signaling and Mitochondrial Dysfunction in Mod		12.420	W81XWH-11-1-0051	-\$46
In-vivo functional muscle regeneration utilizing an impl	287	12.420	WFUHS441082CF12/W81XWH1420004	\$304,097
Locally applied statins to reduce scarring	287	12.420	WFUHS441012 SR-02//W81XWH-13-2-0054	\$157,089
PASTOR	99	12.420	2366 PO# 773333/W81XWH-12-2-0133	\$703,072
Pathophysiology of Post Amputation Pain	182	12.420	000801928//W81XWH-11-1-0815	\$9,844
Peer-led Suicide Prevention: Promoting Healthy Family Ro	269	12.420	416496-G//W81XWH-14-1-0322	\$119,700
Preclinical testing of a novel method to block TGFB prot		12.420	W81XWH-13-1-0234	\$172,874
Prevention of Bone Loss after Acute SCI by Zoledronic Ac		12.420	W81XWH-14-2-0193	\$260,473
PsychoMotor and Error Enabled Simulations: Modeling Vuln	181	12.420	3164//W81XWH-13-1-0080	\$16,430
Role of mRNA methylation in prostate cancer		12.420	W81XWH-14-1-0023	\$9,871
rTMS: A Treatment to Restore Function after Severe TBI	39	12.420	Pape-VA CDMRP//W81XWH-14-1-0568	\$72,567
Stabilized Hemoglobin Wound Healing Development	103	12.420	Agmt 10/21/11 // W81XWH-11-1-0629	-\$8,497
Targeted reinnervation as a means to treat neuromas asso		12.420	WX1XWH-13-2-0100	\$340,428
Therapeutic Value of PLK1 Knockdown in Combination with		12.420	W81XWH-10-1-0246	\$3,070
Two-step Approach for Advanced Prostate Cancer Manageme	n	12.420	W81XWH-15-1-0105	\$14,502
				\$4,430,101

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
1.3.2: Ergodic Control for Optimal Information Acquisiti		12.431	W911NF-14-1-0461	\$103,421
10.2: Adoption of Innovations in Work Networks		12.431	W911NF-14-1-0259	\$165,699
10.4: Properties Controlling Synchronization in Networks		12.431	W911NF-15-1-0272	\$19,746
4pi-Steradian Curved And Lensless Imagers (4pi-SCALE) 1.		12.431	W911NF-13-1-0485/P00003/P00004	\$669,662
9.4: Next Generation Nano-electronics Utilizing Piezoele		12.431	W911NF-15-1-0068	\$56,692
A Comprehensive Study of Surface Defects in traditional		12.431	W911NF-15-1-0091	\$21,432
Ab initio design of noncentrosymmetric metals: crystal e		12.431	W911NF-15-1-0017	\$30,785
Capacitance-Voltage Measurement of Type-II Superlattice		12.431	W911NF-12-2-0009/P00005	\$12,660
Complex Dynamics and Systems: Controlling Energy Flow in		12.431	W911NF-13-1-0290	\$51,088
Computational Analysis and Screening of Materials		12.431	W911NF-12-1-0130 Mod. P00005	\$53,360
Creating and Manipulating High-Dimensional Photonic Enta		12.431	W911NF-12-1-0542/P00006	\$81,837
Engineering Synthetic Ribosomes (Topic 9.1)		12.431	W911NF-11-1-0445/P00004	\$222,696
Heme-Containing Metal-Organic Frameworks for the Oxidati		12.431	W911NF-15-1-0119	\$22,079
High-Performance Single-Photon Sources via Spatial Multi		12.431	W911NF-12-1-0397	\$26,368
Identification of Genetic and Brain Molecular a		12.431	W911NF-10-1-0066/P00007	-\$2,472
Infinite Coordination Polymer Nano- and Micro-Particles		12.431	W911NF-11-1-0229	\$71,060
Infinite Coordination Polymer Particles from Polymeric C		12.431	W911NF-15-1-0151	\$17,956
In-situ, Nanosecond, High Resolution TEM Instrumentation		12.431	W911NF-12-1-0366	\$522
Laser Filamentation Science	239	12.431	6501622/05//W911NF-11-0297	\$23,120
Missile Impact with Material Comminution: New Concept -		12.431	W911NF-15-1-0240	\$2,182
Modular Extracellular Sensor Architecture and Multigenic		12.431	W911NF-11-2-0066 Mod: P00006	\$258,696
Multiscale Design and Manufacturing of Hybrid DWCNT-Poly	1	12.431	W911NF-09-1-0541/P00007	\$583,205
New Theoretical and Experimental Methods for Predicting	261	12.431	C00045065-5//W911NF-14-1-0359 mod.1	\$190,254
PECASE: Organic Ligands as Tools to Analyze and Control		12.431	W911NF-11-1-0075/P00005	\$200,643
Precision Chemical Dynamics and Quantum Control of Ultra	234	12.431	1000 G SA978//W911NF-14-1-0378	\$259,531
Section II, A2, G-7.5 Metal-Organic Framework Materials		12.431	W911NF-13-1-0229-P00004	\$345,774
Socio-Cognitive Networks: Theory & Data Driven Approache		12.431	W911NF-14-1-0686	\$158,237
Stabilization of Reactive Chemical Species and Fundament		12.431	W911NF-14-1-0168/P00001	\$54,062
Strong Electron-Photon Coupling using Plasmonic Light Co		12.431	W911NF-11-1-0390/P00003	\$131,947
Synthesis of Metastable New Materials Without Critical E		12.431	W911NF-15-1-0006	\$223,778
TOPIC 1.3.4 Infrared Detectors: Demonstration of Dual-Ba		12.431	W911NF-13-1-0412/P00002	\$305,285
Ultrabroadband Two-Dimensional Coherent Optical Spectrom		12.431	W911NF-14-1-0551	\$149,997
Validated Predictive Modeling of Engineered Cellulose Ma		12.431	W911NF-13-1-0241	\$89,642
				\$4,600,944

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
500 GHz Optical Sampler for Advancing Nonlinear Processi		12.630	ArW911NF-14-1-0591	\$137,445
Microscopic Computational Analysis of Fiber-Matrix Inter		12.630	W912HZ-12-P-0137	\$42,380
Information Network Academic Research Center: An Integra	249	12.630	W911NF-09-2-0053//2014-02516-01	\$42,631
Social/Cognitive Networks Academic Research Center	184	12.630	A71357//W11NF-09-2-0053 Y4 & 5	\$49,962
Trust, Influence and the Enhanced Human Performance of M	21	12.630	9500012803//Job13765321//W911NF-09-2-0053 Mod.0001	<u>\$62,486</u> \$334,904
Macroscopic Quantum Communications Using Photonic Qudits	S	12.910	W31P4Q-13-1-0004/P00007	\$1,427,347
Network Sciences Collaborative Technology Alliance	21	12.9500010212 // Agmt 11/10/10 // W911NF	9500010212/0013//W911NF-09-2-0053 Mod 0021	\$321,887
STTR Phase-II: High Speed Room Temperature Single Photon	165	12.Agmt 2/11/13 // W911NF-13-C-0028	Agmt 2/11/13 // W911NF-13-C-0028	\$187,212
Fabric Plasmonic Nanosensors for Chemical Warfare Agents	152	12.Agmt 4/15/13 //W911NF-13-C-0051	Agmt 4/15/13 //W911NF-13-C-005 P00003	\$151,174
Numerical Simulation of the Micromechanical Behavior of	75	12.PO No. 4791//W912HZ-12-C-0020	PO No. 4791//W912HZ-12-C-0020	-\$2
Conformal Photovaltaic Module Low Observability (ConPhor	143	12.SR-1006-1-09-14//W15QKN-12-9-1006	SR-1006-1-09-14//W15QKN-12-9-1006	\$120,603
The Coevolution of Multi-Dimensional Dynamic Networks of		12.W5J9CQ-12-C-0017	W5J9CQ-12-C-0017 Mod. P00010	\$304,028
Coupling between Pore Water Fluxes, Structural Heterogen		12.W912HQ-10-C-0024	W912HQ-10-C-0024/P00003	-\$720
Assistant Secretary of Defense for Health Affairs				
Radioprotective functions of Deinococcus Mn complexes fo	99	12.750	2361 // HT9404-12-1-0020	\$9,770
Defense Advanced Research Projects Agency				
Architectural and Microstructural Optimization of Braide	123	12.910	2001175094 Amd 7//W91CRB-10-1-0004	\$118,164
Exploring Flexible Multimodal Instruction of Intelligent		12.910	D12AP00026/0001	\$66,566
In Vivo SERS Nanoplatforms for Diagnostics		12.910	HR0011-13-2-0002 Mod. P0004	\$380,604
Seizing the third dimension in correlated oxide thin fil	64	12.910	N66001-12-1-4224 - PR No: 1300271031	\$54,473
Spherical Nucleic Acids for In Vivo Therapeutics		12.910	HR0011-13-2-0018/P00008	\$1,668,895
Using Temporal Phase Signatures to Predict and Control B		12.910	D12AP00023/0010	\$1,231,127
Web-scale Active Learning		12.910	D11AP00268	\$52,706
				\$3,572,535
Understand and Utilize Context-Aware Information Dissemi	114	12.5004213330-4912038360-W911NF-12-C0028	5004213330//No. W911NF-12-C-0028	\$54,517
The MIT-Broad Foundry: TA-2	140	12.5710003941//HR0011-15-C-0084	5710003941//HR0011-15-C-0084	\$36,515
Development of a Portable Microwave Atomic Clock Using P	63	12.Agreement 11/13/14 // D14PC00134/0001	Agreement 11/13/14 // D14PC00134/0001	\$15,010
Automated Approaches to Cellular Engineering and Biomanu	56	12.D14PC00005/0001	D14PC00005/0001	\$140,027
IPA to the Defense Advanced Research Projects Agency (DA		12.IPA Agmt 01/30/2013	IPA Agmt 01/30/2013	\$96,314
IPA to the Defense Advanced Research Projects Agency (DA		12.IPA Agmt 1/29/15	IPA Agmt 1/29/15	\$157,258
				(Cartinua

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Defense Security Cooperation Agency				
Novel Light Sources Based On Nonlinearity Enhanced By Na	89	12.PO#4440432059	PO#4440432059/1	\$64,398
Defense Threat Reduction Agency				
Hierarchically engineered porous materials for the prote		12.351	HDTRA1-14-1-0014	\$448,705
Sensing Fissile Materials at Long Range		12.351	HDTRA1-09-1-0044/P00004	-\$23,942
Synthesis, Experimental Investigation and Mechanistic Co		12.351	HDTRA1-10-1-0023/P00005	<u>\$411,847</u> \$836,610
Department of Defense				
Parkinson Associated Risk Factor Study (PARS): Evaluatin	112	12.420	Agmnt 8/30/07	\$1,465
WRMC Pain Management	147	12.MED0026//W911QY-13-C-0103	MED0026//W911QY-13-C-0103	\$28,559
WRMC Pain Management	147	12.MED0035//W911QY-12-C-0039	MED0035//W911QY-12-C-0039	\$121,015
Missile Defense Agency				
Development of high energy laser analysis software along	63	12.Agmt 3/26/2013 // HQ0277-13-C-7404	Agmt 3/26/2013 // HQ0277-13-C-7404	\$1,800
Navy				
A Bio-inspired Underwater Robot for Station keeping with		12.300	N00014-14-1-0594	\$389,718
Algorithms for Mixed Integer and Stochastic Optimization		12.300	N00014-12-1-0051-P00007	\$20,881
All Fiber Adaptive Two-Wave Mixing Demodulator and Adapt		12.300	N00014-13-1-0165-P00003	\$29,460
An Analogical Approach to Autonomy and Social Inference		12.300	N00014-13-1-0470/P00004	\$399,081
Atomically Precise Control and Characterization of Graph		12.300	N00014-11-1-0463	\$474
Autonomous Vehicle Dynamic Navigation System		12.300	N00014-11-1-0516-P00008	\$33,299
Central Pathways for Auditory Nociception		12.300	N00014-14-1-0709	\$70,093
Conductive DNA Systems and Molecular Devices		12.300	N00014-11-1-0729 Mod. P00009	\$1,238,037
Critical MASS (Midwest Association for Science and Servi	41	12.300	Agmt 6/16/15//N00014-12-1-0738	\$12,331
Cutset Sampling Topologies for Intelligence, Surveillanc		12.300	N00014-14-1-0215/P00002	\$102,082
Cyberalloys 2020: Naval Materials by Design		12.300	N00014-12-1-0455 P00008	\$243,298
Drugs to Stimulate Neurite Regeneration from Damaged Coc		12.300	N00014-12-1-0173	\$188,900
Drugs to Stimulate Neurite Regeneration from Damaged Coc		12.300	N00014-15-1-2130	\$108,321
Dynamically Textured Polymer Surfaces		12.300	N00014-13-1-0172	\$316,466
Elastomeric Polymer-by-Design for Blast-Induced Shock-Wa	236	12.300	10302059-007//N0014-09-1-1126	\$33,838
Engineered Ribosomes for the Production of Sequence Defi		12.300	N00014-11-1-0363 Mod. P00006	\$35,026
Functional Crystals Through Encodable Hard and Soft Matt		12.300	N00014-15-1-0043	\$429,985
Functionalized Two-Dimensional Nanoelectronic Heterostru		12.300	N00014-14-1-0669 P00003	\$215,309

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

12.300 12.300 12.300 12.300 12.300 12.300 12.300 12.300	N00014-15-1-2098 N00014-14-1-0781 N00244-09-1-0071 N00014-14-1-0313 P00001 N00014-14-1-0111 N00014-14-1-0070 Mod. No. A00002	-\$303 \$120,823
12.300 12.300 12.300 12.300 12.300	N00244-09-1-0071 N00014-14-1-0313 P00001 N00014-14-1-0111	\$120,823
12.300 12.300 12.300 12.300	N00014-14-1-0313 P00001 N00014-14-1-0111	-\$303 \$120,823 \$128,757
12.300 12.300 12.300	N00014-14-1-0111	
12.300 12.300		\$128 757
12.300	N00014-14-1-0070 Mod. No. A00002	ψι20,/0/
		\$119,105
12 200	N00014-14-1-0675 P00002	\$1,055,486
IZ.JUU	A12480//N000014-13-1-0173	\$59,603
12.300	N00014-15-1-2226	\$8,638
12.300	N00014-15-1-2443	\$50,993
12.300	N00014-14-1-0434	\$106,892
12.300	A002181204 Amd 7//N00014-11-1-0690	\$385,584
12.300	N00014-13-1-0331-P00002	\$170,290
12.300	N00014-12-1-0228	\$1,645
12.300	N00014-15-1-0046	\$32,331
12.300	N00014-13-1-0556	\$165,131
12.300	N00014-14-1-0697	\$130,424
12.300	1553361 // N00014-15-1-2809	\$11,685
12.300	Agmnt 6/9/15 //FA9550-14-1-0030	\$125,833
12.300	1(GG010550)//N00014-14-1-0741	\$91,210
12.300	N00014-13-1-0034 P00005	\$11,103
12.300	N00014-13-1-0760-P00005	\$158,555
12.300	N00014-12-1-0425	\$90,656
		\$7,258,569
12.910	N66001-11-1-4179	-\$127
12.910	N66001-08-1-2044/P00004	<u>-\$203</u> -\$330
12 1200266716 // Acmt //28/15 // N68225	1200266716 // Agmt 4/28/15 // N68225 14 C 0040	\$99,644
	•	\$55,044 \$1,637
		-\$2,869
	•	-\$2,809 \$3,341
	•	\$3,341 \$159,396
12.Ayint 2/14/14 // 1000300-10-0124	Ayiiit 2/ 14/ 14 // 100330-13-6-0124	
12 Agent 4/0/14 // NG0225 12 C 0242	$\Lambda_{am} + 1/0/11/DOOO2/NE0225 12 C 0212$	CEC 790
12.Agmt 4/8/14 // N68335-13-C-0342 12.C13K11518(K00183)//N66001-12-C-4211	Agmt 4/8/14 / P0002 // N68335-13-C-0342 C13K11518(K00184)//N666001-12C-4211 Amd 4	\$56,738 \$921,675
	12.300 12.300 12.300 12.300 12.300 12.300 12.300 12.300 12.300 12.300	12.300 N00014-13-1-0331-P00002 12.300 N00014-12-1-0228 12.300 N00014-15-1-0046 12.300 N00014-13-1-0556 12.300 N00014-14-1-0697 12.300 1553361 // N00014-15-1-2809 12.300 Agmt 6/9/15 //FA9550-14-1-0030 12.300 1(GG010550)//N00014-14-1-0741 12.300 N00014-13-1-0034 P00005 12.300 N00014-13-1-0760-P00005 12.300 N00014-12-1-0425 12.300 N00014-12-1-0425 12.910 N66001-08-1-2044/P00004 12.1300366716 // Agmt 4/28/15 // N68335-13 Agmt 11/09 // 1300273835 // N68335-13-C-0025 12.4gmt 11/09 // 1300273835 // N68335-13 Agmt 11/09 // 1300273835 // N68335-13-C-0025 12.Agmt 12/21/0 // N00014-10-C-0420 Agmt 11/22/10 // N00014-10-C-0420 12.Agmt 12/31/14 // N68335-13-C-0379 Agmt 12/31/14 // N68335-13-C-0379 12.Agmt 2/14/14 // N68936-13-C-0124 Agmt 2/14/14 // N68936-13-C-0124

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
High Performance Solar-Blind FPAs for Next Generation Mi	153	12.MPTNU-12-0084//N00014-12-C-0084	MPTNU-12-0084//N00014-12-C-0084	\$1,602
Office of Naval Research Basic Research Challenge- Enhan	58	12.P.O. 13-0005311//N00014-13-C-0160	P.O. 13-0005311 Release 4 // N00014-13-C-0160	\$283,510
Biologically-derived Medicines on Demand	132	12.P010152319//N66001-13-C-4024	P010152319 Mod 02//N66001-13-C-4024	\$14,989
Theory-Driven Protocols for Replacing Elemental	177	12.PO No. 1210 // N00014-14-C-0050	PO No. 1210 // N00014-14-C-0050	\$66,578
Data-driven Discovery of Novel Thermoelectric Materials	177	12.1267//N66001-15-C-4036	1267//N66001-15-C-4036	\$17,389
Department of Defense Total				\$35,396,098
Department of Education				
Proposal for Funding a Comprehensive National Resource C	249	84.015	2015-01858-01 // P015A140048	\$88,253
Fulbright-Hays Doctoral Dissertation Research Abroad		84.022	P022A130061	\$38,230
Fulbright-Hays Doctoral Dissertation Research Abroad		84.022	P022A140038	\$200
				\$38,430
Developing Optimal Strategies in Exercise and Survival S	181	84.133	CL3802, CC81039//H133B140012	\$29,425
Rehabilitation Engineering Research Center on Prosthetic		84.133	H133E080009-11	\$42,550
Rehabilitation Strategies, Techniques, and Interventions	181	84.133	3037//H133E130019	\$25,227
				\$97,202
Reading for Understanding Across Grades 6 through 12: Ev	248	84.305	E43311 490530 // R305F100007	\$468,045
Teaching Perceptual and Conceptual Processes in Graph In		84.305	R305A120531-15-7	\$424,782 \$892,827
An Efficacy Trial of Enhanced Milieu Teaching Language I	283	84.324	2114-010140/R324A090181	\$6,382
I-STEM Network: Math and Science Statewide (MASS)	30	84.366	Agmt 5/27/15	\$118,222
New Terrain for Preservice and Inservice Teachers of Sci	46	84.366	25140-7531//928-100 12060-21592-2013-84158-170003	\$32,287
New Terrain Next Generation Science Teaching Project – P	193	84.366	21-62530-FY15//S366B130007	\$52,992
				\$203,501
ARRA - Project READS: Using Data to Promote Summer Read	ing & Cl 94	84.396	108089-5046464//U396B100195-01	\$47,265
Institute of Education Sciences				
A Summer RCT Training Institute for Established Research		84.305	R305B130023 - 14	\$268,438
Advanced State Specific Design Parameters for Randomized	241	84.305	5898-NU//R305D140019	\$42,481
Better Warranted Quasi-Experimental Practice for Evidenc		84.305	R305D100033	-\$2,387
The accompanying footnotes are an integral part of the Schedule of Exp	enditures of Federal	I Awards - 38 -		(Continued)

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
CALDER - State and Local	12	84.305	01023-03230 Mod. 2//R305C120008	\$409,709
Center for Interactive Knowledge Utilization	242	84.305	1551539 Mod 1//R305C140008	\$73,041
Continuing Support for the Development of SREE: The Soci		84.305	R305U100002-13/6	\$281,800
Multidisciplinary Program in Educational Sciences		84.305	R305B080027/01	\$1,780
Multidisciplinary Program in Educational Sciences		84.305	R305B140042-15	\$424,467
Post Doctoral Research Training Fellowship in Education		84.305	R305B100027 - 14	\$72,384
Prevention of Truancy in Urban Schools through Provision		84.305	R305A120809-13	\$486,323
Proposal for an RCT Training Institute	148	84.305	RC100872NU//R305U110001	-\$3,225
Proposal to Conduct Annual Workshops on Better Quasi-Exp		84.305	`R305B140029	\$135,527
State Longitudinal Data Systems Public-Use Project	241	84.305	5897-NU//R305D140045	\$42,280
State-Specific Design Parameters for Designing Better Ev	241	84.305	5796-NU/Amd 4//R305D110032	-\$1
				\$2,232,617
NCSER-EIEL Goal 3: An Efficacy trial of J-EMT:	283	84.324	3403-019297//R324A150094	\$25,419
National Institute on Disability and Rehabilitation Research				
Development of A Low-Cost Dilatancy-Based System for Ort		84.133	H133G110266-13	\$16,102
Enhancing Written Communication in Persons with Aphasia:	181	84.133	2185 // H133G120123	\$5,075
Improving Measurement of Medical Rehabilitation Outcome	182	84.133	80474//H133B090024	\$7,121
Machines Assisting Recovery from Stroke and Spinal Cord	181	84.133	CC 81765//H133E120010 Amd. 2	\$2,556
Northwestern University Advanced Rehabilitation Research		84.133	H133P130013	\$84,485
Rehabilitation Research Training in Neurologic Communica		84.133	H133P120013 - 14	\$50,519
Rehabilitation Sciences for Basic Scientists & Engineers		84.133	H133P110013-13	\$36,902
The Development of a Commercial Rehabilitation Device to		84.133	H133G100208	\$64,809
The Development of an Algorithm for Intuitive Control of		84.133	H133G120287	\$55,889
The Effect of Resistance to Participant-Supported Reachi		84.133	H133G110245	<u>\$16,570</u> \$340,028
Department of Education				ə 340,0 28
Office of Innovation and Improvement				
Validation of the Effectiveness of an Innovative Early M	291	84.411	s00025133.1//U411B120053-12A	\$3,113
Department of Education Total				\$3,975,037
Department of Energy				
A Scintillating Xenon Bubble Chamber for Dark Matter Det		81.049	DE-SC0012161-0001	\$144,044
Antiferromagnetism and Superconductivity		81.049	DE-FG02-05ER46248/ Mod 0011	\$224,847
Approaches to Integrated Photochemical Systems for Solar		81.049	DE-FG02-99ER14999 Mod. 0016	\$345,199
The accompanying footnotes are an integral part of the Schedule of Exp	enditures of Federal	Awards	- 39 -	(Continued)

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Argonne-Northwestern Solar Energy Research (ANSER) Cente	9	81.049	DE-SC0001059/0005	\$3,763,713
ARRA - Center for Integrated Training in Far-from-Equilibrium	а	81.049	DE-SC0000989	\$66,760
ARRA - Chemical Control of Charge Trapping and Charge Tran	isfer	81.049	DE-SC0003998	\$60,418
Center for Bio-Inspired Energy Science (CBES)		81.049	DE-SC0000989-0002	\$2,415,771
Collaboration with Photosynthetic Antenna Research Cente	288	81.049	WU-HT-11-05-MOD-7 PO No. 2910644P //DE-SC0001035	\$138,349
COOLR: A New System for Dynamic Thermal-Aware Computir	ng	81.049	DE-SC0012531/0001	\$53,459
Coordination-Chemistry-Derived Materials Featuring Nanos		81.049	DE-FG02-08ER15967/005	\$25,455
Damsel: A Data Model Storage Library for Exascale Scienc		81.049	DE-SC0005309	-\$69
Department of Energy Computational Science Graduate Fell	130	81.049	Letter 9/16/14	\$2,218
Department of Energy Computational Science Graduate Fell	130	81.049	Letter 9/16/14	\$1,000
Dynamic Visualization and Control of Emergent Phases in	172	81.049	Sub. 5076-NU-DOE-2375//DE-SC0012375	\$25,447
Effect of Low Dose Irradiation on NFKB Signaling Networ		81.049	DE-SC0001271/005	\$187,720
EFRC/UMN: Inorganometallic Catalysts	259	81.049	A004527502//DE-SC0012702	\$793,804
Electrode Optimization Parameters of SiNode Material for	203	81.049	Agmt 12/12/14 // DE-SC0009467 // Amd 1	\$53,064
Electronic Structure Theories of Singlet Fission		81.049	DE-SC0010265/A0001	\$51,160
Electrostatic Driven Self-Assembly Design of Functional		81.049	DE-FG02-08ER46539	\$199,087
Enabling Exascale Hardware and Software Design through S		81.049	DE-SC0005343	-\$96
Epitaxial Multifunctional Oxide Heterostructures		81.049	DE-FG02-06ER46346/0009	\$139,973
Fundamental Studies of Light-Induced Charge Transfer, En		81.049	DE-FG02-87ER13808/A028	\$92,826
Granular Constraints and Size Effects in Polycrystalline		81.049	DE-SC0010594	\$142,242
High Performance Nano-Crystalline Oxide Fuel Cell Materi		81.049	DE-FG02-05ER46255/04	\$169,937
Hybrid Halide Perovskites: Advancing Optoelectronic Mate	238	81.049	KK1508//DE-SC0012541	\$92,044
Imaging Carrier Generation, Transport, and Collection in		81.049	DE-FG02-07ER46401/002	-\$213
Institute for Environmental Catalysis		81.049	DE-FG02-03ER15457	\$850,544
Kinetics and Thermodynamics of Metal and Complex Hydride		81.049	DE-FG02-07ER46433	\$92,901
Light-Driven Charge Transfer in Face-to-Face Donor-Space		81.049	DE-FG02-96ER14684	\$207,377
Materials Genomics	177	81.049	P.O. 1057 // DE-SC0006222	\$325
Materials Science of Electrodes and Interfaces for High-		81.049	DE-FG02-08ER46536 0005	\$133,570
Mechanical Properties and Microstructural Evolution in A		81.049	DE-FG02-98ER45721	\$47,255
Metastable Vortex Lattices-Properties and Applications	266	81.049	202248//DE-SC0005051	-\$31
Molecular Nanocages for Catalysis: An Investigation of E		81.049	DE-FG02-01ER15184 Mod 0014	\$94,603
Nanoengineering of Complex Materials		81.049	DE-FG02-00ER45810-0018	\$478,648
Nanoporous Materials Genome: Methods and Software to O	р 259	81.049	A003127002 Amd. 3//DE-SC0008688	\$250,590
New Methods for Atomic Structure Determination of Nanosc		81.049	DE-FG02-01ER45945	\$120,291
Nonlinear Optimization and Applications		81.049	DE-FG02-87ER25047/0029	\$101,124
Paths to Discovery at the LHC: Dark Matter and Track Tri		81.049	DE-SC0014073	\$54,993

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Probing Coherent States of Light and Matter in Two-Dimen		81.049	DE-SC0012130/ Mod 0001	\$106,022
Research in High Energy Physics		81.049	DE-SC0010143/ Amd 0002	\$806,005
Revolutionary Materials for Solid State Energy Conversio	148	81.049	61-3212A/Amd 4//DE-SC0001054	\$132,398
Scalable and Power Efficient Data Analytics for Hybrid E		81.049	DE-SC0005340	-\$10,315
Scalable Data-Management, Analysis, and Visualization (S		81.049	DE-SC0007456	\$140,247
SISGR: Single Molecule Chemical Imaging at Femtosecond T		81.049	DE-SC0001785 0006	\$539,161
Solid State Solar-Thermal Energy Conversion Center (S3TE	140	81.049	5710003775//DE-SC0001299	\$152,004
Sparse Grid Scenario Generation and Interior Algorithms		81.049	DE-SC0005102	\$183,005
Strong Field Coherent Dynamics and Control. From Alignme		81.049	DE-FG02-04ER15612/0011	\$51,220
Strong Interaction Studies with Medium Energy Probes		81.049	DE-FG02-87ER40344-0035	\$312,952
Supported Organometallic Complexes: Surface Chemistry, S		81.049	DE-FG02-86ER13511/033	\$28,802
Surface Plasmon Enhanced Chemistry		81.049	DE-SC0004752/ Mod 0004	\$214,618
Templating Routes to Supported Oxide Catalysts by Design		81.049	DE-SC0006718/003	\$184,014
The Evolution of Topologically Complex Structures: Coars		81.049	DE-FG02-99ER45782/013	\$117,487
				\$14,577,969
A Novel Lubricant Formulation Scheme for 2% Fuel Efficie		81.086	DE-EE0006449	\$130,998
Rapid Freeform Sheet Metal Forming: Technology Developme	80	81.086	A10-P014-164103//RQ13-235R07//DE-EE0005764	\$295,998 \$426,996
Efficient Discovery of Novel Multicomponent Mixtures for		81.087	DE-FG36-08GO18136 Mod: 0010	\$45,776
Computational Design and Performance Prediction of Creep	272	81.089	A15-0315-S001//DE-FE0024054	\$44,384
Computational Design of Creep-Resistant Alloys and Exper	272	81.089	OR-A11-0263-S002-A04//DE-FE0005868	\$39,060
Scalable and Cost Effective Barrier Layer Coating to Imp	290	81.089	14-749-NU//DE-FE0023407	<u>\$43,762</u> \$127,206
DOE NNSA Stewardship Science Graduate Fellowship Program		81.112	Letter 9/26/11//DE-FC5208NA28752	\$1,735
DOE NNSA Stewardship Science Graduate Fellowship Program	n 130	81.112	Letter 9/26/11//DE-FC52-08NA28752	\$762
High-Pressure Elastic Properties of Minerals, Glasses an	33	81.112	4-10469-03 Amd 3//DE-NA002006	<u>\$45,353</u> \$47,850
NEET-3: Reactor Materials - Predictive Characterization		81.121	DE-NE0000678	\$125,682
Solid Acid Fuel Cell Stack for Distributed Generation Ap	194	81.135	C2015.0008 // DE-AR0000495	\$24,370
Nonlinear Ultrasonic Diagnosis and Prognosis of ASR Dama		81.00127346//DE-AC07-05ID14517	00127346//DE-AC07-05ID14517	\$353,611

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Novel Metal Sulfides to Achieve Effective Capture and Du	19	81.00127985//DE-AC07-05ID14517	00127985//DE-AC07-05ID14517	\$250,983
Development of High-Performance Cast Crankshafts	36	81.C274812//DE-EE0006428	C274812//DE-EE0006428	\$113,649
Fermi Joint Appointment - Eric Dahl	78	81.Agmt 6/27/12 // DE-AC02-07CH11359	Agmt 6/27/12 // DE-AC02-07CH11359	\$69,140
Laura Fields Fermilab Intensity Frontier Fellowship 2014	78	81.P.O. 616001//DE-AC02-76CH03000	P.O. 616001//DE-AC02-76CH03000	\$4,000
Development of a New, Lightweight Alloy for Advanced Cyl	84	81.DE-EE0006082 // PO# TCS67912-001	DE-EE0006082 // PO# TCS67912-001	\$214,537
Nonlinear Ultrasonic Techniques to Monitor Radiation Dam	87	81.00126931//RC936-S2	RC936-S2//00126931	\$102,502
"Giant" Nanocrystal Quantum Dot for High-Efficiency Soli	133	81.237430 // 277798 DE-AC52-06NA25396	237430 // 277798 DE-AC52-06NA25396	-\$2,160
Develop and, then, numerically test a fracture model for	133	81.267313 // DE-AC52-06NA25396	267313 // DE-AC52-06NA25396	\$15,298
Novel Tailored-Precipitate Ferritic (TPF) Steels for Rea	133	81.277798 // 236658 // DE-AC52-06NA25396	236658 Mod. 2	\$91,593
Center for Inverse Design: A New Approach to Material Sc	150	81.XCI-0-40427-01 // DE-AC36-08G028308	XCI-0-40427-01/M06// DE-AC36-08G028308	\$103,034
Global Threat Reduction Initiative	170	81.CO No. 194806//DE-AC05-76RL01830	CO No. 194806//DE-AC05-76RL01830	\$11,064
Global Threat Reduction Initiative - Maintenance Agreeme	170	81.90247//DE-AC05-76RL01830	90247//DE-AC05-76RL01830	-\$2,980
Energy Frontier Research Center for Solid-State-Lighting	196	81.P.O. #947617/4	P.O. #947617/4	\$13,241
High Efficiency Solar Thermochemical Reactor for Hydroge	196	81.PO 1513586//DE-AC04-94AL85000	PO 1513586//DE-AC04-94AL85000	\$78,890
Hobbes: OS and Runtime Support for Application Compositi	196	81.1403164/2	1403164/7 // DE-AC04-94AL85000	\$129,161
Argonne Joint Appointment - Hupp	219	81.Agmt. 10/23/14	Agmt. 10/23/14	\$40,704
Argonne Joint Appointment - Kanatzidis	219	81.Agmt. 08/20/14	Agmt. 08/20/14	\$164,852
Argonne Joint Appointment - Low	219	81.Agmt. 10/14/14	Agmt. 10/14/14	\$96,796
Argonne Joint Appointment - Poeppelmeier	219	81.Agmt. 11/14/14	Agmt. 11/14/14	\$163,575
Argonne Joint Appointment - Wasielewski	219	81.Agmt 11/12/14	Agmt 11/12/14	\$53,139
Argonne Joint Appointment Agreement - Nguyen	219	81.Agmt. 09/09/14	Agmt. 09/09/14	\$24,283
Argonne Joint AppointmentFrancis Petriello	219	81.Agmt 07/13/12 // DE-AC02-06CH11357	Agmt 07/5/13 // DE-AC02-06CH11357	\$609
Argonne Joint AppointmentPoeppelmeier	219	81.Agmt 07/13/12 // DE-AC02-06CH11357	Agmt 07/23/13 // DE-AC02-06CH11357	\$5,572
Argonne Joint AppointmentWasielewski	219	81.Agmt 3/9/11 // W-31-109-ENG-38	Agmt 7/5/13 // DE-AC02-06CH11357	\$4,633
ARRA - Support for Daikang Yan	219	81.3J-30081/3J-30081-0018A	3J-30081/3J-30081-0018A	\$10,371
Biomimetic Hybrid Architectures for Solar Chemical Energ	219	81.3J-30081-0007A (0007B)//DE-AC02-06CH1	3J-30081-0007A (0007B)//DE-AC02-06CH11357	\$162,631
Center for Electrochemical Energy Science - II	219	81.4F-32002//DE-AC02-06CH11357	4F-32002//DE-AC02-06CH11357	\$576,597
Center for Emergent Superconductivity (CES)	219	81.3J-30081-0046A //DE-AC02-06CH11357	3J-30081-0046A //DE-AC02-06CH11357	\$45,558
Complex Oxide Heterostructures	219	81.3J-30081-0008A	3J-30081-0008A	\$7,825
Develop Few-atom Clusters for Solar Fuels Catalysis	219	81.3J-30081-0047A	3J-30081-0047A	\$28,590
Development and Application of Modeling Software	219	81.3J-30081-0021A//BOA 3J-30081	3J-30081-0021A//BOA 3J-30081	\$5,904
Development of Rail Mode Energy and Emissions Characteri	219	81.3J-30081/3J-30081-0028A	3J-30081/3J-30081-0028C	\$21,347
Emine Begum Gulsoy-Joint NU/Argonne Appointment	219	81.Agmt 12/5/14	Agmt 12/5/14	\$7,701
Energy-Economic Systems Analysis of Emerging Manufacturi		81.3J-30081-0022A	3J-30081-0022A	\$72,852
Exciton Dissociation in Single Quantum Dot-Molecule	219	81.Invoice# ANLNW50K-2	Invoice# ANLNW50K-2	\$2,176
Institute for Atom-Efficient Chemical Transformations (I	219	81.9F-31924//DE-AC02-06CH11357	9F-31924//DE-AC02-06CH11357	\$120,784

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
James Rondinelli-Joint NU/Argonne Appointment	219	81.Agmt 07/17/2015	Agmt 07/17/2015	\$29,522
Joint Appointment Agreement - Petriello	219	81.Agmt. 08/26/14	Agmt. 08/26/14	\$112,477
Joint Appointment Agreement - Stair	219	81.Agmt. 08/27/14	Agmt. 08/27/14	\$103,595
Joint Appointment Agreement for Gabriel Abelof	219	81.5010100-137	5010100-137	\$35,006
Joint Appointment Ian Low	219	81.Agmt 7/13/12 // DE-AC02-06CH11357	Agmt 7/5/13 // DE-AC02-06CH11357	\$635
Joint Appointment Joseph Hupp	219	81.Agmt 7/22/2012 // DE-AC02-06CH11357	Agmt 7/5/2013 // DE-AC02-06CH11357	\$75
Joint Appointment Mercouri Kanatzidis	219	81.Agmt 07/22/2012//DE-AC02-06CH11357	Agmt 07/5/2013//DE-AC02-06CH11357	\$18,958
Joint Appointment Peter Stair	219	81.Agmt 08/18/11 // W-31-109-ENG-38	Agmt 7/23/13 // DE-AC02-06CH11357	-\$449
Joint Appointment Sonbinh Nguyen	219	81.Agmt 07/13/12 // DE-AC02-06CH11357	Agmt 07/23/13 // DE-AC02-06CH11357	-\$150
Joint Center for Energy Storage Research	219	81.3F-31142 // DE-AC02-06CH11357	3F-31142-M0008 // DE-AC02-06CH11357	\$167,349
Lei Fang - Joint NU/Argonne appointment	219	81.56905-00-105	56905-00-105	\$102,307
Li Ion Battery X-ray Interface Studies	219	81.3J-30081 REVISION NO. 0014B	3J-30081 REVISION NO. 0014B	\$42,510
Midwest Center for Structural Genomics	219	81.1F-30202 M0004//DE-AC02-06CH11357	1F-30202 M0010//DE-AC02-06CH11357	\$292,663
Mineral Surface and Interface Synchrotron X-ray Studies	219	81.3J-30081-0009A	3J-30081-0009A	\$2,069
Modeling Degradation of Battery Materials	219	81.3J-30081/3J-30081-0027A	3J-30081/3J-30081-0027A	\$11,143
Monolayer Semiconductor Quantum Dots for Efficient Energ	219	81.Award Letter 8/14/14	Award Letter 8/14/14	\$19,006
Nanolaminate Coatings for Improved Nuclear Fuel Cladding	219	81.8J-00061-0043A	8J00061//8J00061-0043A Revision No. 0043D	\$62,282
Optimizing Superconductor Transport Properties	219	81.3J-30081-0024A	3J-30081-0024A //DE-AC02-06CH11357	\$35,406
Protected High-Capacity Anodes for Li-ion Battery Applic	219	81.Check 10/9/13	Check 10/9/13	\$25,367
Raman Spectroscopy of Catalysis	219	81.8J-00061-0031A/ Revision No. 0031C	8J-00061-0031A/ Revision No. 0031E	\$168,877
Rational Synthesis of Superconductors	219	81.3J-30081/3J-30081-0017A	3J-30081-0017F//DE-AC02-06CH11357	\$111,538
Small Worlds Project Development of algorithms and model	219	81.3J-30081-0030A//DE-AC02-06CH11357	3J-30081-0030A//DE-AC02-06CH11357	\$38,933
Structural Characterization in Photocatalysis	219	81.3J-30081-0039A// DE-AC02-06CH11357	3J-30081-0039A// DE-AC02-06CH11357	\$17,693
Student support for Angela Chang	219	81.3J-30081/3J-30081-0045A/0045B	3J-30081/3J-30081-0045A/0045B	\$8,450
Student support for Daniel Hannah	219	81.3J-30081-0044A	3J-30081-0044A	\$3,193
Student support for Matthew Kirschner	219	81.3J-30081-0043A	3J-30081-0043A	\$2,178
Student support for Michael Wagner	219	81.3J-30081-0042A	3J-30081-0042A	\$4,381
Support for Daikang Yan	219	81.3J-30081/3J-30081-0038A	3J-30081/3J-30081-0038A	\$29,167
Support for Joseph Sklenar	219	81.3J-30081/3J-30081-0029A Rev 0029B	3J-30081-0029 A Rev 0029C	\$43,738
Support for Junjing Deng	219	81.3J-30081/3J-30081-0011A	3J-30081/3J-30081-0011A	\$2,350
Support for Junjing Deng	219	81.3J-30081-0033A	31-30081-0033A/ 0033C	\$37,777
Support for Kenan Li	219	81.3J-30081/3J-30081-0012A	3J-30081/3J-30081-0012A	\$2,350
Support for Kenan Li	219	81.3J-30081-0035A	3J-30081-0035A/ 0035D	\$38,266
Support for Matthew Dietrich	219	81.3J-30081/3J-30081-0037A	3J-30081/3J-30081-0037A	\$5,037
Support for Young Pyo Hong	219	81.3J-30081-0002A	3J-30081-0002B//DE-AC02-06CH11357	\$2,350
Support for Young Pyo Hong	219	81.3J-30081-0036A	3J-30081-0036B	\$36,350

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Support for Yue Sun	219	81.3J-30081/3J-30081-0010A	3J-30081/3J-30081-0010A	\$2,350
Support for Yue Sun	219	81.3J-30081-0034A	3J-30081-0034A	\$12,254
Synchrotron X-Ray and Computational Studies of Strains	219	81.3J-30081-0006A//BOA 3J-30081	3J-30081-0006D//BOA 3J-30081	\$43,430
Synchrotron X-ray Studies of Nanostructured Polymer Film	219	81.3J-30081-0013A Revision No. 0013B	3J-30081-0013A Revision No. 0013B	\$21,833
Synthesis and Modification of Graphene for Catalytic and	219	81.3J-30081-0015A Revision No. 0015C	3J-30081-0015A Revision No. 0015C	\$24,255
Synthesis and Modification of Graphene for Catalytic and	219	81.3J-30081-0016A Revision No. 0016C	3J-30081-0016A Revision No. 0016C	\$63,946
Tailored Interfaces in Electrical Energy Storage (TIES)	219	81.9F-31901//DE-AC02-06CH11357	9F-31901//DE-AC02-06CH11357	\$41,839
The Design of Novel A2B2O5 Oxide Heterostructures	219	81.3J-30081-0040A	3J-30081-0040A	\$45,882
Unconventional Signatures for Characterizing Culture Con	219	81.3J-30081-0032A	3J-30081-0032B	\$6,890
Understanding Complex Oxide Surfaces in Reactive Environ	219	81.3J-30081/3J-30081-0019A	3J-30081/3J-30081-0019A	\$47,210
Understanding Complex Oxide Thin Film Synthesis	219	81.3J-30081-0031A	3J-30081-0031A	\$39,240
Understanding Roles of Ultrafast and Coherent Electronic	219	81.4F-3232//DE-AC02-06CH11357	4F-3232//DE-AC02-06CH11357	\$200,773
Understanding Roles of Ultrafast and Coherent Electronic	219	81.5B-30061//DE-AC02-06CH11357	5B-30061//DE-AC02-06CH11357	\$3,053
Using Hard X-rays to Accelerate the Synthesis of Materia	219	81.3J-30081/3J-30081-0041A	3J-30081/3J-30081-0041A	\$29,110
Yifeng Liao-Joint NU/Argonne appointment	219	81.Agmt 11/12/2014	Agmt 11/12/2014	\$16,010
Microplane Constitutive Model for Carbon-Polymer Laminat	220	81.13-2856-AMP// DE-EE0005661	13-2856-AMP// DE-EE0005661	\$41,298
Maintenance and Operations Activities Related to the US	224	81.P.0. #575208 // DE-AC02-07CH11359	P.O. 575208/Revision 8	\$31,277
Intermediate Temperature Fuel Cell Stack	221	81.PO2603659//Agmt 1215334//DE-AR0000498	P02603659//Agmt 1215334//DE-AR0000498	\$8,770
Thermoelectric Transport Properties from Materials Proje	232	81.7218473//DE-AC02-05CH11231	7218473//DE-AC02-05CH11231	\$4,212
Enzyme-Embedded, Microstructural Reactors for Industrial	233	81.B612160//DE-AC52-07NA27344	B612160//DE-AC52-07NA27344	\$24,901
Fluid Interfaces Reactions, Structures, and Transport (F	282	81.4000087020-2//DE-AC05-000R22725	4000087020-2//DE-AC05-000R22725	-\$5,041
Geochemical Equilibria and Reaction Dynamics: Atomic- to	282	81.4000125713/DE-AC05-000R22725	4000125713/DE-AC05-000R22725	\$85,628
Advanced Research Projects Agency-Energy				
Versatile Single-Component Protein Scaffolds for Methane		81.135	DE-AR0000435 Mod 0004	\$988,727
National Energy Technology Laboratory				
Integrated Computation Materials Engineering (I	80	81.086	RQ15-016R02//DE-EE0006867	\$122,165
National Nuclear Security Administration				
Bayesian Methods for Data Integration		81.113	DE-NA0002520	\$77,781
Perceptual Data Analysis and Semantic Information Extrac		81.113	DE-NA0000431	\$7,066
Ternary Heavy Metal Halide Semiconductors for Y-Radiatio		81.113	DE-NA0002522	\$286,578 \$371,425
Department of Energy Total				<u>\$371,425</u> \$22,421,747
Department of Health and Human Services				

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Evaluation of the Dementia-Capable Home & Community Serv	109	93.051	DCG1407//90DS2004-01-00	\$18,170
National Health Education Program on Lupus for Healthcar	10	93.137	Agmt 01-29-15 / 1CPIMP141065-01-00	\$75,994
Administration for Children and Families				
Expanding the Cycle of Opportunity: Simultaneously Educa		93.600	90YR0073-01-00	\$135,322
Expanding the Cycle of Opportunity: Simultaneously Educa		93.600	90YR0073-02-00	\$285,507
				\$420,829
CareerAdvance: A Dual-Generation Programs Effects		93.647	90PH0020-03-00	\$83,070
CareerAdvance: A Dual-Generation Programs Effects on Fam		93.647	90PH0020-04-00	<u>\$306,734</u> \$389,804
CareerAdvance	50	93.Agmt 1/28/11	Agmt 11/11/14 (Amd 2)	\$255,186
Administration for Community Living				
Enhancing Written Communication in Persons with Aphasia:	181	93.433	CL#2185//900F0034-01-00	\$3,404
Improving Measurement of Medical Rehabilitation Outcome	181	93.433	CC#80474//90RT5008-01-00	\$48,222
INTERPRETING COPD DYSPNEA CHANGE: SENSITIVITY, RESPO	ONSIV 181	93.433	CC#80498//901F0078-01-00	\$10,717
Machines Assisting Recovery from Stroke and Spinal Cord	181	93.433	CC 81765//H133E120010	\$59,285
Northwestern University Advanced Rehabilitation Research		93.433	90AR5019-01-00	\$66,036
Rehabilitation Research Training in Neurologic Communica		93.433	90AR5015-01-00	\$37,520
Rehabilitation Sciences for Basic Scientists & Engineers		93.433	90AR5010-01-00	\$85,324
Rehabilitation Strategies, Techniques, and Interventions	181	93.433	3037//90ER5013-01-00	\$52,511
The Development of a Commercial Rehabilitation Device to		93.433	90IF0005-01-00	\$235
The Development of an Algorithm for Intuitive Control of		93.433	90IF0090-01-00	\$87,381
The Effect of Resistance to Participant-Supported Reachi		93.433	90IF0020-01-00	\$16,767
				\$467,402
Developing Optimal Strategies in Exercise and Survival S	181	93.443	CL3802, CC81039//90RT5027-01-00	\$23,570
Agency for Healthcare Research and Quality				
Health Services Research Training Grant	240	93.225	FP037911//2T32HS000084	\$126,344
Northwestern University-University of Chicago HSR Postdo		93.225	2T32HS000078-17	\$431,814
Northwestern University-University of Chicago HSR Postdo		93.225	4T32HS000078-18	\$30,447
				\$588,605

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Best Practices For Integrating Clinical Decision Support		93.226	1R18HS022767-01	\$186,998
Comparative Effectiveness of Dynamic Patterns on Glucose	39	93.226	1R01HS018542	-\$4,841
Comparing Options for Management: Patient-centered Resul	66	93.226	2038737 / 1P50HS023418-01	\$45,338
Creating simulation-based performance assessment tools f	283	93.226	VUMC38171 // R18 HS020415	\$4,237
EHR Based Medication Complete Communication Strategy to		93.226	5R18HS023459-02	\$348,403
Engaging Patients and Hospitals to Expand Public Reporti		93.226	5R21HS021857-03	\$384,190
Improving ED Quality and Safety by Enhancing Opera		93.226	5K08HS019005-05	\$72,398
Improving Outpatient Safety of Older Adults through Elec		93.226	1R21HS024071-01	\$11,969
Improving the Quality of Pediatric Emergency Care Using		93.226	5R01HS020270-06	\$743,907
Innovative Methods for Modeling Longitudinal Medical Cos		93.226	5R01HS020263-04	\$461,469
Midwest Small Practice Care Transformation Research Alli		93.226	1R18HS023921-01	\$436,331
NICU-2-Home: Using HIT to Support Parents of NICU Gradua		93.226	R21HS020316	\$3,321
Northwestern University – Patient-centered Intervention		93.226	1K12HS023011	\$577,739
NU Center to Advance Equity in Clinical Preventive Servi		93.226	5P01HS021141-03 REVISED	\$675,554
Pediatric Measurement Center of Excellence	145	93.226	Amend //5U18HS020498-04	\$504,075
Tools for Optimizing Medication Safety (TOP-MEDS)		93.226	7U19HS021093-03	\$772,560
Use of Simulation-Based Mastery Learning for Thoracentes		93.226	5R18HS021202-03	\$303,489
, C				\$5,527,137
The National Implementation of Team STEPPS	96	93.80784//HHSA2902010000I Task#9	80784//HHSA2902010000I Task#9	\$8,814
Continued National Implementation of Team STEPPS	96	93.80797 // HHSA290201000025I TO 2	80797 // HHSA290201000025I TO 2	\$15,000
Comprehensive Patient Safety and Medical Liability Commu	96	93.HHSA290201000025I//80322	HHSA2902010000251//80322	\$71,212
Centers for Disease Control and Prevention				
Capacity Building and Technical Assistance Activities	94	93.067	109671-5077619 // u/5UGGH000024-03	\$125,703
Implementation of Programs for the Prevention, Care and	94	93.067	109470-5058795//5U2GPS001966-04	-\$1,006
				\$124,697
Prevention of the Complications of Bleeding Through HTC'	90	93.184	553/ 5U27DD000862-02	\$23,119
\$				
The roles of TfRs and HSPA5 in Pu uptake		93.262	5R010H010469-02	\$124,419
The roles of TfRs and HSPA5 uptake		93.262	5R010H010469-03	\$315,982
				\$440,401
Chicago Community-Acquired Pneumonia Consortium II		93.283	U18IP000490	-\$1,845
Center for Adolescent Health Promotion and Disease Preve	123	93.542	2002058887 // U48 DP001919	\$977
The accompanying footnotes are an integral part of the Schedule of Exp	enditures of Federal	Awards - 46 -		Continued

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
HIV Behavioral Surveillance Activities	40	93.940	26940//5U1BPS003260	\$108,659
HIV Behavioral Surveillance Activities	40	93.940	30626//U1BPS003260	\$120,799 \$229,458
				əzz3,430
Effectiveness of a National Health Care Community Partne		93.945	5U58DP002718-05 Revised	\$562,856
Illinois Perinatal Quality Collaborative (ILPQC)	108	93.946	063-48260-1900-0100/U38DP005367	\$111,818
Illinois Perinatal Quality Collaborative (ILPQC)	108	93.946	66380016D	\$21,551
				\$133,369
Biostatistical Support for HIV Outpatient Study (HOPS)	38	93.Agmt Signed 2/21/12//200-2011-41872	Amend. 2 10/03/2014//200-2011-41872	\$58,518
Evaluation of Rapid HIV Self-Testing Among MSM in High P	138	93.Agmt signed 2/22/12//200-2011-41989	Agmt signed 2/22/12//200-2011-41989	\$82,920
HIV Outpatient Study	38	93.Agreement Date: 6/11/12//CDC No. 200-	Agreement Date: 6/11/12//CDC No. 200-2011-41872	\$197,786
Tracking needs, increasing awareness, and supporting dec	28	93.BO-52873-NU//200-2012-52873	B0-52873-NU//200-2012-52873	\$38,874
Centers for Medicare & Medicaid Services				
Community Rx System: Linking Patients with Community-Ba	240	93.610	FP050938E//1C1CMS330997-01-01	\$363,033
Dissemination of the Aging Brain Care Program	110	93.610	Agr. 10/14/2014//1C1CMS331000-03-00	\$30,570
Geriatric Emergency Department Innovations (GEDI WISE)	101	93.610	0254-5703-4609/C1CMS331055-03-00	\$1,005,320
Health Care Innovation Challenge: Improving Quality and	60	93.610	1259//1C1CMS331052-01-01	-\$1,126
Health Care Innovation Challenge: Improving Quality and	60	93.610	1616//1C1CMS331052-01-01	\$6,539
Integrated Inpatient/Outpatient Care for Patients at Hig	240	93.610	FP050658-C // 1C120120011832	\$11,652
				\$1,415,988
CHIPRA Quality Demonstration Grant Project	95	93.767	3001//MED124-A1	\$26,474
Estimating Benefits in Risk Reduction from Cardiovascula	151	93.106955//HHSM-500-2012-00008I	106955//HHSM-500-2012-00008I	\$54,810
Patient Safety Education Program - National Content Deve	69	93.2242-000-NWU/HHSM5002011000151IDIQ	2242-000-NWU/HHSM5002011000151IDIQ	\$30,932
Patient Safety Education Program - Hospital Engagement C	125	93.Fully-executed 2/28/12	Fully-executed 2/28/12	\$12,827
Food and Drug Administration				
Phase 2 Study of Esophageal String Test in Diagnosing	248	93.103	2013-018545-02-01 AS//1R01FD004086	\$62,118
Health Resources and Services Administration				
Hemophilia Liver Transplantation OLTX Observational Stud	98	93.110	H30MC24050	\$8,832
Hemophilia Treatment Center (HRSA Award)	90	93.110	H30MC24052	\$26,488
				\$35,320

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Evaluation of a Culturally Competent Website on Living K		93.134	4 R390T22059-03-02	\$224,050
Graduate Psychology Education Program		93.191	1 D40HP25719-01-00	\$145,723
Graduate Psychology Education Program		93.191	5 D40HP257190300	<u>\$23,753</u> \$169,476
Northwestern McGaw Family Medicine Residency Program, N	Мс	93.530	2T91HP21542-03-01	\$2,790,030
Northwestern McGaw Family Medicine Residency Program, N		93.530	6 T91HP21542-01-06	\$651,389
				\$3,441,419
Faculty Development in Primary Care Program		93.884	D55HP23201-04-00	\$6,684
Physician Faculty Development in Primary Care Program		93.884	1D55HP23201-03	\$101,277
				\$107,961
Building Data Infrastructure in the Safety Net to Conduc	7	93.001C-06//HHSH25201400001C	001C-06//HHSH25201400001C	\$6,517
Building Data Infrastructure in the Safety Net to Conduc	7	93.001C-07//HHSH25201400001C	001C-07//HHSH25201400001C	\$8,899
Building Data Infrastructure in the Safety Net to Conduc	7	93.001C-08//HHSH25201400001C	001C-08//HHSH25201400001C	\$1,316
National Institutes of Health				
American Heart Association Tobacco Regulation and Addict	11	93.077	FX-ATRAC-NWU-02//1P50HL120163-01	\$77,874
Association of ALS to gene-environment mediated changes		93.113	5R01ES022310-03 REVISED	\$597,547
Carbon Nanotube Structure-Activity Relationships for Pre	234	93.113	0521 G RA276 //1R01ES022698	\$134,283
Epigenetic Mechanisms of PM-Mediated CVD Risk	264	93.113	5032970//5R01ES020836-04	-\$38,423
Ex Vivo Female Reproductive Tract Integration In a 3D Mi		93.113	1UH2ES022920-01	-\$4,114
Ex Vivo Female Reproductive Tract Integration In a 3D Mi		93.113	3UH3TR001207-04S1	\$1,582,466
Gene-Environment Interaction of ZnT8 Cadmium - A Link to		93.113	1K08ES020880-03	\$182,502
Histone Modifications and Respiratory Effects of Traffic		93.113	1R21ES020984-01A1	\$97,052
Mechanisms of airborne particulate matter induced thromb	240	93.113	FP058473/7R01ES015024	\$58,091
Mechanisms of Airborne Particulate Matter Induced Thromb		93.113	5R01ES015024-07	-\$36,733
Mitigation of Asbestos-Induced Alveolar Epithelial Cell		93.113	5R01ES020357-04 REVISED	\$363,921
Molecular and Epigenetic Mitochondriomics of Air Particl	94	93.113	112474-5052023//5R01ES021733-03	\$8,920
NRSA fellowship in support of The Role of Mitochondrial		93.113	5F30ES019815-04	\$3,885
Signaling in the Lung Induced by Particulate Matter Air		93.113	5R01ES013995-10	\$347,694
				\$3,297,091

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Biologically Inspired Polymer Adhesives		93.121	5R37DE014193-12 REVISED	-\$12
CFM: Longitudinal Outcomes in Children pre-Kindergartene	200	93.121	10837SUB // 5R01DE022438-02	-\$14,013
Cortico-Striatal Plasticity in the Transition to Chronic		93.121	5R01DE022746-04	\$815,259
Craniofacial Microsomia: Longitudinal Outcomes in Child	200	93.121	10838SUB//5R01DE022438-02	\$1,912
Epigenetic Profiling of Oral Cancer Cells		93.121	5R21DE024388-02	\$213,501
Matrix Component Interactions in Bone, Dentin, and Inver		93.121	5R01DE001374-52	\$153,599
Nanoscale structure and phase composition of sound and c		93.121	1R03DE025303-01	\$6,113
Nanotechnology Strategies for the Growth of Bones and Te		93.121	5R01DE015920-10	\$898,613
NRSA: SoxE Regulation of Neural Crest Development		93.121	5F31DE021922-04 REVISED	\$35,310
				\$2,110,282
A Personalized Genomic Medicine Pilot Program Using the		93.172	5U01HG006388-04	\$1,017,300
Gene Ontology Consortium	118	93.172	Agmt 4/21/15//5U41HG002273-13	\$82,994
				\$1,100,294
A Family-Genetic Study of Language in Autism		93.173	5R01DC010191-06 REVISED	\$121,187
Acoustic and Perceptual Effects of WDRC Amplification		93.173	5R01DC006014-11	\$126,553
Anatomical Physiology of Semantic Associations in Primar		93.173	5R03DC013386-02	\$150,844
Aphasia Rehabilitation: Modulating Cues, Feedback, and P	182	93.173	Agr. 10/07/2014//R01DC011754	\$15,705
Artificial Grammar Learning in Aphasia: An Implicit Lear		93.173	5F31DC013204-02	\$28,064
Attention-depdendent neural oscillations in the human ol		93.173	4R00DC012803-03	\$89,039
Attention-dependent neural oscillations in the human olf		93.173	1K99DC012803-01	\$21,870
Auditory Function at the Base of the Human Cochlea		93.173	5F31DC013710-02	\$29,519
Behavioral and Neurologic Factors in Speech Learning		93.173	5R01DC008333-06	\$53,293
Can Consumers and Audiologists Detect Ear Disease Prior		93.173	R21DC013115-02	\$182,090
Cellular Mechanisms Underlying Corticocollicular Modulat	268	93.173	0033928 (124432-1) A1//R56DC031272	\$139,976
Characterizing Variability in Hearing Aid Outcomes Among		93.173	5R01DC012289-04	\$313,136
Core Center for Integrated Research on Human Communicati		93.173	5P30DC012035-03	\$275,894
Defining molecular mechanisms in the SLC26 family of pro		93.173	1R03DC014553	\$38,292
Dynamic Interaction Among Proteins in Hair Cells		93.173	5R01DC011813-04	\$426,127
Elucidating the Role of Type II Afferent Neurons in Audi		93.173	F31 DC012013	-\$2
Functional Expression of Human Trace Amine-Associated Re		93.173	5R21DC013188-02	\$181,983
Genetic Analysis of Glomerular Map Formation		93.173	5R01DC009640-05	\$11,306
Genetic Determinats of Taste Preferences and Risk of Met		93.173	7R03DC013373-02	\$88,239
Insm1 in Development of Spiral and Vestibular Ganglia		93.173	1F31DC012483-01	\$8,275
Interactive-specialization of language impairment	273	93.173	UTA14-001199//R01DC013274	\$2,477

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Language in Primary Progressive Aphasia		93.173	5R01DC008552-09	\$627,204
Mapping and function of odorant receptors in the human o		93.173	1R01DC014426-01	\$293,228
Mechanisms Regulating Synaptic Function in the Developin		93.173	1R03DC013841-01A1	\$17,035
Nanotechnological Regeneration of Spiral Ganglion Neuron		93.173	5K08DC013829-02	\$225,712
Networks Underlying Visual Modulation of Speech Percepti		93.173	1K99DC013828-01A1	\$90,835
Neural Correlates of Auditory Function and Training in O		93.173	5R01DC010016-05	\$212,396
Neurobiology of Language Recovery in Aphasia: Natural Hi		93.173	5P50DC012283-03	\$2,566,216
NRSA Predoc F31 Fellowship for J Howard in support of: N		93.173	5F31DC013500-02 REVISED	\$16,338
NRSA: Translational Research in Communication Sciences a		93.173	5T32DC009399-05	\$52,553
Online measure of selective attention and neural functio		93.173	5F31DC014221-02	\$29,956
Perceptual Coding and Moducation of Odor Obje		93.173	R01DC010014	-\$46,677
Perceptual Coding and Modulation of Odor Objects in the		93.173	5R01DC010014-07	\$272,224
Peripheral Mechanisms of Hearing		93.173	5R01DC000419-24	\$352,026
Pre-Implantation Communication Treatment for Children wi		93.173	5R03DC012639-04	\$157,236
Processing of Spoken Language in Young Children Who Use	163	93.173	G1A62450//1R15DC01-1605-01	\$15,669
Proteome Biology of Noise Induced Hearing Loss		93.173	4R00DC013805-02	\$128,973
Role for B-cell Mediated Olfactory Loss in Chronic Rhino		93.173	5K23DC012067-02	\$185,273
Sensory Mechanisms of Voice Control		93.173	5R01DC006243-10 REVISED	\$40,381
Spatiotemporal Coding in the Human Olfactory System		93.173	R21DC012014	\$2,504
Spatiotemporal Mechanisms of Olfactory Processing in the		93.173	5R01DC013243-03	\$311,757
Structural Basis for KCNE Modulation of the KCNQI Channe	283	93.173	VUMC42969//R01DC007416	\$46,895
Studies in Cochlear Hair Cell Transduction		93.173	5R01DC000089-45	\$448,488
Talker-Listener Alignment During Speech Production and P		93.173	5R01DC005794-09	\$191,076
The role of parent phenotype in parent-mediated language		93.173	1R01DC014709-01	\$56,904
The Roles of Espins in Hair Cell Stereocilia		93.173	2R01DC004314-14	\$309,969
Trace Amine-Associated Receptors and Olfactory Behavior		93.173	5R01DC013576-02	\$578,727
Understanding the Benefits of Infrared Nerve Stimulators		93.173	5R01DC011855-04	\$516,310
Understanding the Voice Control System in Parkinson's Di	201	93.173	NW0001//1R03DC013883-01	\$4,869
				\$10,007,944
Brain mechanisms for clinical placebo in chronic pain		93.213	5R01AT007987-03	\$1,170,121
Investigating Pain Processing in the Brain, Brainstem, a		93.213	5F32AT007800-03	\$73,746
Mechanisms of Probiotic Analgesia		93.213	5R01AT007701-02	\$323,075
-				\$1,566,942

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Circadian Timing, Sleep and Adiposity		93.233	5K23HL109110-04	\$114,447
Sleep Disturbance and Risk for Adverse Pregnancy Outcome		93.233	R01HL105549	\$129,703
				\$244,150
1/2 - Online Collaborative Learning Intervention to Prev	248	93.242	2015-02053-01-00//R34MH102478	\$3,501
1/2 - Online Collaborative Learning Intervention to Prev		93.242	1R34MH102478-01	\$69,404
2/2 - Suicide Prevention in Chinese Older Adults		93.242	5R34MH100393-02	\$81,402
A Family-Genetic Study of Autism and Fragile X Syndrome		93.242	5R01MH091131-04	\$674,185
A Mobile Behavioral Monitoring Intervention for Bipolar		93.242	5R34MH100460-03	\$237,680
Acute Estradiol Regulation of Excitatory Synapses		93.242	5R01MH095248-04 REVISED	\$403,723
Aging and Antipsychotic Efficacy - Epigenetic Mechanisms		93.242	5R21MH100919-02 REVISED	\$102,470
Antipsychotic Treatment Effects on Attention and Working		93.242	K23MH083126	\$50,722
Artificial Intelligence in a Mobile Intervention for Dep		93.242	5R01MH100482-03	\$475,559
Behavioral Relevance of Active Dendritic Mechanisms of I		93.242	5R01MH101297-03	\$359,418
Center for Prevention and Early Intervention	123	93.242	PO #2002044103 // P30 MH086043	-\$286
Characterizing the Hippocampal-thalamic-prefrontal Circu		93.242	5F31MH099769-02	\$4,002
Collaborative Data Synthesis for Adolescent Depression T		93.242	7 R01 MH040859-26	\$803,164
Connecting Patients and Therapists Using a Tech-Based Tr		93.242	5K08MH102336-02	\$114,444
Core C:Genomics, Proteomics & Pheontyping; Conte Center	240	93.242	FP046983-E//P50MH094267	\$124,395
Cross-Cultural Neuroimaging of Emotion in South Africa,		93.242	1R21MH098789-01	\$36,922
Developing an Integrated Mental Health Model for Home Vi		93.242	7 R34 MH093514-03	\$155,691
Development of a Mobile System for Self-Management of Sc	60	93.242	1258R74//R34MH100195-03	\$33,032
Developmental Characterization of Preschool Disruptive B		93.242	5R01MH082830-05 REVISED	-\$7,149
Dimensions of Early Temper Loss and Low Concern: Clinica		93.242	2U01MH082830	\$913,758
Early Traumatic Stress Exposure: Neurodevelopmental Mech	244	93.242	UCHC6-410-59202 // U01-MH090301	\$127,519
Early Traumatic Stress Exposure: Neurodevelopmental Mech	244	93.242	UCHC6-41364241-01//U01-MH090301	\$992
Effectiveness Trial of Youth Suicide Prevention Delivere	269	93.242	416177-G//R01MH091452	\$59,258
Epigenetic modulation of antipsychotic-induced side effe		93.242	1R36MH100912-01A1	-\$2,556
Evaluation of antidepressant-like effects of hippocampal		93.242	5R21MH104471-02	\$213,797
Examining Several Possible Causes of GxE Non-Replication		93.242	1F32MH091955-01	-\$2,605
Harnessing the Power of Text Messaging to Invigorate ANS	117	93.242	Agmt 7/10/14//R01MH096660	\$110,893
Identification of cell type specific actions of antipsyc	188	93.242	AGMT 6/30/14 // P50MH090963	\$207,052
IGFI and Depression		93.242	5R01MH094835-04	\$330,288
Internet Psychotherapy for Treating Bipolar Disorder in	268	93.242	0046483(126383-1)//1R34MH107541-01	\$488
Kainate receptor signaling in striatal synaptic function		93.242	5F31MH099807-03	\$35,877
LATIN-MH: Latin America Treatment and Innovation Network	83	93.242	2013.86612.001//U19MH098780	\$97,948

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title P	ass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Mechanisms of Stress-Enhanced Aversive Conditioning		93.242	5R01MH078064-08	\$397,017
Mobile Applications for Depression: Comparing Cognitive		93.242	1F31MH106321-01	\$29,346
Mobile Technology to Engage and Link Patients and Provid		93.242	R34MH095907	\$156,435
Molecular mechanisms of Abnormal Dendritic Spine Plastic		93.242	5R01MH097216-04	\$734,530
Necessary Role of PFC-MTL Interactions in Memory Tested	26	93.242	4500001672//5P50MH094263-04REV	\$150,565
Noninvasive Manipulation of Hippocampal-Cortical Brain N		93.242	1R01MH106512-01A1	\$8,457
NRSA: Multivariate Pattern Analysis and Memory Reactivat		93.242	5F31MH100958-02 REVISED	\$12,801
Plasticity of Auditory Cortical Circuits in Schizophreni	268	93.242	003877 (1245412-1)/R01MH07533	\$113,903
Positive Affect Regulation for HIV Prevention in People		93.242	7K24MH093225-05	\$132,556
Positive affect skills for depression: Optimizing intern		93.242	5R34MH101265-02	\$188,909
Postsynaptic roles of ankyrin		93.242	1R01MH107182-01	\$164,967
Preclinical and Patient Studies of Affective Disorders i		93.242	5R21MH098793-02	\$118,194
Primary Care Internet-Based Depression Prevention for Ad	248	93.242	2011068050502//5R01MH09003505	\$33,307
Recording Neural Activities onto DNA	181	93.242	3024//1R01MH103910-01	\$391,712
Reducing HIV Stigma to Improve Health Outcomes for Afric	279	93.242	747641 / R01MH098675	\$190,638
Regularity in Parenting: a Biopsychosocial Model for Tra		93.242	1F31MH105092-01A1	\$9,633
Relationships as a Context for HIV Prevention in Vulnera		93.242	R21MH095413	-\$1,594
Risk for Bipolar Disorder: Reward-Related Brain Functio	213	93.242	360955-NW Amd 1//R01MH077908-06A1	\$15,877
Role of Kalirin Signaling in Synaptic Plasticity		93.242	5R01MH071316-10	\$235,495
SchizConnect: Large-Scale Schizophrenia Neuroimaging Dat		93.242	5U01MH097435-03	\$448,937
Sex Differences in Acute Estradiol Regulation of the Syn		93.242	5R21MH099572-02 REVISED	\$116,330
Sleep Homeostasis, Plasticity and Memory		93.242	5R01MH092273-05	\$316,565
Small GTPase signaling in spines		93.242	2R01MH071316-11A1	\$16,662
Stepped Telemental Health Care Intervention for Depressi		93.242	5R01MH095753-02	\$742,703
SYMPTOM DIMENSIONS OF THREAT-AND REWARD-RELATED NE	UROCIR 234	93.242	0875 G SA507 // 5 R01 MH100117-02	\$282,349
Technology Assisted Intervention for the Treatment and P		93.242	5P20MH090318-05	\$788,926
Test of an intervention to improve retention in HIV care	20	93.242	101679807//5R01MH085527-04	\$60,358
The Hippocampal System and Relational (Declarative) Memo	249	93.242	2011-00082-02-00//5R01MH062500	\$300,957
The role of glutamate receptors in compulsive and persev		93.242	5R01MH099114-04	\$485,545
Training Program in Neurobiology of Information Storage		93.242	5T32MH067564-13	\$211,109
				\$12,668,177
Alcohol Biomarkers in Post Liver Transplant Patients		93.273	5K24AA015390-10	\$183,213
Brain-Gut Circadian Rhythm Interactions in Alcohol-Induc	190	93.273	5R01AA020216-05/4 // 5R01AA020216	\$96,889
College Alcohol Assessment and Intervention Training Sim	202	93.273	amend. 002//1R44AA022265	\$82,999
Epigenetic Consequences of Prenatal Alcohol Exposure		93.273	3R01AA017978-05S1 REVISED	\$68,909
The accompanying footnotes are an integral part of the Schedule of Expendence	litures of Federal	Awards	- 52 -	(Continued)

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Modulation of epigenetically controlled cardiac repair m		93.273	5K01AA022134-02	\$119,084
Newborn Phosphatidylethanol Screening to Detect Fetal Al		93.273	1U01AA023176-01A1S1	\$31
Virtual Role-Plays to Train Cognitive-Behavioral Treatme	202	93.273	Agr. 10/24/2014//1R44AA023719-01	\$5,047
				\$556,172
A Multilevel Network Model of Drug Use and HIV Racial Di		93.279	1 K08 DA037825-01A1	\$89,952
A Systems-Level Approach to Studying HIV/AIDS Susceptibi		93.279	5R01DA033773-04	\$829,398
Center for Prevention Implementation Method for Drug Abu		93.279	3P30DA027828-05S1	\$1,085,945
Chemokine Receptor Function in the Nervous System		93.279	5R01DA013141-15	\$235,019
Cognitive-Affective Substrates of Smoking: Targets for M		93.279	1K23DA037913-01A1	\$21,362
Comparative Effectiveness of Adding Weight Control to Sm	5	93.279	Agr. 8/17/14//1R01DA031147-A3	\$35,867
Different Components of Nicotine-Induced Upregulation of	240	93.279	FP052975//1R01DA035430	\$55,145
Distress Intolerance on Smoking Lapse among Motivated vs		93.279	7F32DA036947-02	\$2,758
Drug Abuse, Incarceration, Health Disparities in HIV/AID		93.279	5R01DA028763-05	\$1,197,702
Efficacy of Internet-Based HIV Prevention		93.279	5R01DA035145-04	\$862,609
fMRI-based biomarkers for multiple components of pain	242	93.279	1550991//DA035484	\$30,663
Gene-Environment Interactions Effects on HIV Risk		93.279	R01DA025039	-\$1,418
Investigating change in HIV risk in a self-monitoring di		93.279	1R03DA035704-01	\$127,801
KiiDS: Knowing about Intervention Implementation in Dete	71	93.279	T443871/U01 DA036233	\$15,006
Measuring Coalition Capacity to Foster Program Sustainme	271	93.279	63501087//1R34DA037516-01A1	\$6,124
Multilevel Influences on HIV and Substance use in a YMSM		93.279	5U01DA036939-02	\$1,262,490
New Inactivators of GABA Aminotransferase for Addiction		93.279	5R01DA030604-04 REVISED	\$360,609
NRSA for J. Puckett in Support of Predictors of Substanc		93.279	1F32DA038557	\$49,079
Prenatal Smoking and the Substrates of Disruptive		93.279	5R01DA023653-05 REVISED	\$263,993
RCT of an integrative intervention for non-treatment-see	237	93.279	8244sc//R01DA033854-Amend 1	\$22,688
Syndemic Development and HIV Risk Among Vulnerable Young	j 15	93.279	901310//R01 DA025548	\$86,832
The Development and Analysis of a Macro-Network of Vulne		93.279	5R03DA033906-02 REVISED	\$25,576
Training for a New Interdisciplinary Research Workforce		93.279	5T90DA022881-04 REVISED	-\$47,145
Trajectories of Drug Abuse in High Risk Youth		93.279	R01 DA019380	\$217
UIUC Neuroproteomics and Neurometabolomics Center on Cel	249	93.279	2014-01446-01//2P30DA018310-11	\$245,021
Vulnerability to Drug Use & HIV: Advancing Prevention fo	246	93.279	RR376-411/4945376//2P30DA027627	\$147,103
				\$7,010,396
Tech-Based Depression and Anxiety Treatment for Youth in		93.281	5K08MH094441-04	\$135,825
Understanding the Role of Epac2 in Cognitive Function		93.282	5F30MH096457-03	\$44,589

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
A Formalism for Customizing and Training Intelligent Ass		93.286	5R01EB019335-02	\$132,074
A Multi-Scale Modeling Construct of Knee Mechanics follo	181	93.286	2894//5U01EB015410	\$52,194
Antifouling Peptide Mimetic Polymers		93.286	5R01EB005772-07	\$357,149
Antigen Loaded Particles for Tolerance Induction	258	93.286	3003425601//7R01EB013198-05	\$97,401
Antigen Loaded Particles for Tolerance Induction	258	93.286	Sub#3003585891//2R01013198-06	\$20,671
Antigen Loaded Particles for Tolerance Induction		93.286	5R01EB013198-04	\$875
Application of core-shell TiO2 Nanoconjugates		93.286	5R01EB002100-08	-\$421,928
Bioactive Scaffolds for Regeneration in Spinal Cord Inju		93.286	3R01EB003806-10	\$721,063
Center of Excellence for Mobile Sensor Data-to-Knowledge	256	93.286	5-40312//1U54EB020404-01	\$155,566
Controlled Release Scaffolds for Nerve Regeneration	258	93.286	2R01EB005678-09	\$39,364
Controlled Release Scaffolds for Nerve Regeneration		93.286	5R01EB005678-08 REVISED	\$64,702
Development of MRI-based Cerebral Oxygen Extraction Frac		93.286	5R21EB017928-02	\$137,200
Enhancing Biomedical Engineering Senior Design at Northw		93.286	5R25EB013060-05	\$24,068
High-throughput molecular-specific cell nanocytology for		93.286	5R01EB016983-03	\$379,986
Interdisciplinary Graduate Education in Movement and Reh		93.286	5T32EB009406-05	\$64,324
Magnetic Nanocomposites for Catheter-Directed Drug Deliv		93.286	5R21EB017986-02	\$234,468
Mechanisms of Light Scattering in Living Tissue		93.286	5R01EB003682-08	\$299,409
Microconnectomics of neocortex: a multiscale computer mo	209	93.286	100-1120566-69379/1U01EB017695-01A1	\$159,758
Point of Care test development for Chlamydia	124	93.286	126644// 2U54EB007958-06	\$38,050
Preclinical Investigation of a Bioengineered Vascular Gr		93.286	5R01EB017129-03	\$402,118
Protein-Releasing Microporous Scaffolds for Cell Replace		93.286	5R01EB009910-04 REVISED	-\$16,867
q-Modulated Magnetic Resonance Imaging Contrast Agents		93.286	5R01EB005866-08	-\$5,334
SCH: Interface Monitoring System to Promote Residual Lim		93.286	5R01EB019337-02	\$244,845
Shape Control and Transfection of Self-Assembled Polymer	123	93.286	2001383961-Amd 1//1R21EB013274-01A1	\$9,891
Shape Control and Transport Properties of DNA-Copolymer	123	93.286	2002586569//1R01EB018358-01A1	\$30,161
Steroid-Based Contrast Agents for Magnetic Resonance Ima		93.286	5R01EB014806-04	\$390,745
Understanding Real-Life Falls in Amputees using Mobile P	181	93.286	CL3719//1R01EB019406-01A1	\$34,408
				\$3,646,361
Adjunct Vitamin D as a Means to Reduce the Disparity in	289	93.307	WSU14035//5R01MD005849	\$5,238
Biological and Environmental modifiers of Vitamin D3 and	228	93.307	281315//7R01MD007105-04	\$32,379
Community Participatory Intervention with High-Risk Afri	62	93.307	500573SG044/R24 MD002748	\$30,603
Ethics in HIV Prevention Research Involving LGBT Youth		93.307	1R01MD009561	\$378,609
Extending Cancer Navigation to Underserved Suburban Wome	9	93.307	R24MD001650	\$283,074
Latino vs. Non-Latino Disparities in Advance Care Planni	120	93.307	14050708-02//1R01MD007652-01A1	\$27,788

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Longitudinal associations of neighborhood-level racial r	258	93.307	3002936277//P-60MD002249	\$6,669
The Price of Debt: The Unequal Burden of Financial Debt	253	93.307	Sweet-001//1R01MD007723-01	\$134,447
				\$898,807
FYN Inhibition by AZD0530 for Alzheimer's Disease	236	93.310	67NWU/M15A11884	\$432
National Research Mentoring Network for a Diverse Biomed	259	93.310	N004306901//1U54MD009479-01	\$17,495
National Research Mentoring Network for a Diverse Biomed	280	93.310	580K801//1U54MD009479-01	\$19,386
NIH Director's Pioneer Award: Reconstructing Sub-cellula		93.310	8DP1EB016540-05	\$329,119
Regulatory Circuits Controlling Regenerative Growth		93.310	1DP2DE024365-01	\$440,814
				\$807,246
Northwestern Demonstration for Accrual to Clinical Trial	268	93.350	9010570 (125118-5)//3UL1TR000005	\$144,592
Northwestern University Clinical & Translational Science		93.350	1U54TR001018-01	\$3,840,168
Gene Expression Profiling in Scleroderma to Discover Th		93.350	SPARC 15-03-A	\$10,568
				\$3,995,328
EHR-Based Health Literacy Strategy to Promote Medication		93.361	5R01NR012745-05	\$611,947
HippoPCI Hippocampal Predictors of Cognitive Impairment		93.361	5R01NR014182-04	\$608,093
Interventions for Symptom Management in Older Patients w	237	93.361	8729sc//1R01NR015223	\$15,665
Life Enhancing Activities for Family Caregivers of Peopl	237	93.361	8431sc//R01NR014435-02	\$9,244
Medtable: An EMR Strategy to Promote Patient Understandi	249	93.361	2009-01352-02//R01NR011300	\$300
Optimizing Kidney Transplant Patients' Informed Consent		93.361	5R21NR013660-02	\$74,762
Pivotal Career Decisions Guiding Potential Women Science		93.361	R01NR011987	-\$2,064
Quality of Life in Caregivers of Traumatic Brain Injury:	258	93.361	3002557849//R01NR013658	\$73,841
Refinement and expansion of the Palliative Care Research	66	93.361	203-8504/5/U24NR014637-02	\$23,665
Video Information Provider for HIV-Associated Non-AIDS (48	93.361	1(GG012114-01)//R01NR015737	\$976
				\$1,416,429
Annual International Science of Team Science Conference		93.389	5R13TR000046-05	\$9,130
Development of a Novel Laser Instrument for Advanced Med		93.389	5R21EB015899-03	\$86,635
Mentoring and Research in Mouse Pathobiology		93.389	5K260D010945-04 REVISED	\$104,047
Northwestern University Clinical and Translational Scien		93.389	8TL1TR000108-05	-\$18
Science Club: Building a Science Community Parternship w		93.389	R25RR026021	\$230,591
				\$430,385

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Adapting Patient Navigation To Promote Cancer Screening		93.393	5R01CA163830-04	\$291,50
Aldo-Keto Reductase Family 1 Member B10 AKR1B10 in Pancr	r	93.393	5R01CA164041-04	\$327,87
AMPK as a Molecular Target for Chemoprevention by Apigen		93.393	5R21CA161181-02	\$57,853
Antiretroviral Therapy Strategies to Lower Cancer Risk i	128	93.393	115-9568-4/R01CA165937	\$14,52
Apigenin Restores TSP-1 Expression in UVB-Irradiated Ker		93.393	5R01CA172669-03 REVISED	\$567,28
Assessing PROMIS Other Simple Patient-Reported Measures	141	93.393	1R01CA154537/ PO# 63663940	\$93,32
Behavioral Activation and Varenicline for Smoking Cessat		93.393	5R01CA184211-02	\$468,12
Cancer Risk After Renal Transplant in Autoimmune Disease		93.393	1R03CA165139-01A1	-\$79,70
Cancer Risk: Advancing knowledge in systemic rheumatic d	185	93.393	5449//CA173822	\$46,87
Co(III) Schiff Base Complexes as Selective and Irreversi		93.393	5R03CA167715-02	\$12,042
Contralateral Prophylactic Mastectomy: The Patient Decis		93.393	5R21CA175950-02	\$194,393
E=MC2: Environment-Driven Mathematical Modeling for Clin	92	93.393	10-15885-05-G2//5U54CA143970-05	\$15
Extended Duration Varenicline for Smoking Among Cancer P	267	93.393	559692//1R01CA165001-04	\$253,954
Genistein-Mediated Regulation of Prostate Cancer Cell Mo		93.393	5R01CA122985-05	-\$12,10
GSK3B Mediates Radiation-Induced Cytotoxicity in Hippoca	166	93.393	R01CA163838/PO#RF01315746	-\$4
Herpesvirus Gene Expression in Transformed Cells		93.393	5R01CA021776-36 REVISED	\$265,03
HPV and the DNA Damage Response		93.393	5R01CA142861-05	\$166,294
HPV Vaccination among Low-Income Hispanic Adolescents		93.393	5R21CA178592-03	\$98,153
Improving Longitudinal Quality of Life Assessment in Hep		93.393	1R03CA173025-01A1	\$54,49
In Vivo Model of Epstein-Barr Virus Latency		93.393	5R01CA073507-17	\$324,842
Inhibition of pancreatic carcinogenesis via targeting c-		93.393	5R01CA172431-03	\$337,934
Inhibitors of the Epstgein-Barr Entry Machinery	207	93.393	60137701-40455-B//R01CA117794	\$172,21
Integration of Palliative Care Training into Oncology		93.393	5R25CA163198-04	\$29,67
Interactions Between Intermediate Filaments and Nucleus		93.393	5R01CA031760-31	\$40,20
Kaposi's Sarcoma-associated Herpesvirus Mimics of Cellul		93.393	5R01CA180813-02	\$375,62
Life Cycle of Human Papillomaviruses		93.393	5R37CA074202-18	\$210,84
Low-Literacy Physician-Patient Intervention Promoting Co		93.393	R01CA140177	-\$20
Mastectomy Reconstruction Outcomes Consortium (MROC) Stu	u 258	93.393	3002091262//5-R01-CA152192-05	\$77,62
Meta-Analysis of Positive Psychology Interventions for C		93.393	1R03CA184560-01	\$42,38
MiR-182 overexpression in early tumorigenesis of high gr		93.393	1R21CA167038-01A1 REVISED	\$75,40
Molecular Etiology of Cervicovaginal Adenosis by in Uter	166	93.393	60044683//R01CA154358	\$11,57
Mutations of Chromatin and its Modifying Machineries in		93.393	1R35CA197569-01	\$40,57
N-3 Fatty Acid-Induced Akt Suppression: Chemoprevention		93.393	3R01CA161283-03S1 REVISED	-\$6,50
On Campus: Prosthesis Control by Forward Dynamic Simulat	182	93.393	81876//1R01EB011615-01A1	\$25,71
Prostate Cancer Susceptibility: The ICPCG Study	141	93.393	63778898//5U01CA089600-11	\$23,40
Regulation of Human Papillomavirus Gene Expression		93.393	5R01CA059655-20 REVISED	-\$15,95

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Regulation of Human Papillomavirus Gene Expression		93.393	5R01CA059655-22 REVISED	\$318,851
Role of the Ndc80 Loop Domain and Cdt1 in Kinetochore Mi		93.393	4R00CA178188-03	\$205,466
ROS and HIFa as molecular targets for chemoprevention in		93.393	5R01CA168292-04	\$210,682
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Posit		93.393	5R01CA152799-05	\$162,804
Social-Emotional Contexts of Adoloscent Smoking Patterns	248	93.393	Agmt 11/18/10//P01CA098262	\$1,349
Targeted eHealth intervention to reduce fear of recurren		93.393	1R21CA173193-01A1 REVISED	\$120,324
The National Person-Centered Assessment Resource (PCAR)		93.393	5U2CCA186878-02	\$1,649,100
Training primary care physicians to perform melanoma opp		93.393	1R21CA182725	\$24,435
Tumor Targeted Nanobins for the Treatment of Metastatic		93.393	5U01CA151461-05	\$275,971
				\$7,554,371
(PQD5) imaging systemic tissue injuries induced by antic		93.394	5R01CA185214-02	\$532,041
A Comparison of Interventions to Teach Melanoma Patients		93.394	R01CA154908	\$422,095
A Phase IB/II Trial of ALT-801 in Combination with Cispl	8	93.394	CA-ALT-80-01-10//5R44CA097550-07	\$4,686
Administrative Supplement: Patient-Specific Predictive M	279	93.394	758290//3R01CA164371-03S1	\$73,377
Biophotonics to Couple Pancreatic with Upper GI Screenin		93.394	1R01CA183101-01A1	\$198,221
Detection of 5-hmC as a Novel Screening Biomarker for Pa		93.394	1R21CA187869-01A1	\$34,106
ECOG Pathology Coordinating Office: Human Specimen Banki	82	93.394	2U24CA114737-08 // PCOGBCMP21	\$135,187
EDRN Pre-Validation Study (EDRN Core Funding)	25	93.394	Activity#0361801 // 4451 // U01CA086402	\$34,088
EDRN Pre-Validation Study/Rectal Nanocytology for Coloni	25	93.394	Activity#0361801//Agmt ID 4542//U01CA086402	\$279,156
Imaging in 2020-VIII: Integrating Molecular Imaging and		93.394	5R13CA162890-03	\$5,864
MRI of Early, Non-Invasive Rodent Mammary Cancers	240	93.394	46968-FP000101/R01CA133490	-\$19,639
MRI-Guided Irreversible Electroporation Ablation for Liv		93.394	1R01CA196967-01	\$21,032
MRI-Monitored Delivery of Sorafenib-Eluting Microspheres		93.394	1R01CA181658-01A1	\$144,122
Nanoscale/Molecular Analysis of Fecal Colonocytes for Co		93.394	5R01CA165309-04	\$637,437
Optical Nanoscale Analysis of Buccal Cells: Transforming		93.394	5R01CA155284-04	\$530,368
Patient-Specific Predictive Modeling that Integrates Adv	279	93.394	748962//R01CA164371	-\$39,978
Quantitative MRI-Guided Nanoembolization for Liver Cance		93.394	5R01CA159178-05	\$473,903
Spectral Markers for Early Detection of Colon Neoplasia	25	93.394	BMC# 3728 Amd 4// 7U01CA111257	\$111,232
Spectroscopy of Blood Supply Changes in Early Precancer		93.394	5R01CA109861-08	\$92,023
Sun Protection Internet-based Program for Kidney Transpl		93.394	1R21CA173196-01 Revised	\$53,018
Targeted Transcatheter Magneto-Mechanical Therapy for He		93.394	1R21CA173491-01A1	\$148,808
Transforming Colorectal Cancer Screening through Multimo	25	93.394	3727//3R01CA156186-06 Amd 3	\$313,168

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA
American College of Surgeons Oncology Group - PSA Agreem	65	93.395
CDK4/6 Inhibitor Therapy for Glioblastoma Multiforme	86	93.395
Children's Oncology Group Central Reviewer	42	93.395
Discovery of Selective MAP2K4 Inhibitors to Target Metas		93.395
ECOG and ACRIN Consolidation - CI Committee	82	93.395
ECOG Clinical Trials - Operations Supplement	82	93.395
ECOG Cytogenetics CYTO39YZ-00	68	93.395
ECOG-ACRIN NCI Community Oncology Research Program (NC	OR 67	93.395
ECOG-ACRIN NCI Community Oncology Research Program (NC	OR 68	93.395
ECOG-ACRIN NCORP Research Base: Cancer Care Delivery Res	s 68	93.395
ECOG-ACRIN Nursing Committee	68	93.395
ECOG-ACRIN Operations Center (PI Committee)	68	93.395
EMR Adverse Drug Event Detection for Pharmacovigilance	254	93.395
Exploiting synthetic-lethal interactions to target tripl		93.395
High Density Lipoprotein Nanoparticles for siRNA Deliver		93.395
Home-Based Symptom Management via Reflexology for Advar	nc 148	93.395
Improving Adherence to Oral Cancer Agents and Self Care	148	93.395
Institutional Membership-Alliance for Clinical Trials in	6	93.395
Intimacy-Enhancing Couples' Intervention for Localized P	191	93.395
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, a		93.395
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induce		93.395
Magnetic Micelles for Catheter-Directed Sorafenib Delive		93.395
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Pa	215	93.395
Molecular Targeting of Diffuse Large B-Cell Lymphoma	54	93.395
Nanovalve Platform: Targeted, Controlled Release of Anti	234	93.395
Novel Biophotonics Methodology for Colon Cancer Screenin		93.395
NRG Oncology Foundation, Inc: Member Institution Purchas	164	93.395
NU JWU07M1 - Multicenter Selective Lymphadenectomy for N	vl 122	93.395
Radiation Therapy Oncology Group Cooperative Extension A	9	93.395
Small molecule CXCR4 modulators as molecular probes for		93.395
SPORE in Prostate Cancer: Admin Core		93.395
Targeting BET Bromodomain in Pancreatic Cancer		93.395
Targeting EZH2 in Germinal Center Derived B-Cell Lymphom	120	93.395
Tele-based Psychosocial Intervention for Symptom Managem		93.395
The Role of Cidofovir and Structural Analogs as Adjuvant	210	93.395

Sponsor Award Number	FY15 Expense
GCID Site: 73/ Agmt 3-23-01	\$14,630
410676_GR410676//R01CA159467	\$223,032
9500010213-XXXX//U10CA098543	\$14,699
1R01CA188015-01A1	\$152,391
Sub#GICEAMAB-00//232517-U10CA086802	-\$1,463
Check 071026 / U10CA021115-38	\$2,040
U10CA180820-01-NWU 1//U10CA180820	\$23,838
1UG1CA189828-01-NWU1/UG1CA189828-01	\$113,701
1UG1CA189828-01-NWU1/UG1CA189828-01	\$9,320
UG1CA189828	\$8,383
U10CA180820-01-NWU3	\$3,606
U10CA180820-01-NWU2	\$32,863
WA00237720/RFS2015095	\$68,201
4R00CA175700-03	\$169,659
5R01CA167041-04	\$397,442
RC100551NWU//R01CA157459-01	\$42,767
RC103514NU//R01CA162401	\$26,481
Fully-executed 11/13/13	\$52,458
8164//5R01CA140297-05	\$30,671
2R01CA152601-06A1	\$128,988
5R01CA152601-05 REVISED	\$186,850
1R21CA185274-01A1	\$60,083
5010960-SERV//R01CA164311	\$3,272
14060822 Amendment #6//R01CA143032	\$94,313
0518 G MB529 // 5 R01 CA133697 - 05	\$27,687
5R01CA128641-05	\$907,349
Agmt Signed 9/5/14	\$35,320
Agmt signed 11.11.11// P01CA029605	\$1,541
Prime Grant # CA21661	\$197,240
1R01CA189074-01A1	\$70,695
3P50CA090386-10S1 REVISED	\$288,635
5R01CA186885-02	\$265,354
14040470//1R01CA187109-01	\$71,147
5R01CA157809-04	\$631,484
571003 B.01//R01CA184283	<u>\$171,100</u>
	\$4,525,777

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
(B7H1) Mediated Immunosuppression in Glioma		93.396	5R01CA164714-03	\$282,023
Active Viral Hepatitis Diagnostics to Support Prevention		93.396	5UH2CA189965-02	\$335,601
Activin Signaling and Regulation in the Colon		93.396	5R01CA141057-04	-\$46
An In vivo Metastasis Sensor	258	93.396	3003585711//7R01CA173745-04	\$175,315
An In vivo Metastatis Sensor		93.396	5R01CA173745-03 Revised	\$38,732
Arsenic Trioxide Activated Pathways in Malignant Cells		93.396	5R01CA121192-09	\$293,917
CD73 and Tumor Immunity		93.396	5R01CA149669-06	\$440,894
DICE - a natural cancer surveillance mechanism - a new r		93.396	1R35CA197450-01	\$38,697
Dot 1 Complex, Transcriptional Elongation Control and Hu		93.396	7R01CA089455-15	\$132,497
ELMO1, Dock180 and Glioma Invasion		93.396	5R01CA130966-4	-\$6,139
Elucidating the Role of miR-31 in Retinoblastoma Invasio	15	93.396	901481-NU//R21CA167225	\$15,710
Fas protects cancer stem cells from death		93.396	1R01CA178048	\$194,123
Genetic Modifiers for Cancer Stem Cells in Secondary MDS		93.396	5R21CA159203-02 REVISED	\$138,239
Influence of AKT Pathway on Progesterone Receptor Functi		93.396	5R01CA155513-02	\$352,276
Integrating Epigenomic and Nuclear Receptor Signaling in		93.396	1R01CA196270-01A1	\$50,626
Interferon-Induced SLFNs and Tumorigenesis		93.396	5R01CA161796-05	\$302,670
Investigating the mechanisms of CD44s splice isoform in		93.396	1R01CA182467-02	\$290,486
Mechanism and Control of the "Predatory," Levy Walks of		93.396	5R21CA173232-02	\$106,641
Mechanisms of Leukemogenesis in Down Syndrome		93.396	2R01CA101774-13	\$308,694
Microsystems for Targeting Levy Walks in Metastatic Canc		93.396	5R21CA173347-03	\$115,360
Mitochondrial Metabolism and ROS Regulate Lung Cancer		93.396	5R01CA123067-09	\$193,629
Mnk Pathways and IFN-responses in Malignant Cells		93.396	5R01CA155566-05	\$300,130
Modulation of Oncogenic Signaling in Glioblastomas		93.396	3R01CA159811-04S1	\$428,242
Molecular Targets of Tranlocation T(14:4) in Multiple My	288	93.396	WU-14-307//1R01CA175349	\$17,739
Proinflammatory T Regulatory Cells in Colon Cancer		93.396	1R01CA160436-01A1	-\$80
Prostate Cancer Recurrence: models and mechanisms		93.396	5R01CA167966-04	\$347,435
Regulation of Desmosomal Cadherins in Oral Cancer		93.396	5R01CA122151-09	\$191,380
Regulation of MicroRNA Silencing by Tumor Suppressor PTE		93.396	5R21CA161483-02	-\$3,596
Role of a Novel THAP-Family Protein in Transcription and		93.396	R01 CA133755	-\$2,243
Role of Cdc25A in Breast Cancer		93.396	5R01CA112282-10	\$208,194
Role of Oncogenic Kinase Pim-1 in Prostate Cancer		93.396	5R01CA123484-08	\$446,514
Signal Transduction of Type 1 Interferons in Malignant C		93.396	5R01CA077816-17	\$338,318
Signal Transduction of Type I Interferons in Malignant C		93.396	5R01CA077816-14	-\$90
Sirt2 Directs Kras IR Cell Resistance and Tumorigenesis		93.396	5R01CA182506-02	\$274,315
The COMPASS family of H3K4 methylases in development and	d	93.396	7R01CA150265-07	\$426,665
The Role of Beta-Adrenergic Signaling in Prostate Cancer		93.396	5R00CA129565-05	-\$3,058

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
The role of deubiquitinating enzyme USP33 in Slit-Robo s		93.396	5R01CA175360-02	\$404,418
The Role of Fas as a Tumor Promoter		93.396	5R01CA112240-10 REVISED	\$222,629
The role of ICSBP in the pathogenesis of chronic myeloid		93.396	5R01CA174205-03	\$378,983
The Role of MicroRNAs in Tumor Progression		93.396	5R01CA149356-14	\$175,292
The Role of NOV (CCN3) in Prostate Cancer Progression		93.396	5R01CA172384-02	\$374,743
Transcriptional Functions and Targets of the MMSET Prote		93.396	5R01CA123204-05 REVISED	-\$329
Triad1 regulates myelopoiesis and functions as a leukemi		93.396	1R01CA195642	\$76,291
UTX, MLL and Pathogenic Deregulation of Histone Methylat		93.396	5R01CA180475-02	\$275,439
				\$8,677,276
Brain Tumor SPORE Grant (Project 4: Overcoming Local and	237	93.397	7876sc//2P50CA097257-12	\$142,767
Coding, Decoding, Transfer, and Translation of Informati		93.397	5U54CA143869-05 REVISED	\$1,246,579
ECOG/FSTRF PSA for ECOG Clinical Trial Protocols	82	93.397	Agmt 8/13/12 / U01CA021115	\$285,480
Improving Quality of Life among Hispanic/Latino Breast,	275	93.397	157149/156826//U54CA153511	\$130,663
Nanomaterials for Cancer Diagnostics and Therapeutics		93.397	5U54CA151880-05	\$2,129,245
NU NEIGHBORS: A Social Science Partnership to Reduce Can		93.397	5P20CA165592-04	\$206,067
Spatio-Temporal Organization of Chromatin and Informatio		93.397	1U54CA193419-01	\$160,944
SPORE in Prostate Cancer		93.397	1P50CA180995-01A1	\$1,819
Targeting the Multiple Myeloma Epigenome: Project 4	59	93.397	1145412 / 5 P50 CA100707-12	\$166,808
The Robert H. Lurie Comprehensive Cancer Center		93.397	3P30CA060553-18S5	-\$46
The Robert H. Lurie Comprehensive Cancer Center		93.397	3P30CA060553-21S1	\$4,775,933
				\$9,246,259
A Highly Specific, Tissue-Permeable Inhibitor of Gli Tra		93.398	1F31CA186761-02	\$33,357
Alternative Splicing of Amyloid Precursor-Like Protein 2		93.398	1F30CA196118-01	\$23,805
Assessment, Development and Application of Positive Psyc		93.398	5K07CA158008-03	\$101,999
Cancer Nanotechnology in Imaging and Radiation Oncology		93.398	5R25CA132822-04	\$165,101
Carcinogenesis Training Program		93.398	5T32CA009560-29	\$327,811
Clinical Oncology Research Training Program		93.398	T32CA079447	\$179,231
Development & Dissemination of Education in Pediatric Pa	43	93.398	Agr. 10/14/14//5R25CA151000-05	\$68,767
Development of an MRI gene and application to probing th		93.398	5F31CA174281-03 REVISED	\$43,767
Fellowship for Chelsey Spriggs: The Role of The Fanconi		93.398	5F31CA192801-02	\$32,440
Molecular Mechanism of Hepatocyte Growth Factor Signalin		93.398	5F30CA177193-03	\$45,206
Novel Pathway Analysis Methods for Identifying Genomic c		93.398	5K22CA148779-03	\$140,786
NRSA Fellowship for A. Cogswell in Support of A Novel R		93.398	5F32CA189413-02	\$47,351
NRSA Fellowship for Elizabeth Tarasewicz in Support of:		93.398	5F31CA168106-03	\$11,395

Research Type/Federal Grantor/Subagency/Project Title Pass-th	rough ID (CFDA	Sponsor Award Number	FY15 Expense
NRSA Fellowship in Support of Synthesis and Evaluation o	ç	93.398	5F31CA132617-03	-\$1,800
NRSA Postdoc Fellowship for E Beauchamp in support of: T	(93.398	1F32CA183536-01	\$48,137
NRSA: Depth-Resolved Imaging of Alterations in Mucosal M	ę	93.398	5F31CA144561-04	\$1,569
Overcoming Temozolomide Resistance using MGMT-targeting	ę	93.398	5F30CA174058-03 REVISED	\$36,976
Real-Time Analysis of Diet and Activity Data	ę	93.398	5K07CA154862-04	\$122,146
Targeted Delivery of Nanodiamonds for Breast Cancer Imag	ę	93.398	5F30CA174156-03	\$61,321
The role of E-cadherin phosphorylation in regulating cel	ę	93.398	5F30CA171944-02	\$48,281
The Role of HMGN2 in Enhancing Transcription During Prol	ę	93.398	5F30CA171858-04	\$43,089
Training Program in Oncogenesis and Developmental Biolog	ę	93.398	5T32CA080621-12	\$174,204
Training Program in Oncogenesis and Developmental Biolog	ę	93.398	T32CA080621	\$13,704
Training Program in Signal Transduction in Cancer	Ş	93.398	5T32CA070085-19	\$176,763
				\$1,945,406
ECOG-ACRIN Patient-Centered Outcomes and Survivorship Co	82 9	93.399	POSC28LW-00//5U10CA037403-28	-\$1,821
Acute Kidney Injury and Double Negative T Cells	123	93.647	2002524940//1R01DK104662-01	\$2,835
ARRA - Genome-Wide Association Scan of Polycystic Ovary Syndrom	(93.701	R01HD057223	-\$26
ARRA - POINT: Platelet-Oriented Inhibition in New TIA	70 9	93.701	Agreement signed 11/9/10 // 1U01NS026835-01A1	\$24,006
ARRA - Use of Behavioral Economics to Improve Treatment of Acut	271 9	93.701	H47012//RC4AG039115	-\$386
CTOT-18: A Retrospective Multicenter Study to Determine	101 9	93.701	0255-1358-4424//U01AI063594	\$1,618
ECOG PCO-RL: Interaction of Anti-Angiogenic and Cytotoxi	267 9	93.701	560098//5R01CA139003-04	-\$3,095
				\$22,117
4D Magnetic Resonance Imaging for Atrial Flow Assessment	(93.837	5R21HL113895-02 REVISED	\$121,236
A novel gut microbial-dependent nutrient metabolite and	264 9	93.837	5101819//K01HL127159	\$10,028
A novel implementation and social network strategy for a	Ş	93.837	5K23HL118139-03	\$147,977
ACTG Supplemental Funding for Protocol A5314	27 9	93.837	7389sc//5R01HL117713-02	\$28,383
Acute Coronary Syndrome Quality Improvement in Kerala (A	Ş	93.837	4R00HL107749-03	\$248,187
Association of Sleep Disorders with Cardiovascular Healt	27 9	93.837	105963//5R01HL098433-05	\$34,333
AsthmaNet Clinical Trials	172 9	93.837	NWUHL098115 // 5U10HL098115	\$563,648
Atrial arrhythmias and Ca2+ waves in HF: simulation and	Ş	93.837	5R01HL119095-02	\$620,869
BEST-CLI: Trial to Compare Best Endovascular versus Best	157 9	93.837	Agr. 8/7/14 // U01HL107407	\$20,492
Beyond PECAM: Mechanisms of Transendothelial Migration	g	93.837	5R37HL064774-13 REVISED	\$265,402
Blood Markers of Vulnerability in High Risk Vascular Pat	g	93.837	R01HL089619	\$124,662
Cannabimimetic Treatment of Obstructive Sleep Apnea: A P	248 9	93.837	2011-06400-01-02-KM / UM1HL112856	\$539,691
Cardiomyopathy Genomes Project	(93.837	1R01HL128075-01	\$55,826

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Cardiovascular Regenerative Medicine		93.837	5P01HL108795-05	\$2,168,608
Chicagoland Metropolitan AsthmaNet Consortium		93.837	5U10HL098096-07	\$976,458
Childhood Origins of CHD Disparities: Neural & Immune Pa		93.837	1R01HL122328-01A1	\$348,223
Comparing and Combining Bortezomib and Mycophenolate in		93.837	1R34HL122558-01A1	\$61,579
Comprehensive Cardiac Structure-Function Analysis in Hea		93.837	5R01HL117888-02	\$470,985
Computer Modeling and Cardiac MR of Structural Factors o		93.837	R21HL110041	\$13,308
CXCR4-c-Kit Signaling and BM Progenitor Cell Recruitment		93.837	5R01HL113541-04	\$350,894
Decrypting Variants of Uncertain Significance in Long-QT		93.837	5R01HL122010-02	\$1,175,380
Determinants of Midlife & Longitudinal Change in Cogniti	128	93.837	RNG200103-NW//R01HL122658	\$30,613
Disruption of Autonomic Pathways in the Left Atrium by I		93.837	5R01HL093490-05 REVISED	-\$18,890
E2F1 in Cardiac Neovascularization		93.837	5R01HL093439-04 Revised	-\$61,846
Efferocytosis Directed Inflammation Resolution and Repai		93.837	3R01HL122309-02S1	\$352,015
Efferocytosis in CVD & Inflammation		93.837	R00HL097021	-\$3,684
Epidemiologic Determinants of Cardiac Structure and Func	287	93.837	WFUHS 110855//5R01HL104199-04	\$33,861
Exploiting Tie2 Activation for the Treatment of Vascular		93.837	5R01HL124120-02	\$399,354
Exploring the roles of Gi and S1Pr1 in endothelial barri		93.837	7K08HL105657-05	\$86,647
F32 for Mazen Saadi Albaghdadi in Support of: Evaluation		93.837	5F32HL118976-03	\$47,771
Favorable Cardiovascular Health and the Compression of M		93.837	5R01HL118289-02	\$307,884
Femoral Plaque Composition, Oxidative Stress, and Corona		93.837	5R01HL109244-04	\$390,154
FIGHT: Functional Impact of GLP-1 for Heart Failure Trea	66	93.837	193603//U10HL084904	\$9,967
Functional Cardiovascular 4D MRI in Congenital Heart Dis		93.837	5R01HL115828-04	\$420,883
Genotype-Phenotype Discordance in Long QT Syndrome	35	93.837	RES126034 Amd 1//R01HL124245	\$33,621
HCMR - Novel Predictors of Outcome in Hypertrophic Cardi	102	93.837	Study# 2222/0003//1U01HL117006-01A1	\$43,675
Hemodynamic Loading of the Left Ventricle and Aorta in A		93.837	5K25HL119608-02	\$119,040
Hispanic Community Children's Health: Study of Latino Yo	264	93.837	5-31265//5R01HL102130-04	\$23,728
Hypercapnia and Neutrophil Function in Pulmonary Host De		93.837	5K01HL108860-05	\$152,261
Identifying risk factors for subclinical myocardial dise	123	93.837	2002507820 Amend. # 1// R01HL126552	\$26,963
Imaging Vascular Phosphatidylethanolamine		93.837	5R01HL102085-05	\$214,073
Implantable Monitor-Guided Anticoagulation for Non-Perma	23	93.837	01027545//7R34HL113404-03	\$69,746
IRONOUT-HF: Oral Iron Repletion effects On Oxygen UpTake	66	93.837	177494/200464/029692//U10HL084904	\$4,904
Joint Effect of Malpractice Risk and Financial Incentive	85	93.837	14-M49//7R01HL113550-02	\$70,605
Longitudinal Study of Cognition, Health Literacy, and Se	101	93.837	0255-4335-4609//R01 HL105385	\$218,349
Low InTensity Exercise intervention for peripheral arter		93.837	1R01HL122846-01A1	\$166,721
Make Better Choices (MBC) - Multiple Behavior Change in		93.837	5R01HL075451-09	\$359,780
Maternal-Offspring Metabolics: Family Intervention Trial		93.837	3U01HL114344-04S1	\$940,231
Mechanisms of Oxygen Sensing		93.837	5R21HL112329-02	\$103,920

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Mechanisms of sulfonylurea receptor mediated cardiomyopa		93.837	1R01HL122109	\$330,894
Mechanistic Insights into the Cardioprotective Effects o		93.837	5K02HL107448-05	\$103,518
Mediators of Atherosclerosis in South Asians in America	237	93.837	8696sc//2R01HL093009-05	\$71,197
Mediators of impaired fetoplacental angiogenesis in feta		93.837	1R01HL119846-01A1	\$112,899
Metabolomics-Measured Urinary Metabolites/Diet & BP, 17		93.837	5R01HL084228-08	\$261,527
Modeling the role of the genome in chemotherapy induced		93.837	4R00HL121177-02	\$8,638
MtDNA variant modifiers of cardiopulmonary responsivenes	245	93.837	UFDSP00010117//PR01HL121023	\$12,964
Multi-Center Trial of Limiting PGY2&3 Resident Work Hour	27	93.837	108591 / U01HL111478	-\$14,452
Multi-Ethnic Study of Autoimmunity and Cardiovascular Di		93.837	5R01HL104047-04 REVISED	\$226,214
NEAT:Nitrates Effect on Activity Tolerance in Heart Fail	66	93.837	200464//U10HL084904	\$24,959
Neonatal Long QT Syndrome and Sudden Infant Death		93.837	5R01HL083374-08	\$184,423
NO Inhibits Arterial Injury After Vascular Procedures vi		93.837	5R01HL108118-05	\$504,605
Non-invasive detection of heart transplant rejection wit		93.837	5F31HL117618-03	\$32,932
Novel Approaches to Ischemic Tissue Repair		93.837	R01 HL095874	-\$328
Novel Vehicles for Targeted Cardiovascular Repair		93.837	5R01HL116577-03	\$1,075,621
NRSA F32 for Matthew DeBerge in support of: Efferocytosi		93.837	1F32HL127958	\$22,271
NRSA F32 Postdoc Fellowship for Elaine Gregory in suppor		93.837	1F32HL114255-01A1	\$1,556
nuMOM2b Hearth Health Study Capitation Funding Memorand	lu 186	93.837	0214047//1U10HL119991	\$163,476
PACEmaker & ß-Blocker Therapy Post-Myocardial Infarct		93.837	5U01HL080416-04 REVISED	\$162,174
PAI-1 and Vascular Senescence		93.837	5R01HL051387-19	\$481,293
Parents' Dense and Supportive Social Networks Facilitate		93.837	5F32HL119021-02 REVISED	\$46,956
Pathophysiological Significance of Atrial Fibrillation E		93.837	1R01HL125881-01A1	\$25,864
Pediatric Heart Transplantation: Transitioning to Adult	15	93.837	901477-NU//1R34HL111492-02	\$60,909
Phagocyte Intoxication by ExoU in Pseudomonas Pneumonia		93.837	5F30HL107092-04 Revised	\$18,674
PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study	27	93.837	104005//5R01HL091069-04	\$8,670
Pregnancy as a Window for Future Cardiovascular Health		93.837	5U10HL119992-03	\$91,702
Pregnancy as a Window to Future Cardiovascular Health: A	186	93.837	888-15-16-12//4-312-0214047-51982L	\$22,539
Transition from Risk Factors to Heart Failure: Prevalenc	287	93.837	WFUHS114486//R01HL127028	\$549
PROgenitor Cell Release Plus Exercise to Improve Functio		93.837	5R01HL107510-05	\$1,069,338
Progression of Coronary Atherosclerosis in MACS	123	93.837	2002350097//R01HL125053	\$105,693
Refining Conceptual Models for the Role of Health Litera	25	93.837	0341401//1R01HL116630	\$138,800
REPRIEVE A5332 and A5333s	139	93.837	PS#225707//U01HL123336-01	\$1,616
Research Coordination Unit - Translating Basic Behaviora	190	93.837	U01HL097894	\$110,261
Research Training in CVD Epidemiology and Prevention		93.837	5T32HL069771-12 REVISED	\$189,671
Research Training in CVD Epidemiology and Prevention		93.837	T32HL069771	-\$189
Respiratory and Metabolic Adaptation to Hypoxia		93.837	2R01HL035440-27	\$46

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
REVIVE-IT Randomized Evaluation of VAD InterVEntion Befo	258	93.837	3001810570 // HHSN268201100026C	-\$10,178
Risk Stratification in Older Persons with Acute Myocardi	294	93.837	Agmt 8/30/13//R01HL115295	\$31,296
Role of CC Chemokine Ligand 23 in Chronic Rhinosinusitis		93.837	5R21HL113913-02 REVISED	\$118,140
Sarcoglycan in Myopathy and Muscle Membrane Stability		93.837	7R01HL061322	\$251,144
Social and Cultural Influences on Cardiovascular Risk in		93.837	5R01HL120725-02	\$756,799
Statistical methods to correct for measurement error in		93.837	1R01HL127491-01	\$43,185
Study of Cardiac Mechanics in Systemic Hypertension		93.837	5R01HL107577-04	\$208,501
Targeting Depression and Nicotine Dependence to Promote		93.837	1F31HL129494-01	\$1,910
The F-Bar Protein CIP4 in WAS-Dependent Thrombocytopenia		93.837	R21HL106462	-\$16,962
The Role of CD99 in Leukocyte Transendothelial Migration		93.837	5F30HL116100-03	\$49,771
The Role of Group 1 CD1-Restricted T Cells in Atheroscle		93.837	5R21HL112186-02 REVISED	\$121,110
The Role of MicroRNA210 in Cardiomyocyte Response to Ich		93.837	5R01HL104181-04	\$232,636
The Roles of Endothelial Cell PECAM and the LBRC in leuk		93.837	5R01HL046849-23	\$214,109
Therapeutic Mechanisms of Human CD34 Exosomes		93.837	1R01HL124187	\$14,184
Training Grant in Circadian and Sleep Research		93.837	5T32HL007909-17	\$271,972
Translating a Heart Disease Lifestyle Intervention into		93.837	5R21HL113743-02 REVISED	-\$1
Vascular Surgery Scientist Training Program		93.837	5T32HL094293-05	-\$8,134
Vascular Surgery Scientist Training Program		93.837	5T32HL094293-07	\$195,357
				\$21,020,834
5 -Hydroxytryptophan Regulation of Endothelial Cell Sign		93.838	5R01HL111624-03	\$421,748
A Randomized Double-Blind Placebo-Controlled Trial of Ga	81	93.838	0000788107//5U01HL102547-03	\$9,806
Chitinase1 as a biomarker and therapeutic target in scle	29	93.838	00000755//5R01HL115813-02	\$9,266
CNS Pathways Integrating Respiratory and Metabolic Contr		93.838	5R01HL122921-02	\$512,282
CPAP Protocol: Effect of Positive Airway Pressure on Red	13	93.838	Award Letter 8/17/12	\$65,343
Effects of Hypoxia on Alveolar Epithelial Cytoskeleton		93.838	5R01HL079190-09	\$73,695
Genes Mediating Innate Immune Suppression by Hypercapnia	1	93.838	5R01HL107629-04 REVISED	\$321,279
Glucocorticosteroid Action in Inflammatory Disease		93.838	5R37HL068546-30	-\$1,310
Glucocorticosteroid Action In Inflammatory Disease		93.838	5R37HL068546-32	\$288,873
High carbon dioxide impairs lung repair		93.838	1K08HL125940-01A1	\$1,897
Lung Function Decline and Disease Risk from Young Adulth		93.838	5R01HL122477-02	\$527,548
Metabolic Regulation of Pulmonary Vascular Remodeling		93.838	5R01HL122062-02 REVISED	\$665,165
MFMU Network Capitation for ALPS Study	85	93.838	Agmt 4/25/14//U01HL098354	\$13,704
Molecular Mechanisms of Central Chemoreception in Breath		93.838	5R01HL095731-04	\$4,483
Multi-Level Understanding of Social Contributors to SES		93.838	5R01HL108723-03	\$626,073
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma I	234	93.838	1460 G KB116 / R01HL089901	-\$4,279

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
New Approaches for Empowering Studies of Asthma in Popul	123	93.838	2001428327//5R01HL104608-04	\$45,064
Pathophysiology of Acute Lung Injury		93.838	2P01HL071643-11A1	\$9,377
Pathophysiology of Alveolar Epithelial Lung Injury		93.838	5P01HL071643-10 REVISED	\$423,245
Pulmonary Microvascular Blood Flow and Cor Pulmonale Par	48	93.838	5(GG007619) // R01HL093081	\$23,338
Pulmonary Vascular Changes in Early Chronic Obstructive	48	93.838	5-36361/ A02/ 5 R01HL093081-04	-\$275
Redox Regulation of Vascular cGMP Signaling in Neonatal		93.838	5R01HL109478-05	\$396,720
Regulation of Inflammation and Acute Lung Injury by the		93.838	5R01HL114763-02 REVISED	\$571,527
Respiratory and Metabolic Adaptation to Hypoxia		93.838	5R01HL035440-26	\$124,602
Right Ventricular-Pulmonary Vascular Interactions in Pul	280	93.838	337K960/R01HL105598	\$165,245
Role and Regulation of Sodium, Potassium ATPase in Lung		93.838	5R37HL048129-21	\$463,300
Role for Wnt/beta-Catenin Signaling in Alveolar Repair a		93.838	5R01HL094643-04 REVISED	\$135,389
Role of Group 1 CD1-restricted T cells in Mycobacterium		93.838	1F32HL126376-01	\$17,081
Role of the Na K ATPase Beta 1 subunit in alveolar epith		93.838	5R01HL113350-03	\$410,524
Role of vimentin in influenza A-induced acute lung injur		93.838	5R01HL124664-02	\$547,811
Role of Wnt/b-Catenin Signaling in Pulmonary Fibrosis		93.838	5K08HL093216-05	\$29,106
Safety and Efficacy of Aerosolized Xylitol in Cystic Fib	250	93.838	1001066707//5U01HL102288-03	-\$22,798
Study of Soy Isoflavones in Asthma (SOYA)		93.838	U01HL087987	-\$26,176
Substrate Stiffness Regulates Alveolar Epithelial Cell B		93.838	5R01 HL092963-05 Revised	\$79,509
The deleterious effects of hypercapnia on the lungs		93.838	2R01HL085534-09	\$363,379
The Injurious Effects of Hypercapnia on the Alveolar Epi		93.838	5R01HL085534-08 REVISED	\$102,669
Training Program in Lung Science		93.838	5T32HL076139-10 REVISED	-\$4,276
Training Program In Lung Sciences		93.838	5T32HL076139-12	\$426,951
Treating Lung Inflammation by Targeting Siglecs	123	93.838	2001901746//5P01HL107151-05	\$259,189
Trial of Late SURFactant (TOLSURF) to Prevent BPD (Clini	237	93.838	6069sc / U01HL094338	\$34,447
				\$8,110,521
Aberrant Megakaryopoiesis in the Myeloproliferative Neop		93.839	5R01HL112792-03	\$488,847
Autonomic, Endothelial, and Inflammatory Correlates of S		93.839	4R01HL092140-03	\$7,187
Coboglobins-Cobalt-Substituted Hemoglobins and Myoglobin		93.839	5R01HL013531-41	-\$116,304
Cyclin E Regulation in Normal and Neoplastic Hematopoies		93.839	5R01HL098608-03	\$17
EHR Anticoagulants Pharmacovigilance	254	93.839	WA00273405/RFS2015140	\$63,181
Electron Transfer Within Protein Complexes		93.839	5R01HL063203-17 REVISED	\$332,411
FGF-23 and the Risk of Stroke and Cognitive Decline	257	93.839	66917H/5R01HL108623-04	\$60,673
Functional Analysis of mDia Formins in Hematopoietic Ste		93.839	5R00HL102154-04	\$129,440
Membrane-Cytoskeletal Remodeling in Platelet Biogenesis		93.839	1K08HL114871-01A1	\$30,260
Motors Regulating Targeted Recycling of the Lateral Bord		93.839	5F31HL114374-03	\$33,779

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Quantitative renal oxygenation assessment with compartme		93.839	1F31HL123360-01A1	\$23,039
Vascular-Targeted Genomic and Genetic Strategies for Acu	248	93.839	2012-04562-04-00//R01HL111656-03	\$7,141
				\$1,0 <mark>59,671</mark>
A novel desmosomal COP9 signalosome complex in epidermal	l	93.846	1F32AR066465	\$23,360
A prospective study of human bone adaptation using a nov	293	93.846	15-210750-00//7R01AR063691-03	\$12,520
A regulatory checkpoint in the pathogenesis of inflammat		93.846	3R01AR064349-03S1	\$324,543
Adaption and Validation of PROMIS for use in Vasculitis	267	93.846	560224//1R01AR064153-01 - PO#3100291	\$6,821
Adipokine Modulation of Fibrosis: Novel Scleroderma Path		93.846	1R03AR066343-01A1	\$39,411
Association of genetic and autoantibody signatures with	226	93.846	000504653-SC002//1R01AR064820-01A1	\$53,396
Biomarkers and Pathogenesis of Systemic Sclerosis (NIAMS	26	93.846	4500001687//5P50AR06078-04	\$30,099
Caspase 8: A Novel Suppressor of Dendritic Cell-Mediated		93.846	5K01AR064313-03	\$133,598
Desmoplakin Assembly and Function in EpidermisDesmoplaki		93.846	5R37AR043380-20	\$513,030
Developing a Nrf2 activator for the treatment of sclerod	57	93.846	Agr. FE 11/11/2014//1R41AR066418-01	\$127,227
Development of a Novel RA/Atherosclerosis Mouse Model		93.846	5R01AR064546-03	\$305,758
Dynamic Instability in Persons with Knee Osteoarthritis		93.846	R01AR048748	\$654
EphA/Ephrin-A Signaling in Epidermal Differentiation and		93.846	5R01AR062110-04	\$443,383
Failed Regeneration in the Muscular Dystrophies: Inflamm	267	93.846	554991//5U54AR052646	\$205,749
Failed Regeneration in the Muscular Dystrophies: Inflamm	267	93.846	564991//5U54AR052646	\$5,376
Function of Desmoglein 1/Pemphigus Foliaceus Antigen		93.846	5R01AR041836-23	\$528,115
Functional and Structural Links Between Cadherin Adhesio		93.846	5R01AR057992-05	\$273,304
Gene expression signatures for treatment response in sys	37	93.846	Agr. 10/06/2015//5R44AR061920-03	\$65,793
Genome Wide Association Study in African Americans with	226	93.846	Agmnt 11/14/13 //R01AR057202	-\$7,499
Human Rheumatoid Arthritis in Mice		93.846	5R03AR061593-02	\$64,273
In Situ Measurement of Sarcomere Operating Range in Pass		93.846	5R21AR062867-02 REVISED	-\$23
Inflammasome adaptor and effectors in Cryopyrinopathies		93.846	1K01AR066739-01A1	\$38,552
Intercadherin Interactions in Epithelial Cells		93.846	5R01AR044016-18	\$344,953
Knee OA: Predictors and Outcomes of Physical Inactivity-		93.846	5R01AR054155-08	\$341,030
Long-term Significance of Pre-radiographic Lesions in Pe		93.846	R01AR065473-02	\$726,261
Mechanisms Underlying Heterotopic Ossification		93.846	1R01AR066539-01A1	\$172,190
Mobil-Wise: Mobile Phone Remote Coaching After Worksite	190	93.846	Agmt 4/24/15//1R21AR065054-01A1	\$62,359
Molecular Basis of Fibrosis: Regulation of Collagen		93.846	5R01AR042309-21	\$17,358
Molecular biomarkers of improvement for patients with sy	60	93.846	R284/1R21AR068035-01 REVISED	\$3,016
NIAMS Multidisciplinary Clinical Research Center in Rheu		93.846	5P60AR064464-03	\$829,217
NIAMS: Core Center - Proteomics and Clinical Core	26	93.846	4500001682//5P30AR061271-04	\$136,785
Northwestern University Skin Disease Reseach Core Center		93.846	2P30AR057216	\$683,491

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Northwestern University Skin Disease Research Core Cente		93.846	P30AR057216	-\$1,200
OAI Ancillary- Prediction of Incident and progressive OA	228	93.846	238323 Amend 1//R01AR066601	\$19,427
Osteoarthritis Progression and Sensory Pathway Alteratio	190	93.846	5R01AR064251-03 Amd 2	\$193,374
Planning Activity and Nutrition Trial in Lupus to Energi		93.846	5U34AR064513-02	\$351,997
Post Graduate Program In Cutaneous Biology		93.846	5T32AR060710-04	\$134,754
Postdoctoral Rheumatology Training		93.846	5T32AR007611-14	\$308,931
Predictive ability of gene expression signatures in skin		93.846	5K23AR059763-03	\$142,513
PROMIS Statistical Center		93.846	U54AR057951	\$252,910
Pt Reported Outcomes Measurement Information System Tec	h	93.846	3U54AR057943-04S3	\$244,699
RhEumatoid Arthritis SynOvial tissue Network (REASON)		93.846	3UH2AR067687-01S2	\$141,473
Role of CCR7 in Clinical Response in Inflammatory Arthri		93.846	5R21AR065076-02	\$160,082
Role of Stress-Response Protein gp96 in the Persistence		93.846	R01AR055240	-\$15,172
Sedentary Behavior Characteristics, Sedentary Profiles,		93.846	1R21AR068500-01	\$4,912
Simultaneous Targeting of IRE1a in B Cells and Macrophag		93.846	5R01AR066634-02	\$377,269
Synthetic Oleananes: Innovative Treatment of Fibrosis		93.846	5R03AR065800-02	\$48,032
Targeting Adiponectin Signaling: Novel Peptide Therapy f		93.846	1R21AR064925-02	\$241,804
The GIT2-PIX-PAK Complex in T cell Migration, Activation		93.846	5K01AR059754-06	\$100,675
The Vasculitis of Kawasaki Disease		93.846	1R21AR068041-01	\$14,234
Therapeutic Role for P21 in Suppressing IL-1 beta Mediat		93.846	5R01AR050250-10	\$194,038
Topical Delivery of siRNA Nanoconjugates: Suppressing Ep		93.846	5R01AR060810-04	\$321,523
Topically-delivered Mutation-specific Gene Targeting for	77	93.846	AGMT 8/15/14//1R43R066387-01	\$72,007
Topically-delivered Targeted Gene Suppression of Immune	77	93.846	AGMT 11/10/14//1R41AR066438	\$88,000
Validation of PROMIS Measures in Children with Brain Tum		93.846	5R01CA174452-04	\$240,793
				\$10,141,175
A Multi-Center Study of Acute Liver Failure in Adults	276	93.847	GM0111125//U01DK058369	\$138,259
A novel autophagy gene beclin 2 in the prevention of typ		93.847	5R00DK094980-04 REVISED	\$376,341
A2ALL-Patient Safety System Improvements in Living Donor		93.847	R01DK090129	\$581,142
Adduct Dipstick for Diagnosis of Acetaminophen Toxicity	17	93.847	034815 // R42 DK079387	-\$7,186
Adult Life Predictors of Genitourinary Disorders	128	93.847	115-9107-03-M1//5R01 DK084997-04	\$83,874
An Assessment of Liver Disease in HIV-infected and HIV/H		93.847	5K23DK095707-03	\$147,822
Basic Science Training Grant in Urology		93.847	5T32DK062716-10	\$112,892
Brain imaging based strategies for treating UCPPS pain		93.847	1R01DK100924-01	\$182,302
Calcium Handling and Secondary Hyperparathyroidism in Ch		93.847	5K23DK087858-06	\$289,034
Chemokine Mechanisms in Chronic Pelvic Pain		93.847	5R01DK083609-05	\$231,224
Cholestasis and the Unfolded Protein Response		93.847	5R01DK093807-04	\$399,832

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Circadian control of nutrient-sensing and fuel utilizati		93.847	1K01DK105137-01	\$35,854
Clinical Islet Transplantation: Data Coordinating Center	250	93.847	1001259991/2U01DK070431-11	\$145,892
Collaborative Islet Transplant Registry (CITR)	70	93.847	CITR Agmt 4/22/2013	\$6,779
Community Translation of a Lifestyle Intervention to Imp		93.847	5R18DK083941-06	\$355,918
Community-Clinic Partnership to Promote Physical Activit		93.847	1R56DK099680-01A1	\$152,924
Defining Clinically Relevant Phenotypes of PPI Non-Respo		93.847	5R01DK092217-03	\$220,650
Diabetes Prevention Program Outcomes Study- Phase 2		93.847	5U01DK048380-21	\$192,615
Disordered Mineral Metabolism in the CKiD Children: Role	237	93.847	7904sc//R01DK084978	\$25,838
DPPOS Follow-Up		93.847	2U01DK048380-22	\$112,428
ECDI Coupled Cells for Tolerance in Allogeniec Islet Cel		93.847	DP2 DK083099	-\$763
Effect of Barrier Function on HIV Interactions in the GI		93.847	1R21DK105865-01	\$2,402
Epidemiology of Diabetes Interventions and Complications	35	93.847	RES509274//DK094157	\$132,832
Establishing Immunological Tolerance to Transplanted Pan	283	93.847	VUMC38573/2 U01 DK072473-07	\$309
F32 for Joseph Stephen Uzarski in Support of: Delineatin		93.847	1F32DK103499-01A1	\$3,862
Fellowship for Roger Warren Sands in support of: Program		93.847	5F30DK088518-03	\$243
FGF23 and Cardiovascular Disease in CKD		93.847	5R01DK081374-09	\$469,886
FGF-23 and Clinical Outcomes in ADPKD patients	243	93.847	FY15.269.001/AMD 2//5R01DK094796-03	\$222,169
FGF23 and mineral metabolism in Acute Kidney Injury		93.847	5R21DK100754-02	\$100,903
GATA1 Mutation in Defective Erythropoiesis		93.847	5R01DK101329-03	\$383,426
Genetics and Evolution of Fetal Human Fat Accretion Duri		93.847	5R01DK099820-03	\$290,332
Genetics and Genomics of Maternal Glycemia During Pregna		93.847	5R01DK097534-03	\$321,775
Hearing Impairment in Long-Term Type 1 Diabetes	35	93.847	RES508623//1DP3DK101074-01	\$17,657
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follo)	93.847	5U01DK094830-04	\$3,345,804
Impact of Emerging Health Insurance Designs on Diabetes	93	93.847	AH000527//1R01DK100304-01	\$13,138
Impact of phosphate and FGF23 reduction on intermediate		93.847	5R01DK102438-02	\$278,499
Induction of Donor Tolerance in Renal Transplants	180	93.847	BDDB01 6899927v2 // R42 DK074331	-\$47,600
Integration of Feeding and Glucose Metabolism by the Cir		93.847	5R01DK090625-04	\$184,666
Interplay of Dietary Lipid and Circadian Dysregulation i		93.847	5R01DK100814-02	\$594,915
Investigation of FFAR2 as a novel regulator of pancreati		93.847	1F31DK102371-01A1	\$6,422
Living Donor Liver Transplant - Predictive Models for Lo		93.847	5U01DK062467-12	\$33,304
Maternal Obesity and Gestational Diabetes: Impact on Me		93.847	5R01DK095963-03	\$381,158
Measuring Human BAT Volume and Activity by Quantitative	15	93.847	901494-NU//R21DK103145	\$45,929
Mechanisms of Erythroblast Enucleation		93.847	2R56DK074693-06	-\$20,830
Med1 in Liver Metabolism, Regeneration and Cancer		93.847	5R01DK097249-03	\$314,320
Mentored Patient Oriented Research in Mineral Metabolism		93.847	5K24DK093723-04	\$235,148
Methylomics of prenatal GDM: Natural history & lifestyle	171	93.847	1R01DK100790-50363-S2	\$61,001

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Mouse Urinary Bladder Identifying Targets to Treat Overa		93.847	1R01DK095775-01A1	\$118,512
Multifunctional Printed Scaffolds for Enhancing Hepatocy		93.847	5K01DK099454-03	\$146,614
Neurobiological Mechanisms Underlying Effectiveness of C	234	93.847	1556GQB924//5R01DK096606-03	\$17,271
Neutrophil interactions with apical ICAM-1 regulate inte		93.847	5K01DK101675-03	\$134,548
NRSA F30 Fellowship for Alison Affinati in Support of: D		93.847	F30DK085936	\$41,882
NW University Program in Endo Diabetes and Hormone Actio		93.847	5T32DK007169-36	\$304,765
Optimization and control of hepatocyte activity via biof		93.847	5K08DK101757-02	\$175,479
Opt-IN: Optimizing Intensive Lifestyle Interventions for		93.847	5R01DK097364-04	\$409,636
Pathogenesis of Diabetic Nephropathy		93.847	5R01DK060635-14	\$310,328
Patients' and Providers' Perspectives on Metformin for D	240	93.847	FP047431//P30DK092949	\$9,738
Pelvic Pain and Depression		93.847	5U01DK082342-07	\$892,371
PERL: A multicenter clinical trial of allopurinol to pre	126	93.847	1987203-6 AMEND 1UC4DK1101108-01	\$442,756
Phenotype of urinary symptoms and relationships with gen		93.847	5U01DK097779-04	\$378,154
Pilot Studies Targeting Mineral Metabolism in CKD		93.847	5U01DK099930-04	\$286,742
Pregnancy-Related Risk Factors and Glucose Intolerance i	128	93.847	RNG200279-05//R01DK106201	\$7,894
Probiotic Analgesia for Pelvic Pain		93.847	1R56DK102807-01 REVISED	\$135,474
Promotora-Led Intervention to Promote Weight Loss in Lat		93.847	7K23DK095981-04	\$182,726
Proteomics of Primary Hyperoxaluria Type I: A Rare Calci	141	93.847	63868181//U54DK083908	\$14,884
Quality of Informed Consent for Adult-to-Adult Living Do		93.847	R03DK091786	\$20,332
Randomized, double blind, prospective trial investigatin	264	93.847	5-34106//5U01DK092239-03	\$2,986
Regulation of FGF23 by DMP1 in Health and in Chronic Kid		93.847	1R01DK101730-01A1	\$12,556
Regulation of FGF23 in Chronic Kidney Disease (CKD) by i		93.847	1R01DK102815-01A1	\$6,335
Regulation of metabolism and diabetes mellitus by triste		93.847	5F30DK102341-02	\$36,477
Role of FGF23 in Mineral Metabolism Across the Spectrum		93.847	5R01DK076116-09	\$303,347
Signaling Pathways in Renal Fibrogenesis		93.847	5R01DK049362-17	\$299,802
Strategies for ACE2 Amplification to Treat Diabetic Kidn		93.847	R01DK080089	-\$41,800
T cells in Chronic Pelvic Pain		93.847	3R01DK094898-03S1	\$396,764
The Esophagogastric Junction in Health and Disease		93.847	5R01DK056033-14	\$295,018
The mechanics of symptom generation in dysphagia		93.847	5R01DK079902-07	\$390,293
The role of emergency granulopoiesis in the pathogenesis		93.847	5R01DK098812-02	\$311,996
The Role of PAI-1 and Circadian Disruption in the Pathog		93.847	5K08DK095992-03	\$107,646
The Role of the Amygdala in Weight Gain Susceptibility	121	93.847	225 / R01DK085579	\$4,480
The roles of pleckstrin-2 as a functional node in erythr		93.847	1R01DK102718	\$167,916
Training Grant in Gastrointestinal Physiology and Psycho		93.847	5T32DK101363-02	\$143,527
Transcriptional Coactivators in Liver Function		93.847	R01DK083163	\$102,798
Transplant Surgery Scientist Training Program		93.847	5T32DK077662-09	\$147,723

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Tryptase - PAR2 axis involved in urinary voiding dysfunc		93.847	1F32DK104544-01	\$39,881
Urinary Renin Angiotensin System in Diabetes		93.847	1R01DK104785-01A1	\$58,587
Vitamin D and type 2 diabetes (D2d study)	216	93.847	5008752-SERV//U01DK098245-03	\$209,011
Vitamin D Catabolism in Chronic Kidney Disease	279	93.847	UWSC7707//5R01DK099199-02	\$34,152
				\$18,214,942
Self-administered CBT for IBS: A Multicenter Trial	208	93.848	R928233//1U01DK077738	\$90,670
Interactive Mechanisms of Pelvic Pain		93.849	5U01DK082342-05	-\$17,917
(CREST-2) Trial: Carotid Revascularization and Medical M	142	93.853	SP0031679//U01NS080168-01A1	\$14,884
A New Genetic Tool for Analyzing Protocadherin Diversity		93.853	5R03NS079879-02	\$11,403
A Novel Calcium Channel Antagonist for Neuroprotection i		93.853	1U01NS080409-01	-\$26,320
A Primate Model of an Intra-Cortically Controlled FES Pr		93.853	5R01NS053603-10	\$375,300
A role for beta-arrestins in mGluR-dependent plasticity		93.853	5R21NS088916-02	\$240,793
Acetylcholine Receptor Gene in Slow-Channel Syndrome	240	93.853	43277//R01NS033202	\$11,914
AMES Treatment of the Impaired Leg in Chronic Stroke Pat	14	93.853	2 // R44NS060192-02/03	-\$10,059
Assessing Aberrant Motor Learning in Parkinsons Disease	176	93.853	41880-A//1R21NS083578-01A1	\$52,620
B7-H1 Expressing Macrophages Mediate Immunosupression in	n	93.853	5R00NS078055-04	\$216,557
Behavioral and molecular responses to high-intensity exe		93.853	1F31NS084723-02 REVISED	\$29,078
Body-machine interfaces after spinal injury: rehabilitat		93.853	F31NS090877	\$28,984
BRAF Mutation in Malignant Astrocytoma Origin, Evolution		93.853	5R01NS080619-04	\$251,488
Cajal-Retzius cells and neuronal signaling in postnatal		93.853	3R01NS064135-06S1	\$525,697
Cellular dissection of herpes simplex encephalitis with	188	93.853	5R01NS072381-05/Amend. 2	\$131,791
Cellular Pathways Underlying Polyglutamine Degeneration		93.853	5R01NS062051-05	\$169,853
Cerebellar Microcircuits: Organization and Development		93.853	R01NS009904	\$97,457
Cerebral Small Vessels in Motor and Cognitive Decline		93.853	7R01NS085002-03 REVISED	\$6,823
Chemokine Signaling in Diabetic Neuropathy		93.853	5K08NS079482-03	\$272,277
Chronic Pain and Emotional Learning and Memory		93.853	R01NS057704 REVISED	-\$491
Circadian Dysfunction, Encephalopathy, and Cognitive Out		93.853	1K23NS092975-01	\$21,854
C-kit Signaling Pathways Regulate EAE Susceptibility in		93.853	5F31NS084691-03	\$42,135
Clinical Coordination Center for STEADY-PD3		93.853	5U01NS080818-02	\$2,746,040
Clinical Research Sites for the Network of Excellence in		93.853	5U10NS077271-05	\$273,960
Coding properties of Vibrissal-Responsive Trigeminal Gan		93.853	1R01NS093585-01	\$55,683
Combined Approach to Genetic Modifiers of Inherited Epil		93.853	5R01NS053792-13	\$299,493
Computer Models of Normal and Abnormal Discharge Pattern	279	93.853	747752 // R01 NS062200-05A1	\$2,210
Computer Simulations of Populations of Mammalian Motor U		93.853	5R01NS071951-05	\$161,265

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Concordance of TDP-43 Inclusions with Cortical Atrophy a		93.853	5R01NS085770-02	\$300,141
Cortical Pathophysiology of Pain		93.853	5R01NS035115-16	\$70,926
CRCNS: Collaboration on High Resolution Maps of Synapses		93.853	5R01NS077601-03 REVISED	\$119,164
Determinants of Neurodegenerative Decline in Primary Pro		93.853	1R01NS075075-01A1	\$370,762
Development of a Bidirectional Brain Machine Interface		93.853	5R01NS048845-09	\$494,861
Development of excitatory V2a connectivity within spinal		93.853	1F32NS087889-01A1	\$37,074
Development of mouse models of optineurin-linked ALS		93.853	5R21NS081474-02	-\$12,930
Development of Novel MR Imaging for Ischemic Stroke Eval		93.853	1R01NS093908-01	\$13,458
Disease Mechanisms in Human Ubiquilinopathy		93.853	5R01NS078504-04	\$520,315
Dopaminergic and Muscarinic Signaling in the Striatum		93.853	5R01NS034696-18	-\$2,045
Dopaminergic and Muscarinic Signaling in the Striatum		93.853	5R01NS034696-20	\$491,815
DProt#99-705: Carotid Revascularization Endarterectomy v	255	93.853	Agmt 06-16-03/ R01 NS038384-05	\$11,163
Electrical and Mechanical Properties of Motor Units in a		93.853	5R01NS077863-05	\$509,062
Elp1 function in Familial Dysautonomia		93.853	1R56NS089626-01A1	\$42,732
Estrogen-Induced Hippocampal Seizure Susceptibility		93.853	3R01NS037324-15S1	\$56,831
Exploratory Study of Different Doses of Endurance Exerci	243	93.853	FY15.160.002 AMD2 / R01NS074343	\$189,077
Function and dysfunction of brain networks for the flexi		93.853	F32NS083340-03	\$57,144
Functional Development of Motor Networks		93.853	2R01NS067299-06A1	\$286,388
Functional Development of Motor Networks		93.853	5R01NS067299-05 REVISED	\$99,026
Functions of filamin in brain development and diseases		93.853	1R01NS087575-01A1	\$43,409
Galectin Modulation of Glutamate Receptors and Neuronal		93.853	5R01NS080598-03	\$396,686
General Motor Control Mechanisms and Disease Training Pr		93.853	5T32NS041234-15 REVISED	\$306,054
Generation of High Passage and Immortalized Human Microg		93.853	5R21NS084210-02	\$224,645
Genetic labeling and visualization of CSMN in models of		93.853	5R21NS085750-02	\$190,975
Genetic Modifiers of Childhood Epilepsy		93.853	5R01NS084959-02	\$302,939
HCN channel trafficking in epilepsy		93.853	3R01NS059934-07S1	\$415,070
HCN Channel Trafficking in Epilepsy		93.853	R01NS059934 REVISED	-\$310
Hereditary Defects in Human Sodium Channels		93.853	5R01NS032387-23	\$455,135
Immobilizing Gradients of Neurotrophic Factors On an Ali		93.853	5F32NS077728-03	\$52,703
Immunoregulation and Pathology of Chronic Relapsing EAE		93.853	5R01NS026543-26	\$209,411
Improving neurologic outcome measurement for interventio	247	93.853	7/225/27/NU-03 Amend3//1R25NS080949-01	\$102,596
In Vivo Analysis of Cortical Projection Neurons		93.853	5R21NS087479-02	\$244,841
Induced Pluripotent Stem Cell Core for NINDS Investigato		93.853	5P30NS081774-04	\$340,146
Information Processing in the Thermosensory System of Dr		93.853	1F31NS093873-01	\$6,422
Innate and Adaptive Immunity in Epileptogenesis	15	93.853	901464-NU/5R01NS073768-05	\$63,749
Innate Regulation and CD+Th1/17 Immunityin TMEV-Induced		93.853	5R01NS062365-05	\$94,678

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Integration of synaptic excitation and inhibition in the		93.853	1F31NS092329-01	\$18,791
Interneuron and Motoneuron Properties in Chronic Spinal	227	93.853	AGMT 7/14/15//R01NS047567	\$76,114
Intrinsic Plasticity and Information Storage in Cerebell	240	93.853	FP038885//R01NS62771	\$24,213
lonic currents and spiking in cerebellar nuclear neurons		93.853	2R56NS039395-14	-\$4,741
lonic currents and spiking in cerebellar nuclear neurons		93.853	5R37NS039395-15	\$574,078
Kainate Receptors in Signaling Between Hippocampal Mossy		93.853	1R21NS090040-01	\$127,783
L-DOPA-induced dyskinesias and dysregulation of striatop		93.853	5F32NS084735-02	\$25,599
Learning and Adaptation of Multi-Joint Arm Movements	182	93.853	03.81823// NS035673-10A2	\$2,911
Maternal Outcomes and Neurodevelopmental Effects of Anti	71	93.853	T268223//U01NS038455	\$74,090
Mechanical Signals and Trigeminal Ganglion Neuron Respon		93.853	1F31NS090872-01A1	\$3,820
Mechanisms Governing Neuronal Development		93.853	5R01NS020013-28	-\$99,327
Mechanisms of Distorted Inputs in Chronic Spinal Injury		93.853	5R01NS089313-02	\$334,330
Mechanisms of EarlY Recurrence in Intracranial Atheroscl	257	93.853	662706//5R01NS084288-02	\$39,156
Mechanisms Regulating Reduced c-Kit-Dependent EAE Susce	р	93.853	1R21NS081598-01	\$461
MicroRNAs and Perinatal Hypoxia-Ischemia		93.853	1R01NS086945-01A1	\$1,690
Minimally Invasive Surgery plus rt-PA for ICH Evacuation	123	93.853	2001995429//U01NS080824-02	\$3,814
Molecular basis of Scapuloperoneal SMA and Charcot-Marie		93.853	5R01NS078287-04	\$341,331
Molecular Basis of Somatic Sensation		93.853	5R01NS044363-10 REVISED	-\$28
Motor Cortical Function During Motor Learning with a Bra		93.853	1F31NS092356-01	\$17,364
Myoelectric Computer Interface to Reduce Muscle Co-Activ		93.853	5R21NS084069-02	\$196,497
Myoferlin in muscle membrane fusion and repair		93.853	5R01NS047726-11	\$283,348
Neural mechanisms of memory stability and change		93.853	1F32NS087885	\$50,094
Neural Systems for the Dynamic Use of Memory		93.853	5R00NS069788-04 REVISED	\$102,053
Neurogenetic Approaches to Study Directed Behavior in Dr		93.853	5R01NS086859-02	\$339,252
Neurological Emergencies Treatment Trials: Clinical Coor	258	93.853	3002108368 Amend No.4//U01NS056975	\$27,798
Neuromechanical Substrates for Post Stroke Asymmetric Ga	182	93.853	81841//R01 NS064084 A4	\$4,038
NeuroNEXT Clinical Trials	139	93.853	Master Agrmnt 2/27/12/ U10NS077271	\$47,445
Neuroprotection Exploratory Trials in Parkinson's Diseas		93.853	5U10NS053377-07	\$25,654
Neuroprotection Studies in PD: A Coordinating Center	269	93.853	416634 / U01NS043128	\$22,398
Novel Tools for Evaluation and Prediction of Radiotherap		93.853	7R01NS060752-05 REVISED	\$34,910
NRSA F31 Predoctoral Fellowship for Sarah Brooker in sup		93.853	5F31NS089154-02	\$32,493
NRSA Fellowship for Warren Alexander McGee in support of		93.853	1F30NS090893-01	\$28,289
NRSA Fellowship in Support of the Role of Beta-Catenin i		93.853	5F30NS051864-04 REVISED	-\$89
PDiPS Cell Line Consortium	144	93.853	400790//1U24NS078338-02	-\$143
Protein Acetylation and Selective Autophagy		93.853	5R01NS070168-4	\$180,598
Regulating fibrosis and muscle growth in the muscular dy		93.853	5P01NS072027-06	\$337,725

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Regulation of neural progenitor cell migration by store-		93.853	1R01NS094011-01	\$6,318
Regulation of neuronal survival by gamma protocadherins		93.853	5R21NS079880-02	\$172,051
Regulation of Neurotransmitter Metabolism		93.853	R01NS020778	\$169,208
Reverse Engineering Motor Unit Discharge	279	93.853	UWSC8225*(BP02840)//1R01NS085331-01	\$164,812
Rhythmicity and Synchrony in the Basal Ganglia		93.853	5P50NS047085-10	-\$1,214
Rhythmicity and Synchrony in the Basal Ganglia		93.853	5P50NS047085-13	\$1,488,426
Role of 4.1 Proteins in Kainate Receptor Localization an		93.853	5R01NS071952-04	\$54,983
Role of mTORC2 in GBM - Development of a Novel Therapeut	136	93.853	233303-05015//5R01NS073831-05	\$7,999
Scanlmage: Flexible Software for Laser Scanning Microsco	285	93.853	R24NS086549-NU Amd 1	\$68,514
Spatial and Temporal Scales of Motor Sequence Learning	182	93.853	03.81839 Amendment #3//P01NS044393-06A1	-\$54,376
Spatiotemporal Integration of Mechanical Information in		93.853	1F31NS092335-01	\$11,543
Spinal Muscular Atrophy: Inducing SMN Expression	15	93.853	901483-NU/2R01NS060926-05A1	\$54,128
Store-Operated Channels in the Nervous System		93.853	5R01NS057499-08 REVISED	\$378,748
Stretch Reflex Contributions to Multijoint Coordination	182	93.853	03.81888-Amd 3/2R01NS053813-05	\$64,944
Striatopallidal GABAergic Signaling in Mouse Models of P		93.853	5R01NS069777-05	\$291,151
Stroke Trials Network - Regional Coordinating Stroke Cen		93.853	5U10NS086608-03	\$346,413
SUDEP Translational Research Alliance – SUTRA	35	93.853	RES509424//5U01NS090407-01	\$46,842
Synaptic Circuit Organization of Motor Cortex		93.853	5R01NS061963-05	-\$7,225
Synaptic Circuit Organization of Motor Cortex		93.853	5R01NS061963-08	\$334,262
Synaptic Transmission, Plasticity and Integration in the		93.853	5R37NS041280-17	\$392,534
Targeting the NMDA receptor-mediated disruption of auton		93.853	1F31NS090845-01	\$31,649
The Interaction of IDO and TRegs Leads to Immunosuppress		93.853	5R00NS082381-04	\$257,644
The Neural Control of Internal Joint State		93.853	5R01NS086973-02	\$227,612
The Prefrontal Cortex in Neuropathic Pain		93.853	R01 NS064091	-\$7,331
The Representation of Uncertainty in the Sensorimotor Sy	182	93.853	RIC 81881-NU/ R01 NS074044 AMD 4	\$209,933
The role of a-synuclein accumulation in lysosomal hydrol		93.853	1R01NS092823-01	\$9,097
The Role of Lysosomal Glucocerebrosidase in Synucleinopa		93.853	5R01NS076054-06	\$342,054
The Role of MicroRNAs in Schwaan Cell Development and Di		93.853	R01NS071081	\$67,343
The role of neonatal kainate receptors in developing hip		93.853	5R21NS082785-02 REVISED	\$175,049
The role of Sirt1 in Huntington's Disease		93.853	5R01NS080331-2	\$510,650
The role of UCHL1 on the health and stability of upper m		93.853	5R01NS085161-03	\$427,207
The role of uncertainty for motor learning and adaptatio	181	93.853	81378 NU//2R01NS063399-06	\$13,290
The Role of Uncertainty in Human Motor Learning and Adap	182	93.853	03.81830 Amendment #5//R01NS06339-A102	\$44,997
The Stroke Hyperglycemia Insulin Network Effort (SHINE)	278	93.853	GC12107-145617//U01NS069498	\$12,690
Therapeutic Candidates for Huntington's Disease: From Le	139	93.853	217143//1U01NS066912-01A1	-\$4,255
Tr1-Specific Tolerance: A Novel Treatment of Multiple Sc	179	93.853	Agmt Signed 7/17/12	\$7,892

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Training in Neurotherapeutics Discovery and Development	230	93.853	5R25NS077582-04 Amd 3	\$14,507
Training Program in the Neuroscience of Human Cognition		93.853	5T32NS047987-10	\$300,190
Treatment of Chronic Stroke with AMES+ EMG Biofeedback	14	93.853	2 (amendment #2) // R44NS060192	-\$10,773
Understanding the cellular basis of Movement Disorders		93.853	5R01NS082351-03	\$550,821
Validation of the HD-HRQOL (Huntington Disease Health Re	258	93.853	3002420992//5R01NS077946-A1	\$79,668
Wrist/Grasp Muscle Activity Patterns for EMG-neural Inte		93.853	5F31NS083166-03	\$32,514
				\$23,663,120
A Development-Specific Mechanism of Pathogenesis in HSV		93.855	1F30AI116106-01A1	\$9,993
A novel mouse model to monitor inflammasome activation i		93.855	1R21AI120618-01	\$17,459
A surface-exposed region of the UL37 protein that is ess		93.855	1F32AI116044-01A1	\$11,742
ACTG LOC Protocol A5320 Vice-Chair	27	93.855	110236//5UM1Al068636-09	\$6,298
ACTG LOC Protocol Co-Chair for Protocol A5322	27	93.855	110229/5UM1AI068636-09	\$11,624
ACTG Research Group DMC Committee Chair	27	93.855	110009//5UM1Al068636-09	\$22,544
ACTG, Aids Clinical Trials Group - Berzins SASC Leadersh	27	93.855	110007//5UM1Al058636-09	\$8,570
Age related Differences in Chronic Rhinosinusitis and Na		93.855	1K23AI110731-01	\$73,022
Aging and Fracture Risk Among HIV-infected and HIV-uninf	123	93.855	2001586404//R01Al093520	\$126,247
AhR Activation in Th17 and Treg Cell Differentiation		93.855	5R01AI089954-05	\$315,977
AIDS Clinical Trial Group Network Protocol Funds	27	93.855	Mod 1 //2UM1AI068636-08	\$179,753
AIDS Clinical Trial Group Network Protocol Funds - Cost	27	93.855	111672//5UM1Al068636-09	\$121,507
AIDS Clinical Trials Group - ARTS Chair Support	27	93.855	110009/5UM1AI068636-09	\$17,493
AIDS Clinical Trials Group - Protocol Chair for Protocol	27	93.855	110237//UM1AI068636 A5303	\$8,959
AIDS Clinical Trials Group - Protocol Chair Support A532	27	93.855	110237//5UM1Al068636-09	\$4,826
AIDS Clinical Trials Group - Protocol Vice-Chair for Pro	27	93.855	110237//UM1AI068636 A5273	\$9,288
AIDS Clinical Trials Group- Chair Support for Protocol A	27	93.855	110229//5UM1A1068636-09	\$13,572
Alloantigen Delivery Via ECDI-Fixed Cells for Tolerance	259	93.855	N002854801//5U01AI102463-04	\$243,418
ALPHA-HERPESVIRUS TRANSPORT IN AXONS		93.855	2R01Al056346-11	\$283,614
Alpha-Herpesvirus Transport on Axons		93.855	5R01AI056346-10 REVISED	\$16,712
Alpha-herpevirus Assembly Egress and Viral Particle Hete		93.855	5R01AI080658-05 REVISED	\$136,312
Analysis of HIV-1 Uncoating		93.855	5F32A1089359-03	-\$226
Anti IL5 and Churg Strauss Syndrome: a double blind, pla	155	93.855	6182014/5U01Al097073-03	\$36,431
Anti-TSLP (AMG 157) plus antigen-specific immunotherapy	22	93.855	FY15ITN011//1UM1AI109565	\$71,121
ARRA - Randomized Double-Blind Phase 2 Study Comparing the	e Effi 205	93.855	CRB-DCR01-S-10-00247//HHSN272200900001/2/3I	\$79,555
Assembly and Function of the Gonococcal Pilus		93.855	1R56AI114821-01A1	\$133,841
Bioresponsive Combination Microbicide Delivery System fo		93.855	7R33AI071971-06	\$449,593
Cervical/Vaginal Mucus and Microbicides		93.855	5R33A1094584-05	\$608,213

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Chicago Clinical Trials Unit		93.855	5UM1AI069471-09 REVISED	\$2,029,968
Chicago Women's Interagency HIV Study (WIHS V)	97	93.855	50612-324-NWU1-AI034993//5U01AI034993	\$22,490
Chronic Rhinosinusitis Integrative Studies Program (CRIS		93.855	5U19AI106683-03	\$2,071,137
Consortium of Eosinophilic Gastrointestinal Disease Rese	44	93.855	Sub#135408//1U54AI117804-01	\$13,502
Continuation Funding for the Immune Tolerance Network [I	22	93.855	FY15ITN048//5UM1AI109565-02	\$2,990
CRISPR Cas Genes and Legionella Pneumophila Infection		93.855	5R21AI103451-02	\$133,395
CTOT-11: Novel Therapies to Improve Renal and Cardiac Al	27	93.855	105087 // U01 Al063623	\$15,359
Dengue Human Immunology Project Consortium (DHIPC)	101	93.855	0255-8617-4609//1U19Al118610-01	\$12,209
Development of Novel Anti-Biofilm Compounds for Treating	2	93.855	ASI//2R44AI092952-02A1	\$70,802
Development of Tissue Explant Models for Microbicide Eva		93.855	5R33AI076968-05 REVISED	-\$8,496
DLL4 Regulation of T Cell Migration in EAE		93.855	5R01Al101378-03	\$337,587
Do Early Maternal Antibodies Facilitate Oral Transmissio	214	93.855	15-04442.003//R01DE023049-05	\$232,867
Drug at the Right Place & Concentration: Optimizing Comb	4	93.855	310841//5U19AI103461-03	\$208,792
Drug at the Right Place and Concentration: Optimizing Su	4	93.855	310841 Amd. 3//5U19AI-103461	\$149,646
Drug at the Right Place and Concentration: Optimizing Su	4	93.855	310841//5U19Al103461-03	\$132,525
Early Events in Mucosal SIV Pathogenesis	217	93.855	1R01Al084793-01//TUL-HSC-161-09/1	\$4,524
Effectiveness, Safety and Value of Integrating Molecular		93.855	1R34Al118493-01	\$3,921
Efficacy of Ustekinumab (Anti-IL_12/23) followed by Abat	22	93.855	FY14ITN086//1UM1AI109565-02	\$20,294
EoE Clinical Study 2: Consortium of Eosinophilic Gastroi	44	93.855	135409//1U54Al117804	\$27,278
Expanding Small Molecule Functional Metagenomics through	113	93.855	AGMT 07/25/2014//2R44Al094885-02	\$247,729
Function of Vibrio Vulnificus MARTX Toxin During Early G		93.855	5R01Al098369-04	\$253,472
Genetics of Iron Acquisition by Legionella Pneumophila		93.855	5R01Al034937-19	\$269,512
Genomics for Transplantation: Discovery and Biomarkers	199	93.855	5-50962//2 U19 Al063603-08	\$197,004
Global innate immune responses to HIV-1 infection	195	93.855	Agreement Date: 12/9/11 // Al090935-02	-\$46,424
Global innate immune responses to HIV-1 infection: Proje	197	93.855	55648-12649-NWU//7P01Al090935-05	\$333,931
Glucocorticoids and glucocorticoid receptor translationa		93.855	5R21AI113935-02	\$228,393
Group 1 CD1 in Infectious Disease and T Cell Development		93.855	5R01Al057460-11 REVISED	\$130,540
Group 1 CD1-restricted Autoreactive T cells in Inflammat		93.855	1R21Al117238-01	\$89,103
HIV Centers for Underrepresented Populations in Research	15	93.855	915279-NU//46118547//2UM1Al069536	\$31,182
Host-Pathogen Interactions in a Failing Global lineage o	223	93.855	USTTB/NU/1R01Al110386-01-2014	\$103,376
How beta;-catenin expands Foxp3+RORγt+ Pro-inflam	nm 240	93.855	FP054763-B//1R01AI108682	\$6,624
Identification and Inference for Longitudinal Causal Med	94	93.855	114153-5086067//5R01Al104459-03	\$9,941
Identification of the Initial Targets of Transmission		93.855	5R01Al094595-05 REVISED	\$735,654
Immune-modifying nanoparticles to promote tolerance to S	259	93.855	N003747802//511K873/U01AI102456	\$3,571
Immunology and Molecular Pathogenesis Training Program		93.855	5T32Al007476-19	\$250,469
IMPAACT Network Leadership and Operations Center (LOC) G	15	93.855	915335-NU//PTCL032002286299/UM1Al068632	\$82,428

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Improving Food Allergy Management through an Electronic		93.855	5R21AI103433-02	\$179,272
Integrating Mechanistic Insights from Diverse Models to		93.855	1P01AI112522-01A1	\$210,830
Intravaginal Ring Delivery of Safe & Effective Microbici	4	93.855	31528A//U19AI076980	\$826
Mechanisms of Gonococcal Pilin Antigenic and Phase Varia		93.855	5R37AI033493-22	\$435,816
Mechanisms of MCMV reactivation in immunodeficient trans		93.855	5R01AI112911-02	\$525,807
Mechanistic Studies of Patatin-like Toxins		93.855	5R01AI053674-11	\$397,919
Mesenchymal Stem Cell Therapy for Active Systemic Lupus	146	93.855	MUSC14-037//R34AI114453	\$12,209
Metabolic Heterogeneity and Antibiotic Susceptibility in		93.855	5R01Al081983-05	\$430,725
Microbicide Delivery System to Target Lymphoid Organs	1	93.855	5R33A1082738//5R21A1082738-05-A2	\$33
Microscopic Analysis of the Interaction of HIV with the	190	93.855	5P01AI082971-05 Amd. 4//5P01AI08297	\$3,311
Molecular Genetics of the Gonococcus		93.855	5R01Al044239-15	\$156,562
Molecular Mechanism of V. Vulnificus MARTX Toxin in Path		93.855	5R01Al092825-05	\$328,414
Multicenter AIDS Cohort Study		93.855	5U01Al035039-21 REVISION2	-\$356,666
Multicenter AIDS Cohort Study		93.855	5U01Al035039-23 REVISED	\$3,447,893
Multicenter AIDS Cohort Study - Part B (Baltimore Center	123	93.855	2001627366//5U01AI085042-20 REVISED	-\$9,184
Multicenter AIDS Cohort Study - Part B (Baltimore Center	123	93.855	2002279322//U01AI035042-22	\$16,780
New Paradigms in Gene Regulation During Influenza Virus		93.855	5U01AI082984-06	-\$5,592
Northwestern University Allergy Immunology Research Prog		93.855	2T32AI083216-06	\$2,227
Northwestern University Allergy Immunology Research Prog		93.855	5T32Al083216-05	\$122,627
Novel asthma pathogenesis genes in the mucosa of the hum		93.855	1R21AI115055-01A1	\$86,609
Novel long-acting microbicide and contraceptive intraute	67	93.855	Sub#140181-2//5R01AI112009-02	\$222,276
NRSA F31 Fellowship for Rangel in support of The Role of		93.855	5F31AI089015-05 REVISED	\$44
NRSA Fellowship for A. DuMont in Support of Mechanism of		93.855	5F32AI114130-02	\$51,616
Optimizing Clinical Use of Polymyxin B: Teaching an Old	289	93.855	WSU15102//R01AI119446	\$9,733
Patient-Oriented Research on Hospital-Acquired Pathogens		93.855	5K24AI104831-03	\$101,066
Pilot Study: Consortium of Eosinophilic Gastrointestinal	44	93.855	135407//1U54Al117804	\$18,302
Post Genome-Wide Association Study of Food Allergy	123	93.855	2001358062 // 5U01 Al090727-04	\$9,284
Prevention of HIV Transmission/acquistion through inform	135	93.855	14-17-107//R01Al110373	\$87,228
Project 3: An 'omics' approach towards influenza A repli	101	93.855	0254-3243-4609//5U19AI106754-03	\$340,613
Prospective Observational Evaluation of the Association	66	93.855	UM1AI104681	\$1,610
Proteogenomics for Organ Transplantation: Prediction, Di		93.855	5U01Al084146-05 REVISED	\$2,225,525
Proteomic Predictors of Chronic Kidney Disease in Liver		93.855	5R21Al113916-02	\$4,015
Pseudomonas Aeruginosa Genomic Islands and Virulence		93.855	5R01AI075191-05 REVISED	-\$20,311
Regulation of Allergic Inflammation by Histamine		93.855	5R01AI076456-08	\$426,114
Regulation of cytosolic pattern recognition receptor sig		93.855	5R01Al099009-02	\$507,149
Regulation of food allergy and anaphylaxis by IL 33		93.855	5R01Al105839-02	\$332,800

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Role of CTCF in HPV replication and viral DNA looping		93.855	1R21AI120492-01	\$17,072
Role of the Plasminogen Activator Protease During Pneumo		93.855	5R01AI093727-05	\$396,814
Role of Thymic Stromal Lymphopoietin in Chronic Rhinosin		93.855	1R01AI104733-01A1	\$367,922
S. aureus and Regulatory T cells in the Failure of Oral		93.855	5K23AI100995-03	\$85,498
SIV Transmission in Male NHP	230	93.855	201015485-01 Amend #5//R01Al094620	\$91,478
Small, noncoding RNAs and the evolution of Yersinia pest		93.855	5R21AI103658-02	\$188,475
Structural and Functional Studies of gp42 and HLA Class		93.855	5R01AI076183-13	\$524,369
SubProject* Mechanisms of B Cell Responses in Autoimmune	e 66	93.855	203-4117//5U19AI056363-10REV	\$87,768
Sustained Long Acting Prevention Against HIV Program Ope		93.855	1UM1AI120184-01 REVISED	\$86,049
Targeting Siglec-8/-F to treat eosinophil and mast cell		93.855	5R01AI072265-09	\$416,170
The impact of HIV status and race on disparities in pros	226	93.855	000338217-SP021-004//P30AID27767-25	-\$63,683
The Outer Surface of Vibrio cholerae	273	93.855	UTA13-001016//R01Al076322	\$16,238
The Pathogenesis of Kawasaki Disease		93.855	2R56AI106030-13A1	\$318,234
The regulation and function of CD1d-restricted T cells		93.855	5R01AI043407-16	\$423,968
The Role of Group 1 CD1-restricted T Cells in Infectious		93.855	2R56AI057460-12	\$2,585
The Role of MHC Class Ib in T Cell Development and Infec		93.855	5R01AI040310-18	\$349,665
The roles of Sirt1, a deacetylase, in immune tolerance a		93.855	5R01AI079056-07	\$395,739
The roles of Synoviolin in immune tolerance and autoimmu		93.855	5R01AI108634-02	\$458,067
The Structure and Function of the Influenza Virus Genome		93.855	5R01AI020201-31	\$281,533
Third Coast Center for AIDS Research		93.855	1P30AI117943-01 REVISED	\$143,819
Training Program in Viral Replication		93.855	5T32AI060523-10	\$449
Translational Control of Gene Expression during Poxvirus		93.855	7R21AI105330-02 REVISED	\$206,041
Translational Research Training in Infectious Diseases		93.855	5T32AI095207-04	\$132,079
Type II Secretion and Legionella Pneumophila Infection		93.855	5R01AI043987-15	-\$3
Type II Secretion and Legionella pneumophila Infection		93.855	5R01AI043987-17	\$228,199
Type III Secretion Inhibitors for Anti-Infective Therapy	149	93.855	Agmt Signed 8/07/13 // R44Al068185	-\$12,704
UAB Center for AIDS Research	226	93.855	000503356-SP013-007//P30AI027767-26	\$143,588
Unconventional APC Inducing Autoimmune Th17 Cell Expansi		93.855	5R01AI041985-33	\$407,010
UTI Immune Modulation by LPS Structure		93.855	5F31AI106357-03 REVISED	\$37,141
Validating Targets in P. Aeruginosa Type III Secretion U	149	93.855	Agmt Signed 3/25/14 // 5R01Al099269	\$139,393
Virulence Mechanisms of the Emerging Pathogen Stenotroph		93.855	1R21Al117082-01	\$48,971
Virulence-Associated Accessory Genomic Elements of Pseud		93.855	5F32AI108247-02	\$43,788
Women's Health Inter-Network Scientific Committee	27	93.855	110009//2UM1AI068636	\$10,894
Women's Interagency HIV Study	97	93.855	50612-324-NWU2-AI034993//5U01AI034993	\$44,983

\$27,745,844

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
A Computational Biology Approach to Mapping Nucleosomes		93.859	5R01GM107177-02	\$285,798
Activation Mechanisms of Store-Operated Calcium Channels		93.859	1R01GM114210-01	\$53,755
Activities of nucleoprotein complexes visualized in sing		93.859	5R01GM105847-03	\$239,517
Alpha catenin phosphorylation in adhesion		93.859	5F31GM101959-02	\$16,497
Analysis of Novel Virus-Induced RNAs		93.859	1R01GM111652-01A1	\$13,477
Architectures for the Macromolecule-Mediated Assembly of		93.859	1F32GM105403-01	\$47,120
Assembly and epigenetic inheritance of the human centrom		93.859	7R01GM111907-02	\$457
Biotechnology Predoctoral Training Program		93.859	5T32GM008449-20	\$1,122
Biotechnology Predoctoral Training Program		93.859	5T32GM008449-22	\$275,392
Capturing Transient Protein Structures on Multiple Spati		93.859	1R01GM115761-01	\$9,530
Carbene Catalysis Strategies for Organic Synthesis		93.859	5R01GM073072-09	\$289,732
Career Decision-Making of Future Minority Biomedical Sci		93.859	5R01GM085385-08	\$421,651
Cellular and Molecular Basis of Disease Training Program		93.859	5T32GM008061-33	\$749,040
Characterization of the antiviral and nuclear regulatory		93.859	5R01GM101975-04	\$339,801
Characterization of the P1B-5ATPase Hemerythrin-like and		93.859	5F32GM105339-03	\$54,395
Chemistry of Life Processes Predoctoral Training Program		93.859	5T32GM105538-03	\$179,828
Chromatin Modifications by Histone Ubiquitination and Me		93.859	5R01GM069905-14	\$412,753
Coboglobins-Cobalt-Substituted Hemoglobins and Myoglobin		93.859	9R01GM111097-43	\$723,124
Control and Function of Ndr/LATS Signaling Systems		93.859	5R01GM084223-07	\$293,233
Copper Acquisition by Methanotrophs.		93.859	5F32GM110934-02	\$52,647
Cryo Ptychography Combined with X-Ray Fluorescence Analy		93.859	5R01GM104530-03	\$355,510
Design, Synthesis, and Biology of Inhibitors of Neuronal		93.859	5F32GM109667-02	\$55,690
Development of dictyBase, an online informatics resource		93.859	2R01GM064426	\$170,251
Development of DictyBase, an Online Informatics Resource		93.859	5R01GM064426-12	\$364,907
Developmental Dynamics of Ciliated Epithelia		93.859	2R01GM089970-06	\$170,257
Developmental Dynamics of Ciliated Epithelia		93.859	5R01GM089970-05	\$247,044
Direct Determination of the Distribution of Fitness Effe	245	93.859	UFDSP00010414//R01GM107227	\$196,222
DNA zip codes and the spatial organization of the yeast		93.859	5R01GM080484-08	\$432,516
Enhanced Dynamic Range Proteomic Analysis: Phase II	187	93.859	Agmt 08/07/14//5R42GM103419-05	\$20,000
Eukaryotic Post-Translational Modifications		93.859	5R01GM067193-12	\$257,995
Excitability in Dictyostelium Development		93.859	5K25GM098875-03	\$73,242
Exploration of Novel Silyl Derived d1 Synthon Equivalent		93.859	1F31GM116532-01	\$7,723
F32 for Michael Wandling in Support of: The Impact of Pu		93.859	1F32GM113513-01 REVISED	\$30,357
Global Characterization of Protein Palmitoylation in Try		93.859	5R01GM102689-03	\$426,515
High Throughput Screening for Small-molecules Facilitati		93.859	5R01GM110045-02	\$228,502
Identifying Microenvironment Regulators that Control Ste		93.859	1F32GM108395-01A1	\$49,184

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Identifying the best collaborators to conduct clinical t	94	93.859	152451.5080936.0102/1U01GM112623-01	\$43,156
Information Processing by Post-Translational Modificatio	94	93.859	152213.5081815.0003//1R01GM105375-0	\$46,095
Integrative informatics approach to develop safe glucoco		93.859	1R01GM112945-01A1	\$6,763
International Population Study on Macronutrients and BP		93.859	R01HL050490	\$277,111
Investigation into the Dynamic Zn Proteome during Mammal		93.859	1F32GM115052-01	\$20,035
Mass Spectrometric Studies of Thiotemplate Biosynthesis		93.859	5R01GM067725-12	\$115,629
Measuring signaling pathway dynamics during tissue growt	258	93.859	5R01GM097220-05	\$50,470
Measuring Signaling Pathway Dynamics During Tissue Growt		93.859	5R01GM097220-03	\$601
Mechanism of Nuclear Signaling and cell-cell adhesion by		93.859	5R01GM076561-09	\$257,977
Mechanisms of CRISPR Interference		93.859	5R01GM093769-04 REVISED	-\$7,776
Mechanisms of hnRNPM in Alternative Splicing Regulation		93.859	1R01GM110146-02	\$280,012
Mechanisms of Kinesin Self-Regulation		93.859	5R01GM072656-09	\$169,297
Mechanisms of Nuclear Body Biogenesis SubK RFUMS	189	93.859	Agreement Date: 3/26/15//R01GM090156	\$59,898
Medical Scientist Training Program		93.859	5T32GM008152-29	\$1,185,453
Mentoring for Success: Developing Fundamental Skills for		93.859	5R25GM079300-09	\$468,843
Metalloregulation by MerR and Fur Protein Families		93.859	5R01GM038784-27	\$366,907
MicroRNA Regulation of Biological Mechanisms		93.859	2R01GM077581-09A1	\$131,794
MicroRNA Regulation of Biological Mechanisms		93.859	5R01GM077581-08	\$12,315
Molecular Biophysics Training Grant		93.859	5T32GM008382-23	\$260,539
Molecular Mechanisms of Basolateral Targeting in Polariz		93.859	2R01GM070736-10A1	\$2,231
Molecular Mechanisms of Basolateral Targeting in Polariz		93.859	R01GM070736	\$74,281
Molecular Mechanisms of Gene Silencing by RNAi		93.859	5R01GM068743-12	\$301,829
National Infrastructure for Standardized and Portable EH	141	93.859	64073742//5R01GM105688-02	\$124,549
NetLogo 2.5D - Phase 2	123	93.859	2002150531//8DP1 GM 105382-05	\$9,950
Neural Crest Ontogeny and the Control of Stem Cell Attri		93.859	1R01GM116538-01	\$7
New Methods for the Concise Synthesis of Bioactive Polyc		93.859	5R01GM085322-05	\$45,033
Northwestern University - Select Teaching and Research T		93.859	5K12GM088020-05	\$29,013
Nuclear Organization Aberrations Underlying Systemic Lup		93.859	1F32GM115046-01	\$17,487
Nucleotide Substitution in tRNA		93.859	5R01GM037552-26 REVISED	\$120,027
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Sp	88	93.859	SP00011584-01//5R01GM104498-04	\$178,166
Particulate methane monooxygenase		93.859	5R01GM070473-11	\$286,925
Pharmacological Inhibitors of Nedd4 ubiquitin ligase as		93.859	1R01GM115632-01	\$3,618
Predictive Modeling of Collective Swimming in Bacterial	172	93.859	4674-NU-DHHS-4978//5R01GM104978-03	\$65,593
Regulation and Function of Intermediate Filaments in Cel		93.859	5P01GM096971-05	\$1,747,929
Regulation of Microtubule Motors		93.859	5R01GM052111-16	\$536,250
Regulation of SoxE Function During Neural Crest		93.859	5R01GM077288-04	\$2,015

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Regulatory Roles of Zinc Fluxes in Metalloprotein Occupa		93.859	1R01GM115848-01	\$62,553
Research Careers for Hispanic Students: Testing the Mult	248	93.859	2011-01963-01-00//5R01GM098515-02	\$12,121
Selective Inhibition of Neuronal Nitric Oxide Synthase		93.859	5R01GM049725-19	\$291,188
Src kinase phosphoregulation of the human mitotic kinesi		93.859	5R01GM107209-03	\$520,935
Structural Biology of Copper Homestasis	123	93.859	2000995734/3 // 5 P01 GM067166-09	\$76,527
Structural Biology of Membrane Scaffolds		93.859	5R01GM094479-04	\$205,706
Structural mechanism of membrane remodeling during herpe	216	93.859	Amend 1 FE 3/27/2015/R01GM111795//R01GM111795	\$79,553
Structural Mechanisms in Semaphorin Signaling		93.859	5R01GM098259-04	\$243,832
Structural Studies of a Spectrin/Ankyrin Complex		93.859	5R01GM057692-15	\$126,769
Structural Studies of RNase P		93.859	5R01GM058443-16	\$419,495
Structural Studies of Type I Topoisomerases		93.859	5R01GM051350-19 REVISED	\$172,821
Structure and Function of the Trypanosome Flagellar Memb		93.859	5R01GM093359-09	\$85,511
Structure and Specificity in Metal Ion Homeostatis		93.859	5R01GM058518-17	\$277,434
Super-resolution microscopy of nuclear lamin and spindle	33	93.859	5-10490-01//R01GM106023	\$137,381
Synthetic Information Systems for Better Informing Publi	286	93.859	431698-19980-Mod 01//2U01GM070694-10	-\$424
Targets for Design of Drug Combinations that Select agai		93.859	1R01GM113238-02	\$283,752
The Academy for Future Science Faculty Diversity through		93.859	5R01GM107701-03	\$340,818
The Dictyostelium Stock Center		93.859	2R01GM087371	\$115,912
The Dictyostelium Stock Center		93.859	5R01GM087371-05 REVISED	\$164
The Endocrine Society Minority Access Program Evaluation	72	93.859	Agmt dated 04/08/2014	\$15,908
The role of the microtubule regulators Kif4 and EB1 in H	48	93.859	1(GG010108)//1P01GM105536-01A1	\$715,181
The Structure and Function of Perinucleolar Compartment		93.859	5R01GM078555-08	\$303,393
Tissue morphogenesis: A study of molecular machines and		93.859	5R01GM098077-03	\$263,678
Tube size control by Src and Yorkie/YAP		93.859	1R01GM108964-01	\$337,530
Virus Imaging Core P50 GM082545 CHEETAH	277	93.859	10027535-02//P50GM082545-A1	\$283,908
Why Do Research Prizes Have Effects on Minorities'		93.859	5R01GM098568-03	\$143,935
Zinc Regulation of Germline and Embryo Development in Ca		93.859	5F31GM112478-02	\$35,323
				\$20,385,710
The Inflammatory Response Pathway in the Etiology of Pol		93.864	R01HD057450	\$394,226
A Longitudinal Study of Loss of Imprinting in First Trim	48	93.865	1GG010138-01//7R21HD068873	\$74,981
A pharmacokinetic evaluation of levonorgestrel implant a	262	93.865	34-2009-2030-002//5R21HD074462	\$8,421
A Preschool Biomarker for Literacy		93.865	5R01HD069414-04	\$340,834
A Randomized Study to Abate Truancy and Violence in Grad		93.865	5R01HD067500-06 REVISED	\$875,098
Adolescent Social Relationships and Immune, Endocrine		93.865	5F32HD076563-02	\$51,055

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Amantadine + rTMS as a Neurotherapeutic for Disordered C	39	93.865	Pape-VA 0005//1R21HD075192	\$13,020
Application of Targeted Reinnervation for People with Tr	181	93.865	CL4098//1R01HD081525-01	\$3,320
Biological Embedding of Early-Life SES		93.865	5R01HD058502-06 REVISED	\$19,508
Career Development in Women's Health (CDWH)		93.865	5K12HD055884-09	\$538,392
Center for Reproductive Research after Disease		93.865	5P50HD076188-03	\$1,521,265
Characterizing the Role of Male Circumcision in HIV Sexu		93.865	5K08HD060451-05	\$75,426
Cloning Genes that Cause Mental Retardation	91	93.865	AGMT 02/25/15//R01HD039331	\$71,142
Cognitive Architecture of Bilingual Language Processing		93.865	5R01HD059858-05	\$248,709
Cortical Priming to Optimize Gait Rehabilitation Post St	248	93.865	2013-03653-02-00JH/5R01HD075777-02	\$34,630
Deubiquitinating Enzymes as Targets for Male Contracepti	15	93.865	901501-NU//1U01HD084046-01	\$7,846
Development of a serum biosignature for ectopic pregnanc	267	93.865	564595//R01HD07627901A1	\$65,858
Effect of a patient-centered decision app on TOLAC: An	237	93.865	8231sc//1R01HD078748-01A1	\$192,410
Effect of Injury Severity and Location on Spasms Post SC		93.865	1K01HD084672-01	\$7,352
Effect of Neural Constraints on Movement in Stroke		93.865	5R01HD039343-13	\$382,935
Effects of Male Circumcision on Human Penile Epithelia		93.865	5R03DK096989-02 REVISED	\$8,828
Endometriosis and Retinoids		93.865	4R37HD038691-16	\$54,595
Endometriosis and Retinoids		93.865	R37HD038691	\$253,794
Engineering Career Development Center in Movement and Re		93.865	5K12HD073945-04	\$871,368
Engineering for Neurologic Rehabilitation	181	93.865	Agmt 3/24/15//5R24HD050821	\$7,746
Genes, Androgens and Intrauterine Environment in PCOS		93.865	2P50HD044405-13	\$931,156
Hormonal Signals that Regulate Ovarian Differentiation		93.865	5P01HD021921-25	\$98,465
Improving Mobility for Bilateral Transfemoral Amputees w	283	93.865	2404-017266//1R21HD076124	\$38,297
Intensive Rehabilitation Research Grant Writing Workshop	146	93.865	MUSC14-024//T15HD074546	\$12,074
INTER-CAMBIO: Community-Academic Meetings to Bridge Ini	t	93.865	1R13HD075494	\$18,361
Intersecting Roles of Parents and Early Education in Pro		93.865	5F32HD076557-02	-\$527
Linking language and cognition in infancy: Entry points		93.865	1R01HD083310-01	\$109,931
Manipulating cGMP Pathway to Impact Vascular Developmen	t	93.865	5R21HD077336-02	\$165,166
MFMU Network Capitation Agreement	85	93.865	Agmt 4/25/14//U10HD036801	\$255,690
Motor impairment related changes in muscles properties i		93.865	1R01HD084009-01A1	\$67,094
Motor Learning in a Customized Body-Machine Interface fo	181	93.865	CC#81750//R01HD072080	\$105,789
Neural Development and Disorders of Math Processing		93.865	5R01HD059177-05	\$45,453
Neuromuscular Mechanisms Underlying Poor Recovery from V	V	93.865	5R01HD079076-02	\$366,336
NICHD Maternal Fetal Medicine Units Network		93.865	5U10HD040512-16	\$298,199
Non-Invasive Method to Evaluate the Quality of Human Ooc	183	93.865	Agmt. 5/23/13//1R41HD070567-01A1	-\$125
NRSA F32 for Daniel John Stieh in support of: Analysis o		93.865	5F32HD080540-02	\$50,640
nuMoM2b Capitation Funding	186	93.865	AGMT 9/24/10 // U10HD063020	-\$150,762

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
nuMOM2b Sleep Disordered Breathing Substudy	186	93.865	3-312-0212512-50759L//U10HD063036	\$1,605
Oncofertility Consortium Annual Conference		93.865	2R13HD063248-05A1 REVISED	\$25
Oncofertility Consortium Annual Conference		93.865	5R13HD063248-04	\$5,150
Optimizing Medication Management for Mothers with Depres	S	93.865	1U54HD085601-01	\$10,241
Pathophysiology and Rehabilitation of Neural Dysfunction		93.865	5T32HD007418-24	\$234,357
Pathways Linking Social Disparities, Inflammation, and H		93.865	1R01HD074765-01A1	\$36,752
Phonetic echoes of cognitive disruptions in speech produ		93.865	5R21HD077140-02	\$113,678
Pilot newborn screening project for identification and p	277	93.865	10019947-01/R01HD069045	\$17,507
Prenatal Cytogenetic Diagnosis by Array-based Copy Numbe	48	93.865	10 (GG006961-04))//5U01HD055651-07	\$10,629
Preterm Birth in Nulliparous Women: An Understudied Popu		93.865	5U10HD063020-04	\$94,893
Prognostic Biomarkers to Predict Progression of Pediatri	15	93.865	901484-NU/5R01HD074596-02	\$134,198
Promoting Safe Use of Pediatric Liquid Medications: A He	159	93.865	12-00512/ /5R01HD070864-02	\$112,994
Remediating Academic and Non-Academic Skills Deficit amo	240	93.865	FP053700//1P01HD076816	\$7,523
Research Career Development in Obstetrics and Gynecology		93.865	2K12HD050121-11	\$26,797
Research Career Development in Obstetrics and Gynecology		93.865	5K12HD050121-09	\$336,791
Role of MicroRNA-29 in Uterine Leiomyoma Pathogenesis		93.865	1R21HD077479-02	\$184,916
Rural African American Young Adults' Pathways to Psychos	246	93.865	RR376-410/4708620//2R01HD030588	\$53,060
Self-regulation as a Health-Protective Factor in Adverse		93.865	5F32HD078048-02	\$50,600
Sensorimotor Adaptation During Powered Prosthesis Contro		93.865	1F31HD080335-01A1	\$26,795
Statistical Learning, Memory Systems, and Sleep-Based Me		93.865	5F32HD078223-02	\$48,326
Tailored Outcomes for Female Urinary Incontinence	292	93.865	9594//R21HD069962	\$11,349
The Effect of Wrist Motion on Pattern-Recognition-Based		93.865	5F31HD078092-02	\$40,872
The Fetal Adrenal Gland as a Predictor of Spontaneous Pr	48	93.865	7(GG006282)//5 R21 HD068809-02	-\$3,219
The Lis1-Nde1 Pathway in Cerebral Cortical Development		93.865	R01HD056380	-\$45,010
The Reproductive Window in Young Adult Cancer Survivors	236	93.865	55368070 // R01HD080952	\$7,959
Toddlers' Initial Representation of Verbs: Effects of De		93.865	1R03HD067485-01A1	\$39,256
Training in the Neurobiology of Movement and Rehabilitat		93.865	5T32HD057845-05	\$234,943
Uterine Leiomyoma Development in Mouse Models	148	93.865	5R01HD072489-03//RC103124NU	\$681
Uterine Leiomyoma Research Center Program		93.865	2P01HD057877-06A1	\$76,383
Uterine Leiomyoma Research Center Program		93.865	5P01HD057877	\$9,095
Xenograft Study on the Growth-Control of Human Uterine L		93.865	5R01HD064402-05	-\$601
Young Men's Health and the Transition to Fatherhood		93.865	5K23HD060664-05	\$105,745
				\$10,124,060
A novel, nanoparticle-based molecular MRI probe for earl		93.866	5R21AG045637-02	\$276,523
Alterations of Sleep and Circadian Timing in Aging: Admi	240	93.866	39915/A6//P01AG011412	\$32,119
The accompanying footnotes are an integral part of the Schedule of Exp	enditures of Federal	Awards	- 82 -	(Continued)

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Alzheimer's Disease Core Center		93.866	5P30AG013854-20	\$1,245,269
Alzheimer's Disease Neuroimaging Initiative - 2 (ADNI-2)	236	93.866	67-ADNI-2//U01 AG24904	\$21,446
Alzheimer's Drug Discovery Using Unique Nanotechnology P		93.866	5R21AG041953-02	\$19,443
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disea	236	93.866	45893177//2U19AG010483-22	\$57,393
BACE1 as a Therapeutic Target for Alzheimer's Disease		93.866	5R01AG022560-13	\$434,303
Breaking the Cycle of Poverty Among Seniors and Their Fa		93.866	R03AG040690	\$34,516
C. elegans Model for Neurodegenerative Diseases of Aging		93.866	4R37AG026647-11	\$138,689
C. elegans Model for Neurodegenerative Diseases of Aging		93.866	5R37AG026647-10	\$232,068
Cardiovascular and HIV/AIDS Effects on Brain Structure/F	268	93.866	0013027(122144-4)//5R01AG034852-05	\$56,799
Community-Generated Palliative Care Telemedicine for Rur	270	93.866	15-2746//R21AG046772	\$17,938
Comparative Effectiveness of Customary F&S vs Fit and St	248	93.866	2011-06769-01-02 / R01AG039374	\$19,290
Developing a Longitudinal Resource for Genetic Research	280	93.866	482K930//R01AG041868	\$59,179
Disordered Proteostasis as a Driver of Disease in the Ag		93.866	1P01AG049665-01	\$172,735
Epidemiology of Psychological Distress in a Chinese Agin	190	93.866	5R01AG042318-02//5R01AG042318	\$30,726
Exceptional Cognitive Aging: Neuropsychologic, Anatomic		93.866	5R01AG045571-02	\$356,082
Fellowship for J. Pitt in Support of Astrocytic regulati		93.866	1F32AG047782-01	\$51,410
High-Dimensional Movement Analysis as a Diagnostic Tool		93.866	5F31AG045017-02	\$46,211
Hospital Discharge and Cognitive Changes in Older Adults		93.866	5R21AG042640-02	\$72,803
Integrative Analysis of Longitudinal Studies of Aging	169	93.866	9008468_NU//P01AG043362	\$173,703
Integrative Pathways to Health and Illness	280	93.866	618K166///P01AG020166	\$106,837
Intervention to Enhance Lateral Balance Function and Pre	252	93.866	SR00001473 // R01AG033607 Amend 4	\$8,843
LitCog II: Health Literacy and Cognitive Function		93.866	5R01AG030611-08	\$498,648
Living Well With Later Life Multimorbidity: A Biopsychos	175	93.866	4102-56030//1R01AG041750-01A1	\$16,326
Mechanisms of Aging and Dementia Training Program		93.866	5T32AG020506-14	\$319,071
Mechanisms Regulating Tau Alternative Pre-mRNA Splicing		93.866	5R01AG033004-05	\$280,616
Multidimensional Pathways to Healthy Aging Among Filipin	264	93.866	5-31773 Amd. 3//5R01AG039443-04	\$227,221
National Alzheimer's Coordinating Center	279	93.866	762188//2U01AG016976-16	\$33,181
National Health Literacy Mapping to Inform Healthcare Po	264	93.866	5050165//1R01AG046267-01A1	\$36,550
Noninvasive Stimulation to Improve Hippocampal-Dependent		93.866	1R01AG049002-01	\$141,246
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clin	262	93.866	36-5360-2141-001 // R01 AG037120	\$44,312
NRSA Fellowship in Support of Neurobiological Substrates		93.866	1F31AG043270-01A1	\$2,359
Optimal Older Donor and Recipient Matching to Enhance Li		93.866	1R21AG049385-01A1	\$7,807
Personality and Well-Being Trajectories in Adulthood		93.866	5R01AG018436-15	\$449,605
Physical Exercise to Prevent Disability (The Life Study)	245	93.866	UFDaSP00010684/U01AG022376	\$284,102
Preclinical Alzheimer's Disease Drug Development of Nove		93.866	3U01AG043415-04S1	\$697,227
Probabilistic Thinking and Economic Behavior	258	93.866	3001554603//5-P01-AG026571-07	\$31,805

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
RESveratrol To Improve Outcomes in oldeR pEople with PAD		93.866	5R21AG047510-02	\$184,938
Role of CK2 in NMDAR trafficking during development and		93.866	4R00AG041225-02	\$222,378
Self-Reported Health and Function among Older Adults and		93.866	5R03AG042354-02	-\$8,684
Slow Outward Currents & Learning in Aging Hippocampus		93.866	5R37AG008796-23 REVISED	\$113,007
Slow Outward Currents and Learning In Aging Hippocampus		93.866	4R37AG008796-24	\$457,078
Strategies for the Treatment of Dysphagia in Patients wi		93.866	5R21AG042755-02	\$77,474
Surgical Simulations to Optimize the Treatment of Wrist		93.866	5F31AG041627-03 REVISED	\$322
Sustaining quality of life of the aged: Heart transplant		93.866	1 R01 AG047416-01A1	\$13,981
Testosterone Trial	267	93.866	554529//U01AG030644	\$5,038
The Aging Kidney in HIV-Infection: Biomarkers for Early	162	93.866	1520//1R01AG034853	\$15,376
Therapeutic Effect of Intranasal Insulin on Cognition, F	236	93.866	42756369///7RF1AG041845-02	\$10,796
				\$7,826,105
Corneal Epithelial Stem Cells		93.867	5R01EY006769-26	\$403,810
Critical Period Plasticity and Binocular Matching		93.867	5R01EY020950-04 REVISED	-\$6,371
Critical Period Plasticity and Binocular Matching in the		93.867	5R01EY020950-06	\$496,014
Deciding Where to Look Next: Frontal Eye Field's Role du		93.867	1F31EY025532-01	\$2,467
Diabetic Retinopathy Clinical Research Network Chair Gra		93.867	1U10EY023207	\$258,572
Eye Movement Maps in Superior Colliculus		93.867	5R21EY023060-02	\$235,101
First Line Antimetabolites as Steroid-sparing Treatment	237	93.867	7925sc//U10EY021125	\$759
Function of Basal Synapses at Mammalian Photoreceptors		93.867	5R01EY012141-18	\$471,927
Hyperspectral Imaging of the Normal and Age-related Macu	159	93.867	12-01177 Proj #100944//5R01EY021470-03	\$197,360
Light responses and microcircuitry of two novel amacrine		93.867	1F32EY025930-01	\$3,713
Long-term Follow-up of Patients Who Participated in the	123	93.867	Agmt. 4/4/13//2U10EY014660	\$2,380
Mechanisms of anterior segment development and corneal n		93.867	2R01EY019484-01A1	\$132,400
Mechanisms of Anterior Segment Development and Corneal N	J	93.867	R01EY019484	-\$127,538
Multidisciplinary Visual Sciences Training Program		93.867	1T32EY025202-01 REVISED	\$24,352
Multimodal Retinal Functional Imaging for Diab	79	93.867	800003006-01//7R01EY019951-03	-\$65,100
Multimodal Retinal Functional Imaging for Diabetic Retin	79	93.867	800006243-01//7R01EY019951-05	\$495,914
Neural Mechanisms of Fixation Choice While Searching Nat		93.867	5R01EY021579-04	\$348,683
Novel Antiangiogenic Peptides for Treatment of Exudative	280	93.867	457K284 // 1R24EY022883-01	-\$190,159
Novel Antiangiogenic Peptides for Treatment of Exudative	280	93.867	553K221 // 5R24EY022883-02	\$670,124
Novel Antiangiogenic Peptides for Treatment of Exudative	280	93.867	553K221 Amd 2//5R24EY022883-03	\$298,418
NRSA: The flexibility of individuation and ensemble repr		93.867	5F32EY023508-03	\$49,359
Role of Host Cell Factors in Herpes Simplex Virus (HSV)		93.867	R21EY021306	-\$5,352
Signal Processing in the Inner Retina		93.867	2R01EY018204	\$571,727

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title Pas	s-through ID	CFDA	Sponsor Award Number	FY15 Expense
Signal Processing in the Inner Retina		93.867	5 R01 EY018204-05	-\$204,873
The Mechanical Basis of Primary Open Angle Glaucoma		93.867	2R01EY019696-06	\$65,641
The Mechanical Basis of Primary Open Angle Glaucoma		93.867	5R01EY019696-05	\$282,593
The Retinal Microenvironment in Diabetic Retinopathy		93.867	5R01EY021165-05	\$410,359
The Role of Insm1a in Photoreceptor Differentiation	251	93.867	3048109606-15-039//R01EY021769	\$33,526
The Role of MicroRNAs in Corneal Epithelial Homeostasis		93.867	5R01EY019463-06	\$387,542
Understanding Diabetic Eye Disease in the Underserved Us		93.867	5R21EY024050-02	\$150,708
Understanding Feature-based Auditory-Visual Interactions		93.867	5R01EY021184-03	\$104,952
				\$5,499,008
A New Generation Clinical Decision Support System	268	93.879	0038305 (124684-1) // R01LM01163	\$184,991
A Novel Graph Processing Architecture to Ascertain & Mon		93.879	5K01LM011973-02	\$154,564
Improving the Efficiency and Efficacy in Authoring Essen		93.879	5R00LM011389-04	\$232,089
Informatics Platform for Mammalian Gene Regulation at Is		93.879	7R01LM011297-02	\$346,415
MEETING CLINICIANS' INFORMATION NEEDS WITH HIGHLY TAIL	OR 277	93.879	10028048-02//R01LM011416 AMEND 3	\$72,744
Multidimensional Computer Adaptive Testing for Patient R		93.879	1R01LM011962-01A1	\$63,368
				\$1,054,171
Diabetic Retinopathy Clinical Research Network	119	93.988	Agmt 12/13/12 // U10 EY14231	\$7,273
Developing Innovative Interdisciplinary Biomedical Engin		93.989	1D43TW009374-03	\$251,115
Evaluating Pre-Hospital Systems of Care for Patients wit	283	93.989	VUMC44158//5R25TW009337-03	\$77,783
Medical Education Partnership Initiative	247	93.989	7/225/27/NU-05 // R24TW008878-05	\$182,786
Multidisciplinary NeuroAIDS Research Training to Improve		93.989	5D43TW009608-03	\$273,553
Northwestern and Jos University Research Training Progra		93.989	1D43TW009575-01A1 REVISED	\$399,399
				\$1,184,636
Ad5.hAC6 Gene Transfer for CHF	284	93.08082-NU SUB//CRB-HLBI1-S-10-00076	08082-NU SUB//CRB-HLBI1-S-10-00076	\$15,125
Folic Acid and Zinc Supplementation Trial (FAZST)	277	93.10026957-03//HHSN27520100007C	10026957-03//HHSN27520100007C	\$38,333
Early Therapeutics Development With Phase II Emphasis	240	93.5-27050 / HHSN261201100071C	5-27050 / HHSN261201100071C	\$421
Jackson Heart Study Field Center NHLBI-HV-13-10	260	93.66102690414-04NWU/HHSN268201300047C	66102690414-04NWU/HHSN268201300047C	\$35,234
COMPASS: Capturing and Analyzing Sensor and Self-Report	76	93.Agmt 1/9/14//HHSN261201300055C	Agmt 1/9/14//HHSN261201300055C	\$101,728
Atopic Dermatitis Research Network (ADRN)	155	93.Agmt 6/26/12//HHSN272201000020C	Agmt 9/5/12//HHSN272201000020C	\$254,042
Combined Top Down and Bottom Up Proteomics of CompRef Ca	131	93.Agmt No. 13XS108//HHSN261200800001E	13XS108 MOD 4 //HHSN261200800001E	\$253,967
Intergovernmental Personnel Act (IPA) Agreement for Warr		93.Agmt Signed 9/19/13	Agmt Signed 9/19/13	\$44,545
Development of a Patient-Reported Outcomes Instrument to	70	93.Agmt. 4/2/13//HHSN271201000024C	Agmt. 4/2/13//HHSN271201000024C	\$99,116

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
ECOG PCO-RL: BIQE1512	82	93.BIQUE1512-00//HHSN261200800001E	BIQUE1512-00//HHSN261200800001E	\$6,989
Multi-Site Study of the Efficacy of Speech Perception Tr	49	93.CDT-2013-6//R33DC011174-02	CDT-2013-6//R33DC011174-02	\$113,731
Protocol IRC002 "A Randomized, Open-Label, Phase 2, Mult	205	93.HHSN261200800001E/11XS088	HHSN261200800001E/11XS088	\$847
Cancer Prevention Agent Development Program: Early Phase		93.HHSN2612012000351	HHSN26120120035I / Task Order 008	\$586,639
Coronary Artery Risk Development in Young Adults (CARDIA		93.HHSN268201300027C	HHSN268201300027C	\$919,262
Center for Structural Genomics of Infectious Diseases		93.HHSN272201200026C	HHSN272201200026C	\$5,031,174
National Children's Study: Vanguard Study (South ROC)		93.HHSN275201200007I	HHSN2752012000071	\$10,911,857
Asthma Cohort Support Contract		93.HHSN275201300013C	HHSN275201300013C	\$712,751
Islet Isolation Facilities to Produce Islets for Basic S	45	93.HHSN27620090006C	HHSN27620090006C	\$157
Phase I and II Clinical Trials of Cancer Chemopreventive		93.N01-CN-35157/004	N01-CN-35157	\$294,596
Longitudinal Studies of Coronary Heart Disease Risk Fact		93.N01-HC-48049	N01-HC-48049	-\$74
Multi-Ethnic Study of Atherosclerosis (MESA) - Field Cen		93.N01-HC-95164/Amend #25	N01-HC-95164 / Mod 35	\$942,666
Impact of Aggressive Empiric Antibiotic Therapy and Dura	245	93.UF11289//97591//HHSN272201000043C	00111894/UFDSP00010035//HHSN272201000043C	\$102,859
Multi-Ethnic Study of Atherosclerosis (MESA) Chicago Fie	279	93.UWSC8539//HHSN268201500003I	UWSC8539//HHSN268201500003I	\$14,942
Office of Minority Health				
Addressing Lupus Health Disparities Adapting Culturally-		93.137	1 CPIMP151087-01-00	\$9,290
Office of the Director, National Institutes of Health				
Self-Organization of the Human Genome		93.310	1DP20D008717-01	\$436,287
A SPECT_CT Scanner for Preclinical Imaging Studies		93.351	1S100D016398-01A1	\$59,760
Science Club Summer Camp: Training Teachers and Youth in		93.351	1R250D020222-01	\$16,613
				\$76,373
Office of the National Coordinator for Health Information Techno	plogy			
ARRA - The Chicago HIT Regional Extension Center	07	93.718	90RC0020	\$1,356,060
ARRA - Electronic Health Record (EHR) Regional Extension Cent	ter 106	93.778	90RC0020 // 2013-38-006 A	\$861,715
CMS ONC CHIPRA Project – Subject Matter Expertise Relate	24	93.Agr. 07/07/2014//HHSP23320095627WC	Agr. 07/07/2014//HHSP23320095627WC	-\$9
Substance Abuse and Mental Health Services				
Lake County BHTCC	55	93.243	LC# 15058//H79SM061684	\$44,075
National Child Traumatic Stress Initiative (NCTSI) Cate	167	93.243	Agreement Date: 1/28/14	\$58,064
National Child Traumatic Stress Initiative Treatment and		93.243	5U79SM061254-03 REVISED	\$270,017

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
National Child Traumatic Stress Initiative Treatment and Trauma Informed Youth Services Initiative	295	93.243 93.243	U79SM059313 Agrmnt 012610	-\$2,700 \$435
	235	JJ.Z+J	Agimint 012010	\$369,891
National Child Traumatic Stress Initiative (NCTSI) – Cat Department of Health and Human Services Total	295	93.Agreement Date: 10/1/12	Agreement Date: 2/27/2014	\$75,420 \$281,691,770
Department of Homeland Security				
ARI-MA: Design and Growth of High Density, Wide Band-Gap)	97.077	2010-DN-077-ARI042-05	-\$47,127
Chalcogenide semiconductors for g-ray detection from ear		97.077	2014-DN-077-ARI086-01	\$255,748 \$208,621
Next Generation Semiconductor Detectors for Identificati	178	97.C14-09//Agmt 2-25-14//HSHQDC-13CB0039	C14-09//Agmt 2-25-14//HSHQDC-13-C-B0039	\$249,806
Monolithic, Widely Tunable, Quantum Cascade Laser Source	161	97.HSHQDC-13-C-00034	HSHQDC-13-C-00034/P00002	\$317,286
Novel Compound Semiconductor Radiation Detectors	161	97.SUB-01//HSHQDC-14-R-B0009	SUB-01//HSHQDC-14-R-B0009	\$245,593
Federal Emergency Management Agency				
FEMA Vehicle Crash Study: Firefighter Injury Reduction t	228	97.044	229812//EMW-2013-FP-00351	\$28,455
Department of Homeland Security Total				\$1,049,761
Department of Justice				
IPA Assignment Agreement, Department of Justice		16.Agreement 02/15/2013	Agreement 02/15/2013	-\$6,934
Bureau of Justice Assistance				
Sheriff Women's Justice Program	104	16.738	412229	\$172,788
Sheriff's Women's Justice Program	104	16.738	410229//2010-DJ-BX-0015	\$22,862
				\$195,650
Federal Bureau of Investigation				
Array x Array: Screening and Ultrasensitive Detection of	216	16.DJF-15-1200-K-0001726	DJF-15-1200-K-0001726	\$223,052
Biodiagnostic Approaches to Human Profiling Through Nano		16.DJF-15-1200-K-0001730	DJF-15-1200-K-0001730	\$440,916
National Institute of Justice				
Judgments About Forensic Identification Evidence	16	16.560	z11-423//2008-DN-BX-0003	\$11,592

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Office of Justice Programs				
Northwestern Juvenile Project: Archiving Data, Part I		16.540	2012-JR-FX-0005	\$140,112
Trajectories of Delinquency and the Juvenile Justice Sys		16.541	2013-JF-FX-0057	\$480,778
Department of Justice Total				\$1,485,166
Department of Labor				
Building "LINCS" for Supply Chain Management (Leveraging		17.282	TC-25004-13-60-A-17	\$80,077
Department of Labor Total				\$80,077
Department of Transportation				
Enabling On-line Logistics Services Auction Platform (OL	248	20.701	557K314//298K012	\$23,624
Enhancing Sleep Efficiency on Towboats in the U.S. Inlan	154	20.NCFRP-45//DT0S59-06-G-00039	NCFRP-45//DT0S59-06-G-00039	\$157,437
Federal Highway Administration				
Analysis, Modeling, and Simulation (AMS) Testbed Develop	24	20.105952SB1M	105952SB1M	\$100,097
Tools for Tactical Decision-Making/Advancing Me	132	20.13-014//P010160797//DTFH61-12-D-00020	13-014//P010160797 R1//DTFH61-12-D-00020	\$32,896
Deployment of Weather-Responsive Traffic Estimation and	198	20.DTFH61-12-D-00038//0A-F-204-13-19	P010137863//DTFH61-12-D-00038//OA-F-204-13-19	-\$136
Integrated Modeling for Road Condition Predicti	132	20.0A-F-204-13-19 // DTFH61-12-D-00050	OA-F-204-13-19 // DTFH61-12-D-00050	\$57,421
Department of Transportation Total				\$371,339
Department of Veterans Affairs				
Edward Hines, Jr. VA Hospital				
Intergovernmental Personnel Act (IPA) agreement for Meng		64.018	IPA Agmt. signed 12/22/2014 (578/151)	\$38,479
Intergovernmental Personnel Act Agreement for Kenzie Cam		64.018	IPA Agmt. signed 09/01/2015	\$5,404
IPA Agmt for Inger Burnett-Zeigler		64.018	578/151	\$1,901
VA IPA: A Comparison of Two Surgical Procedures that Res		64.018	Letter 10/03/13	\$237
				\$46,021
Hines VA Contract for Elisa Gordon		64.VA69D-15-P-3249	VA69D-15-P-3249	\$14,987
James A. Haley Veterans' Hospital				
IPA for Kallen: Measuring Quality of Life in Veterans wi		64.018	IPA Agmt signed 12/23/2014	\$13,577
IPA for Sally Jensen: Measuring Quality of Life in Veter		64.018	673-D57052 (Year 03 PO Number)	\$17,826
				\$31,403

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
James J. Peters VA Medical Center				
Development of the Blood Pressure Symptom Subdomain for		64.VA243-12-C-0234	VA243-12-C-0234	\$1,813
Extending Veteran Participation in the Validation of the		64.VA243-13-C-0050	VA243-13-C-0050	\$7,260
Jesse Brown VA Medical Center				
2014 IPA Agreement for Michael Dixon		64.018	Agmt Signed 08/15/2014	\$31,331
Craig Heckathorne VA IPA		64.018	IPA Agmt. 10/31/2014	-\$1,561
Intergovernmental Personnel Act for Ling Bei		64.018	IPA Agmt signed 12/05/2014	\$32,977
Intergovernmental Personnel Act for Pritin Soni		64.018	Agreement Date: 10/2/12	-\$269
Intergovernmental Personnel Agreement for Krishan Kumar		64.018	IPA Agmt. Signed 07/30/2014	\$63,415
IPA Agmt for John Brinkmann		64.018	IPA Agmt Signed 2/25/15 (IPA0028657)	\$17,384
IPA Agmt for Recep Nigdelioglu		64.018	Agreement Date: 09/12/2013	\$2,732
IPA for Paul Cheresh		64.018	Agr. 08/28/2014	\$55,426
VA IPA - Antonella Sassano		64.018	IPA Agmt. Signed 10/10/2014	\$51,862
VA IPA Agmt for Luisa Isabel Morales Nebreda		64.018	IPA Agmt. Signed 08/28/2014	\$43,565
VA IPA Agmt. for Linda India		64.018	IPA Agmt. Signed 02/27/2015	\$3,725
VA IPA Agreement for Janet Martinez		64.018	IPA Agmt. Signed 09/16/2014	\$14,956
VA IPA Agreement for Kazumi Ebine		64.018	IPA Agmt. Signed 03/20/2015	\$16,711
VA IPA Agreement for Qun Jiang		64.018	IPA Agmt. Signed 09/16/2014	\$14,356
VA IPA Agreement for Vera Shively		64.018	IPA Agmt. Signed 09/16/2014	\$50,035
VA IPA for David Williams		64.018	IPA Agmt. Signed 08/28/2014	\$54,255
VA IPA for Ewa Kosciuczuk		64.018	Agmt. signed 09/24/2014 (537/151)	\$44,023
VA IPA for Saul Soberanes		64.018	IPA Agmt. Signed 08/28/2014	\$51,116
VA IPA for Weiqi Huang		64.018	IPA Agmt. signed 12/5/14 (537/151)	\$39,525
				\$585,564
Tuscaloosa VA Medical Center				
Intergovernmental Personnel Agreement: Development of a		64.018	679-D55001 (Year 04)	\$11,874
Department of Veterans Affairs Total				\$698,922
Institute of Museum and Library Services				
Variations on Video: Building the Next Generation Librar	110	45.312	PO#1054476/BL-4347417-NU // LG-05-11-0167-11	\$13,380
Institute of Museum and Library Services Total				\$13,380

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
National Aeronautics and Space Administration				
A New Insight into Open Cluster Internal Dynamics and Ne	204	43.001	GO3-14043B//NAS-8-03060	\$9,119
An X-Ray View of Hypervelocity Star HVS5	204	43.001	G04-15137X/NAS8-03060	\$4,579
Impact of Long Duration Space Flight on Cardiac Structur	156	43.001	CA02203//NCC-9-58-174	\$21,569
Joint Chandra/XMM/EVLA Monitoring of the Gas Cloud G2 as	s 204	43.001	G03-14121X Amd 2//NAS8-03060	\$25,012
Life Underground	271	43.001	65904754//NNA13AA92A	\$24,686
Modeling Black Hole X-Ray Binaries in Globular Clusters	204	43.001	TM5-16004X//NAS8-03060	\$20,237
Optical Instrumentation for the Development of Space Ope	61	43.001	10-007MH//NNX09AU90A	-\$170,992
The Balloon-borne Large Aperture Submillimeter Telescope	267	43.001	560958//NNX13AE50G//Amd 3	\$139,858
The Origin of Diffuse 6.4 keV Line Emission from two Clo	204	43.001	GO3-14086X	-\$174
The Physics of Black Hole Feedback	204	43.001	PF3-140106-Amd 1//NAS8-03060	-\$2,799
				\$71,095
2010 NASA Training Grant Announcement/National Space Gr	a 249	43.2010-04000-01 // NNX10AK65H	2010-04000-06 // NNX10AK65H	\$47,078
Modeling the Origins of Sub-subgiant Stars	206	43.HST-AR-13910.001-A//NAS5-26555	HST-AR-13910.001-A//NAS5-26555	\$44,060
SOFIA Wide-Field Far-IR Polarimetry and Fine-Structure-L	32	43.Subk No. 1478794//NNN12AA01C	Subk No. 1478794-007//NNN12AA01C	\$145,943
NASA Ames Research Center				
Effects of Spaceflight on Gastrointestinal Microbiota in		43.007	NNX15AL05G	\$55,185
FORCAST Observations of Sgr C at the Galactic Center	225	43.012	SOF0099//NAS2-97001	\$5,002
"Weather on Substellar Worlds: Mapping the Atmospheres o	32	43.RSA No: 1442438	RSA No: 1442438	-\$16
NASA George C. Marshall Space Flight Center				
Coarsening of Dendritic Solid-Liquid Mixtures: The Low V		43.001	NNX14AB73G 000003	\$122,660
NASA Goddard Space Flight Center				
Accreting Binary Populations from Billions of Years Ago		43.001	NNX12AL39G/000001	\$1,911
Confirming Small Planets and Measuring Their Masses with		43.001	NNX14AB88G/000003	\$50,487
Deciphering Kepler's Planetary Systems		43.001	NNX14AD21G	\$19,745
Dynamical Modeling of Dense Star Clusters with a Paralle		43.001	NNX14AP92G/000002	\$136,375
Dynamics of Extrasolar Planetary Systems		43.001	NNX12AI86G 000003	\$98,100
Improving the Performance of X-Ray Optics with Magnetost		43.001	NNX11AG05G-000007	\$167,816
Lipid Biomarkers of the Deep Subsurface Biosphere		43.001	NNX15AM08G	\$8,885
Low Frequency Gravitational Wave Astrophysics		43.001	NNX13AM10G/000003	\$44,539
Swift Monitoring of the Encounter Between SGR A* and the		43.001	NNX14AC30G	\$12,853
Synthesis and Analysis of Putative Secondary Organic Aer		43.001	NNX13AN8-9H	\$228

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

(Continued)

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
The Architectures of Near-resonant Kepler Planets		43.001	NNX14AG98G-000001	\$76,973
The Physical Nature of Circum-Galactic Gas		43.001	NNX15AB22G	\$16,676
Titan's Impact Craters and Associated Fluvial Features:		43.001	NNX13A002H 000001	\$27,383
				\$661,971
Implementing a Near-Optimal Optical Receiver for Inter-P		43.008	NNX12AN27H/000004	\$66,544
Multiple Undergraduate Research Projects	249	43.008	2015-05200-09//NNX154AI05H	<u>\$28,922</u> \$95,466
Broadband Electrically Tunable Monolithic Mid-Infrared L		43.009	NNX13AT10G/000001	\$212,325
Excitronics Based on Carbon Nanomaterials: A Pathway Tow		43.009	NNX11AM87H-000004	\$81,573
Integrating Two-Dimensional Nanomaterials and Molecular		43.009	NNX12AM44H/ 000003	\$70,255
Tailorable Porous Ceramics via Freeze Casting		43.009	NNX11AM91H	\$67,864
				\$432,017
Aperture: A Precise Extremely large Reflective Telescope		43.012	NNX15AL89G	\$29,954
NASA John F. Kennedy Space Center				
NASA Self-Repairing Fatigue Damage in Metallic Structure		43.002	NNX13AR52A	\$49,922
NASA John H. Glenn Research Center at Lewis Field				
Coarsening in Solid-Liquid Mixtures II		43.002	NNX07AW01G/00004	\$2,632
NASA Lyndon B. Johnson Space Center				
HERO Twin Astronaut Study Consortium (TASC) Project: Met National Aeronautics and Space Administration Total		43.003	NNX14AH26G	<u>\$54,757</u> \$1,817,726
National Science Foundation				
3D Braided Composite Structures - Experimental Character		47.041	CMMI-1435950	\$191,778
3D Near Field e-Writing with Submicron Resolution		47.041	CMMI-1404489	\$71,659
3D Tissue Inks: Multifunctional 3D Printing Materials Pl		47.041	IIP-1508285	\$28,974
A Novel Non-Contact Technique for Dynamic Loading of Thi		47.041	CMMI-1130924	\$6,581
A Quantum-Eraser Approach to Heralding High-Quality Sing		47.041	ECCS-1232022/003	\$105,434
Addressing Geographical Disparities in Transplant Organ		47.041	CMMI-1131568	\$72,215
Advancing Dynamic Relief Response: Integration of New Da		47.041	CMMI-1265786	\$85,344
Advancing the Capabilities of Adaptive Management Techni		47.041	CMMI-0928184/001	-\$28,723
The accompanying fact at a an integral part of the Sabadula of Eve	onditures of Endoral	Awarda	1	Continued

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title Pass-throug	h ID CFDA	Sponsor Award Number	FY15 Expense
An Interatomic Potential for LixSi Alloys and Its Applic	47.041	CMMI-1200075	\$28,287
An Optimal Design of Experiments Approach for Reliable R	47.041	CMMI-1436574	\$85,150
Assessing Supply Chain Technology Variability and Enviro	47.041	CBET-1236837	\$60,511
BIOMOLECULAR CELL INJECTION WITH NANOFOUNTAIN PROBE SYST	111 47.041	IIP-1330151	\$20,159
Biophotonic Detection of Field Carcinogenesis of Pancrea	47.041	CBET-1340617	\$112,811
CAREER: A Hybrid Approach for Flexible Nanomanufacturin	47.041	CMMI-0955195	\$17,578
CAREER: Engineering Non-Growth Metabolism for High-Yield	47.041	CBET-1452549	\$37,083
CAREER: Functional Imaging to Prevent Blindness	47.041	CBET-1055379	\$53,474
CAREER: Mechanics of Geomaterials Exposed to Multi-Physi	47.041	CMMI-1351534	\$100,355
CAREER: Rational design of a biomimetic nanomaterial lib	47.041	CBET-1453576	\$27,366
CDI-Type II: Cyber-Enabled Discovery in Neuromechanical	47.041	CMMI-0941674	\$94,225
Collaborative Research in Biophotonics: Towards High-Res	47.041	CBET-1066776/001	\$60,276
Collaborative Research: Analysis and Solution Methods fo	47.041	CMMI-1361942	\$9,221
Collaborative Research: Binary Constrained Convex Quadra	47.041	CMMI-1334639	\$42,894
Collaborative Research: CybeR-Enabled Demand-Interactive	47.041	CMMI-1402911	\$72,719
Collaborative Research: Elucidation and Evaluation of St	47.041	CBET-1435228	\$35,999
Collaborative Research: Engineering Polymer Nanodielectr	47.041	CMMI-1334929	\$90,005
Collaborative Research: Ergodic Trajectories in Discrete	47.041	CMMI-1334609	\$78,980
Collaborative Research: Fundamentals of Material Behavio	47.041	CMMI-1463459	\$3,802
Collaborative Research: Integrated Measurement and Predi	47.041	CBET-1264963	\$49,669
Collaborative Research: Laser-driver Micro-Transfer Prin	47.041	CMMI-1300846-03	\$6,158
Collaborative Research: Leveraging Noncontact Dimensiona	47.041	CMMI-1265709	\$23,620
Collaborative Research: Manipulation Thz Wave Using Thre	47.041	ECCS-1232134	\$50,358
Collaborative Research: Molecular Basis for Protein Sorp	47.041	CBET-1264696-002	\$99,932
Collaborative Research: Nonlinear Ultrasonic Wave Mixing	47.041	CMMI-1363221	\$17,778
COLLABORATIVE RESEARCH: Optimizing Direct-Marketing Stra	47.041	CMMI-1335104-02	\$81,598
Collaborative Research: The Positive Role of Queues on C	47.041	CMMI-1301090	\$37,963
Collaborative Research: The Unintended Ecological Conseq	47.041	CBET-1067751	\$66,392
Collaborative Research: Tribochemically Induced Gelation	47.041	CMMI-1200529	\$49,683
Collaborative Research: Virtual Full-Duplex Wireless Net	47.041	ECCS-1231828/002	\$92,974
Control of Hybrid Locomotion with Impacts	47.041	CMMI-1436297	\$57,609
Curved Waterjet-Guided Laser Micro-Manufacturing	47.041	CMMI-1234491	\$73,081
Cutting and Shuffling: A New Dynamical Systems Paradigm	47.041	CMMI-1435065	\$84,550
Design and Control Principles for Mobile Health Care Ope	47.041	CMMI-1131298	\$96,892
Design and Development of Fire-Resistant Ferritic Steels	47.041	CMMI-1130000	\$38,003
Digital Loft: A Learning Platform for Instructors and Tr	47.041	IIP-1550565	\$3,078

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Direct Measurement of the Role of Confinement and Chemis		47.041	CMMI-1235355/001	\$95,653
Distribution and Moment-Robust Optimization Models and A		47.041	CMMI-1100868	\$48,476
DMREF: A Fundamental Approach to Study the Effect of Str		47.041	CMMI-1235480	\$248,409
DMREF: Collaborative Research: Simulation-Based Design o		47.041	CBET-1234305	\$89,897
EAGER: New Biophotonics and Computational Molecular Dyna	l	47.041	CBET-1249311	\$50,006
EAGER: Spatial and Spectral Beam Control of Angled-Cavit		47.041	ECCS-1359779	\$100,389
EAGER-Collaborative Research: New Concept of Sorption Hy		47.041	CMMI-1153494	-\$988
EFRI 2-DARE: Scalable Growth and Fabrication of Anti-Amb		47.041	EFRI-1433510	\$388,366
EFRI-BioFlex: Miniature, Low-cost Fiber-optics Technolog		47.041	EFRI-1240416	\$735,884
EFRI-BioSA: Bio-Inspired Arrays of Haircell Sensors for		47.041	EFRI-0938007	\$116,703
EFRI-BSBA: Nanoactuation and Sensing of Neural Function	248	47.041	NSF-EFRI-0938072	\$38,630
EFRI-BSBA: Photonic Technique for Sensing and Understand		47.041	EFRI-0937987	\$101,444
Electrochemical Society Symposium on GaN and SiC Power T		47.041	ECCS-1444374	\$5,000
Engineering a recombinant methane monooxygenase to conve	174	47.041	PNU-001//IIP-1346523	\$14,505
Enhancing Identifiability of Computer Simulation Models		47.041	CMMI-1233403	\$90,886
Excessive Bridge Deflections: Inverse Analysis to Identi		47.041	CMMI-1129449	\$224,748
Fractal Mechanics of Stretchable Piezoelectrics for Mech		47.041	CMMI-1400169	\$2,767
Friction in Full View		47.041	CMMI-1400618	\$53,898
Functionalities Emerging in Adaptive Brain Networks thro		47.041	CMMI-1435358	\$84,619
GOALI - Collaborative Research: Fundamental Study and P		47.041	CMMI-1301127	\$74,799
GOALI Portfolio of Renewable Energy Generation		47.041	CMMI-1201151	\$43,295
GOALI/Collaborative Research: Electrically-Enhanced Prec		47.041	CMMI-1100787	\$85,836
GOALI/Collaborative Research: Reliable Prediction of End		47.041	CMMI-1434834	\$28,522
GOALI: Effects of Gas in Design and Verification of Blas		47.041	CMMI-1235440	\$91,222
GOALI: Models and Methods for Marathon Course Design usi		47.041	CMMI-1405231	\$94,436
GOALI: Quantifying Input Uncertainty in Stochastic Simul		47.041	CMMI-1068473	\$17,604
GOALI: Strength Loss in Clays During Earthquake and Othe		47.041	CMMI-1434876	\$142,853
Green Solution-Processing of All-Carbon and Carbon-Rich		47.041	CMMI-1130407	\$76,872
Health Systems Optimization Workshop		47.041	CMMI-1445448	\$14,791
I-Corps: Three-Demensional Printing of a Customizable		47.041	IIP-1519687	\$18,912
IDR: Engineering Electroactive-Polymer-Based Phononic Cr		47.041	CMMI-1130948	\$95,800
Investigating the Effect of Pore Fluids on the Stability		47.041	CMMI-1234031	-\$319
Investigation of Oxide Nanophotonic Devices		47.041	ECCS-1201853	\$52,706
Laser-Induced Plasma Micro-Machining (LIP-MM)		47.041	CMMI-0969776	-\$3,965
Managing Downstream Patient Flow Processes Using Improve		47.041	CMMI-1335585	\$28,592
Man-made Hazard Mitigation of Reservoir Dams: Monte Carl		47.041	CMMI-1237920	\$1,806

Research Type/Federal Grantor/Subagency/Project Title Pa	ss-through ID	CFDA	Sponsor Award Number	FY15 Expense
Models and Algorithms for Risk Adjusted Optimization wit		47.041	CMMI-1131386	\$116,758
Molecular Organization and Transport in Synthetic and Bi		47.041	CBET-1403058	\$64,844
Monolithic Nanofabrication: A Bottom-up Approach for Man		47.041	CMMI-1462633	\$52
MRI: Instrument Development: Additive Rapid Prototyping		47.041	CMMI-1429658	\$251,868
Multidimensional Network Analysis for Analyzing and Pred		47.041	CMMI-1436658	\$112,953
Multi-Objective Robust Stochastic Planning and Schedulin		47.041	CMMI-0928936	-\$428
Multiscale and Multiphysics Simulation of Reinforced Con		47.041	CMMI-1435923	\$87,378
Nanoscale Science and Engineering Center for Scalable an	229	47.041	00006258 // CMMI-0751621	-\$14,893
Neuroprotective Engineering Based on Innate Responses to		47.041	CBET-1403036	\$85,877
NSF/DOE Thermoelectrics Partnership: SEEBECK: Saving Ene		47.041	CBET-1048728/004	-\$3,911
OPTICENT HEALTH-FUNCTIONAL IMAGING FOR EARLY DISEASE	DET	47.041	IIP-1507501	\$11,284
PFI: AIR-TT: Hybrid Tri-pyramid Robot: A Novel Type of D		47.041	IIP-1414394	\$86,119
PFI:BIC: A Smart, "Always-on" Health Monitoring System		47.041	IIP-1534120	\$1,387
PFI-AIR: Technology Translation - Highly Sensitive Eye-s		47.041	IIP-1500314	\$16,266
Photonic-jet Coupled Optical Antenna for Near Room Tempe		47.041	ECCS-1310620	\$124,961
Physical Design and Feedback Control of Hybrid Mechanica		47.041	CMMI-1200321	\$130,822
Process Modeling and Enhancements of Laser-Induced Plasm		47.041	CMMI-1335014	\$40,067
REU Site: Research Experience for Undergraduates in Nano		47.041	EEC-1359004	\$82,063
Robust Design to Account for Geometric Imperfections in		47.041	CMMI-1130640	\$40,009
Room Temperature, High Power, Monolithic Optical THz Sou		47.041	ECCS-1231289/002	\$155,087
Service Systems with Outbound Work and Blending		47.041	CMMI-1436518	\$75,022
Shrinkable and Stretchable NanoManufacturing		47.041	CMMI-1069180	\$183,735
Soil Slip Versus Flow Failure in Rain-infiltrated Slopes		47.041	CMMI-1324834	\$83,706
Structural Dynamics of Polymer and Surfactant Solutions		47.041	CBET-1336269	\$66,348
Surface Plasmon Photoacoustic Imaging of Subsurface Obje		47.041	CMMI-1031574	-\$59
SusChEM: Using theory-driven design to tailor novel nano		47.041	CBET-1438721	\$67,708
Synchrotron Studies and Computational Modeling of Flow-I		47.041	CMMI-1334719	\$99,367
Tunable Continuous Wave THz Source Based on a Room Tempe		47.041	ECCS-1306397	\$51,627
Two-compartment microfluidic bioreactor with functionali		47.041	CBET-1265029	\$217,859
Ultra-High Performance Fiber Reinforced Concrete Structu	286	47.041	478708-19980//CMMI-1201087	\$104,094
Using Biofluiddynamics to Interrogate the Spinal Circuit		47.041	CBET-1066575	\$51,470
US-Japan Materials Genome (MG) Workshop		47.041	CMMI-1541818	\$12,194
				\$8,248,183
Amenable and recurrent actions of finitely generated gro		47.049	DMS-1352173	\$70,869
An Atom-Probe Tomography and Lattice Kinetic Monte Carlo		47.049	DMR-1207539/ Amd 003	\$69,963
The accompanying footnotes are an integral part of the Schedule of Expendi	tures of Federal	Awards - S	94 —	(Continued

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Analysis on Manifolds		47.049	DMS-1502632	\$40,669
Approximation properties of groups and operator algebras		47.049	DMS-1439377	\$52,689
Architecture of Planetary Systems: Solar and Extrasolar		47.049	AST-1109776	\$55,969
ATD: A Mixture Modeling Framework for Statistical Identi		47.049	DMS-1043080	\$9,527
Bioengineering Single Crystal Growth		47.049	DMR-1106208/004	\$59,132
Bio-Resorbable and Eco-Resorbable Electronics Material	216	47.049	Agmt 01/14/2013//DMR-1242240	\$103,828
Biouptake of Mercury: Speciation and Processes at the Ce		47.049	CHE-1308504	\$73,026
Broadband, Quasi-Crystalline, and Low-Symmetry Plasmonic		47.049	DMR-1006380	-\$302
CAREER: Arithmetic of Cohomological Automorphic Forms		47.049	DMS-0846285/004	\$35,938
CAREER: Interfacial Assembly of Soft Layered Materials		47.049	DMR-0955612/001	\$103,288
CAREER: Ligand Engineering of Structure and Electronic F		47.049	DMR-1454688	\$20,861
CAREER: Planet Formations in the Age of Kepler		47.049	AST-1352369	\$15,718
CAREER: Quantum Phases and Non-Equilibrium Dynamics of S		47.049	PHY-1055993	\$103,425
CAREER: Rescue and Control of Complex Networks of Dynami		47.049	DMS-1057128	\$222,674
CAREER: Synthesis and Studies of One-Dimensional Magnets		47.049	DMR-1351959	\$130,750
CAREER: Synthesis of molecular electronic-spin based qub		47.049	CHE-1455017	\$15,507
CAREER: Theories for Magnetic Properties of Lanthanide a		47.049	CHE-1351598	\$114,084
CCI Phase II: Center for Sustainable Nanotechnology	280	47.049	630K475//1503408	\$24,303
CDS&E: Black Holes in Dense Star Clusters		47.049	AST-1312945	\$163,436
CEMRI: Multifunctional Nanoscale Material Structures		47.049	DMR-1121262 Amd 007	\$3,175,324
Charge Transfer as a Probe of the Permeability of Organi		47.049	CHE-1400596	\$107,234
Chirality in Aerosol Chemistry		47.049	CHE-1111418/02	\$209,178
Cohomological and singularity invariants via Hodge modul		47.049	DMS-1405516	\$69,969
Collaborative Research: Modern Oil-based Paints: A Mec		47.049	DMR-1241667	\$68,074
Collaborative Research: CDS&E: FIRE: Physically-Predicti		47.049	AST-1412836	\$90,692
Collaborative Research: Computational Thermochemistry of		47.049	DMR-1309957 Amd 001	\$67,776
Collaborative Research: Factorization Homology and the C		47.049	DMS-1508040	\$36,844
Collaborative Research: Fluctuating Hydrodynamics of Sus		47.049	DMS-1418672	\$21,856
Collaborative Research: High-Throughput Quantification o		47.049	DMR-1505103	\$8,744
Collaborative Research: Investigating Structural Dynamic		47.049	CHE-1363007	\$100,318
Collaborative Research: Mathematics and Climate Change R		47.049	DMS-0940262/001	\$110,347
Collaborative Research: Methods for Stochastic and Nonli		47.049	DMS-1216567	\$26,848
Collaborative Research: NanoMine: Data Driven Discovery		47.049	DMR-1310292	\$44,013
Collaborative Research: Size Effects on Magneto-Mechanic		47.049	DMR-1207282	\$70,539
Collaborative Research: Size-Effect Driven Nanoparticle		47.049	DMR-1508323	\$2,957
Collaborative Research: Sustainable Energy Pathway: Deve		47.049	CHE-1230217	\$165,012

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Complexity of Disordered Systems		47.049	DMS-1517864	\$39,805
Construction of the COUPP-500kg Bubble Chamber for Dark	240	47.049	FP052629-C//PHY-1242637	\$143,531
Dark Matter and Neutrino Physics with Cryogenic Detector		47.049	PHY-1550658	\$62,307
Design and Synthesis of Non-Equilibrium Systems		47.049	CHE-1308107	\$141,591
Designing Multi-scale Nanomaterials with Structural		47.049	CHE-1058501/002	\$125,985
Deterministic and Stochastic Models of Water Limited Eco		47.049	DMS-1517416	\$27,374
Dielectric Effects in Dynamical Self-Assembly of Anisotr		47.049	DMR-1310211-001	\$79,036
Disorder Effect on Magnetism in Dilute Magnetic Semicond		47.049	DMR-1305666	\$150,964
Distribution of Word Maps in Groups		47.049	DMS-1303205	\$62,438
DMREF/Collaborative Research: Computationally Driven Tar		47.049	DMR-1333335	\$105,541
DMREF: Simulation-Driven Design of Highly Efficient MOF		47.049	DMR-1334928	\$490,809
Doping in Non-Planar Heterostructures		47.049	DMR-1308654 Amd 002	\$132,500
Dynamics with a combinatorial flavor		47.049	DMS-1500670	\$49,363
EAGER: Towards Atomic-Scale Imaging of Hybrid Nanomateri		47.049	DMR-1341391	\$77,847
Emphasis Year in Geometric Analysis at Northwestern Univ		47.049	DMS-1454077	\$48,335
Excitations, Topological Defects and Quantum Transport i		47.049	DMR-1106315	\$115,220
Factorization Homology and the Topology of Manifolds		47.049	DMS-1207758	\$15,125
First Passage and Optimal Stopping Problems for Subordin		47.049	DMS-1109506	\$39,744
FRG: Development and Validation of Novel Computational T	258	47.049	3002103959 // DMR 1105409	\$28,753
Geometry and Analysis on Calabi-Yau and Hermitian Manifo		47.049	DMS-1308988	\$74,526
Geometry, Representation theory, and Langlands duality.		47.049	DMS-1402928/001	\$59,235
Geometry, Representation Theory, and the Langlands Progr		47.049	DMS-1069316	\$8,852
Global Harmonic Analysis and Quantum Dynamics		47.049	DMS-1206527-001	\$96,563
Gravitational-Wave Astrophysics: Getting Ready for the A		47.049	PHY-1307020/002	\$154,051
Hardness and Elasticity of Superhard and Ultrahard Mater		47.049	DMR-1508577	\$34,107
High-throughput Computational Discovery of New Nanoporou	l	47.049	DMR-1308799	\$57,887
Homological Mirror Symmetry for Calabi-Yai Hypersurfaces		47.049	DMS-1104779	\$10,749
Interest Rate Modeling at the Zero Lower Bound: Applicat		47.049	DMS-1514698	\$3,231
Intrinsically Acentric High-Response Electro-Optic Multi	35	47.049	RES504561/A1//DMR-0423914 Mod. 5	\$142,989
Investigation of High Strain-Rate Deformation and Failur		47.049	DMR-1408901/ Amd. 001	\$85,796
IRES: Nanomaterials undergraduate Research in Germany (N		47.049	IIA-1460031	\$1,037
Knots, Sheaves, and Mirrors		47.049	DMS-1406024	\$54,405
Linear Partial Differential Equations on Singular Spaces		47.049	DMS-1265568	\$68,480
Liquid Surfaces and Interfaces: X-Ray Studies		47.049	DMR-1006432	-\$1,047
Local and Global Chromatic Stable Homotopy Theory		47.049	DMS-1308916	\$68,688
Manipulating Multi-Spin Dynamics in Systems Targeting Or		47.049	CHE-1266201	\$147,210

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

(Continued)

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expens
Materials World Network: Chemical and Biological Approac		47.049	DMR-1108350	\$227,89
Mathematical Modeling of Biomembranes		47.049	DMS-1312935	\$56,31
Microlocal Category		47.049	DMS-1105832	\$17,40
Midwest Topology Seminar		47.049	DMS-1413786	\$10,48
Moduli Spaces of complex dynamical systems		47.049	DMS-1517080	\$104,65
Molecular Ion Entanglement Detection by Single-Molecule		47.049	PHY-1404455	\$269,92
Molecular Plasmonics: Single Nanoparticle Assemblies, Si		47.049	CHE-1152547/001	\$170,31
MRI: Development of a Cryogenic Sample Preparation Instr		47.049	DMR-1229693	\$125,82
Multifunctional Nanodiamond Platforms for Targeted Imagi	234	47.049	1350GRB519//DMR1343991	-\$3
Multiple-Scale Mathematical Models of Ultra-Short-Pulse		47.049	DMS-1211912	\$45,72
Multi-Scale Analysis of Lignin for Drop-In Biofuels		47.049	CHE-1314063	\$143,39
Nanoscale Curvature Effects on the Properties of Anisotr		47.049	CHE-1507790	\$4,36
NEB: Scalable Sensing, Storage and Computation	268	47.049	0024232 (011288-1)	\$68,93
New Directions in Modularity		47.049	DMS-1404620	\$59,23
New Lewis Bases for Chemical Catalysis		47.049	CHE-1152010	\$74,45
New Stereoselective Fragment Coupling Reactions for Orga		47.049	CHE-1361173	\$23,04
Nonequilibrium States of Topological Quantum Fluids and		47.049	DMR-1508730	\$5,48
Nonlinear PDEs and complex geometry		47.049	DMS-1406164	\$63,60
Novel Algorithms for Nonlinear Optimization		47.049	DMS-1216920	\$91,01
Organization of Charged Molecules in Heterogeneous Media		47.049	DMR-1309027	\$34,52
Organo-f-Element Chemistry: Integrated Synthetic, Mechan		47.049	CHE-1213235	\$219,19
Participant Support for Foundations of Molecular Modelin		47.049	DMR-1513429	\$22,00
Phase I Center for Chemical Innovation, Nanoparticles an	280	47.049	416K242//CHE-1240151	\$90
Plasmon-Exciton Energy Transfer in Metal Nanocavities		47.049	DMR-1306514	\$154,22
Postdoctoral Research Fellowship for Dean Russell Baskin		47.049	1103436	\$1,11
Preparation, Characterization, and Application of Monodi		47.049	DMR-1006391-04	\$103,09
Quantum Coherent Phenomena in Superconducting Heterostru	l	47.049	DMR-1006445	\$5,12
REU Site: Preparing a Diverse Workforce through Interdi		47.049	AST-1359462 Amd 002	\$93,48
Ricci Curvature and Geometric Analysis		47.049	DMS-1406259	\$82,26
Shape and Dimensional Precision in Polymeric Nanostructu		47.049	DMR-1006713	-\$6,69
Shape and Dimensional Precision in Polymeric Nanostructu		47.049	DMR-1508731	\$22,22
Silicon-Based Porous Ceramics via Freeze-Casting Precera	31	47.049	7E-1095775//1411218	\$55,33
Solid State Chemistry of Chalcogenides for Materials Dis		47.049	DMR-1104965-001	\$50,34
Solid-State Oxides and Oxide-Flourides		47.049	DMR-1307698	\$122,37
Solution-Processed Monodisperse Nanoelectronic Heterostr		47.049	DMR-1505849	\$16,18
Spectrum Sharing in the Shadow of Uncertainty: Risk, Inc		47.049	AST-1343381	\$255,72

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Spin Coherences in Photosystem I Reaction Center Protein		47.049	CHE-1112258	\$4,574
Statics and Dynamics of Spatially and Dimensionally Cons		47.049	DMR-1507810	\$6,158
Statistical Inference Based on an Integrated Likelihood		47.049	DMS-1308009	\$33,272
Statistical Mechanics of DNA-Protein Interactions and Ch		47.049	DMR-1206868	\$113,714
Statistical Methods for Functional Metagenomics Analysis	228	47.049	69026//DMS-1222592	\$139,285
Stimuli-Responsive Supramolecular Assemblies		47.049	CHE-1149314 Amd. 002	\$104,489
Structures and excited state dynamics of self-assembled		47.049	CHE-1465045	\$28,888
Surface Chemical Synthesis of Catalytic Structures		47.049	CHE-1058835	-\$43
Surface Structure of Oxides		47.049	DMR-1206320	\$73,938
Surface/interface order in liquids with electrostatic co		47.049	DMR-1309589/ Amd 002	\$138,560
Synthesis and Coherent Vibrational Laser Spectroscopy of		47.049	CHE-1212692	\$171,032
Synthesis and Properties of Complex Crystalline and Glas		47.049	DMR-1410169	\$44,303
The Center for Chemistry at the Space-Time Limit (CaSTL	231	47.049	2009-2255/A5//CHE-0802913	-\$3,875
The Center for Chemistry at the Space-Time Limit (CaSTL)	231	47.049	2014-3122//CHE-1414466	\$456,411
The Interplay of Ergodic Theory, Additive Combinatorics,		47.049	DMS-1200971	\$62,204
The Massive Black Hole at the Center of the Galaxy and I		47.049	AST-1109753/002	\$195,335
The Midwest Probability Colloquium		47.049	DMS-1449300	\$22,270
Theoretical Modeling Inertial Phenomena in Chaotic Advec		47.049	PHY-1001198/002	\$20,790
Theory and Computation for Self-Assembly in Soft Matter		47.049	CHE-1147335	\$162,090
Topological Surface States and New Phases in Superfluid		47.049	DMR-1103625/004	\$127,931
Toughness and Friction of Model Polyelectrolyte Gels		47.049	DMR-1410968	\$149,502
Toward physically-predictive modeling of massive black h		47.049	AST-1517491	\$5,348
UTSA-NU Partnership for Research and Education in Materi	274	47.049	H1001-04 NWU - Amd 5//DWR-0934218	\$60
				\$13,713,790
CAREER: The Role of Sulfur in Regulating the Marine Carb		47.050	EAR-0955969	\$83,047
CMG Workshop on the Formulation of a Multi-Institutional		47.050	EAR-1025539	\$6,881
CO2 evasion from the Greenland ice sheet		47.050	PLR-1304686/002	\$109,648
Collaborative Research: Assessing the Impact of Small,		47.050	PLR-1304675	\$84,553
Collaborative Research: High-resolution Cretaceous terr		47.050	EAR-1424474	\$16,367
Collaborative Research: A Multi-Proxy Approach to Early		47.050	EAR-1053351	\$5,809
Collaborative Research: Bighorn Basin Coring Project (BB		47.050	EAR-0958717	\$48,178
Collaborative Research: Geophysical Investigation of the		47.050	EAR-1148088	\$77,064
Collaborative Research: Role of Interfacial Turbulence i		47.050	EAR-1215898	\$65,844
Collaborative Research: Superior Province Rifting Earths		47.050	EAR-0952345	\$83,309
Critical Zone Observatory Network for Intensively Manage	249	47.050	2013-04254-03//EAR-1331906	\$69,156

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
ELT COLLABORATIVE RESEARCH: Perturbation of the Marine		47.050	EAR-1338312	\$106,653
Expedition 341 South Alaska Margin, USSSP Support	53	47.050	BA-109//OCE-0652315	\$2,808
Hazards SEES Type 2: From Sensors to Tweeters: A Sustain	268	47.050	0036115(011529-3)//OCE-1331463	\$62,525
Hydration State of the Transition Zone and Lowermost Man		47.050	EAR-1452344	\$32,532
INSPIRE Track 1: Earthcasting fluvial systems: Physical		47.050	EAR-1344280	\$227,158
Postdoctoral Research Fellowship for David Vinson: Host		47.050	EAR-1249916	\$1,592
The Subduction Margin Carbon Cycle: A Preliminary Assess		47.050	OCE-1144483	\$80,237
				\$1,163,361
A Low-Cost Integrated Agent-based Modeling and Physical		47.070	IIS-1438813	\$89,994
AF: Small: Combinatorial Algorithms and Computational Co		47.070	CCF-1217770	\$92,006
BPEC: Computational Thinking in STEM: A Whole-School Mod		47.070	CNS-1441041	\$225,051
CAP: Collaborative Research: Building a Network to Advan		47.070	IIS-1239599	\$826
CAREER: Coherent Computational Imaging: Micro Measureme	n	47.070	IIS-1453192	\$5,940
CAREER: Energy-Efficient and Energy-Proportional Silicon		47.070	CCF-1453853	\$36,514
CAREER: Mechanism Design		47.070	CCF-0846113/002	\$9,401
CAREER: Natural Activities as an Avenue to Next Generati		47.070	IIS-0953943/005	\$31,246
CAREER: Networked Game Theory and Mechanism Design		47.070	CCF-1055020	-\$1,501
CAREER: Web Information Extraction: Scaling and Integrat		47.070	IIS-1351029/001	\$65,537
CC-NIE Networking Infrastructure: High Performance Scien		47.070	ACI-1341013	\$29,163
CGV: Medium: Collaborative Research: Visualizing Compari		47.070	IIS-1162067 Amd 3	\$58,811
CHS: Large: Collaborative Research: TextureShop: Tools		47.070	IIS-1518602	\$17,774
CHS:Small: Robust Interactive Audio Source Separation		47.070	IIS-1420971	\$83,997
CI-EN: Collaborative: Run Your Research with Redex		47.070	CNS-1405756	\$88,088
CIF:Small: Many-user Information Theory: A New Paradigm		47.070	CCF-1423040	\$77,437
CINET	286	47.070	478455-19980//ACI-1032677/005	\$47,087
Collaborative Research: Chameleon: A Large-Scale, Reconf		47.070	CNS-1419138 (Inc.1550342)	\$39
Collaborative Research: Responses of the Rodent Vibrissa		47.070	IIS-1208118	\$178,373
Collaborative Research: Understanding Climate Change: A		47.070	CCF-1029166/003	\$420,479
CPS: Large: Cybernetic Interfaces for the Restoration of	182	47.070	81838-Amd 7 // CNS-0932263	\$64,248
CPS: Synergy: Collaborative Research: Mutually Stabilize		47.070	CNS-1329891	\$121,430
CRII: CHS: Remote Paper Prototype Testing for Mobile App		47.070	IIS-1464315	\$6,378
DIP: Modeling in Levels		47.070	IIS-1441552	\$320,236
EAGER: Collaborative Research: Some Assembly Required: U		47.070	IIS-1249137	\$3,400
EAGER: Scalable Big Data Analytics		47.070	IIS-1343639	\$179,749
EAGER: Understanding Online Communication for Older Adul		47.070	IIS-1533340	\$31,104

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
EAGER:Collaborative Research: Model based Autonomic Clou		47.070	CNS-1265347	\$43,222
EXP: Augmenting Household Technologies for Learning and		47.070	IIS-1123574	\$164,388
EXP: Collaborative Research: Engaging Interdisciplinary		47.070	IIS-1217225	\$28,974
EXP: Digital Lofts: Online Learning Environments for Rea		47.070	IIS-1320693 002	\$314,649
EXP: Transforming High School Science via Remote Online		47.070	IIS-1216389	\$288,386
Future Technology to Preserve College Student Health and		47.070	IIS-1545751	\$27,770
GENI Experimental Environment	281	47.070	Agmt 01/01/2014//CNS-1346688	\$22,205
GENI Spiral 4: Prototype GENI Multi-Services Network Exc	21	47.070	BBN Ref ID 14303 PO #9500012297//CNS-1346688	\$110,504
HCC: Medium: Collaborative Research: Force Feedback for		47.070	IIS-1302422	\$293,646
HCC: Medium: Collaborative Research: Surface Haptics via		47.070	IS-0964075-005	\$3,129
HCC: Small: Building Audio Interfaces with Crowdsourced		47.070	IIS-1116384	\$126,500
HCC-SMALL: A Joint Action Approach to Understanding and		47.070	IIS-1217143/003	\$107,894
ICES: Large: Collaborative Research: Towards Realistic M		47.070	CCF-1101717	\$152,769
ICES: Small: Collaborative Research: Understanding the R		47.070	CCF-1216095	\$198,608
ICES: SMALL: Mechanism Design With Information-Sensitive		47.070	CCF-1216006	\$74,420
III: Large: Collaborative Research: Moving Objects Datab		47.070	IIS-1213038	\$27,789
III: Small: Inferring First Movers in Large-Scale Networ	258	47.070	3003577874//IIS-1538827	\$44,001
InquirySpace: Technologies in Support of Student Experim	51	47.070	243-02.01//IIS-1147621	\$108,295
InstaGENI: A Meso-Scale National Distributed Facility Wi	100	47.070	IIL-RG-03/ Mod. 2	\$6,082
IRNC: RXP: StarLight SDX - A Software Defined Networking		47.070	ACI-1450871	\$470
MRI: Equipment Development: Bimanual Robotic Manipulatio		47.070	CNS-1229566	\$54,191
NeTS: Small: A Dual-Objective Platform for Internet Expe		47.070	CNS-1218287	\$79,619
NeTS: Small: Endpoint User Profile Control		47.070	CNS-1319086	\$79,106
NeTS: Small: WaveCube: A Scalable, Fault-Tolerant, High-		47.070	CNS-1219116	\$104,997
NeTS:Large: Collaborative Research: Context-Driven Manag		47.070	CNS-0910952/005	\$79,953
NetSE: Large: Collaborative Research: Contagion in Large		47.070	CNS-1010904	\$22,801
NetSE: Medium: Collaborative Research: Auditing Internet		47.070	CNS-1064595	\$117,272
NRI: Autonomous Synthesis of Haptic Languages		47.070	IIS-1426961	\$80,599
NRI: Electrosense imaging for underwater telepresence an		47.070	IIS-1427419	\$304,398
NRI: Small: Modeling, Quantification, and Optimization o	181	47.070	2953//IIS-1317379	\$14,200
NRI-Small: Collaborative Research: Addressing Clutter an		47.070	IIS-1208479	\$1,427
RI Small: Computational Models of Context-awareness and		47.070	IIS-0916607	\$85,916
RI: Medium: Collaborative Research: Learning Representat		47.070	IIS-1065270	\$95,802
RI: Medium: Planning and Control for Dynamic Robotic Man		47.070	IIS-0964665	\$67,444
RI: Small: Contextual Mining and Learning for Video Scen		47.070	IIS-1217302/001	\$117,397
RI: Small:Hierarchical Planning, Estimation, and Control		47.070	IIS-1018167	-\$103

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

ShT: SHARS: IOM: Invariant Carrying Machine for Hardwa 47.070 CNS 1441855 ShT 226 SHF: Medium: Collaborative Research: Semantics Engineeri 47.070 CCF-1084474 386.104 SHF: Small: Collaborative Research: Semantics Engineeri 47.070 CCF-1218070,001 319.85 SHF: Small: Collaborative Research: Ensite Fidelity, Tr 47.070 CCF-1218070,001 319.85 SHF: Small: Indeparity Compiler and Architecture Design 47.070 CCF-1116610 312.333 SHF: Small: Indeparity Compiler and Architecture Design 47.070 CCF-1116610 312.333 SHF: Small: Indeparity Compiler and Architecture Design 47.070 CCF-1402489,001 \$109.821 SHF: Small: Indeparity Compiler and Architecture Design 47.070 CCF-1402489,001 \$109.821 SHF: Manul: Indeparitie Compiler and Architecture Design 47.070 CCF-1402601 \$22.807 SNCS: Lowenging Shand Scali Interest is a Control Comparitie Algorithms if a Control 47.070 CNS-134820 \$37.155 Trevel Support for the Organizatioant Computation 47.070 CNS-134820 \$37.155 Trevel Support for the Organizatioant Computation 47.070 CNS-134820	Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
SHE: Small: Collaborative Research: A systematic Aproace 47 070 CCF-111950 \$243 SHE: Small: Collaborative Research: Easter Heister Heist	SaTC: STARSS: ICM: Invariant Carrying Machine for Hardwa		47.070	CNS-1441695	\$31,226
SHE Small: Collaborative Bessarch: Designing a Pariant- 47.070 CCF-121970/0/01 \$19.8,74 SHE Small: Collaborative Bessarch: Designing a Pariant- 47.070 CCF-1219768 \$89.066 SHE Small: Internal-Aware High-Performance DRAM Archite 47.070 CCF-101610 \$123.339 SHE Small: Thermal-Aware High-Performance DRAM Archite 47.070 CCF-102980(01 \$10.8,21 SHE Small: Thermal-Aware High-Performance DRAM Archite 47.070 CCF-1422480(01 \$22.8,07 SHE Small: Collaborative Research: Excitable Algorithms f 47.070 CCF-142980(01 \$22.8,07 Support for the Organizational Communication 47.070 CNS-134820 \$37.100 Trew Missional Content Cenne Scalable Algorithms and Archite 47.070 CNS-134820 \$37.155 TWC: Modium: Collaborative Research: Experione Based Acc 47.070 CNS-134820 \$71.555 TWC: Medium: Collaborative: Interest in a Compatible Wir 47.070 CNS-134820 \$71.555 TWC: Medium: Collaborative: Research: Experime Based Acc 47.070 CNS-134820 \$71.555 TWC: Medium: Collaborative: Interest in a 47.070 CNS-134820 \$71.555 \$126.572	SHF: Medium: Collaborative Research: Semantics Engineeri		47.070	CCF-1064474	\$86,164
SHF: Small: Collaborative Research: Elastic Fuelity: T 47.070 CCF-1218788 \$88,066 SHF: Small: Integrating Compiler and Architecture Design 47.070 CCF-0116610 \$212,333 SHF: Small: Integrating Compiler and Architecture Design 47.070 CCF-0116610 \$212,333 SHF: Small: Integrated Circuits 47.070 CCF-0107746 \$22,020 SHF: Small: Integrated Circuits 47.070 CCF-1422489/001 \$109,821 SHF: Small: Integrated Circuits 47.070 CCF-0409601 \$22,807 SGCS. Leveraging Shared Social Interest in a Content Cen 47.070 CNS-0594087 \$87,310 Travel Support for the Organizational Communication 47.070 CNS-1314620 \$71,555 TWC: TP Option: Modurin: Collaborative: Incentive Compatible Wir 47.070 CNS-123673 \$126,572 TWC: TP Option: Modurin: Collaborative: Integrated Circuits and Artifying and 47.070 CNS-113861 \$133,550 TWC: TP Option: Modurin: Collaborative: Mork 2014 Docto 47.070 CNS-113861 \$13,555 TWC: TP Option: Modurin: Collaborative Wark 2014 Docto 47.070 CNS-113861 \$13,626 TWC: TP Option: Moduri	SHF: Small: Collaborative Research: A Systematic Approac		47.070	CCF-1115550	-\$243
SHF: Small: Integrating Compiler and Achitecture Design 47.070 CCF-1016510 \$123,339 SHF: Small: Thermal-Aware High-Performance DRAM Architec 47.070 CCF-1016746 -\$23,020 SHF: Small: Thermal-Aware High-Performance DRAM Architec 47.070 CCF-1422489/001 \$109,821 SHF: Small: Thermal-Aware High-Performance DRAM Architec 47.070 CCF-1422489/001 \$109,821 SHF: Small: Thermal-Aware High-Performance DRAM Architec 47.070 CCN-1422489/001 \$106,824 SCE: Leveraging Shared Social Interest in a Communication 47.070 CNN-5964087 \$57,310 Travel Support for the Organizational Communication 47.070 CNN-122837 \$126,527 TWC: SEF: Medium: Collaborative: Intentive Computer 47.070 CNN-122837 \$126,572 TWC: Medium: Collaborative: Intentive Computer 47.070 CNN-122837 \$126,572 TWC: TPP option: Medium: Collaborative: Intentive Computer 47.070 CNN-108790 \$125,570 TWC: SEF: Medium: Collaborative: Intentive Computer 47.070 CNN-108790 \$125,572 VWC: TPP option: Medium: Collaborative: Intentive Computer 47.070 CNN-108790 \$126,366 </td <td>SHF: Small: Collaborative Research: Designing a Patient-</td> <td></td> <td>47.070</td> <td>CCF-1219070/001</td> <td>\$196,874</td>	SHF: Small: Collaborative Research: Designing a Patient-		47.070	CCF-1219070/001	\$196,874
SHE: Small: Thermal-Mayner High-Performance DRAM Architec 47.070 CCF-0316746 -452.020 SHE: Small: Thermal-Monitoring in 3D Integrated Circuits 47.070 CCF-1422489/001 \$109,821 SHE: Small: Thermal-Monitoring in 3D Integrated Circuits 47.070 CCF-1402489/001 \$522,807 Succ. Leaveraging Shared Social Interest in a Content Cen 47.070 CNS-1211375 \$106,924 Tc: Medium: Collaborative Research: Experience-Based Acc 47.070 CNS-1211375 \$107,924 Two: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1242548 \$4,147 Two: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1314620 \$77,855 Two: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1406790 \$77,859 Two: Computer Supported Cooparative Work 2014 Doctvo Wrk 2014 Doctvo 47.070 CNS-1138461 \$35,750 WORKSHOF: Compatitive Support Econoparative Work 2014 Doctvo Wrk 2014	SHF: Small: Collaborative Research: Elastic Fidelity: Tr		47.070	CCF-1218768	\$89,066
SHF: Small: Thermal Monitoring in 3D Integrated Circuits 47.070 CCF-1422489/001 \$109,821 SHF: Small: Thermal Monitoring in 3D Integrated Circuits 47.070 CCF-14294801 \$22,807 SCS: Leveraging Shared Social Interest in a Content Cen 47.070 CNS-10984087 \$87,310 Tr: Medium: Collaborative Research: Experience-Based Acc 47.070 CNS-0984087 \$87,310 Trew SBE: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-134620 \$71,555 TWC: SBE: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1228357 \$126,552 TWC: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-138461 \$135,750 TWC: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-138461 \$135,750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 CNS-138461 \$135,750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 CNS-138461 \$136,860 XPS: FULL: Pt: Design and Synthesis of New Energy-effici 47.074 CSE-1533656 \$1,064 ZPS: Predictive Toxicology Assessment and Safe Implemen 234 47.074 CSE-1428444	SHF: Small: Integrating Compiler and Architecture Design		47.070	CCF-1116610	\$123,339
SHF.Medium:Collaborative Research: Scalable Algorithms f 47.070 CCF-1408601 \$22.807 SuCS: Leveraging Shread Social Interest in a Content Con 47.070 CNS-1211375 \$105.924 TC: Medium: Collaborative Research: Experience Based Acc 47.070 CNS-0994087 \$67.310 Travel Support for the Organizational Communication 47.070 CNS-1314620 \$71.155 TWC: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1228357 \$8126,572 TWC: TP Option: Medium: Collaborative: Identifying and 47.070 CNS-1138461 \$8135,750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 CNS-1138461 \$8135,750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 CNS-1138461 \$8132,649 SVPS: FULL: FP: Design and Synthesis of New Energy-effici 47.074 MCB-1118613-003 \$8122,649 CAREER: The Virtual Whisking Rat: Linking Mechanics an 47.074 MCB-1138613 \$81,862 Collaborative Research: Explorend Texture Scander Based Acc 47.074 MCB-1341414 \$81,862 Collaborative Research: Collociting the Synthesis of New Energy-effici 47.074 MCB-1341344	SHF: Small: Thermal-Aware High-Performance DRAM Archite	ec	47.070	CCF-0916746	-\$23,020
SoCS: Leveraging Shared Social Interest in a Content Cen 47.070 CNS-1211375 \$106,924 TC: Medium: Collaborative Research: Experience-Based Acc 47.070 CNS-0964087 \$67.310 Travel Support for the Organizational Communication 47.070 CNS-1211375 \$106,924 Two SEE: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1314620 \$71,555 TWC: Medium: Collaborative: Incentive Computer 47.070 CNS-122857 \$126,572 TWC: TPO Collaborative: Incentive Computational 47.070 CNS-134620 \$77,859 Type 1: Casting a Wide Net: Applied Computational 47.070 CNS-1360764 \$2.38 WDRS:HDP: Computer Supported Cooperative Work 2014 Dacto 47.070 CNS-1360764 \$2.38 VPR: FULL: FP: Design and Synthesis of New Energy-effici 47.074 CNS-046088/005 \$74,445 CEHI: Predictive Toxicology Assessment and Safe Implemen 234 47.074 SUK 6821 G Na121 / FAU 4-449045-AN-22264 \$818,862 Collaborative Research: Glyconegineering Without Borders 47.074 SUK 6821 G Na121 / FAU 4-449045-AN-22264 \$818,862 Collaborative Research: Glyconegineering Without Borders 47.074	SHF: Small:Thermal Monitoring in 3D Integrated Circuits		47.070	CCF-1422489/001	\$109,821
TC: Medium: Collaborative Research: Experience-Based Acc 47.070 INS-0964087 \$67,310 Travel Support for the Organizational Communication 47.070 INS-1342548 \$41,47 TWC SBE: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1314820 \$71,555 TWC: Medium: Collaborative: Neuroscience Meets Computer 47.070 CNS-1314820 \$77,855 TWC: TTP Option: Medium: Collaborative: Identifying and 47.070 CNS-1318461 \$73,555 TWC: Computer Supported Cooperative Work 2014 Docto 47.070 CNS-1318461 \$23,385 XPS: FULL: FP: Design and Synthesis of New Energy-effici 47.070 CNS-133656 \$1,064 Support for the Virtual Whisking Bat: Linking Mechanics an 47.074 CCF-1533656 \$1,064 CEIN: Predictive Toxicology Assessment and Safe Implemen 234 47.074 CSI GNA210 / DBI-03030117 \$42 Celliver Evology Assessment and Safe Implemen 234 47.074 CSI GNA210 / DBI-0303017 \$42 Cellive Toxicology Assessment and Safe Implemen 234 47.074 CSI GNA210 / DBI-0303017 \$42 Cellive Toxicology Assessment and Safe Implemen 234 <td< td=""><td>SHF:Medium:Collaborative Research: Scalable Algorithms f</td><td></td><td>47.070</td><td>CCF-1409601</td><td>\$22,807</td></td<>	SHF:Medium:Collaborative Research: Scalable Algorithms f		47.070	CCF-1409601	\$22,807
Travel Support for the Organizational Communication 47.070 IIIs-1342548 \$4,147 TWC: SBE: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1314620 \$71.555 TWC: Medium: Collaborative: Incentive Compatible Wir 47.070 CNS-1314620 \$72.557 TWC: Medium: Collaborative: Incentive Computer 47.070 CNS-1408790 \$77.859 TWC: TTP Option: Medium: Collaborative: Identifying and 47.070 CNS-133461 \$135.750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 CCF-1533656 \$1.064 XPS: FULL: FP: Design and Synthesis of New Energy-effici 47.074 CCF-1533656 \$1.064 CAPREER: The Virtual Whisking Rat: Linking Mechanics an 47.074 US-0846088/005 \$74.445 CEIN: Predictive Toxicology Assessment and Safe Implemen 234 47.074 US-0846088/005 \$74.445 Collaborative Research: Exploiting the Syntegron Techno 47.074 US-0846088/005 \$74.445 Collaborative Research: Exploiting the Syntegron Techno 47.074 US-1135481 \$182.652 Collaborative Research: Exploiting the Syntegron Techno 47.074 MCB-1335482 \$111.433 </td <td>SoCS: Leveraging Shared Social Interest in a Content Cen</td> <td></td> <td>47.070</td> <td>CNS-1211375</td> <td>\$106,924</td>	SoCS: Leveraging Shared Social Interest in a Content Cen		47.070	CNS-1211375	\$106,924
TWC SBE Medium: Collaborative: Incentive Computer 47.070 CNS-1314620 \$71,555 TWC: Medium: Collaborative: Neuroscience Meets Computer 47.070 CNS-1228357 \$126,572 TWC: TIP Option: Medium: Collaborative: Identifying and 47.070 CNS-134661 \$71,555 TWC: Stating a Wide Net: Applied Computational 47.070 CNS-138461 \$8135,750 WORKSH0P: Computer Supported Cooperative Work 2014 Docto 47.070 IIS-1350764 \$2.336 XPS: FULL: FP: Design and Synthesis of New Energy-effici 47.070 IIS-1350764 \$2.336 XPS: FULL: FP: Design and Synthesis of Metalloenzymes 47.074 CF-1533656 \$1.064 CHE: Predictive Toxicology Assessment and Safe Implemen 234 47.074 IOS-046088/005 \$74,445 CEIN: Predictive Toxicology Assessment and Safe Implemen 234 47.074 IOS-046088/005 \$74,445 Collaborative Research: Exploiting the Syntegron Techno 47.074 IOS-046088/005 \$74,445 Collaborative Research: Exploriting the Syntegron Techno 47.074 MCB-1141414 \$189,752 Collaborative Research: Exploriting the Syntegron Techno 47.074 MC	TC: Medium: Collaborative Research: Experience-Based Acc		47.070	CNS-0964087	\$67,310
TWC: Medium: Collaborative: Neuroscience Meets Computer 47.070 CNS-1228357 \$126,572 TWC: TTP Option: Medium: Collaborative: Identifying and 47.070 CNS-1408790 \$77,859 Type 1: Casting a Wide Net: Applied Computational 47.070 CNS-1138461 \$135,750 WORKSHOP: Computer Supported Cooperative Work 2014 Docto 47.070 IIIS-1350764 \$2.336 XPS: FULL: FP: Design and Synthesis of New Energy-effici 47.070 CCF-1533656 \$1.064 Stable Stable Stable \$5.961,078 \$5.961,078 Biophysical Studies of Metalloenzymes 47.074 MCB-1118613-003 \$182,649 CAREER: The Virtual Whisking Rat: Linking Mechanics an 47.074 IOS-0846088/005 \$74,445 CEIN: Predictive Toxicology Assessment and Safe Implemen 234 47.074 OS21 G NA210 // DBI-0830117 \$42 CellN: Predictive Toxicology Assessment and Safe Implemen 234 47.074 MCB-1314141 \$199,752 Collaborative Research: Exploiting the Syntegron Techno 47.074 MCB-1335862 \$111,433 IDBR: Type A: The Nanosizer: A 47.074 DBI-1353862/001 \$315,776	Travel Support for the Organizational Communication		47.070	IIS-1342548	\$4,147
TWC: TTP Option: Medium: Collaborative: Identifying and47.070CNS-1408790\$77,859Type 1: Casting a Wide Net: Applied Computational47.070CNS-1138461\$135,750WORKSHOP: Computer Supported Cooperative Work 2014 Docto47.070IIS-1350764\$2,336XPS: FULL: FP: Design and Synthesis of New Energy-effici47.070CCF-1533656\$1.064Biophysical Studies of Metalloenzymes47.074MCB-1118613-003\$182,649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.07405.21 G NA210 // DBI-0830117\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117\$42Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: IDBR: Type A: The Nanosizer: A47.074MCB-134563\$7.892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074MCB-1353652/2001\$315,776Investigation of the Yeast Prion [SWH-]47.074MCB-1323552/001\$315,776Investigation of the Yeast Prion [SWH-]47.074MCB-1323552/001\$315,776Investigation of the Yeast Prion [SWH-]47.074MCB-132355\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1323552/001\$315,776Investigation of the Yeast Prion [SWH-]47.074MCB-132355\$36,043Micromechanical Analysis of Chromosome Structure47.074MCB-1325	TWC SBE: Medium: Collaborative: Incentive Compatible Wir		47.070	CNS-1314620	\$71,555
Type 1: Casting a Wide Net: Applied Computational47.070CNS-1138461\$135,750WORKSHOP: Computer Supported Cooperative Work 2014 Docto47.070IIS-1350764\$2,336XPS: FULL: FP: Design and Synthesis of New Energy-effici47.070CCF-1533656\$1,064Biophysical Studies of Metalloenzymes47.074MCB-1118613-003\$182,649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.07410S-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117-\$42Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Clycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: Clycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: Clycoengineering Without Borders47.074MCB-1122135\$112,924IDBR: Development of Higher Figenmode Ultrasound Bioprob47.074MCB-1122135\$173,489Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.07410S-1456830\$40,185Rocky Mountain Sustainability and Science Network: Enhan47.07410S-145683	TWC: Medium: Collaborative: Neuroscience Meets Compute	r	47.070	CNS-1228357	\$126,572
WORKSHOP: Computer Supported Cooperative Work 2014 Docto47.070IIS-1350764\$2,336XPS: FULL: FP: Design and Synthesis of New Energy-effici47.070CCF-1533656\$1.064Biophysical Studies of Metalloenzymes47.074MCB-1118613-003\$182,649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117-\$42Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Iolgo: Gipmening Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353862\$111,493IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI-J]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1122135\$173,489Micromechanical Analysis of Interno Specificity47.074MCB-1022117\$145,006Regulation of the Yeast Prion [SWI-J]47.074MCB-1022117\$145,003Regulation of Hox Colonsization Specificity47.074IOS-1456833\$40,185Recky Mountain Sustainability and Science Network: Enhan47.074G-3342-1//DBI-0956059\$20,006	TWC: TTP Option: Medium: Collaborative: Identifying and		47.070	CNS-1408790	\$77,859
XPS: FULL: FP: Design and Synthesis of New Energy-effici47.070CCF-1533656\$1.064Biophysical Studies of Metalloenzymes47.074NCB-1118613-003\$182.649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117-\$42CellN: Predictive Toxicology Assessment and Safe Implemen23447.074SubK 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$112,9249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1122117\$145,006Regulation of Hos Colonization Specificity47.074IOS-1456830\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan47.074G-3342-1//DBI-0956059\$20,006	Type 1: Casting a Wide Net: Applied Computational		47.070	CNS-1138461	\$135,750
Biophysical Studies of Metalloenzymes47.074MCB-1118613-003\$182,649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074SubK 0521 G RA112 // FAU 4-449045-AN-22264\$88,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$189,752Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1022117\$143,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.07410S-1456830\$40,185Reticulospinal Execution of Innate Decision-Making47.07410S-1456830\$40,085Rocky Mountain Sustainability and Science Network: Enhan47.0746-3342-1//DBI-0956059\$36,043	WORKSHOP: Computer Supported Cooperative Work 2014 D	octo	47.070	IIS-1350764	\$2,336
Biophysical Studies of Metalloenzymes47.074MCB-1118613-003\$182,649CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074O521 G NA210 // DBI-0830117-\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074Subk 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: IDBR: Type A: The Nanosizer: A47.074MCB-1413563\$129,249IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1353982\$111,493IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1021117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$30,043Rocky Mountain Sustainability and Science Network: Enhan47.074G-3342-11//DBI-0956059\$30,043	XPS: FULL: FP: Design and Synthesis of New Energy-effici		47.070	CCF-1533656	\$1,064
CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074Subk 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-14135G3\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456830\$36,043Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					\$6,9 <mark>61,078</mark>
CAREER: The Virtual Whisking Rat: Linking Mechanics an47.074IOS-0846088/005\$74,445CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074Subk 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-14135G3\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456830\$36,043Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006	Biophysical Studies of Metalloenzymes		47.074	MCB-1118613-003	\$182,649
CEIN: Predictive Toxicology Assessment and Safe Implemen23447.0740521 G NA210 // DBI-0830117-\$42CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074Subk 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
CEIN: Predictive Toxicology Assessment and Safe Implemen23447.074SubK 0521 G RA112 // FAU 4-449045-AN-22264\$81,862Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059-\$20,006		234			
Collaborative Research: Exploiting the Syntegron Techno47.074MCB-1341414\$169,752Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
Collaborative Research: Glycoengineering Without Borders47.074MCB-1413563\$7,892Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
Collaborative Research: IDBR: Type A: The Nanosizer: A47.074DBI-1353682\$111,493IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
IDBR: Development of Higher Eigenmode Ultrasound Bioprob47.074DBI-1256188\$129,249IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006	, , ,				
IDBR: Type A: Directly Integratable Photoacoustic Micros47.074DBI-1353952/001\$315,776Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006)	47.074	DBI-1256188	
Investigation of the Yeast Prion [SWI+]47.074MCB-1122135\$173,489Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006			47.074	DBI-1353952/001	
Micromechanical Analysis of Chromosome Structure47.074MCB-1022117\$145,006Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
Regulation of Host Colonization Specificity47.074IOS-1456963\$40,185Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006			47.074	MCB-1022117	
Reticulospinal Execution of Innate Decision-Making47.074IOS-1456830\$36,043Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059\$20,006					
Rocky Mountain Sustainability and Science Network: Enhan4747.074G-3342-1//DBI-0956059-\$20,006					
		47			
	Understanding the Mechanism of Import for Bacterial Tran		47.074	MCB-1121872	\$99,045

\$1,546,838

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
A Cultural and Linguistic Anthropological Analysis of Yo		47.075	BCS-1323769	\$29,113
A Framework for Demand and Pricing Dynamics		47.075	SES-1130382	\$127,710
Approximating Large Contests and other Auction-Like Game		47.075	SES-1325968	\$102,538
Biological links between rhythm and reading		47.075	BCS-1430400	\$142,236
CAREER: Comparative Statics and Dynamic Models		47.075	SES-1151410/003	\$64,810
CAREER: Health, Environmental Issues, and Price Effects		47.075	SES-1156941/004	\$49,670
CAREER: Individuation in Visual Cognition		47.075	BCS-1056730 006	\$83,276
CAREER: Social Networks, Labor Markets and Agricultural		47.075	SES-1254380/002	\$83,956
CAREER: The Impact of Interorganizational Network Evolut		47.075	SES-1264417/003	\$72,058
CDI-Type II: Collaborative Research: Groupscope: Instrum		47.075	BCS-0940851	-\$20,799
Chronological Change In Domestic Economy And Provisionin		47.075	BCS-1419672	\$51,881
Clausal Ellipsis, Its Structure and Online Processing		47.075	BCS-1323245	\$81,802
Collaborative Research: An Empirical Study of Broadban		47.075	SES-1324851	\$24,681
Collaborative Research: Culture, Psychological Distance		47.075	SES-0962185	-\$9
Collaborative Research: Econometric Methods for Models w		47.075	SES-1530534	\$43,419
Collaborative Research: Equilibria in Health Exchanges:		47.075	SES-1260949	\$73,928
Collaborative Research: Extending the Scope of Inference		47.075	SES-1123586	\$394
Collaborative Research: Family Structure and Inequality		47.075	SES-1459631	\$20,314
Collaborative Research: Media Characters: The Unhidden P		47.075	BCS-1251345	\$94,195
Collaborative Research: Mind Mapping Consumers and Activ		47.075	SES-1359610 001	\$79,492
Collaborative Research: SBE Alliance: Great Lakes Allian		47.075	SES-0750621/003	\$14,460
Collaborative Research: Using Web Data to Study U.S. Con		47.075	SES-1155043	\$38,578
Constructions of Traditional Medicine during Decolonizat		47.075	SES-1456984	\$36,858
DNA Examiners: Judgment and Influence		47.075	SES-1356899	\$102,473
Doctoral Dissertation Improvement Grant: A Diachronic In		47.075	BCS-1355082	\$12,507
Doctoral Dissertation Improvement Grant: Keeping It Toge		47.075	BCS-1330995	\$6,300
Doctoral Dissertation Improvement: Conceptualizing the A		47.075	BCS-1455804	\$176
Doctoral Dissertation Research in DRMS: Who's at Stake?		47.075	SES-1427035	\$10,427
Doctoral Dissertation Research in Economics: Essays on t		47.075	SES-1425598	\$25,917
Doctoral Dissertation Research on the Role of Domain-Gen		47.075	BCS-1420820	\$4,666
Doctoral Dissertation Research: The effects of communit		47.075	BCS-1423891	\$2,428
Doctoral Dissertation Research: Human Rights and the War		47.075	SES-1155402	-\$^
Doctoral Dissertation Research: Implications of Housing		47.075	SES-1303677	\$3,021
Doctoral dissertation research: Morphosyntactic mismatch		47.075	BCS-1348677	\$1,015
Doctoral Dissertation Research: Technological Wonder: Th		47.075	SES-1256955	\$6,774
Doctoral Dissertation Research: The Wealthy and Stratifi		47.075	SES-1409232	\$5,769

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Dynamic, Behavioral, and Multi-Agent Persuasion Mechanis		47.075	SES-1427200	\$70,545
Early environments, epigenetics, and inflammation during		47.075	BCS-1440564	\$924
Early Word Learning in English- and Mandarin-Acquiring I		47.075	BCS-1023300	-\$1,135
Engineering Children's Learning		47.075	BCS-1122712	\$1,499
Fostering Positive Interracial Interactions		47.075	BCS-0921728	\$2,726
How Words and Sounds Influence Category Formation in Inf		47.075	BCS-0950376	-\$50
INSPIRE: Gradient Symbolic Computation	123	47.075	2001990798 // BCS-1344269	\$92,434
Interactive-Specialization of Language Development		47.075	BCS-1358794	\$14,590
Investigating the Origin and Development of Analogical P		47.075	BCS-1423917	\$133,651
Latino Suburbia: Examining the Politics of Race and the		47.075	BCS-1127461	\$11,725
Longitudinal Study of Human Male Reproductive Ecology		47.075	BCS-1317133	\$34,114
Manipulating and classifying memory processing during sl		47.075	BCS-1461088	\$26,044
Market Structures for Efficient Spectrum Sharing		47.075	SES-1247984	-\$231
Mechanism Design with Costly Verification		47.075	SES-1227434	\$74,552
Musical and Lexical Tone Deafness		47.075	BCS-1125144	\$44,646
Musical Experience in Older Adults: Impact on Hearing Sp		47.075	BCS-1057556	\$6,706
NCRN-SN: Census Bureau Data Programs as Statistical Deci		47.075	SES-1129475	\$288,413
NSF Intergovernmental Personnel Act (IPA) Assignment - F		47.075	OF 69 # (Rev. 2-89)	\$292,701
Price Discrimination and Competition in Many-to-Many Mat		47.075	SES-1156077	\$89,845
Spatial Intelligence Learning Center	213	47.075	330161-18110-7343-Amd 4//SMA-1041707	\$713,474
SPRF-IBSS: Applying Structural Equation Modeling to Popu		47.075	SMA-1306167	\$94,324
Standard Research Grant: A Comparative Study of ICTs and		47.075	SES-1331060 Amd 2	\$70,013
The Effect of School Finance Reforms on the Distribution		47.075	SES-1324778	\$55,169
The International Cognitive Ability Resource		47.075	SMA-1419324	\$82,422
The LIFE Center: Learning in Informal and Formal Environ	279	47.075	UWSC5427 Amd 7//SMA 0835854-08	\$171,113
Time-Sharing Experiments for the Social Sciences (TESS):		47.075	SES-1227179	\$688,379
Topics in the Organization of Markets		47.075	SES-1123595	\$83,057
				\$4,617,683
CAREER: Blocks, Stickers, and Puzzles: Rethinking Comput		47.076	DRL-1451762	\$21,252
Collaborative Proposal: Learning Linkages: Integrating D		47.076	DRL-1418020	\$41,911
Collaborative Research to Understand the Role of Culture		47.076	DRL-1251516	\$117,192
Collaborative Research: An Interactive Steel Connection		47.076	DUE-1140468	\$30,742
Collaborative Research: Cognitive and Neural Indicators		47.076	DRL-1420599	\$28,182
Collaborative Research: Cultural Epistemologies and Scie		47.076	DRL-1109210	-\$556
Collaborative Research: Leveraging Matched Administrativ		47.076	DRL-1244752	\$261,264

Research Type/Federal Grantor/Subagency/Project Title P	ass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Collaborative Research: Research: Culturally Based Citiz		47.076	DRL-1114530	\$19,384
Collaborative Research: Using Educational DVDs to Enhanc		47.076	DRL-1252121	\$125,959
Enabling Modeling and Simulation-Based Science in the Cl		47.076	DRL-1020101/002	\$228,577
Findings from Empirical Within Study Comparisons About t		47.076	DRL-1228866	\$344,379
FUSE Studios: A New, Interest-Driven Model for Engaging		47.076	DRL-1433724/001	\$254,456
FUSE Studios: An Alternative Infrastructure for STEM Lea		47.076	DRL-1348800	\$426,028
Graduate Research Fellowships Program (GRFP)		47.076	DGE-1324585/004 & 005	\$5,372,714
Graduate Research Fellowships Program (GRFP-GROW)		47.076	DGE-1324585	\$8,215
IGERT: Quantum Coherent Optical and Matter Systems		47.076	DGE-0801685/004	\$63,592
Improving the Generalizability of Findings from Educatio		47.076	DRL-1118978	\$516,823
INSPIRE Track 1: Primary School Organizations as Open Sy		47.076	DRL-1344266/003	\$228,681
Learning Ethnographies of New Engineers: A New Approach		47.076	DRL-1252372	\$167,943
Learning Evolution through Model-Based Inquiry: Supporti		47.076	DRL-1109834	\$233,463
Learning Labs: Using Videos, Exemplary STEM Instruction	212	47.076	2015-02//1417757	\$11,863
Life on Earth	94	47.076	123658-5040002//DRL-1010889	\$8,832
New GK-12: Reach for the Stars: Computational Models for		47.076	DGE-0948017/006	\$405,518
NRT-DESE: Training in Data-Driven Discovery - From the E		47.076	DGE-1450006-001	\$68,236
Supporting Scientific Practices in Elementary and Middle		47.076	DRL-1020316 Amd 005	\$509,864
The CIRTL Network: 25 Research Universities Preparing a	280	47.076	490K851 // DUE-1231286 // Amd 2	\$48,862
				\$9,543,376
Collaborative Research: Response of the Northwestern Gre		47.078	ARC-1108306	\$51,261
Photoacoustic characterization of diffusively scattering	218	47.079	RUE1-7066-VL-12//OISE-9531011	\$9,023
Collaborative Research: FLASH! Fueling Learning Alliance		47.080	OCI-1241324	-\$13,104
Collaborative Research: SCC-SBE: Research Coordination N		47.080	OCI-1244747	\$187,771
EAGER: Discovering Knowledge from Scientific Research Ne		47.080	OCI-1144061	-\$4,490
IRNC: ProNet: TransLight/StarLight	236	47.080	10313546-003//OCI-0962997	\$215,383
				\$385,560
ARRA - CAREER: Infomechanics - The Interdependence of Anima	all	47.082	IOS-0846032	\$148,861
ARRA - CAREER: Resource Attainment and Social Context in Ne	goti	47.082	SES-0847809	\$100,563
ARRA - CAREER: Unlocking the Synthetic Potential of N-Allylhyc	lr	47.082	CHE-0845063	\$80,115
ARRA - Chicago Transformation Teacher Institutes (CTTI)	248	47.082	Agmt 3/5/15 // DUE-0928669	\$46,282

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
ARRA - Collaborative Research: Use of Genome Enabled Tools	to U 263	47.082	10-089//IOS-0843633	-\$98
ARRA - International Materials Institute for Solar Energy Conve)	47.082	DMR-0843962	-\$321
National Science Foundation Total				<u>\$375,402</u> \$46,615,555
Nuclear Regulatory Commission				
Service Lifetime Extension of Nuclear Power Plants: Pred Nuclear Regulatory Commission Total		77.009	NRC-HQ-60-14-G-0003	<u>\$104,754</u> \$104,754
U.S. Environmental Protection Agency				
Development of a Yeast Based Arsenic Biosensor for the R		66.514	FP-91761101-0	\$14,300
Reducing Human Health Risks from Water-Borne Diseases: A		66.514	FP-91729001-3	\$8,850
Tracking Arctic Climate Change with Calcium Isotopes		66.514	FP-91719301-0	\$943
U.S. Environmental Protection Agency Total				\$24,093
Vietnam Education Foundation				
Vietnam Education Foundation Fellowship		85.802	Agmt 2/19/13	\$27,000
Vietnam Education Foundation Fellowship		85.802	F10024M	\$667
Vietnam Education Foundation Fellowship - Hoang Thai Ngu		85.802	Letter 10/14/14	\$1,000
Vietnam Education Foundation Total TOTAL RESEARCH AND DEVELOPMENT CLUSTER				<u>\$28,667</u> \$400,298,207
Student Financial Assistance Cluster				
Department of Education				
Federal SEOG 2013-2014		84.007	P007A131246/FSEOG 2013-2014	\$100,712
Federal SEOG 2014-2015		84.007	P007A141246	\$1,991,443
				\$2,092,155
Federal Work-Study 2013-2014		84.033	P033A131246/FWS 2013-2014	-\$45,382
Federal Work-Study 2014-2015		84.033	P033A141246	\$3,325,378
Federal Work-Study 2015-2016		84.033	P033A151246	<u>\$65,153</u> \$3,345,149
Federal Pell Grant 2013-2014		84.063	P063P131371	-\$4,849
Federal Pell Grant 2013-2014		84.063	P063P141371/Pell Grant	- ₅ 4,045 \$5,106,377
		01.000		\$5,101,528

Schedule of Expenditures of Federal Awards For the Year Ended August 31, 2015

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Federal Direct Loan Program 2013-2014		84.268	P268K141371/Direct Loan	-\$31,104
Federal Direct Loan Program 2014-2015		84.268	P268K151371	\$143,439,077
Federal Direct Loan Program 2015-2016		84.268	P268K161371	\$24,773,820
				\$168,181,793
Federal TEACH Grant 2014-2015		84.379	P379T151371/ TEACH Grant	\$2,973
Department of Education Total				\$178,723,598
TOTAL STUDENT FINANCIAL ASSISTANCE CLUSTER				\$178,723,598
Other Progams				
Agency for International Development				
In silico and In vitro evaluation of Long Acting Contrac	67	98.001	APSA-14-011//AID-0AA-A-10-00068	<u>\$117,944</u>
Agency for International Development Total				\$117,944
Department of Commerce				
National Institute of Standards and Technology				
Development of Roadmap and Consortium for Innovation in		11.609	70NANB14H056	\$152,236
Enhancing Teaching of Standards and Standards Developmer	n 73	11.4095-P004//SB1341-11-CQ-0027;14-285	4095-P004//SB1341-11-CQ-0027;14-285	\$26,000
United States Patent and Trademark Office				
Research Conference on Innovation Economics		11.900	14146034-0000-000	\$5,147
Research Conference on Innovation Economics 2015		11.900	IO 10IAG1500130	\$39,766
Department of Commerce Total				<u>\$44,913</u> \$223,149
Department of Education				
, Jacob K Javits Fellowship Program (Wilhoit)		84.170	P170B100013	\$11,403
Jacob K. Javits Fellowship for Robin Hoecker		84.170	P170B110018 14 & 15	\$13,722
Department of Education Total				\$25,125
Department of Health and Human Services				
Community Programs to Improve Minority Health Grant Prog	137	93.137	FE Agmt. 02-24-15 / 1CPIMP141065-01-00	\$5,306

- 106 -

Research Type/Federal Grantor/Subagency/Project Title Pa	ss-through ID	CFDA	Sponsor Award Number	FY15 Expense
Administration for Children and Families				
Permanency Innovations Initiative	105	93.648	0461569095	\$394,632
Permanency Innovations Initiative	105	93.648	Contract #0461569094	\$2,142
Permanency Innovations Initiative	105	_93.RD648	461569096	<u>\$39,665</u> \$436,439
Centers for Disease Control and Prevention				
Engaging Indigenous Organizations to Sustain and Enhance	3	93.067	Sub under U2GGH00924-02	\$106,329
Evaluating the Chicago Public Schools (CPS) Promoting Ad	248	93.079	12-0604-PRC	\$17,877
Hepatitis C Community Alliance for Testing and Treatment	240	93.270	FP058209-B//U51PS004607	\$97,145
Describing optimal communication features of collaborati	265	93.941	RF0074-2013-001//U65PS004275	\$8,939
Centers for Medicare & Medicaid Services				
FL-IL CHIPRA AHCA Contract No. MED124	95	93.767	agr. 12/01/2013//1Z0C30548-01-00	\$199,889
Health Resources and Services Administration				
Mothers and Babies Illinois: Maternal, Infant and Early	107	93.505	Agr. No. FCSTS03738	\$16,359
Mothers and Babies Illinois: Maternal, Infant and Early	107	93.505	FCSSS03432	<u>\$357</u> \$16,716
National Institutes of Health				
Northwestern University AITRP		93.989	D43TW007995	-\$2,393
Office of the National Coordinator for Health Information Technolo	υqγ			
ARRA - Assisting Access in Implementing E.H.R. and Achieving N		93.718	Agrt dtd 11/08/11 PO 125282	-\$68,466
Substance Abuse and Mental Health Services				
Center for Child Trauma Assessment and Service Planning		93.243	5U79SM061254-03 REVISED	\$290,592
Teen Court Program	160	93.243	Agmt. 05-01-2014/ #1 TI024128-01	<u>\$33,698</u> \$324,290
Department of Health and Human Services Total				<u>\$324,290</u> \$1,142,071
Department of Justice				
International School of Police Staff and Command 4	74	16.EGL0004494-1//DJJ11-C-2180	EGL0004494-1//DJJ11-C-2180	\$59,124

Research Type/Federal Grantor/Subagency/Project Title	Pass-through ID	CFDA	Sponsor Award Number	FY15 Expense
Bureau of Justice Assistance				
Hiring Initiative for the Womens Project: Creating Two N		16.746	2013-FA-BX-0004	\$126,661
Office on Violence Against Women				
Northwestern University Proposal for OVW 2014 Grant to R		16.525	2014-WA-AX-0006	\$13,972
OVW Fiscal Year 2011 Grants to Reduce Sexual Assault, Do		16.525	2011-WA-AX-0005	\$8,744
Department of Justice Total				<u>\$22,716</u> \$208,501
Department of State				
Young African Leaders Initiative	116	19.009	FY14-YALI-NWU-01/S-ECAGD-14-CA-1038	\$5,915
Young African Leaders Initiative	116	19.009	FY15-YALI-NWU-02/S-ECAGD-14-CA-1168	\$85,083 \$90,998
				\$30,330
Establishment of a Center of Journalism Excellence	115	19.501	Agmt Signed 5/8/14	\$146,411
Department of State Total				\$237,409
National Aeronautics and Space Administration				
Meteoritic Nanodiamond Analysis by Atom-Probe Tomography	288	43.001	WU-14-06//NNX13AF53G	\$59,241
National Aeronautics and Space Administration Total				\$59,241
The Corporation for National and Community Service				
Jumpstart Northwestern	127	94.006	JS-SITE #92/ Grant #920200	\$65,284
The Corporation for National and Community Service To	tal			\$65,284
TOTAL OTHER PROGRAMS TOTAL				<u>\$2,078,724</u> \$581,100,529
				φ 301,100,3 23

Schedule of Expenditures of Federal Awards Legend for Pass-Through Award Prime Recipients For the Year Ended August 31, 2015

ID Sponsor Full Name

- 1 Advanced BioDevices, LLC
- 2 Agile Sciences, Inc.
- 3 AIDS Prevention Initiative Nigeria, Ltd.
- 4 Albert Einstein College of Medicine of Yeshiva University
- 5 Alere Wellbeing, Inc.
- 6 Alliance for Clinical Trials in Oncology
- 7 Alliance of Chicago Community Health Services
- 8 Altor BioScience Corporation
- 9 American College of Radiology
- 10 American College of Rheumatology
- 11 American Heart Association
- 12 American Institutes for Research
- 13 American Lung Association
- 14 AMES Technology, Inc.
- 15 Ann & Robert H. Lurie Children's Hospital
- 16 Arizona State University
- 17 Arkansas Children's Hospital Research Institute
- 18 AuraSense, LLC
- 19 Battelle Energy Alliance, LLC, Idaho National Laboratory
- 20 Baylor College of Medicine
- 21 BBN Technologies
- 22 Benaroya Research Institute at Virginia
- 23 Beth Israel Deaconess Medical Center
- 24 Booz, Allen & Hamilton Inwc.
- 25 Boston Medical Center
- 26 Boston University
- 27 Brigham and Women's Hospital
- 28 BrightOutcome Inc.
- 29 Brown University
- 30 Bureau, Henry and Stark County Regional Office of Education
- 31 California Institute of Technology
- 32 California Institute of Technology, Jet Propulsion Laboratory
- 33 Carnegie Institution of Washington
- 34 Carnegie Mellon University
- 35 Case Western Reserve University
- 36 Caterpillar, Inc.
- 37 Celdara Medical, LLC
- 38 Cerner Corporation
- 39 Chicago Association for Research and Education in Science
- 40 Chicago Department of Public Health
- 41 Chicago Public Schools
- 42 Children's Hospital of Philadelphia
- 43 Children's Hospitals and Clinics of Minnesota
- 44 Cincinnati Children's Hospital Medical Center
- 45 City of Hope National Medical Center and Beckman Research Institute
- 46 Clark University
- 47 Colorado State University
- 48 Columbia University
- 49 Communication Disorders Technology, Inc.

ID Sponsor Full Name

- 50 Community Action Project of Tulsa County
- 51 Concord Consortium
- 52 CONRAD Program
- 53 Consortium for Ocean Leadership
- 54 Cornell University
- 55 County of Lake
- 56 Covitect Inc.
- 57 Cureveda, LLC
- 58 D&S Consultants, Inc.
- 59 Dana-Farber Cancer Institute
- 60 Dartmouth College
- 61 Delaware State University
- 62 DePaul University
- 63 Digital Optics Technologies, Inc.
- 64 Drexel University
- 65 Duke Clinical Research Institute
- 66 Duke University
- 67 Eastern Virginia Medical School
- 68 ECOG-ACRIN Medical Research Foundation
- 69 Econometrica, Inc.
- 70 EMMES Corporation
- 71 Emory University
- 72 Endocrine Society
- 73 Energetics Incorporated
- 74 Engility Corporation
- 75 Engineering and Software System Solutions, Inc.
- 76 EveryFit, Inc.
- 77 Exicure, Inc.
- 78 Fermi Research Alliance, LLC, Fermi National Acceloratory Laboratory
- 79 Florida International University
- 80 Ford Motor Company
- 81 Fred Hutchinson Cancer Research Center
- 82 Frontier Science and Technology Research Foundation
- 83 Fundação Faculdade de Medicina
- 84 General Motors Corporation
- 85 George Washington University
- 86 Georgetown University
- 87 Georgia Institute of Technology
- 88 Georgia State University
- 89 Government of Israel Ministry of Defense
- 90 Great Lakes Hemophilia Foundation
- 91 Greenwood Genetic Center
- 92 H. Lee Moffitt Cancer Center & Research Institute
- 93 Harvard Pilgrim Health Care, Inc.
- 94 Harvard University

97

98

- 109 -

- 95 Health Management Associates, Inc.
- 96 Health Research and Educational Trust

Hektoen Institute for Medical Research

Hemophilia Center of Western Pennsylvania

(Continued)

Schedule of Expenditures of Federal Awards Legend for Pass-Through Award Prime Recipients For the Year Ended August 31, 2015

ID Sponsor Full Name

- 99 Henry M. Jackson Foundation for the Advacement of Military Medicine
- 100 Hewlett-Packard Company
- 101 Icahn School of Medicine at Mount Sinai
- 102 ICON Clinical Research, LLC
- 103 IKOR, Inc.
- 104 Illinois Criminal Justice Information Authority
- 105 Illinois Department of Children and Family Services
- 106 Illinois Department of Healthcare and Family Services
- 107 Illinois Department of Human Services
- 108 Illinois Department of Public Health
- 109 Illinois Department on Aging
- 110 Indiana University
- 111 Infinitesimal, LLC
- 112 Institute for Neurodegenerative Disorders
- 113 Intact Genomics, Inc.
- 114 International Business Machines Corporation
- 115 International Center for Journalists
- 116 International Research & Exchanges Board
- 117 Internet Solutions for Kids, Inc.
- 118 Jackson Laboratory
- 119 Jaeb Center for Health Research
- 120 Joan and Sanford I. Weill Medical College
- 121 John B. Pierce Laboratory
- 122 John Wayne Cancer Institute
- 123 Johns Hopkins University
- 124 Johns Hopkins University Applied Physics Laboratory
- 125 Joint Commission Resources, Inc.
- 126 Joslin Diabetes Center, Inc.
- 127 Jumpstart for Young Children, Inc.
- 128 Kaiser Foundation Research Institute
- 129 Kinea Design, LLC
- 130 Krell Institute
- 131 Leidos Biomedical Research, Inc.
- 132 Leidos, Inc.
- 133 Los Alamos National Security, LLC, Los Alamos National Laboratory
- 134 Los Gatos Research, Inc.
- 135 Louisiana State University Health Sciences Center
- 136 Ludwig Institute for Cancer Research
- 137 Lupus Research Institute, Inc.
- 138 MANILA Consulting Group, Inc.
- 139 Massachusetts General Hospital
- 140 Massachusetts Institute of Technology
- 141 Mayo Clinic
- 142 Mayo Clinic Jacksonville
- 143 MC10 Inc.
- 144 McLean Hospital
- 145 Medical College of Wisconsin
- 146 Medical University of South Carolina
- 147 MedPro Technologies, LLC

ID Sponsor Full Name

- 148 Michigan State University
- 149 Microbiotix, Inc.
- 150 Midwest Research Institute, Battelle Memorial Institute
- 151 MITRE Corporation
- 152 MKS Technology, LLC
- 153 MP Technologies, LLC
- 154 National Academy of Sciences
- 155 National Jewish Medical and Research Center
- 156 National Space Biomedical Research Institute
- 157 New England Research Institute, Inc.
- 158 New School
- 159 New York University
- 160 Nicasa, NFP
- 161 Nious Technologies Incorporated
- 162 Northern California Institute for Research
- 163 Northern Illinois University
- 164 NRG Oncology Foundation, Inc.
- 165 NuCrypt LLC
- 166 Ohio State University
- 167 One Hope United
- 168 OptoNet, Inc.
- 169 Oregon Health & Science University
- 170 Pacific Northwest National Laboratory
- 171 Pennington Biomedical Research Center
- 172 Pennsylvania State University
- 173 Princeton University
- 174 Protabit LLC
- 175 Purdue University
- 176 Queens College, CUNY
- 177 QuesTek Innovations LLC
- 178 Radiation Monitoring Devices, Inc.
- 179 Radikal Therapeutics Inc.
- 180 Regenerex LLC
- 181 Rehabilitation Institute of Chicago
- 182 Rehabilitation Institute Research Corporation
- 183 Renova Life Inc.
- 184 Rensselaer Polytechnic Institute
- 185 Research Institute of the McGill University Health Centre
- 186 Research Triangle Institute
- 187 Resonon Inc.
- 188 Rockefeller University
- 189 Rosalind Franklin University of Medicine

195 Salk Institute for Biological Studies

- 190 Rush University Medical Center
- 191 Rutgers University, the State University of New Jersey

196 Sandia Corporation, Sandia National Laboratory

(Continued)

197 Sanford-Burnham Medical Research Institute

- 192 SA Photonics, Inc.
- 193 Sacred Heart University
- 194 SAFCell, Inc.

- 110 -

Schedule of Expenditures of Federal Awards Legend for Pass-Through Award Prime Recipients For the Year Ended August 31, 2015

ID Sponsor Full Name

- 198 Science Applications International Corporation
- 199 Scripps Research Institute
- 200 Seattle Children's Hospital
- 201 Seton Hall University
- 202 SIMmersion LLC
- 203 SiNode Systems Inc.
- 204 Smithsonian Astrophysical Observatory
- 205 Social & Scientific Systems, Inc.
- 206 Space Telescope Science Institute
- 207 Stanford University
- 208 State University of New York at Buffalo
- 209 State University of New York Health Science Center at Brooklyn
- 210 Strategic Pharma-Academic Research Consortium
- 211 Swedish Medical Center
- 212 Teaching Channel
- 213 Temple University
- 214 Texas Biomedical Research Institute
- 215 Tufts Medical Center, Inc.
- 216 Tufts University
- 217 Tulane University
- 218 U.S. Civilian Research & Development Foundation
- 219 UChicago Argonne, LLC, Argonne National Laboratory
- 220 United States Council for Automotive Research
- 221 United Technologies Research Center
- 222 Universal Technology Corporation
- 223 Université de Bamako
- 224 Universities Research Association, Inc., Fermi National Accelerator Laboratory
- 225 Universities Space Research Association
- 226 University of Alabama at Birmingham
- 227 University of Alberta
- 228 University of Arizona
- 229 University of California, Berkeley
- 230 University of California, Davis
- 231 University of California, Irvine
- 232 University of California, Lawrence Berkeley National Laboratory
- 233 University of California, Lawrence Livermore National Laboratory
- 234 University of California, Los Angeles
- 235 University of California, Riverside
- 236 University of California, San Diego
- 237 University of California, San Francisco
- 238 University of California, Santa Barbara
- 239 University of Central Florida
- 240 University of Chicago
- 241 University of Chicago, National Opinion Research Center
- 242 University of Colorado
- 243 University of Colorado Denver
- 244 University of Connecticut Health Center
- 245 University of Florida
- 246 University of Georgia

ID Sponsor Full Name

- 247 University of Ibadan
- 248 University of Illinois at Chicago
- 249 University of Illinois at Urbana-Champaign
- 250 University of Iowa
- 251 University of Kentucky
- 252 University of Maryland, Baltimore
- 253 University of Massachusetts Boston
- 254 University of Massachusetts Medical School
- 255 University of Medicine and Dentistry of New Jersey
- 256 University of Memphis
- 257 University of Miami
- 258 University of Michigan
- 259 University of Minnesota
- 260 University of Connecticut Health Center
- 261 University of Missouri-Columbia
- 262 University of Nebraska Medical Center
- 263 University of New Hampshire
- 264 University of North Carolina at Chapel Hill
- 265 University of North Texas Health Science Center
- 266 University of Notre Dame
- 267 University of Pennsylvania
- 268 University of Pittsburgh
- 269 University of Rochester
- 270 University of South Carolina
- 271 University of Southern California
- 272 University of Tennessee
- 273 University of Texas at Austin
- 274 University of Texas at San Antonio
- 275 University of Texas Health Science Center
- 276 University of Texas Southwestern Medical Center at Dallas
- 277 University of Utah
- 278 University of Virginia
- 279 University of Washington
- 280 University of Wisconsin-Madison
- 281 US Ignite Inc.
- 282 UT-Battelle, LLC, Oak Ridge National Lab
- 283 Vanderbilt University
- 284 Veterans Medical Research Foundation of San Diego
- 285 Vidrio Technologies, LLC
- 286 Virginia Polytechnic Institute and State University
- 287 Wake Forest University Health Sciences
- 288 Washington University in St. Louis
- 289 Wayne State University
- 290 West Virginia University
- 291 WestEd

- 111 -

294 Yale University295 Youth Network Council

292 Women & Infants Hospital of Rhode Island

(Concluded)

293 Worcester Polytechnic Institute

1. ORGANIZATION AND SCOPE OF OPERATIONS

Northwestern University (the "University") is a corporation organized under the laws of the State of Illinois, whose charter establishes a Board of Trustees to oversee the implementation of its mission to carry out research and education. All federal expenditures of the University are included in the scope of the U.S. Office of Management and Budget Circular A-133 audit (the "Single Audit"). The U.S. Department of Health and Human Services has been designated as the University's cognizant agency for the Single Audit.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting — The accompanying schedule of expenditures of federal awards (the "Schedule") summarizes the expenditures of the University and its subsidiaries under programs of the federal government for the year ended August 31, 2015. The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the University, it is not intended to, and does not, present the financial position or changes in net assets of the University.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between the University and agencies and departments of the federal government and all subawards to the University by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Complete CFDA numbers and pass-through numbers are provided on the Schedule when available.

Expenditure and Revenue Recognition — The Schedule presents the expenditures of individual programs. All program outlays, including accrued expenditures and capital outlays, are reported as expenditures. Related revenues are recognized up to award amounts for financial statement and program reporting. Award reporting periods do not necessarily coincide with the fiscal reporting period of the University. Negative amounts presented in the Schedule represent adjustments, in the normal course of business, to expenditures reported in prior years.

Pass-Through Awards — The University receives certain federal awards from pass-through awards of the State of Illinois and other nonfederal organizations. The total amount of such pass-through awards is included in the Schedule.

Subrecipients – The University passes through certain funds to subrecipient organizations.

Schedule of Expenditures of Federal Awards by Federal Agency For the Year Ended August 31, 2015

3. SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS BY FEDERAL AGENCY

Federal Agency	Expenditures
Agency for International Development	\$271,649
U.S. Department of Agriculture	8,035
U.S. Department of Commerce	4,585,524
U.S. Department of Defense	35,396,098
U.S. Department of Education	182,723,760
U.S. Department of Energy	22,421,747
U.S. Department of Health and Human Services	282,833,841
U.S. Department of Homeland Security	1,049,761
U.S. Department of Justice	1,693,667
U.S. Department of Labor	80,077
U.S. Department of State	237,409
U.S. Department of Transportation	371,339
U.S. Department of Veterans Affairs	698,922
Institute of Museum and Library Services	13,380
National Aeronautics and Space Administration	1,876,967
National Science Foundation	46,615,555
Nuclear Regulatory Commission	104,754
The Corporation for National and Community Service	65,284
U.S. Environmental Protection Agency	24,093
Vietnam Education Foundation	28,667

TOTAL

\$581,100,529

4. FEDERAL STUDENT LOAN PROGRAMS

Loans made by the University to eligible students under federal student loan programs and federally guaranteed loans originating with the University and issued to its students during the year ended August 31, 2015, are summarized as follows:

Federal Perkins Loan Program (CFDA 84.038)	\$ 7,192,140
Federal Direct Loan Programs (CFDA 84.268)	168,181,793
Total Federal Student Loan Programs	\$175,373,933

The Perkins and Health Professions Student Loan (HPSL) programs are administered directly by the University and balances and transactions relating to these programs are included in the University's consolidated financial statements. The balances of loans outstanding under the Perkins, HPSL-Medical (CFDA 93.342), and HPSL-Dental (CFDA 93.342) programs were \$40,167,607; \$71,161; and \$152,859, respectively, at August 31, 2015. The University incurred \$250,000 and \$0 in administrative expenses under the Perkins and Federal Work Study programs, respectively, for the year ended August 31, 2015.

5. SCHEDULE OF EXPENDITURES BY SUBRECIPIENTS OF PASS-THROUGH FEDERAL FUNDS

The following is a schedule of expenditures by agencies to whom Northwestern has awarded passthrough federal funds.

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
Department of Commerce		
ASM International	11.609	\$225,317.70
Fayetteville State University	11.609	\$29,044.00
Northern Illinois University	11.609	\$22,457.84
QuesTek Innovations LLC	11.609	\$201,736.07
University of Chicago	11.609	\$542,764.91
Department of Commerce Total		\$1,021,320.52
Department of Defense		
Arizona State University	12.300	\$195,907.55
Duke University	12.300	\$148,323.34
HDT Robotics, Inc.	12.300	\$237,317.23
New York University	12.300	\$228,670.97
University of Akron	12.300	\$50,562.62
University of California, Los Angeles	12.300	\$170,801.50
University of Michigan	12.300	\$46,688.00
University of Texas at Austin	12.300	\$19,208.73
University of Virginia	12.300	\$77,417.38
University of Wisconsin-Madison	12.300	\$69,729.28
Chicago Association for Research and Education in Science	12.420	\$12,629.60
Geneva Foundation	12.420	\$29,628.21
Henry M. Jackson Foundation for the Advancement of Military N		\$61,324.30
Rehabilitation Institute of Chicago	12.420	\$7,770.17
Rehabilitation Institute Research Corporation	12.420	\$17,549.12
University of Calgary	12.420	\$13,781.68
University of Chicago	12.420	\$26,834.69
University of Texas at Arlington	12.420	\$84,293.00
Georgia Institute of Technology	12.431	\$42,365.37
Massachusetts Institute of Technology	12.431 12.431	\$140,718.76 \$51,914.03
University of Connecticut University of Michigan	12.431	\$51,914.03
University of Nebraska-Lincoln	12.431	\$151,500.50
Washington University in St. Louis	12.431	\$55,557.72
Arizona State University	12.800	\$185,310.11
California Institute of Technology	12.800	\$75,898.71
Georgia Institute of Technology	12.800	\$60,811.51
Queens College, CUNY	12.800	\$189,760.87
University of Pittsburgh	12.800	\$176,030.02
University of Texas at Austin	12.800	\$404,213.70
University of Utah	12.800	\$228,917.87
University of Washington	12.800	\$172,756.75
Applied Communication Sciences	12.910	\$11,334.67
AuraSense Therapeutics, LLC	12.910	\$330,668.22
Montana State University	12.910	\$43,158.93
Raytheon BBN Technologies	12.910	\$176,655.92
-	– 115 –	(Continued)

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
SRI International	12.910	\$53,063.5
Stanford University	12.910	\$39,085.1
University of Calgary	12.910	\$26,494.0
University of California, Davis	12.910	\$139,992.1
University of Chicago	12.910	\$125,676.2
University of Michigan	12.910	\$96,497.9
University of Minnesota	12.910	\$93,000.0
University of Texas at Arlington	12.910	\$152,436.1
Georgia Institute of Technology	12.W5J9CQ-12-C-0017	\$117,172.8
Department of Defense Total		\$4,839,351.8
Department of Education		
Rehabilitation Institute of Chicago	84.133	\$13,948.7
Chicago Public Schools	84.305	\$388,625.1
Georgia State University	84.305	\$153,551.0
Michigan State University	84.305	\$23,739.2
Society for Research on Educational Effectiveness	84.305	\$138,104.0
Society for Research on Educational Effectivenesss	84.305	\$103,308.7
University of Chicago	84.305	\$36,084.2
University of Michigan	84.305	\$39,165.6
Department of Education Total		\$896,526.8
Department of Energy		
Colorado State University	81.049	\$4,346.2
Harvard University	81.049	\$191,349.1
New York University	81.049	\$901.4
Pennsylvania State University	81.049	\$140,350.3
Siena College	81.049	\$17,262.4
University of California, Davis	81.049	\$141,189.1
University of Chicago	81.049	\$273,275.2
University of Illinois at Urbana-Champaign	81.049	\$29,331.3
University of Massachusetts Boston	81.049	\$59,969.7
University of Michigan	81.049	\$251,265.4
University of Pittsburgh	81.049	\$62,575.9
University of Wisconsin-Madison	81.049	\$17,049.1
Yale University	81.049	\$543,986.7
University of California, Los Angeles	81.087	\$45,775.9
UChicago Argonne, LLC, Argonne National Laboratory	81.113	\$30,000.0
California Institute of Technology	81.135	\$191,978.5
Protabit LLC	81.135	\$158,722.5
Electric Power Research Institute, Inc.	81.00127346//DE-AC07-05ID14517	\$40,576.2
Georgia Institute of Technology	81.00127346//DE-AC07-05ID14517	\$80,163.2
Battelle Memorial Institute, Pacific Northwest National Laboratory	81.00127985//DE-AC07-05ID14517	\$25,000.0
Department of Energy Total		\$2,305,069.2
Department of Health and Human Services		
Charles Stark Draper Laboratory, Inc.	93.113	\$198,184.7
Dana-Farber Cancer Institute	93.113	\$8,545.0
Harvard University	93.113	\$47,385.3
Massachusetts Institute of Technology	93.113	\$313.7
University of Chicago	93.113	\$33,267.9
. •	116	Continued

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
University of Illinois at Chicago	93.113	\$41,293.8
University of Illinois at Urbana-Champaign	93.121	\$31,997.1
University of Michigan	93.121	\$18,593.1
University of Southern California	93.121	\$191,323.0
National Kidney Foundation of Illinois	93.134	\$14,700.4
University of California, Davis	93.134	\$50,000.0
University of California, San Francisco	93.134	\$19,295.1
Illinois Public Health Association	93.137	\$19,511.6
NorthShore University HealthSystem Research Institute	93.172	\$5,590.6
Advocate Health Care	93.173	\$6,010.9
Boston University	93.173	\$290,095.8
Harvard University	93.173	\$14,576.8
Johns Hopkins University	93.173	\$487,085.9
Massachusetts General Hospital	93.173	\$407,019.5
Mayo Clinic Jacksonville	93.173	\$111,974.1
The University of Texas Health Science Center at San Antonio	93.173	\$20,810.4
University of Castilla, La Mancha	93.173	\$9,751.0
University of Colorado at Boulder	93.173	\$125,611.0
University of North Carolina at Chapel Hill	93.173	\$11,859.4
University of Washington	93.173	\$49,996.5
Center on Halsted	93.191	\$22,881.9
University of Chicago	93.225	\$121,096.5
Advocate Children's Hospital - Oak Lawn	93.226	\$44,084.0
Advocate Lutheran General Hospital	93.226	\$44,084.0
Alliance of Chicago Community Health Services, LLC	93.226	\$158,565.7
American College of Surgeons	93.226	\$21,898.3
Ann & Robert H. Lurie Children's Hospital of Chicago	93.226	\$139,945.6
Brigham and Women's Hospital	93.226	\$825.1
Children's Hospital Colorado	93.226	\$34,619.0
Children's Hospital of Philadelphia	93.226	\$182,077.0
Children's Research Institute	93.226	\$39,574.6
Cincinnati Children's Hospital Medical Center	93.226	\$113,429.2
Discerning Systems Inc.	93.226	\$18,714.5
Erie Family Health Center	93.226	\$19,905.2
Heartland Health Outreach, Inc.	93.226	\$3,846.8
Hektoen Institute for Medical Research	93.226	\$48,349.4
Institute for Safe Medication Practices	93.226	\$27,707.8
Medical College of Wisconsin	93.226	\$9,550.2
National Patient Safety Foundation	93.226	\$26,154.7
Near North Health Service Corporation	93.226	\$29,683.0
North Country HealthCare	93.226	\$58,564.4
Northwestern Medical Faculty Foundation, Inc.	93.226	\$11,772.6
PCC Community Wellness Center	93.226	\$20,771.0
Pennsylvania State University	93.226	\$3,125.6
Rehabilitation Institute of Chicago	93.226	\$87,924.5
University of Chicago	93.226	\$116,158.4
University of Illinois at Chicago	93.226	\$97,700.3
University of North Carolina at Chapel Hill	93.226	\$18,176.9
University of Texas M. D. Anderson Cancer Center	93.226	\$123,589.9
University of Utah	93.226	\$199,108.4
University of Washington	93.226	\$54,361.6

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
Case Western Reserve University	93.233	\$529.0
Research Triangle Institute	93.233	\$41,898.0
Cornell University	93.242	\$33,890.!
George Washington University	93.242	\$108,890.4
Georgia State University	93.242	\$2,611.4
Hektoen Institute for Medical Research	93.242	\$45,136.0
Johns Hopkins University	93.242	\$94,042.2
Aind Research Network	93.242	\$46,692.8
NorthShore University HealthSystem Research Institute	93.242	\$75,347.
Northwestern Memorial Hospital	93.242	\$7,605.
Rehabilitation Institute of Chicago	93.242	\$11,805.
lush University Medical Center	93.242	\$128,712.
Iniversity of California, Irvine	93.242	\$166,701.
Jniversity of California, San Francisco	93.242	\$68,456.
Iniversity of Cape Town	93.242	\$23,898.
Iniversity of Connecticut Health Center	93.242	\$35,948.
Iniversity of Illinois at Chicago	93.242	\$11,368
Iniversity of Miami	93.242	\$383,070
niversity of North Carolina at Chapel Hill	93.242	\$53,560
Iniversity of Oxford	93.242	\$63,695
Iniversity of South Florida - Tampa	93.242	\$13,733
niversity of Southern California	93.242	\$109,274
inca Institute of Nuclear Sciences	93.242	\$38,870
hapin Hall Center for Children	93.243	\$8,387
Iniversity of Chicago	93.243	\$7,983
Chicago Argonne, LLC, Argonne National Laboratory	93.262	\$34,937
niversity of Wisconsin-Madison	93.273	\$9,670
rizona State University	93.279	\$7,888
mory University	93.279	\$189,512
ohns Hopkins University	93.279	\$9,048
ing's College London	93.279	\$51,718
oyola University Chicago	93.279	\$16,030
Nount Sinai School of Medicine	93.279	\$37,130
regon Social Learning Center, Inc.	93.279	\$10,141
esearch Foundation of the City University of New York	93.279	\$157,417
utgers University	93.279	\$19,525
alk Institute for Biological Studies	93.279	\$3,136
anford-Burnham Medical Research Institute	93.279	\$91,043
Iniversity of California, Los Angeles	93.279	\$68,675
Iniversity of California, San Francisco	93.279	\$79,971
Iniversity of Chicago	93.279	\$12,999
Iniversity of Illinois at Chicago	93.279	\$28,871
Iniversity of Miami	93.279	\$164,206
niversity of Nebraska-Lincoln	93.279	\$58,001
Iniversity of Oxford	93.279	\$28,342
niversity of Southern California	93.279	\$92,757
Vayne State University	93.279	\$11,799
arnegie Mellon University	93.286	\$66,940
Iniversity of California, Berkeley	93.286	\$73,803
Jniversity of California, Irvine	93.286	\$64,701
Jniversity of California, San Francisco	93.286	\$88,272.

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
University of Illinois at Chicago	93.286	\$154,178.2
University of Illinois at Urbana-Champaign	93.286	\$46,707.3
University of Memphis	93.286	\$95,911.7
Washington University in St. Louis	93.286	\$22,188.3
Access Community Health Network	93.307	\$123,510.3
Fordham University	93.307	\$107,667.4
Ann & Robert H. Lurie Children's Hospital of Chicago	93.350	\$474,810.7
Access Community Health Network	93.361	\$194,931.0
Northwestern Memorial Hospital	93.361	\$2,054.0
University of Alabama at Birmingham	93.361	\$25,929.5
Boys & Girls Clubs of Chicago	93.389	\$35,623.7
American Institutes for Research	93.393	\$36,601.0
American Legacy Foundation	93.393	\$3,228.3
Brown University	93.393	\$9,502.4
Chinese American Service League	93.393	\$107,580.9
DePaul University	93.393	\$37,698.5
Florida State University	93.393	\$54,540.3
NorthShore University HealthSystem Research Institute	93.393	\$773.4
Rush University Medical Center	93.393	\$34,194.0
University of California, Davis	93.393	\$49,928.4
University of California, Los Angeles	93.393	\$68,395.2
University of California, San Diego	93.393	\$114,642.4
University of Chicago	93.393	\$97,456.2
University of Pennsylvania	93.393	\$174,234.1
University of Pittsburgh	93.393	\$14,668.7
Boston Medical Center	93.394	\$626,124.8
NorthShore University HealthSystem Research Institute	93.394	\$57,750.1
Pennsylvania State University	93.394	\$160,718.4
University of Illinois at Chicago	93.394	\$3,154.3
University of Michigan	93.394	\$3,043.5
University of Wisconsin-Madison	93.394	\$32,023.3
Vanderbilt University	93.394	\$50,836.0
Indiana University	93.395	\$5,274.7
NorthShore University HealthSystem Research Institute	93.395	\$19,504.0
Northwestern Medical Faculty Foundation, Inc.	93.395	\$2,862.1
Saint Louis University	93.395	\$48,748.2
University of Chicago	93.395	\$365,989.9
University of Illinois at Chicago	93.395	\$9,773.5
University of Pittsburgh	93.395	\$59,599.3
University of Southern California	93.395	\$68,062.7
Westside Institute for Science and Education	93.395	\$40,879.0
Ann & Robert H. Lurie Children's Hospital of Chicago	93.396	\$44,486.9
Dana-Farber Cancer Institute	93.396	\$18,058.0
Louisiana State University Health Sciences Center	93.396	\$1,751.1
Mayo Clinic Rochester	93.396	\$14,829.1
Medical College of Wisconsin	93.396	\$182,043.3
Oklahoma Medical Research Foundation	93.396	\$19,149.0
University of Chicago	93.396	\$31,167.4
University of Texas at San Antonio	93.396	\$6,769.0
Ann & Robert H. Lurie Children's Hospital of Chicago	93.397	\$43,776.2
Beckman Research Institute of the City of Hope	93.397	\$27,570.0

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
California Institute of Technology	93.397	\$5,264.4
Dana-Farber Cancer Institute	93.397	\$25,874.88
Fox Chase Cancer Center	93.397	\$35,167.56
Health Research, Incorporated, Roswell Park Cancer Institute Division	93.397	\$20,376.0
Hektoen Institute for Medical Research	93.397	\$8,114.7
Memorial Sloan-Kettering Cancer Center	93.397	\$79,878.00
Ohio State University	93.397	\$18,419.8
University of California, Los Angeles	93.397	\$34,517.52
University of Chicago	93.397	\$98,588.84
University of Illinois at Chicago	93.397	\$85,897.5
Weizmann Institute of Science	93.397	\$42,134.0
Ann & Robert H. Lurie Children's Hospital of Chicago	93.398	\$103,979.8
Medical College of Wisconsin	93.398	\$56,531.50
University of Chicago	93.398	\$41,197.4
Erie Family Health Center	93.530	\$2,040,750.02
Community Action Project of Tulsa County, Inc.	93.600	\$115,908.62
Oklahoma State University	93.600	\$121,555.30
Northwestern Medical Faculty Foundation, Inc.	93.610	\$116,898.33
Northwestern Memorial Hospital	93.610	\$388,425.16
Community Action Project of Tulsa County, Inc.	93.647	\$27,612.1
Oklahoma State University	93.647	\$77,916.02
University of Oklahoma	93.647	\$10,431.02
University of Texas at Austin	93.647	\$45,311.02
Alliance of Chicago Community Health Services, LLC	93.718	\$180,210.32
Ann & Robert H. Lurie Children's Hospital of Chicago	93.718	\$4,400.00
NorthShore University HealthSystem Research Institute	93.718	\$409,200.00
Northwestern Memorial Physicians Group	93.718	\$94,600.00
University of Illinois at Chicago	93.718	\$180,400.00
Ann & Robert H. Lurie Children's Hospital of Chicago	93.767	\$6,227.00
Alliance of Chicago Community Health Services, LLC	93.778	\$201,630.12
Ann & Robert H. Lurie Children's Hospital of Chicago	93.837	\$442,120.76
California State University, Northridge	93.837	\$63,605.86
Center for Chronic Disease Control	93.837	\$72,360.00
Colorado State University	93.837	\$4,464.58
Hektoen Institute for Medical Research	93.837	\$13,546.60
Henry Ford Health System	93.837	\$315.00
Imperial College of Science, Technology and Medicine	93.837	\$83,790.49
Maimonides Medical Center	93.837	\$8,600.00
Rush University Medical Center	93.837	\$203,097.38
Stanford University	93.837	\$20,708.60
Temple University	93.837	\$225,246.88
University of California, San Francisco	93.837	\$398,046.32
University of Chicago	93.837	\$351,796.4
University of Illinois at Chicago	93.837	\$477,290.9
University of Rochester	93.837	\$2,240.00
University of Texas Health Science Center at Houston	93.837	\$3,996.32
University of Washington	93.837	\$22,466.64
University of Wisconsin-Madison	93.837	\$146,779.68
Vanderbilt University Medical Center	93.837	\$562,754.24
Ann & Robert H. Lurie Children's Hospital of Chicago	93.838	\$333,248.90
Kaiser Foundation Research Institute	93.838	\$32,692.60

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
NorthShore University HealthSystem Research Institute	93.838	\$10,567.1
University of Alabama at Birmingham	93.838	\$112,824.9
University of British Columbia	93.838	\$14,522.0
University of California, Los Angeles	93.838	\$270,406.6
University of Chicago	93.838	\$11,993.1
Jniversity of Kentucky	93.838	\$68,162.5
Jniversity of Minnesota	93.838	\$56,281.8
Washington State University	93.838	\$55,090.8
Jniversity of Chicago	93.839	\$2,345.8
Ann & Robert H. Lurie Children's Hospital of Chicago	93.846	\$21,807.7
Columbia University	93.846	\$15,434.0
Memorial Hospital of Rhode Island	93.846	\$101,497.6
NorthShore University HealthSystem Research Institute	93.846	\$74,193.1
Dhio State University	93.846	\$165,882.9
Rehabilitation Institute of Chicago	93.846	\$37,678.0
Rehabilitation Institute Research Corporation	93.846	\$3,179.9
Rush University Medical Center	93.846	\$30,568.4
Temple University	93.846	\$94,035 .1
Iniversity of Alabama at Birmingham	93.846	\$16,764.9
Jniversity of Arizona	93.846	\$13,819.9
Jniversity of California, Los Angeles	93.846	\$12,254.4
Jniversity of California, San Francisco	93.846	\$87,825.7
Iniversity of Maryland, Baltimore	93.846	\$83,542.9
Jniversity of Michigan	93.846	\$15,644.1
Jniversity of Pittsburgh	93.846	\$146,697.8
Nashington University in St. Louis	93.846	\$13,922.0
Nayne State University	93.846	\$73,757.0
Ann & Robert H. Lurie Children's Hospital of Chicago	93.847	\$254,544.7
Asian Human Services, Inc.	93.847	\$23,136.2
Brigham and Women's Hospital	93.847	\$9,819.0
Case Western Reserve University	93.847	\$166,108.3
Chinese University of Hong Kong	93.847	\$160,175.5
Cleveland Clinic Lerner College of Medicine of CWRU	93.847	\$9,757.6
Columbia University	93.847	\$71,233.2
Duke University	93.847	\$571,829.9
George Washington University	93.847	\$11,988.8
Hektoen Institute for Medical Research	93.847	\$20,000.0
Kaiser Foundation Research Institute	93.847	\$477,785.5
ahey Clinic Medical Center	93.847	\$85,897.9
oyola University Chicago	93.847	\$19,241.6
Aanagement and Development for Health	93.847	\$41,022.6
Massachusetts General Hospital	93.847	\$56,580.6
NorthShore University HealthSystem Research Institute	93.847	\$159,924.2
Northwestern Memorial Hospital	93.847	\$937.7
Pennsylvania State University	93.847	\$18,307.4
Rabin Medical Center	93.847	\$228,894.0
Rajavithi Hospital	93.847	\$100,438.9
Royal Group of Hospitals Trust	93.847	\$50,740.6
Rush University Medical Center	93.847	\$25,000.0
Temple University	93.847	\$43,138.4
The Hospital for Sick Children	93.847	\$101,647.8

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
University of Colorado Denver	93.847	\$7,095.59
University of Illinois at Chicago	93.847	\$8,996.91
University of Manchester	93.847	\$185,212.65
University of Miami	93.847	\$50,149.00
University of Pennsylvania	93.847	\$197,415.75
University of the West Indies	93.847	\$117,309.75
University of Utah	93.847	\$17,077.15
Vanderbilt University	93.847	\$25,390.95
Veterans Medical Research Foundation of San Diego	93.847	\$25,989.54
Virginia Commonwealth University	93.847	\$6,726.24
YMCA of Greater Indianapolis	93.847	\$2,423.61
YMCA of the USA	93.847	\$19,384.12
AHS Hospital Corp.	93.853	\$2,000.00
Albany Medical College	93.853	\$2,000.00
Ann & Robert H. Lurie Children's Hospital of Chicago	93.853	\$16,495.50
Banner Alzheimer's Institute	93.853	\$7,078.26
Banner Health	93.853	\$9,960.00
Boston Medical Center	93.853	\$16,075.00
Case Western Reserve University	93.853	\$66,055.25
Centre National de la Recherche Scientifique	93.853	\$69,145.11
Cleveland Clinic Foundation	93.853	\$11,215.00
Columbia University	93.853	\$26,900.00
Dartmouth College	93.853	\$2,000.00
Eastern Connecticut Neurology Specialists, LLC	93.853	\$2,000.00
Emory University	93.853	\$21,340.00
Feinstein Institute for Medical Research	93.853	\$6,115.00
George Mason University	93.853	\$19,581.00
Health Quest Medical Practice, P.C.	93.853	\$19,630.00
Institute for Neurodegenerative Disorders	93.853	\$7,890.00
Johns Hopkins University	93.853	\$5,200.00
King County Public Hospital District No. 2	93.853	\$4,500.00
Louisiana State University	93.853	\$2,000.00
Loyola University Chicago	93.853	\$9,037.38
Massachusetts General Hospital	93.853	\$56,277.88
Medical College of Wisconsin	93.853	\$29,775.00
Medical University of South Carolina	93.853	\$31,925.00
Michigan State University	93.853	\$17,805.00
Ohio State University	93.853	\$10,105.00
Oregon Health & Science University	93.853	\$2,000.00
Pacific Health Research and Education Institute	93.853	\$8,400.00
Park Nicollet Institute	93.853	\$6,980.00
Parkinson's & Movement Disorder Institute	93.853	\$6,980.00
Pennsylvania State University	93.853	\$2,000.00
Rehabilitation Institute of Chicago	93.853	\$44,729.11
Rush University Medical Center	93.853	\$24,739.00
Sentara Healthcare	93.853	\$3,825.00
Stanford University	93.853	\$2,934.78
Universite Laval	93.853	\$3,900.00
University of Alabama at Birmingham	93.853	\$9,095.00
University of Calgary	93.853	\$2,000.00
University of California, Davis	93.853	\$9,206.28

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
University of California, Irvine	93.853	\$2,000.00
University of California, San Diego	93.853	\$27,810.00
University of California, San Francisco	93.853	\$132,821.04
University of Chicago	93.853	\$184,347.14
University of Cincinnati	93.853	\$19,800.0
University of Kentucky	93.853	\$16,940.0
University of Maryland	93.853	\$13,785.0
University of Miami	93.853	\$13,640.0
University of Michigan	93.853	\$9,915.0
University of Minnesota	93.853	\$2,000.0
University of Nebraska Medical Center	93.853	\$6,980.0
University of Nevada, Las Vegas	93.853	\$26,900.0
University of Oklahoma	93.853	\$73,761.9
University of Pennsylvania	93.853	\$8,880.00
University of Rochester	93.853	\$9,315.00
University of Texas at San Antonio	93.853	\$250,319.2
University of Texas Health Science Center at Houston	93.853	\$16,770.00
University of Utah	93.853	\$19,630.00
University of Virginia	93.853	\$19,705.00
University of Washington	93.853	\$211,097.04
Washington University in St. Louis	93.853	\$2,000.00
Weill Cornell Medical College	93.853	\$19,275.00
Ann & Robert H. Lurie Children's Hospital of Chicago	93.855	\$349,409.3
Baylor Research Institute	93.855	\$61,875.00
Children's Healthcare Associates	93.855	\$3,828.00
Children's Hospital Los Angeles	93.855	\$9,665.00
Dana-Farber Cancer Institute	93.855	\$22,804.8
Geisinger Clinic	93.855	\$417,907.8
Hektoen Institute for Medical Research	93.855	\$330,414.0
Loyola University Chicago	93.855	\$13,784.20
Mayo Clinic Jacksonville	93.855	\$54,387.0
Mayo Clinic Scottsdale	93.855	\$183,498.00
Medical University of South Carolina	93.855	\$99,049.00
Midwestern University	93.855	\$7,621.63
Northwestern Memorial Hospital	93.855	\$7,468.00
Rho Federal Systems Division, Inc.	93.855	\$61,547.36
Rush University Medical Center	93.855	\$813,307.13
Scripps Health	93.855	\$42,411.00
Scripps Research Institute	93.855	\$968,961.8
Stanford University	93.855	\$185,953.2
Trinity Health & Wellness Center	93.855	\$327,124.3
Tufts University	93.855	\$23,230.4
Tulane University	93.855	\$717,418.74
University of California, Los Angeles	93.855	\$36,674.80
University of Chicago	93.855	\$513,405.2
University of Nebraska Medical Center	93.855	\$7,232.9
University of Nebraska-Lincoln	93.855	\$15,821.3
University of Washington	93.855	\$455,628.0
University of Wisconsin-Madison	93.855	\$20,841.3
Campbell-Kibler Associates, Inc.	93.859	\$46,517.6

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
Imperial College of Science, Technology and Medicine	93.859	\$10,721.69
King's College London	93.859	\$8,703.00
Northeastern Illinois University	93.859	\$26,950.09
UChicago Argonne, LLC, Argonne National Laboratory	93.859	\$24,551.00
University of California, San Francisco	93.859	\$6,298.41
University of Chicago	93.859	\$150,860.59
University of Connecticut	93.859	\$200,116.49
University of Illinois at Chicago	93.859	\$53,769.45
University of Illinois at Urbana-Champaign	93.859	\$89,060.85
University of Massachusetts Amherst	93.859	\$70,129.84
University of Pennsylvania	93.859	\$241,701.70
University of Texas at El Paso	93.859	\$64,334.32
University of Texas Southwestern Med Ctr at Dallas	93.859	\$225,561.00
Ann & Robert H. Lurie Children's Hospital of Chicago	93.865	\$199,526.94
Bar-Ilan University	93.865	\$12,777.00
Baylor College of Medicine	93.865	\$52,320.45
Boston University	93.865	\$39,255.87
Chicago Public Schools	93.865	\$249,553.79
Harvard University	93.865	\$47,313.84
Medical University of South Carolina	93.865	\$8,085.00
Michigan State University	93.865	\$13,262.25
NorthShore University HealthSystem Research Institute	93.865	\$171,723.93
Ohio State University	93.865	\$147,302.28
Palo Alto Institute for Research and Education, Inc.	93.865	\$3,995.40
Rakai Health Sciences Program	93.865	\$18,197.81
University of California, Irvine	93.865	\$7,247.94
University of California, Los Angeles	93.865	\$16,858.14
University of Chicago	93.865	\$473,695.12
University of Michigan	93.865	\$134,333.70
University of Minnesota	93.865	\$28,976.25
University of North Carolina at Chapel Hill	93.865	\$59,573.55
University of Southern California	93.865	\$135,175.00
University of Texas at Austin	93.865	\$141,194.27
University of Washington	93.865	\$81,282.07
University of Wisconsin-Madison	93.865	\$284,310.91
University of Wisconsin-Milwaukee	93.865	\$143,595.00
Access Community Health Network	93.866	\$26,975.86
Boston University	93.866	\$20,575.80
Columbia University Harvard University	93.866	\$123,603.00 \$27,604.00
	93.866	\$27,504.04
University of Florida	93.866	\$5,822.77
University of Illinois at Urbana-Champaign	93.866	\$22,570.08
University of Wisconsin-Madison	93.866	\$8,213.85
Ann & Robert H. Lurie Children's Hospital of Chicago	93.867	\$124,519.00
Boston University	93.867	\$16,198.22
Duke University	93.867	\$35,586.1
Harvard University	93.867	\$97,488.72
Johns Hopkins University	93.867	\$40,691.57
Rehabilitation Institute Research Corporation	93.867	\$47,193.82
Universitat Regensburg	93.867	\$32,659.20

Erie Family Health Center93Center on Halsted93Puerto Rican Cultural Center93Indiana University93OptumHealth Care Solutions, Inc.93UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of North Carolina at Chapel Hill93Oklahoma State University93Washington University in St. Louis93Center on Halsted93	3.867 3.884 3.940 3.940 3.945 3.945 3.945 3.945 3.945 3.945 3.946 3.989	\$9,729.0 \$24,510.0 \$48,509.2 \$6,450.0 \$24,300.0
Center on Halsted93Puerto Rican Cultural Center93Indiana University93OptumHealth Care Solutions, Inc.93UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93University of North Carolina at Chapel Hill93Washington University in St. Louis93Center on Halsted93	3.940 3.940 3.945 3.945 3.945 3.945 3.945	\$100,412.2 \$9,729.00 \$24,510.00 \$48,509.20 \$6,450.00 \$24,300.00
Puerto Rican Cultural Center93Indiana University93OptumHealth Care Solutions, Inc.93UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Jos University Teaching Hospital93University of Cape Town93University of Ibadan93University of North Carolina at Chapel Hill93Oklahoma State University93University of North Carolina at Chapel Hill93Oklahoma State University in St. Louis93Center on Halsted93	3.940 3.945 3.945 3.945 3.945 3.945	\$24,510.00 \$48,509.20 \$6,450.00 \$24,300.00
Indiana University93OptumHealth Care Solutions, Inc.93UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of North Carolina at Chapel Hill93University93University93University93University93University of North Carolina at Chapel Hill93Washington University in St. Louis93Center on Halsted93	3.945 3.945 3.945 3.945 3.946	\$48,509.20 \$6,450.00 \$24,300.00
OptumHealth Care Solutions, Inc.93UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93University93University93University93University of North Carolina at Chapel Hill93Oklahoma State University in St. Louis93Center on Halsted93	3.945 3.945 3.945 3.946	\$6,450.0 \$24,300.0
UnitedHealth Group, Inc.93YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93University of University93Oklahoma State University93Oklahoma State University93Oklahoma University93Oklahoma State University93Oklahoma University	3.945 3.945 3.946	\$24,300.00
YMCA of the USA93NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Lagos93University of North Carolina at Chapel Hill93University93University93University93University of North Carolina at Chapel Hill93University93University93University93University93Chidana University in St. Louis93Center on Halsted93	3.945 3.946	
NorthShore University HealthSystem Research Institute93Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of North Carolina at Chapel Hill93Oklahoma State University93University of North Carolina at Chapel Hill93Oklahoma State University93Genter on Halsted93	3.946	M40 0F4 0
Ann & Robert H. Lurie Children's Hospital of Chicago93Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93		\$10,051.9
Chicago State University93Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3 980	\$52,024.8
Harvard University93Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	0.000	\$12,521.72
Jos University Teaching Hospital93University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$19,038.00
University of Cape Town93University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$34,274.2
University of Chicago93University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$111,966.43
University of Ibadan93University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$57,841.92
University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$10,129.10
University of Lagos93University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$48,589.04
University of North Carolina at Chapel Hill93Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$12,617.7
Oklahoma State University93Indiana University93Washington University in St. Louis93Center on Halsted93	3.989	\$30,563.92
Indiana University93Washington University in St. Louis93Center on Halsted93	3.Agmt 1/28/11	\$45,017.50
Washington University in St. Louis93Center on Halsted93	3.Agmt No. 13XS108//HHSN261200800001E	\$33,485.00
Center on Halsted 93	3.Agmt No. 13XS108//HHSN261200800001E	\$59,041.00
	3.Agmt signed 2/22/12//200-2011-41989	\$17,500.00
	3.HHSN268201300027C	\$6,584.82
J. Craig Venter Institute 93	3.HHSN272201200026C	\$419,563.48
-	3.HHSN272201200026C	\$353,655.14
	3.HHSN272201200026C	\$75,159.18
	3.HHSN272201200026C	\$1,308,424.77
	3.HHSN272201200026C	\$168,738.75
	3.HHSN272201200026C	\$550,328.9
	3.HHSN272201200026C	\$522,668.5
	3.HHSN272201200026C	\$157,289.1
	3.HHSN275201200007I	\$120,644.69
	3.HHSN2752012000071	\$64,151.49
	3.HHSN2752012000071	\$275,156.0
	3.HHSN275201200007I	\$3,102,710.74
	3.HHSN275201200007I	\$407,843.22
	3.HHSN275201200007I	\$48,047.00
	3.HHSN275201200007I	\$212,622.90
	3.HHSN2752012000071	\$49,932.38
	3.HHSN275201200007I	\$304,485.88
	3.HHSN2752012000071	\$159,842.67
	3.HHSN275201200007I	\$84,905.28
,	3.HHSN275201300013C	\$23,115.4 ⁴
	3.N01-CN-35157/004	\$102,406.6
	3.N01-CN-35157/004	\$148,281.4
		11407014
	3.N01-CN-35157/004	\$16,674.99
Loyola University Chicago 93		

Federal Grantor/Subrecipient Name	CFDA Number	Expenditures
Stanford University	93.N01-HC-95164/Amend #25	\$27,548.91
University of Illinois at Chicago	93.N01-HC-95164/Amend #25	\$18,273.00
Department of Health and Human Services Total		\$46,272,549.79
National Science Foundation		
Boston Medical Center	47.041	\$121,223.92
Purdue University	47.041	\$60,591.59
University of Illinois at Urbana-Champaign	47.041	\$19,216.44
University of Wisconsin-Madison	47.041	\$160,501.26
Clemson University	47.049	\$35,558.93
DePaul University	47.049	\$13,717.00
Harvard University	47.049	\$150,233.63
Missouri University of Science and Technology	47.049	\$20,762.69
University of Arizona	47.049	\$890.18
University of Illinois at Chicago	47.049	\$18,692.75
Michigan State University	47.050	\$48,867.91
Pennsylvania State University	47.050	\$23,093.92
U.S. Geological Survey	47.050	\$49,953.00
University of Notre Dame	47.050	\$66,776.14
University of Pennsylvania	47.050	\$11,250.40
HDT Robotics, Inc.	47.070	\$68,978.37
Stanford University	47.070	\$44,607.14
University of Washington	47.070	\$102,894.61
GFK Custom Research, LLC	47.075	\$342,723.60
National Bureau of Economic Research, Inc.	47.075	\$56,848.00
North Dakota State University	47.075	\$32,907.46
University of Illinois at Chicago	47.075	\$4,707.87
University of Notre Dame	47.075	\$3,001.27
University of San Carlos	47.075	\$27,098.40
American Institutes for Research	47.076	\$190,612.64
Horizon Research, Inc.	47.076	\$35,563.17
Inquire Learning, LLC	47.076	\$37,100.00
Michigan State University	47.076	\$128,435.41
Minnesota State University, Mankato	47.076	\$14,872.43
Stanford University	47.076	\$38,992.63
Teachers College	47.076	\$35,062.00
University of California, Berkeley	47.076	\$84,289.16
University of California, Santa Barbara	47.076	\$26,047.87
University of Colorado at Boulder	47.076	\$68,624.73
University of Editional at Doubler	47.076	\$4,227.24
University of Miniors at Chicago University of Wisconsin-Madison	47.076	\$4,227.24 \$82,003.04
Vanderbilt University	47.076	\$82,003.04 \$21,549.45
Wright State University	47.076	\$36,863.15
National Science Foundation Total	47.070	\$30,803.15 \$2,289,339.40
		÷±,200,000.70
Nuclear Regulatory Commission	77.000	* • 7 000 •0
Engineering and Software System Solutions, Inc.	77.009	\$47,839.42
Nuclear Regulatory Commission Total		\$47,839.42
Grand Total		\$57,671,997.01



Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Board of Trustees Northwestern University Evanston, Illinois

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Northwestern University (the "University"), which comprise the consolidated statement of financial position as of August 31, 2015, and the related consolidated statement of activities and of cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated January 22, 2016.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the University's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Pricewaterhouse Coopers LLP

Chicago, Illinois January 22, 2016



Independent Auditor's Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with OMB Circular A-133

Board of Trustees Northwestern University Evanston, Illinois

Report on Compliance for Each Major Federal Program

We have audited Northwestern University's (the "University") compliance with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2015. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University's compliance.

Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2015.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with OMB Circular A-133 and which are described in the accompanying schedule



of findings and questioned costs as items 2015-001 through 2015-002. Our opinion on each major federal program is not modified with respect to these matters.

The University's response to the noncompliance findings identified in our audit is described in the accompanying corrective action plan. The University's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.

Precewaterhouse Coopers LLP

Chicago, Illinois May 26, 2016

For the Year Ended August 31, 2015

SECTION I — SUMMARY OF AUDITORS' RESULTS

Financial Statements

Unmodified	
Yes	<u>X</u> No
Yes	<u>X</u> None reported
Yes	<u>X</u> No
Yes	X_No
Yes	<u>X</u> None reported
Unmodified	
<u>X</u> Yes	No
Name of Feder	ral Program or Cluster
Student Financial Assistance Cluster	
Research and Development Cluster	
\$3,000,000	
X Yes	No
	Yes Yes Yes Yes Unmodified _X_Yes Name of Feder Student Finan Research and \$3,000,000

SECTION II – FINANCIAL STATEMENT FINDINGS

No findings to be reported.

SECTION III – FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

Finding 2015-001: Notify Students Receiving FSA Funds Prior to the Disbursement

Award Information

Cluster:	Student Financial Assistance Cluster
Grantor:	Department of Education
Award Year:	September 1, 2014–August 30, 2015
CFDA Number:	84.268
CFDA Title:	Federal Direct Student Loans

Condition

To test the compliance related to the disbursement of Federal Student Aid (FSA) funds, we sampled 60 students and found one student did not receive email notification of their loan disbursement prior to funds being disbursed.

Criteria

A general notification must be provided to all students receiving FSA funds notifying the student of the amount of funds the student and his or her parent can expect to receive from each FSA program, including FWS, and how and when those funds will be disbursed. This notification must be sent before the disbursement is made.

Questioned Costs

None identified.

Cause

The University relies on an automated computer function to send email notifications to students regarding the status of loan disbursements and their right to cancel all or part of loans. The instance resulted from an automated computer processing failure.

Effect

One student was not notified timely of a loan disbursement and as such, student would not have been informed of their rights to cancel the loan and applicable loan details, prior to disbursement of the loan.

Recommendation

The University should implement a manual check that includes all types of loan disbursements that email notifications to students for loan disbursements are made timely.

Management's Views and Corrective Action Plan

Management's views and corrective action plan are included at the end of this report.

SECTION III - FEDERAL AWARD FINDINGS AND QUESTIONED COSTS (continued)

Finding 2015-002: Remit Enrollment Reporting Corrections in a Timely Manner

Award Information

Cluster:	Student Financial Assistance Cluster
Grantor:	Department of Education
Award Year:	September 1, 2014–August 30, 2015
CFDA Number:	84.268
CFDA Title:	Federal Direct Student Loans

Condition

Through our testing of 27 enrollment status changes, we noted while all changes were submitted by the University timely to the National Student Clearinghouse ("NSC")—a third party servicer—the enrollment status change was not submitted by NSC to the National Student Loan Data System (NSLDS) within 60 days for 20 students from our sample of 25 students. Enrollment status and effective status change dates were inconsistent between NSLDS and Students' records for 7 and 10 students out of 25 sampled, respectively.

Criteria

Federal regulations governing Title IV student aid programs require institutions, lenders, GAs, and the Direct Loan Servicer to monitor and update the enrollment status of students who receive Federal student loans. Completion of Enrollment Reporting satisfies the regulatory requirements for schools. Under the Direct Loan programs, schools must complete and return within 15 days the Enrollment Reporting roster file placed in their Student Aid Internet Gateway (SAIG) mailboxes sent by the Department of Education via the NSLDS. The institution determines how often it receives the Enrollment Reporting roster file with the default set at every two months, but the minimum is twice a year. Once received, the institution must update for changes in student status, report the date the enrollment status was effective, enter the new anticipated completion date, and submit the changes electronically through the batch method or the NSLDS website. Unless the school expects to complete its next roster within 60 days, the school must notify the lender or the guaranty agency within 15 days, if it discovers that a student who received a loan either did not enroll or ceased to be enrolled on at least a half-time basis (Direct Loan, 34 CFR section 685.309).

The school remains responsible for submitting timely, accurate, and complete responses to Enrollment Reporting roster files and for maintaining proper documentation in accordance with Federal Regulation 34 CFR 682.610(c).

Questioned Costs

None identified.

SECTION III - FEDERAL AWARD FINDINGS AND QUESTIONED COSTS (continued)

Cause

The late reporting was due to NSC not submitting the information timely to NSLDS, as well as lack of monitoring by the University to ensure all changes reported to NSC were ultimately reported timely to NSLDS.

Effect

The effective administration of Title IV loans could be impacted when changes in students' status are not reported timely and accurately. The accuracy of enrollment information is important as a student's enrollment status determines eligibility for in-school status, deferment, grace periods, and repayments, as well as the Government's payment of interest subsidies

Recommendation

The University should institute a control to periodically review enrollment changes and ensure the changes were reported to NSLDS timely.

Management's Views and Corrective Action Plan

Management's views and corrective action plan are included at the end of this report.

SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS

Finding 2014-001–Late Performance of Exit Interviews

Award Information

Cluster:	Student Financial Assistance Cluster
Grantor:	Department of Education
Award Year:	September 1, 2013–August 30, 2014
CFDA Number:	84.038—Federal Perkins Loan

To test the compliance requirements specific to the Perkins loan programs, we selected a sample of 81 Direct Loan and Perkins Loan recipients out of a population of 7,499 recipients. In testing this sample, we identified one Perkins loan recipient who did not receive loan exit counseling within the required 30-day time period. The performance of this exit counseling occurred 130 days after the deadline for the student. The student withdrew from the University after completing the Spring term. However, the student's status was not communicated to the Student Loan Office until the first Fall term exit counseling process. The exit counseling process is based on the term the student withdrew rather than the last date of attendance, and therefore the student was not identified in the exit program until the Fall term.

Recommendation

PwC recommended the University should revise the exit process to include a non-term based program that will identify withdrawals based on the last date of attendance.

Current Status

We have made the necessary changes to the exit process. The process has been changed to better identify borrowers who withdraw from an upcoming academic term and to provide them with exit counseling in a timely manner. The exit process has been revised to include non-term based programming to identify withdrawals.

SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS (continued)

Finding 2014-002—Subawards were not reported to Federal Funding Accountability and Transparency (FFATA) within the required timeframe

Award Information

Cluster:	Research and Development
Grantor:	US Department of Health and Human Services
Award Year:	September 1, 2013–August 30, 2014
CFDA Number:	93.859—Biomedical Research and Research Training

To test the reporting requirements for subawards subject to the Federal Funding Accountability and Transparency Act (FFATA), in the prior year we selected a sample of 25 awards granted during the year and subject to FFATA reporting provisions out of a total population of 495 such awards. In testing this sample, we had identified three subawards that were not reported to Federal Funding Accountability and Transparency Subaward Reporting System (FSRS) within the required timeframe. The reports submitted were 487, 492, and 206 days late for award numbers one, two, and three respectively.

Recommendation

PwC recommended the University implement an overarching review of the full FFATA spreadsheet for both campuses rather than segregating it only by campus. It was also recommended that we reinforce the importance of performing a thorough review of the grant agreements to the individuals in the Office for Sponsored Research.

Current Status

The Office for Sponsored Research enhanced its internal FFATA spreadsheet so that responsibility for FFATA reporting was correctly identified for cross campus awards. The Office for Sponsored Research staff also reviewed data entry and business processes related to FFATA reporting.

Management's Corrective Action Plan Year Ended August 31, 2015

Northwestern

Office of the Vice President for Financial Operations and Treasurer Northwestern University 619 Clark Street, Room 117 Evanston, Illinois 60208-1116

Phone 847-491-7350 Fax 847-467-4777

May 26, 2016

Corrective Action Plan Findings: A-133 Audit Report Fiscal Year Ended August 31, 2015

Listed below is Northwestern University's Corrective Action Plan to resolve audit findings resulting from the FY2015 A-133 audit.

Finding 2015-001: Notify Students Receiving FSA Funds Prior to the Disbursement (SFA)

Management response:

Management agrees with the finding. Corrective action has been implemented to ensure that the Notice of Right to Cancel report (NSWF0041.sqr) is run along with the financial aid authorization/disbursement process (NWFAAD1) even when the authorization/disbursement is run as a one-off job. This will ensure management can review a complete population of students which have been notified of loan disbursements and identify and remediate any failed attempts at notification timely.

Finding 2015-002: Remit Enrollment Reporting Corrections in a Timely Manner (SFA)

Management response:

Management agrees with this finding. The Registrar's Office and the central Financial Aid Offices worked with the National Student Clearinghouse to find ways to make sure our data would be provided in a timely fashion to the NSC and then on to the NSLDS.

The University agrees that Northwestern institute a control to review enrollment information; in fact that was begun in November 2015 when the initial information was received from the Clearinghouse. Currently, the University is spot checking students' enrollment status in NSLDS including confirming correct enrollment change reporting for graduation this spring. In addition, management is exploring other ways of reporting enrollment information and changes including reporting directly to NSLDS, despite the assurances of NSC that their issues have been resolved.

Please contact me at i-stafford@northwestern.edu or 847-491-7350 if you have any questions on these matters.

Ingrid S. Stafford Vice President for Financial Operations and Treasurer